id	sid	tid	token	lemma	pos
ajcp-1634	1	1	pa	pa	PROPN
ajcp-1634	1	2	ge	ge	PROPN
ajcp-1634	1	3	1	1	NUM
ajcp-1634	1	4	pa	pa	PROPN
ajcp-1634	1	5	ge	ge	PROPN
ajcp-1634	1	6	66	66	NUM
ajcp-1634	1	7	american	american	PROPN
ajcp-1634	1	8	journal	journal	NOUN
ajcp-1634	1	9	of	of	ADP
ajcp-1634	1	10	chemistry	chemistry	NOUN
ajcp-1634	1	11	and	and	CCONJ
ajcp-1634	1	12	pharmacy	pharmacy	NOUN
ajcp-1634	1	13	(	(	PUNCT
ajcp-1634	1	14	ajcp	ajcp	NOUN
ajcp-1634	1	15	)	)	PUNCT
ajcp-1634	1	16	unveiling	unveil	VERB
ajcp-1634	1	17	the	the	DET
ajcp-1634	1	18	sars	sar	NOUN
ajcp-1634	1	19	-	-	PUNCT
ajcp-1634	1	20	cov-2	cov-2	NOUN
ajcp-1634	1	21	spike	spike	ADJ
ajcp-1634	1	22	protein	protein	NOUN
ajcp-1634	1	23	:	:	PUNCT
ajcp-1634	1	24	a	a	DET
ajcp-1634	1	25	comparative	comparative	ADJ
ajcp-1634	1	26	analysis	analysis	NOUN
ajcp-1634	1	27	of	of	ADP
ajcp-1634	1	28	vaccine	vaccine	NOUN
ajcp-1634	1	29	development	development	NOUN
ajcp-1634	1	30	approaches	approach	NOUN
ajcp-1634	1	31	and	and	CCONJ
ajcp-1634	1	32	glycosylation	glycosylation	NOUN
ajcp-1634	1	33	implications	implication	NOUN
ajcp-1634	1	34	leonel	leonel	PROPN
ajcp-1634	1	35	c.	c.	PROPN
ajcp-1634	1	36	mendoza1	mendoza1	PROPN
ajcp-1634	1	37	*	*	PROPN
ajcp-1634	1	38	volume	volume	NOUN
ajcp-1634	1	39	2	2	NUM
ajcp-1634	1	40	issue	issue	NOUN
ajcp-1634	1	41	2	2	NUM
ajcp-1634	1	42	,	,	PUNCT
ajcp-1634	1	43	year	year	NOUN
ajcp-1634	1	44	2023	2023	NUM
ajcp-1634	1	45	issn	issn	X
ajcp-1634	1	46	:	:	PUNCT
ajcp-1634	1	47	2834	2834	NUM
ajcp-1634	1	48	-	-	SYM
ajcp-1634	1	49	0116	0116	NUM
ajcp-1634	1	50	(	(	PUNCT
ajcp-1634	1	51	online	online	ADJ
ajcp-1634	1	52	)	)	PUNCT
ajcp-1634	1	53	doi	doi	NOUN
ajcp-1634	1	54	:	:	PUNCT
ajcp-1634	1	55	https://doi.org/10.54536/ajcp.v2i2.1634	https://doi.org/10.54536/ajcp.v2i2.1634	NOUN
ajcp-1634	1	56	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	1	57	article	article	NOUN
ajcp-1634	1	58	information	information	NOUN
ajcp-1634	1	59	abstract	abstract	ADV
ajcp-1634	1	60	received	receive	VERB
ajcp-1634	1	61	:	:	PUNCT
ajcp-1634	1	62	may	may	AUX
ajcp-1634	1	63	05	05	NUM
ajcp-1634	1	64	,	,	PUNCT
ajcp-1634	1	65	2023	2023	NUM
ajcp-1634	1	66	accepted	accept	VERB
ajcp-1634	1	67	:	:	PUNCT
ajcp-1634	1	68	june	june	PROPN
ajcp-1634	1	69	25	25	NUM
ajcp-1634	1	70	,	,	PUNCT
ajcp-1634	1	71	2023	2023	NUM
ajcp-1634	1	72	published	publish	VERB
ajcp-1634	1	73	:	:	PUNCT
ajcp-1634	1	74	july	july	PROPN
ajcp-1634	1	75	03	03	NUM
ajcp-1634	1	76	,	,	PUNCT
ajcp-1634	1	77	2023	2023	NUM
ajcp-1634	1	78	in	in	ADP
ajcp-1634	1	79	december	december	PROPN
ajcp-1634	1	80	2019	2019	NUM
ajcp-1634	1	81	,	,	PUNCT
ajcp-1634	1	82	a	a	DET
ajcp-1634	1	83	mysterious	mysterious	ADJ
ajcp-1634	1	84	pneumonia	pneumonia	NOUN
ajcp-1634	1	85	-	-	PUNCT
ajcp-1634	1	86	causing	cause	VERB
ajcp-1634	1	87	sickness	sickness	NOUN
ajcp-1634	1	88	frightened	frighten	VERB
ajcp-1634	1	89	the	the	DET
ajcp-1634	1	90	world	world	NOUN
ajcp-1634	1	91	.	.	PUNCT
ajcp-1634	2	1	sarscov-2	sarscov-2	NUM
ajcp-1634	2	2	caused	cause	VERB
ajcp-1634	2	3	the	the	DET
ajcp-1634	2	4	acute	acute	ADJ
ajcp-1634	2	5	respiratory	respiratory	ADJ
ajcp-1634	2	6	illness	illness	NOUN
ajcp-1634	2	7	.	.	PUNCT
ajcp-1634	3	1	since	since	SCONJ
ajcp-1634	3	2	march	march	PROPN
ajcp-1634	3	3	11	11	NUM
ajcp-1634	3	4	,	,	PUNCT
ajcp-1634	3	5	2020	2020	NUM
ajcp-1634	3	6	,	,	PUNCT
ajcp-1634	3	7	220,563,227	220,563,227	NUM
ajcp-1634	3	8	covid-19	covid-19	PROPN
ajcp-1634	3	9	cases	case	NOUN
ajcp-1634	3	10	and	and	CCONJ
ajcp-1634	3	11	4,565,483	4,565,483	NUM
ajcp-1634	3	12	deaths	death	NOUN
ajcp-1634	3	13	have	have	AUX
ajcp-1634	3	14	been	be	AUX
ajcp-1634	3	15	reported	report	VERB
ajcp-1634	3	16	worldwide	worldwide	ADV
ajcp-1634	3	17	as	as	ADP
ajcp-1634	3	18	of	of	ADP
ajcp-1634	3	19	october	october	PROPN
ajcp-1634	3	20	2021	2021	NUM
ajcp-1634	3	21	.	.	PUNCT
ajcp-1634	4	1	sarscov-2	sarscov-2	NUM
ajcp-1634	4	2	,	,	PUNCT
ajcp-1634	4	3	like	like	ADP
ajcp-1634	4	4	all	all	DET
ajcp-1634	4	5	coronavirus	coronavirus	NOUN
ajcp-1634	4	6	,	,	PUNCT
ajcp-1634	4	7	appears	appear	VERB
ajcp-1634	4	8	to	to	PART
ajcp-1634	4	9	have	have	VERB
ajcp-1634	4	10	crowns	crown	NOUN
ajcp-1634	4	11	due	due	ADP
ajcp-1634	4	12	to	to	ADP
ajcp-1634	4	13	its	its	PRON
ajcp-1634	4	14	s	s	NOUN
ajcp-1634	4	15	proteins	protein	NOUN
ajcp-1634	4	16	and	and	CCONJ
ajcp-1634	4	17	enters	enter	VERB
ajcp-1634	4	18	host	host	NOUN
ajcp-1634	4	19	cells	cell	NOUN
ajcp-1634	4	20	using	use	VERB
ajcp-1634	4	21	highly	highly	ADV
ajcp-1634	4	22	glycosylated	glycosylated	ADJ
ajcp-1634	4	23	spike	spike	NOUN
ajcp-1634	4	24	(	(	PUNCT
ajcp-1634	4	25	s	s	NOUN
ajcp-1634	4	26	)	)	PUNCT
ajcp-1634	4	27	proteins	protein	NOUN
ajcp-1634	4	28	.	.	PUNCT
ajcp-1634	5	1	s1	s1	NOUN
ajcp-1634	5	2	and	and	CCONJ
ajcp-1634	5	3	s2	s2	PROPN
ajcp-1634	5	4	are	be	AUX
ajcp-1634	5	5	sars	sar	NOUN
ajcp-1634	5	6	-	-	PUNCT
ajcp-1634	5	7	cov-2	cov-2	NOUN
ajcp-1634	5	8	spike	spike	ADJ
ajcp-1634	5	9	protein	protein	NOUN
ajcp-1634	5	10	subunits	subunit	NOUN
ajcp-1634	5	11	.	.	PUNCT
ajcp-1634	6	1	s2	s2	PROPN
ajcp-1634	6	2	controls	control	VERB
ajcp-1634	6	3	transmembrane	transmembrane	ADJ
ajcp-1634	6	4	fusion	fusion	NOUN
ajcp-1634	6	5	,	,	PUNCT
ajcp-1634	6	6	while	while	SCONJ
ajcp-1634	6	7	s1	s1	NOUN
ajcp-1634	6	8	controls	control	VERB
ajcp-1634	6	9	receptor	receptor	NOUN
ajcp-1634	6	10	binding	bind	VERB
ajcp-1634	6	11	.	.	PUNCT
ajcp-1634	7	1	antibodymediated	antibodymediate	VERB
ajcp-1634	7	2	neutralization	neutralization	NOUN
ajcp-1634	7	3	targets	target	NOUN
ajcp-1634	7	4	sars	sar	NOUN
ajcp-1634	7	5	-	-	PUNCT
ajcp-1634	7	6	cov-2	cov-2	NOUN
ajcp-1634	7	7	spike	spike	X
ajcp-1634	7	8	(	(	PUNCT
ajcp-1634	7	9	s	s	NOUN
ajcp-1634	7	10	)	)	PUNCT
ajcp-1634	7	11	proteins	protein	NOUN
ajcp-1634	7	12	,	,	PUNCT
ajcp-1634	7	13	which	which	PRON
ajcp-1634	7	14	are	be	AUX
ajcp-1634	7	15	essential	essential	ADJ
ajcp-1634	7	16	for	for	ADP
ajcp-1634	7	17	viral	viral	ADJ
ajcp-1634	7	18	entry	entry	NOUN
ajcp-1634	7	19	and	and	CCONJ
ajcp-1634	7	20	fusion	fusion	NOUN
ajcp-1634	7	21	.	.	PUNCT
ajcp-1634	8	1	this	this	DET
ajcp-1634	8	2	paper	paper	NOUN
ajcp-1634	8	3	summarized	summarize	VERB
ajcp-1634	8	4	how	how	SCONJ
ajcp-1634	8	5	s	s	VERB
ajcp-1634	8	6	protein	protein	NOUN
ajcp-1634	8	7	was	be	AUX
ajcp-1634	8	8	used	use	VERB
ajcp-1634	8	9	in	in	ADP
ajcp-1634	8	10	newly	newly	ADV
ajcp-1634	8	11	created	create	VERB
ajcp-1634	8	12	and	and	CCONJ
ajcp-1634	8	13	distributed	distribute	VERB
ajcp-1634	8	14	sars	sar	NOUN
ajcp-1634	8	15	-	-	PUNCT
ajcp-1634	8	16	cov-2	cov-2	NOUN
ajcp-1634	8	17	vaccines	vaccine	NOUN
ajcp-1634	8	18	and	and	CCONJ
ajcp-1634	8	19	the	the	DET
ajcp-1634	8	20	implications	implication	NOUN
ajcp-1634	8	21	for	for	ADP
ajcp-1634	8	22	future	future	ADJ
ajcp-1634	8	23	advancements	advancement	NOUN
ajcp-1634	8	24	given	give	VERB
ajcp-1634	8	25	the	the	DET
ajcp-1634	8	26	emergence	emergence	NOUN
ajcp-1634	8	27	of	of	ADP
ajcp-1634	8	28	more	more	ADV
ajcp-1634	8	29	lethal	lethal	ADJ
ajcp-1634	8	30	sars	sar	NOUN
ajcp-1634	8	31	-	-	PUNCT
ajcp-1634	8	32	cov-2	cov-2	NOUN
ajcp-1634	8	33	variants	variant	NOUN
ajcp-1634	8	34	in	in	ADP
ajcp-1634	8	35	this	this	DET
ajcp-1634	8	36	paper	paper	NOUN
ajcp-1634	8	37	.	.	PUNCT
ajcp-1634	9	1	it	it	PRON
ajcp-1634	9	2	also	also	ADV
ajcp-1634	9	3	discussed	discuss	VERB
ajcp-1634	9	4	the	the	DET
ajcp-1634	9	5	role	role	NOUN
ajcp-1634	9	6	of	of	ADP
ajcp-1634	9	7	s	s	NOUN
ajcp-1634	9	8	protein	protein	NOUN
ajcp-1634	9	9	glycosylation	glycosylation	NOUN
ajcp-1634	9	10	in	in	ADP
ajcp-1634	9	11	the	the	DET
ajcp-1634	9	12	viral	viral	ADJ
ajcp-1634	9	13	entry	entry	NOUN
ajcp-1634	9	14	and	and	CCONJ
ajcp-1634	9	15	binding	bind	VERB
ajcp-1634	9	16	mechanism	mechanism	NOUN
ajcp-1634	9	17	of	of	ADP
ajcp-1634	9	18	sars	sar	NOUN
ajcp-1634	9	19	-	-	PUNCT
ajcp-1634	9	20	cov-2	cov-2	NOUN
ajcp-1634	9	21	and	and	CCONJ
ajcp-1634	9	22	the	the	DET
ajcp-1634	9	23	implications	implication	NOUN
ajcp-1634	9	24	for	for	ADP
ajcp-1634	9	25	developing	develop	VERB
ajcp-1634	9	26	adaptive	adaptive	ADJ
ajcp-1634	9	27	immunity	immunity	NOUN
ajcp-1634	9	28	and	and	CCONJ
ajcp-1634	9	29	vaccines	vaccine	NOUN
ajcp-1634	9	30	.	.	PUNCT
ajcp-1634	10	1	the	the	DET
ajcp-1634	10	2	review	review	NOUN
ajcp-1634	10	3	was	be	AUX
ajcp-1634	10	4	carried	carry	VERB
ajcp-1634	10	5	out	out	ADP
ajcp-1634	10	6	through	through	ADP
ajcp-1634	10	7	a	a	DET
ajcp-1634	10	8	deductive	deductive	ADJ
ajcp-1634	10	9	search	search	NOUN
ajcp-1634	10	10	strategy	strategy	NOUN
ajcp-1634	10	11	with	with	ADP
ajcp-1634	10	12	keywords	keyword	NOUN
ajcp-1634	10	13	:	:	PUNCT
ajcp-1634	10	14	covid-19	covid-19	PROPN
ajcp-1634	10	15	vaccines	vaccine	NOUN
ajcp-1634	10	16	,	,	PUNCT
ajcp-1634	10	17	ncov-2019	ncov-2019	ADJ
ajcp-1634	10	18	vaccines	vaccine	NOUN
ajcp-1634	10	19	,	,	PUNCT
ajcp-1634	10	20	coronavirus	coronavirus	NOUN
ajcp-1634	10	21	,	,	PUNCT
ajcp-1634	10	22	covid-19	covid-19	PROPN
ajcp-1634	10	23	vaccine	vaccine	NOUN
ajcp-1634	10	24	development	development	NOUN
ajcp-1634	10	25	,	,	PUNCT
ajcp-1634	10	26	s	s	VERB
ajcp-1634	10	27	protein	protein	NOUN
ajcp-1634	10	28	,	,	PUNCT
ajcp-1634	10	29	and	and	CCONJ
ajcp-1634	10	30	protein	protein	NOUN
ajcp-1634	10	31	glycosylation	glycosylation	NOUN
ajcp-1634	10	32	using	use	VERB
ajcp-1634	10	33	google	google	PROPN
ajcp-1634	10	34	scholar	scholar	NOUN
ajcp-1634	10	35	.	.	PUNCT
ajcp-1634	11	1	the	the	DET
ajcp-1634	11	2	emergence	emergence	NOUN
ajcp-1634	11	3	of	of	ADP
ajcp-1634	11	4	more	more	ADV
ajcp-1634	11	5	transmissible	transmissible	ADJ
ajcp-1634	11	6	and	and	CCONJ
ajcp-1634	11	7	potentially	potentially	ADV
ajcp-1634	11	8	more	more	ADV
ajcp-1634	11	9	lethal	lethal	ADJ
ajcp-1634	11	10	sars	sar	NOUN
ajcp-1634	11	11	-	-	PUNCT
ajcp-1634	11	12	cov-2	cov-2	NOUN
ajcp-1634	11	13	variants	variant	NOUN
ajcp-1634	11	14	,	,	PUNCT
ajcp-1634	11	15	such	such	ADJ
ajcp-1634	11	16	as	as	ADP
ajcp-1634	11	17	the	the	DET
ajcp-1634	11	18	delta	delta	NOUN
ajcp-1634	11	19	variant	variant	NOUN
ajcp-1634	11	20	,	,	PUNCT
ajcp-1634	11	21	highlights	highlight	VERB
ajcp-1634	11	22	the	the	DET
ajcp-1634	11	23	need	need	NOUN
ajcp-1634	11	24	for	for	ADP
ajcp-1634	11	25	continued	continued	ADJ
ajcp-1634	11	26	research	research	NOUN
ajcp-1634	11	27	on	on	ADP
ajcp-1634	11	28	vaccine	vaccine	NOUN
ajcp-1634	11	29	development	development	NOUN
ajcp-1634	11	30	.	.	PUNCT
ajcp-1634	12	1	future	future	ADJ
ajcp-1634	12	2	research	research	NOUN
ajcp-1634	12	3	should	should	AUX
ajcp-1634	12	4	focus	focus	VERB
ajcp-1634	12	5	on	on	ADP
ajcp-1634	12	6	understanding	understand	VERB
ajcp-1634	12	7	the	the	DET
ajcp-1634	12	8	mechanism	mechanism	NOUN
ajcp-1634	12	9	of	of	ADP
ajcp-1634	12	10	the	the	DET
ajcp-1634	12	11	spike	spike	ADJ
ajcp-1634	12	12	protein	protein	NOUN
ajcp-1634	12	13	and	and	CCONJ
ajcp-1634	12	14	how	how	SCONJ
ajcp-1634	12	15	vaccines	vaccine	NOUN
ajcp-1634	12	16	can	can	AUX
ajcp-1634	12	17	effectively	effectively	ADV
ajcp-1634	12	18	target	target	VERB
ajcp-1634	12	19	the	the	DET
ajcp-1634	12	20	mutated	mutate	VERB
ajcp-1634	12	21	regions	region	NOUN
ajcp-1634	12	22	.	.	PUNCT
ajcp-1634	13	1	continued	continue	VERB
ajcp-1634	13	2	monitoring	monitoring	NOUN
ajcp-1634	13	3	and	and	CCONJ
ajcp-1634	13	4	adaptation	adaptation	NOUN
ajcp-1634	13	5	of	of	ADP
ajcp-1634	13	6	vaccination	vaccination	NOUN
ajcp-1634	13	7	strategies	strategy	NOUN
ajcp-1634	13	8	are	be	AUX
ajcp-1634	13	9	essential	essential	ADJ
ajcp-1634	13	10	to	to	PART
ajcp-1634	13	11	control	control	VERB
ajcp-1634	13	12	the	the	DET
ajcp-1634	13	13	ongoing	ongoing	ADJ
ajcp-1634	13	14	covid-19	covid-19	PROPN
ajcp-1634	13	15	pandemic	pandemic	NOUN
ajcp-1634	13	16	.	.	PUNCT
ajcp-1634	14	1	keywords	keyword	VERB
ajcp-1634	14	2	coronavirus	coronavirus	NOUN
ajcp-1634	14	3	,	,	PUNCT
ajcp-1634	14	4	covid-19	covid-19	PROPN
ajcp-1634	14	5	vaccines	vaccine	NOUN
ajcp-1634	14	6	,	,	PUNCT
ajcp-1634	14	7	covid-19	covid-19	PROPN
ajcp-1634	14	8	vaccine	vaccine	NOUN
ajcp-1634	14	9	development	development	NOUN
ajcp-1634	14	10	,	,	PUNCT
ajcp-1634	14	11	ncov2019	ncov2019	PROPN
ajcp-1634	14	12	vaccines	vaccine	NOUN
ajcp-1634	14	13	,	,	PUNCT
ajcp-1634	14	14	protein	protein	NOUN
ajcp-1634	14	15	glycosylation	glycosylation	NOUN
ajcp-1634	14	16	,	,	PUNCT
ajcp-1634	14	17	s	s	NOUN
ajcp-1634	14	18	protein	protein	NOUN
ajcp-1634	14	19	1	1	NUM
ajcp-1634	14	20	college	college	NOUN
ajcp-1634	14	21	of	of	ADP
ajcp-1634	14	22	teacher	teacher	NOUN
ajcp-1634	14	23	education	education	NOUN
ajcp-1634	14	24	,	,	PUNCT
ajcp-1634	14	25	mindoro	mindoro	PROPN
ajcp-1634	14	26	state	state	PROPN
ajcp-1634	14	27	university	university	NOUN
ajcp-1634	14	28	-	-	PUNCT
ajcp-1634	14	29	calapan	calapan	NOUN
ajcp-1634	14	30	city	city	NOUN
ajcp-1634	14	31	campus	campus	NOUN
ajcp-1634	14	32	,	,	PUNCT
ajcp-1634	14	33	philippines	philippine	NOUN
ajcp-1634	14	34	*	*	PUNCT
ajcp-1634	14	35	corresponding	correspond	VERB
ajcp-1634	14	36	author	author	NOUN
ajcp-1634	14	37	’s	’s	PART
ajcp-1634	14	38	e	e	NOUN
ajcp-1634	14	39	-	-	NOUN
ajcp-1634	14	40	mail	mail	NOUN
ajcp-1634	14	41	:	:	PUNCT
ajcp-1634	14	42	leonel.mendoza@minsu.edu.ph	leonel.mendoza@minsu.edu.ph	ADJ
ajcp-1634	14	43	introduction	introduction	NOUN
ajcp-1634	14	44	coronaviruses	coronaviruse	NOUN
ajcp-1634	14	45	are	be	AUX
ajcp-1634	14	46	single	single	ADJ
ajcp-1634	14	47	-	-	PUNCT
ajcp-1634	14	48	stranded	strand	VERB
ajcp-1634	14	49	rna	rna	NOUN
ajcp-1634	14	50	viruses	virus	NOUN
ajcp-1634	14	51	classified	classify	VERB
ajcp-1634	14	52	into	into	ADP
ajcp-1634	14	53	three	three	NUM
ajcp-1634	14	54	genera	genera	NOUN
ajcp-1634	14	55	(	(	PUNCT
ajcp-1634	14	56	alpha	alpha	NOUN
ajcp-1634	14	57	,	,	PUNCT
ajcp-1634	14	58	beta	beta	NOUN
ajcp-1634	14	59	,	,	PUNCT
ajcp-1634	14	60	and	and	CCONJ
ajcp-1634	14	61	gamma	gamma	NOUN
ajcp-1634	14	62	coronaviruses	coronaviruse	NOUN
ajcp-1634	14	63	)	)	PUNCT
ajcp-1634	14	64	,	,	PUNCT
ajcp-1634	14	65	which	which	PRON
ajcp-1634	14	66	correspond	correspond	VERB
ajcp-1634	14	67	to	to	ADP
ajcp-1634	14	68	groups	group	NOUN
ajcp-1634	14	69	1	1	NUM
ajcp-1634	14	70	,	,	PUNCT
ajcp-1634	14	71	2	2	NUM
ajcp-1634	14	72	,	,	PUNCT
ajcp-1634	14	73	and	and	CCONJ
ajcp-1634	14	74	3	3	NUM
ajcp-1634	14	75	of	of	ADP
ajcp-1634	14	76	the	the	DET
ajcp-1634	14	77	coronavirinae	coronavirinae	NOUN
ajcp-1634	14	78	subfamily	subfamily	ADV
ajcp-1634	14	79	,	,	PUNCT
ajcp-1634	14	80	coronaviridae	coronaviridae	NOUN
ajcp-1634	14	81	family	family	NOUN
ajcp-1634	14	82	,	,	PUNCT
ajcp-1634	14	83	and	and	CCONJ
ajcp-1634	14	84	nidovirales	nidovirale	VERB
ajcp-1634	14	85	order	order	NOUN
ajcp-1634	14	86	or	or	CCONJ
ajcp-1634	14	87	superfamily	superfamily	ADV
ajcp-1634	14	88	(	(	PUNCT
ajcp-1634	14	89	weiss	weiss	PROPN
ajcp-1634	14	90	&	&	CCONJ
ajcp-1634	14	91	leibowitz	leibowitz	PROPN
ajcp-1634	14	92	,	,	PUNCT
ajcp-1634	14	93	2011	2011	NUM
ajcp-1634	14	94	)	)	PUNCT
ajcp-1634	14	95	.	.	PUNCT
ajcp-1634	15	1	coronaviruses	coronaviruse	NOUN
ajcp-1634	15	2	infect	infect	VERB
ajcp-1634	15	3	a	a	DET
ajcp-1634	15	4	wide	wide	ADJ
ajcp-1634	15	5	range	range	NOUN
ajcp-1634	15	6	of	of	ADP
ajcp-1634	15	7	animals	animal	NOUN
ajcp-1634	15	8	,	,	PUNCT
ajcp-1634	15	9	both	both	CCONJ
ajcp-1634	15	10	domestic	domestic	ADJ
ajcp-1634	15	11	and	and	CCONJ
ajcp-1634	15	12	wild	wild	ADJ
ajcp-1634	15	13	,	,	PUNCT
ajcp-1634	15	14	and	and	CCONJ
ajcp-1634	15	15	humans	human	NOUN
ajcp-1634	15	16	(	(	PUNCT
ajcp-1634	15	17	pedersen	pedersen	PROPN
ajcp-1634	15	18	&	&	CCONJ
ajcp-1634	15	19	ho	ho	PROPN
ajcp-1634	15	20	,	,	PUNCT
ajcp-1634	15	21	2020	2020	NUM
ajcp-1634	15	22	)	)	PUNCT
ajcp-1634	15	23	.	.	PUNCT
ajcp-1634	16	1	six	six	NUM
ajcp-1634	16	2	strains	strain	NOUN
ajcp-1634	16	3	,	,	PUNCT
ajcp-1634	16	4	namely	namely	ADV
ajcp-1634	16	5	,	,	PUNCT
ajcp-1634	16	6	hcov‐229e	hcov‐229e	INTJ
ajcp-1634	16	7	,	,	PUNCT
ajcp-1634	16	8	hcov‐oc43	hcov‐oc43	PROPN
ajcp-1634	16	9	,	,	PUNCT
ajcp-1634	16	10	hcov‐nl63	hcov‐nl63	ADP
ajcp-1634	16	11	,	,	PUNCT
ajcp-1634	16	12	hku1	hku1	PROPN
ajcp-1634	16	13	,	,	PUNCT
ajcp-1634	16	14	sars	sars	PROPN
ajcp-1634	16	15	-	-	PUNCT
ajcp-1634	16	16	cov	cov	NOUN
ajcp-1634	16	17	,	,	PUNCT
ajcp-1634	16	18	and	and	CCONJ
ajcp-1634	16	19	mers	mer	NOUN
ajcp-1634	16	20	-	-	PUNCT
ajcp-1634	16	21	cov	cov	NOUN
ajcp-1634	16	22	,	,	PUNCT
ajcp-1634	16	23	are	be	AUX
ajcp-1634	16	24	known	know	VERB
ajcp-1634	16	25	to	to	PART
ajcp-1634	16	26	cause	cause	VERB
ajcp-1634	16	27	respiratory	respiratory	ADJ
ajcp-1634	16	28	diseases	disease	NOUN
ajcp-1634	16	29	(	(	PUNCT
ajcp-1634	16	30	hasöksüz	hasöksüz	PROPN
ajcp-1634	16	31	et	et	PROPN
ajcp-1634	16	32	al	al	PROPN
ajcp-1634	16	33	.	.	PROPN
ajcp-1634	16	34	,	,	PUNCT
ajcp-1634	16	35	2020	2020	NUM
ajcp-1634	16	36	)	)	PUNCT
ajcp-1634	16	37	.	.	PUNCT
ajcp-1634	17	1	sars	sars	PROPN
ajcp-1634	17	2	-	-	PUNCT
ajcp-1634	17	3	cov	cov	PROPN
ajcp-1634	17	4	and	and	CCONJ
ajcp-1634	17	5	mers	mer	NOUN
ajcp-1634	17	6	-	-	PUNCT
ajcp-1634	17	7	cov	cov	NOUN
ajcp-1634	17	8	variants	variant	NOUN
ajcp-1634	17	9	infect	infect	VERB
ajcp-1634	17	10	the	the	DET
ajcp-1634	17	11	lower	low	ADJ
ajcp-1634	17	12	respiratory	respiratory	ADJ
ajcp-1634	17	13	tract	tract	NOUN
ajcp-1634	17	14	and	and	CCONJ
ajcp-1634	17	15	are	be	AUX
ajcp-1634	17	16	therefore	therefore	ADV
ajcp-1634	17	17	more	more	ADV
ajcp-1634	17	18	harmful	harmful	ADJ
ajcp-1634	17	19	(	(	PUNCT
ajcp-1634	17	20	mcintosh	mcintosh	PROPN
ajcp-1634	17	21	&	&	CCONJ
ajcp-1634	17	22	peiris	peiris	PROPN
ajcp-1634	17	23	,	,	PUNCT
ajcp-1634	17	24	2009	2009	NUM
ajcp-1634	17	25	)	)	PUNCT
ajcp-1634	17	26	;	;	PUNCT
ajcp-1634	17	27	the	the	DET
ajcp-1634	17	28	others	other	NOUN
ajcp-1634	17	29	,	,	PUNCT
ajcp-1634	17	30	on	on	ADP
ajcp-1634	17	31	the	the	DET
ajcp-1634	17	32	other	other	ADJ
ajcp-1634	17	33	hand	hand	NOUN
ajcp-1634	17	34	,	,	PUNCT
ajcp-1634	17	35	infect	infect	VERB
ajcp-1634	17	36	the	the	DET
ajcp-1634	17	37	upper	upper	ADJ
ajcp-1634	17	38	respiratory	respiratory	ADJ
ajcp-1634	17	39	tract	tract	NOUN
ajcp-1634	17	40	but	but	CCONJ
ajcp-1634	17	41	only	only	ADV
ajcp-1634	17	42	in	in	ADP
ajcp-1634	17	43	moderate	moderate	ADJ
ajcp-1634	17	44	cases	case	NOUN
ajcp-1634	17	45	(	(	PUNCT
ajcp-1634	17	46	fehr	fehr	NOUN
ajcp-1634	17	47	et	et	PROPN
ajcp-1634	17	48	al	al	PROPN
ajcp-1634	17	49	.	.	PROPN
ajcp-1634	17	50	,	,	PUNCT
ajcp-1634	17	51	2015	2015	NUM
ajcp-1634	17	52	)	)	PUNCT
ajcp-1634	17	53	.	.	PUNCT
ajcp-1634	18	1	in	in	ADP
ajcp-1634	18	2	december	december	PROPN
ajcp-1634	18	3	2019	2019	NUM
ajcp-1634	18	4	,	,	PUNCT
ajcp-1634	18	5	the	the	DET
ajcp-1634	18	6	globe	globe	NOUN
ajcp-1634	18	7	was	be	AUX
ajcp-1634	18	8	alarmed	alarm	VERB
ajcp-1634	18	9	by	by	ADP
ajcp-1634	18	10	reports	report	NOUN
ajcp-1634	18	11	of	of	ADP
ajcp-1634	18	12	an	an	DET
ajcp-1634	18	13	emergent	emergent	ADJ
ajcp-1634	18	14	illness	illness	NOUN
ajcp-1634	18	15	of	of	ADP
ajcp-1634	18	16	unknown	unknown	ADJ
ajcp-1634	18	17	origin	origin	NOUN
ajcp-1634	18	18	,	,	PUNCT
ajcp-1634	18	19	characterized	characterize	VERB
ajcp-1634	18	20	by	by	ADP
ajcp-1634	18	21	pneumonia	pneumonia	NOUN
ajcp-1634	18	22	,	,	PUNCT
ajcp-1634	18	23	and	and	CCONJ
ajcp-1634	18	24	epidemiologically	epidemiologically	ADV
ajcp-1634	18	25	related	relate	VERB
ajcp-1634	18	26	to	to	ADP
ajcp-1634	18	27	a	a	DET
ajcp-1634	18	28	seafood	seafood	NOUN
ajcp-1634	18	29	market	market	NOUN
ajcp-1634	18	30	in	in	ADP
ajcp-1634	18	31	the	the	DET
ajcp-1634	18	32	chinese	chinese	ADJ
ajcp-1634	18	33	city	city	NOUN
ajcp-1634	18	34	of	of	ADP
ajcp-1634	18	35	wuhan	wuhan	PROPN
ajcp-1634	18	36	(	(	PUNCT
ajcp-1634	18	37	zhu	zhu	X
ajcp-1634	18	38	et	et	PROPN
ajcp-1634	18	39	al	al	PROPN
ajcp-1634	18	40	.	.	PROPN
ajcp-1634	18	41	,	,	PUNCT
ajcp-1634	18	42	2019	2019	NUM
ajcp-1634	18	43	)	)	PUNCT
ajcp-1634	18	44	.	.	PUNCT
ajcp-1634	19	1	a	a	DET
ajcp-1634	19	2	novel	novel	ADJ
ajcp-1634	19	3	coronavirus	coronavirus	NOUN
ajcp-1634	19	4	(	(	PUNCT
ajcp-1634	19	5	sars	sar	NOUN
ajcp-1634	19	6	-	-	PUNCT
ajcp-1634	19	7	cov-2	cov-2	NOUN
ajcp-1634	19	8	)	)	PUNCT
ajcp-1634	19	9	has	have	AUX
ajcp-1634	19	10	been	be	AUX
ajcp-1634	19	11	identified	identify	VERB
ajcp-1634	19	12	as	as	ADP
ajcp-1634	19	13	the	the	DET
ajcp-1634	19	14	source	source	NOUN
ajcp-1634	19	15	of	of	ADP
ajcp-1634	19	16	the	the	DET
ajcp-1634	19	17	acute	acute	ADJ
ajcp-1634	19	18	respiratory	respiratory	ADJ
ajcp-1634	19	19	infection	infection	NOUN
ajcp-1634	19	20	by	by	ADP
ajcp-1634	19	21	employing	employ	VERB
ajcp-1634	19	22	a	a	DET
ajcp-1634	19	23	“	"	PUNCT
ajcp-1634	19	24	pneumonia	pneumonia	NOUN
ajcp-1634	19	25	of	of	ADP
ajcp-1634	19	26	unknown	unknown	ADJ
ajcp-1634	19	27	etiology	etiology	NOUN
ajcp-1634	19	28	”	"	PUNCT
ajcp-1634	19	29	surveillance	surveillance	NOUN
ajcp-1634	19	30	system	system	NOUN
ajcp-1634	19	31	built	build	VERB
ajcp-1634	19	32	in	in	ADP
ajcp-1634	19	33	the	the	DET
ajcp-1634	19	34	aftermath	aftermath	NOUN
ajcp-1634	19	35	of	of	ADP
ajcp-1634	19	36	the	the	DET
ajcp-1634	19	37	2003	2003	NUM
ajcp-1634	19	38	sars	sar	NOUN
ajcp-1634	19	39	outbreak	outbreak	NOUN
ajcp-1634	19	40	to	to	PART
ajcp-1634	19	41	allow	allow	VERB
ajcp-1634	19	42	early	early	ADJ
ajcp-1634	19	43	detection	detection	NOUN
ajcp-1634	19	44	of	of	ADP
ajcp-1634	19	45	new	new	ADJ
ajcp-1634	19	46	infections	infection	NOUN
ajcp-1634	19	47	(	(	PUNCT
ajcp-1634	19	48	li	li	PROPN
ajcp-1634	19	49	et	et	PROPN
ajcp-1634	19	50	al	al	PROPN
ajcp-1634	19	51	.	.	PROPN
ajcp-1634	19	52	,	,	PUNCT
ajcp-1634	19	53	2020a	2020a	NUM
ajcp-1634	19	54	;	;	PUNCT
ajcp-1634	19	55	zhu	zhu	PROPN
ajcp-1634	19	56	et	et	PROPN
ajcp-1634	19	57	al	al	PROPN
ajcp-1634	19	58	.	.	PROPN
ajcp-1634	19	59	,	,	PUNCT
ajcp-1634	19	60	2019	2019	NUM
ajcp-1634	19	61	)	)	PUNCT
ajcp-1634	19	62	.	.	PUNCT
ajcp-1634	20	1	covid-19	covid-19	PROPN
ajcp-1634	20	2	was	be	AUX
ajcp-1634	20	3	declared	declare	VERB
ajcp-1634	20	4	a	a	DET
ajcp-1634	20	5	“	"	PUNCT
ajcp-1634	20	6	public	public	ADJ
ajcp-1634	20	7	health	health	NOUN
ajcp-1634	20	8	emergency	emergency	NOUN
ajcp-1634	20	9	of	of	ADP
ajcp-1634	20	10	international	international	ADJ
ajcp-1634	20	11	concern	concern	NOUN
ajcp-1634	20	12	”	"	PUNCT
ajcp-1634	20	13	(	(	PUNCT
ajcp-1634	20	14	li	li	PROPN
ajcp-1634	20	15	et	et	PROPN
ajcp-1634	20	16	al	al	PROPN
ajcp-1634	20	17	.	.	PROPN
ajcp-1634	20	18	,	,	PUNCT
ajcp-1634	20	19	2020b	2020b	NUM
ajcp-1634	20	20	)	)	PUNCT
ajcp-1634	20	21	by	by	ADP
ajcp-1634	20	22	the	the	DET
ajcp-1634	20	23	world	world	PROPN
ajcp-1634	20	24	health	health	PROPN
ajcp-1634	20	25	organization	organization	NOUN
ajcp-1634	20	26	(	(	PUNCT
ajcp-1634	20	27	who	who	PRON
ajcp-1634	20	28	)	)	PUNCT
ajcp-1634	20	29	on	on	ADP
ajcp-1634	20	30	the	the	DET
ajcp-1634	20	31	30th	30th	NOUN
ajcp-1634	20	32	of	of	ADP
ajcp-1634	20	33	january	january	PROPN
ajcp-1634	20	34	2020	2020	NUM
ajcp-1634	20	35	,	,	PUNCT
ajcp-1634	20	36	and	and	CCONJ
ajcp-1634	20	37	then	then	ADV
ajcp-1634	20	38	a	a	DET
ajcp-1634	20	39	pandemic	pandemic	NOUN
ajcp-1634	20	40	on	on	ADP
ajcp-1634	20	41	the	the	DET
ajcp-1634	20	42	11th	11th	NOUN
ajcp-1634	20	43	of	of	ADP
ajcp-1634	20	44	march	march	PROPN
ajcp-1634	20	45	2020	2020	NUM
ajcp-1634	20	46	.	.	PUNCT
ajcp-1634	21	1	(	(	PUNCT
ajcp-1634	21	2	olson	olson	NOUN
ajcp-1634	21	3	et	et	PROPN
ajcp-1634	21	4	al	al	PROPN
ajcp-1634	21	5	.	.	PROPN
ajcp-1634	21	6	,	,	PUNCT
ajcp-1634	21	7	2020	2020	NUM
ajcp-1634	21	8	)	)	PUNCT
ajcp-1634	21	9	.	.	PUNCT
ajcp-1634	22	1	on	on	ADP
ajcp-1634	22	2	september	september	PROPN
ajcp-1634	22	3	7	7	NUM
ajcp-1634	22	4	,	,	PUNCT
ajcp-1634	22	5	2021	2021	NUM
ajcp-1634	22	6	,	,	PUNCT
ajcp-1634	22	7	it	it	PRON
ajcp-1634	22	8	was	be	AUX
ajcp-1634	22	9	reported	report	VERB
ajcp-1634	22	10	that	that	SCONJ
ajcp-1634	22	11	there	there	PRON
ajcp-1634	22	12	were	be	VERB
ajcp-1634	22	13	220,563,227	220,563,227	NUM
ajcp-1634	22	14	confirmed	confirm	VERB
ajcp-1634	22	15	covid-19	covid-19	PROPN
ajcp-1634	22	16	cases	case	NOUN
ajcp-1634	22	17	and	and	CCONJ
ajcp-1634	22	18	4,565,483	4,565,483	NUM
ajcp-1634	22	19	confirmed	confirm	VERB
ajcp-1634	22	20	deaths	death	NOUN
ajcp-1634	22	21	globally	globally	ADV
ajcp-1634	22	22	(	(	PUNCT
ajcp-1634	22	23	who	who	PRON
ajcp-1634	22	24	,	,	PUNCT
ajcp-1634	22	25	2021	2021	NUM
ajcp-1634	22	26	)	)	PUNCT
ajcp-1634	22	27	.	.	PUNCT
ajcp-1634	23	1	sars	sar	NOUN
ajcp-1634	23	2	-	-	PUNCT
ajcp-1634	23	3	cov-2	cov-2	PART
ajcp-1634	23	4	is	be	AUX
ajcp-1634	23	5	a	a	DET
ajcp-1634	23	6	member	member	NOUN
ajcp-1634	23	7	of	of	ADP
ajcp-1634	23	8	the	the	DET
ajcp-1634	23	9	betacoronavirus	betacoronavirus	NOUN
ajcp-1634	23	10	genus	genus	NOUN
ajcp-1634	23	11	(	(	PUNCT
ajcp-1634	23	12	perlman	perlman	NOUN
ajcp-1634	23	13	&	&	CCONJ
ajcp-1634	23	14	netland	netland	PROPN
ajcp-1634	23	15	,	,	PUNCT
ajcp-1634	23	16	2009	2009	NUM
ajcp-1634	23	17	;	;	PUNCT
ajcp-1634	23	18	schoeman	schoeman	PROPN
ajcp-1634	23	19	&	&	CCONJ
ajcp-1634	23	20	fielding	fielding	PROPN
ajcp-1634	23	21	,	,	PUNCT
ajcp-1634	23	22	2019	2019	NUM
ajcp-1634	23	23	;	;	PUNCT
ajcp-1634	23	24	vlasova	vlasova	NOUN
ajcp-1634	23	25	et	et	PROPN
ajcp-1634	23	26	al	al	PROPN
ajcp-1634	23	27	.	.	PROPN
ajcp-1634	23	28	,	,	PUNCT
ajcp-1634	23	29	2007	2007	NUM
ajcp-1634	23	30	)	)	PUNCT
ajcp-1634	23	31	,	,	PUNCT
ajcp-1634	23	32	which	which	PRON
ajcp-1634	23	33	is	be	AUX
ajcp-1634	23	34	one	one	NUM
ajcp-1634	23	35	of	of	ADP
ajcp-1634	23	36	the	the	DET
ajcp-1634	23	37	genera	genera	NOUN
ajcp-1634	23	38	of	of	ADP
ajcp-1634	23	39	the	the	DET
ajcp-1634	23	40	orthocoronavirinae	orthocoronavirinae	NOUN
ajcp-1634	23	41	subfamily	subfamily	ADV
ajcp-1634	23	42	(	(	PUNCT
ajcp-1634	23	43	hasöksüz	hasöksüz	PROPN
ajcp-1634	23	44	et	et	PROPN
ajcp-1634	23	45	al	al	PROPN
ajcp-1634	23	46	.	.	PROPN
ajcp-1634	23	47	,	,	PUNCT
ajcp-1634	23	48	2020	2020	NUM
ajcp-1634	23	49	)	)	PUNCT
ajcp-1634	23	50	.	.	PUNCT
ajcp-1634	24	1	it	it	PRON
ajcp-1634	24	2	is	be	AUX
ajcp-1634	24	3	quite	quite	ADV
ajcp-1634	24	4	similar	similar	ADJ
ajcp-1634	24	5	to	to	ADP
ajcp-1634	24	6	the	the	DET
ajcp-1634	24	7	sars	sar	NOUN
ajcp-1634	24	8	-	-	PUNCT
ajcp-1634	24	9	cov	cov	NOUN
ajcp-1634	24	10	virus	virus	NOUN
ajcp-1634	24	11	,	,	PUNCT
ajcp-1634	24	12	which	which	PRON
ajcp-1634	24	13	caused	cause	VERB
ajcp-1634	24	14	a	a	DET
ajcp-1634	24	15	worldwide	worldwide	ADJ
ajcp-1634	24	16	epidemic	epidemic	NOUN
ajcp-1634	24	17	in	in	ADP
ajcp-1634	24	18	2003	2003	NUM
ajcp-1634	24	19	.	.	PUNCT
ajcp-1634	25	1	sars	sar	NOUN
ajcp-1634	25	2	-	-	PUNCT
ajcp-1634	25	3	cov-2	cov-2	PART
ajcp-1634	25	4	share	share	VERB
ajcp-1634	25	5	the	the	DET
ajcp-1634	25	6	identical	identical	ADJ
ajcp-1634	25	7	tropism	tropism	NOUN
ajcp-1634	25	8	and	and	CCONJ
ajcp-1634	25	9	mode	mode	NOUN
ajcp-1634	25	10	of	of	ADP
ajcp-1634	25	11	entry	entry	NOUN
ajcp-1634	25	12	as	as	ADP
ajcp-1634	25	13	sars	sar	NOUN
ajcp-1634	25	14	-	-	PUNCT
ajcp-1634	25	15	cov	cov	NOUN
ajcp-1634	25	16	–	–	PUNCT
ajcp-1634	25	17	about	about	ADV
ajcp-1634	25	18	80	80	NUM
ajcp-1634	25	19	percent	percent	NOUN
ajcp-1634	25	20	(	(	PUNCT
ajcp-1634	25	21	zhou	zhou	X
ajcp-1634	25	22	et	et	PROPN
ajcp-1634	25	23	al	al	PROPN
ajcp-1634	25	24	.	.	PROPN
ajcp-1634	25	25	,	,	PUNCT
ajcp-1634	25	26	2020	2020	NUM
ajcp-1634	25	27	)	)	PUNCT
ajcp-1634	25	28	–	–	PUNCT
ajcp-1634	25	29	because	because	SCONJ
ajcp-1634	25	30	they	they	PRON
ajcp-1634	25	31	use	use	VERB
ajcp-1634	25	32	the	the	DET
ajcp-1634	25	33	same	same	ADJ
ajcp-1634	25	34	cellular	cellular	ADJ
ajcp-1634	25	35	receptor	receptor	NOUN
ajcp-1634	25	36	,	,	PUNCT
ajcp-1634	25	37	angiotensin	angiotensin	NOUN
ajcp-1634	25	38	-	-	PUNCT
ajcp-1634	25	39	converting	convert	VERB
ajcp-1634	25	40	enzyme	enzyme	NOUN
ajcp-1634	25	41	2	2	NUM
ajcp-1634	25	42	(	(	PUNCT
ajcp-1634	25	43	ace2	ace2	PROPN
ajcp-1634	25	44	)	)	PUNCT
ajcp-1634	25	45	(	(	PUNCT
ajcp-1634	25	46	yan	yan	X
ajcp-1634	25	47	et	et	PROPN
ajcp-1634	25	48	a.	a.	PROPN
ajcp-1634	25	49	,	,	PUNCT
ajcp-1634	25	50	2020	2020	NUM
ajcp-1634	25	51	)	)	PUNCT
ajcp-1634	25	52	.	.	PUNCT
ajcp-1634	26	1	like	like	ADP
ajcp-1634	26	2	all	all	DET
ajcp-1634	26	3	coronaviruses	coronaviruse	NOUN
ajcp-1634	26	4	,	,	PUNCT
ajcp-1634	26	5	sarscov-2	sarscov-2	NUM
ajcp-1634	26	6	appears	appear	VERB
ajcp-1634	26	7	to	to	PART
ajcp-1634	26	8	have	have	VERB
ajcp-1634	26	9	crowns	crown	NOUN
ajcp-1634	26	10	because	because	SCONJ
ajcp-1634	26	11	of	of	ADP
ajcp-1634	26	12	the	the	DET
ajcp-1634	26	13	s	s	NOUN
ajcp-1634	26	14	proteins	protein	NOUN
ajcp-1634	26	15	that	that	PRON
ajcp-1634	26	16	protrude	protrude	VERB
ajcp-1634	26	17	on	on	ADP
ajcp-1634	26	18	its	its	PRON
ajcp-1634	26	19	surface	surface	NOUN
ajcp-1634	26	20	(	(	PUNCT
ajcp-1634	26	21	zhao	zhao	PROPN
ajcp-1634	26	22	et	et	PROPN
ajcp-1634	26	23	al	al	PROPN
ajcp-1634	26	24	.	.	PROPN
ajcp-1634	26	25	,	,	PUNCT
ajcp-1634	26	26	2021	2021	NUM
ajcp-1634	26	27	)	)	PUNCT
ajcp-1634	26	28	.	.	PUNCT
ajcp-1634	27	1	sarscov-2	sarscov-2	NUM
ajcp-1634	27	2	uses	use	VERB
ajcp-1634	27	3	these	these	DET
ajcp-1634	27	4	highly	highly	ADV
ajcp-1634	27	5	glycosylated	glycosylated	ADJ
ajcp-1634	27	6	spike	spike	NOUN
ajcp-1634	27	7	(	(	PUNCT
ajcp-1634	27	8	s	s	NOUN
ajcp-1634	27	9	)	)	PUNCT
ajcp-1634	27	10	proteins	protein	NOUN
ajcp-1634	27	11	(	(	PUNCT
ajcp-1634	27	12	wrapp	wrapp	X
ajcp-1634	27	13	et	et	PROPN
ajcp-1634	27	14	al	al	PROPN
ajcp-1634	27	15	.	.	PROPN
ajcp-1634	27	16	,	,	PUNCT
ajcp-1634	27	17	2020	2020	NUM
ajcp-1634	27	18	)	)	PUNCT
ajcp-1634	27	19	.	.	PUNCT
ajcp-1634	28	1	the	the	DET
ajcp-1634	28	2	purpose	purpose	NOUN
ajcp-1634	28	3	of	of	ADP
ajcp-1634	28	4	this	this	DET
ajcp-1634	28	5	research	research	NOUN
ajcp-1634	28	6	is	be	AUX
ajcp-1634	28	7	to	to	PART
ajcp-1634	28	8	describe	describe	VERB
ajcp-1634	28	9	how	how	SCONJ
ajcp-1634	28	10	the	the	DET
ajcp-1634	28	11	sars	sar	NOUN
ajcp-1634	28	12	-	-	PUNCT
ajcp-1634	28	13	cov-2	cov-2	NOUN
ajcp-1634	28	14	s	s	PART
ajcp-1634	28	15	protein	protein	NOUN
ajcp-1634	28	16	was	be	AUX
ajcp-1634	28	17	employed	employ	VERB
ajcp-1634	28	18	in	in	ADP
ajcp-1634	28	19	the	the	DET
ajcp-1634	28	20	development	development	NOUN
ajcp-1634	28	21	of	of	ADP
ajcp-1634	28	22	vaccines	vaccine	NOUN
ajcp-1634	28	23	given	give	VERB
ajcp-1634	28	24	its	its	PRON
ajcp-1634	28	25	critical	critical	ADJ
ajcp-1634	28	26	function	function	NOUN
ajcp-1634	28	27	in	in	ADP
ajcp-1634	28	28	receptor	receptor	NOUN
ajcp-1634	28	29	binding	bind	VERB
ajcp-1634	28	30	and	and	CCONJ
ajcp-1634	28	31	membrane	membrane	NOUN
ajcp-1634	28	32	fusion	fusion	NOUN
ajcp-1634	28	33	in	in	ADP
ajcp-1634	28	34	the	the	DET
ajcp-1634	28	35	sars	sar	NOUN
ajcp-1634	28	36	-	-	PUNCT
ajcp-1634	28	37	cov-2	cov-2	PART
ajcp-1634	28	38	virus	virus	NOUN
ajcp-1634	28	39	and	and	CCONJ
ajcp-1634	28	40	discuss	discuss	VERB
ajcp-1634	28	41	the	the	DET
ajcp-1634	28	42	glycosylation	glycosylation	NOUN
ajcp-1634	28	43	of	of	ADP
ajcp-1634	28	44	its	its	PRON
ajcp-1634	28	45	proteins	protein	NOUN
ajcp-1634	28	46	.	.	PUNCT
ajcp-1634	29	1	specifically	specifically	ADV
ajcp-1634	29	2	,	,	PUNCT
ajcp-1634	29	3	this	this	DET
ajcp-1634	29	4	paper	paper	NOUN
ajcp-1634	29	5	compared	compare	VERB
ajcp-1634	29	6	each	each	DET
ajcp-1634	29	7	approach	approach	NOUN
ajcp-1634	29	8	on	on	ADP
ajcp-1634	29	9	which	which	PRON
ajcp-1634	29	10	s	s	VERB
ajcp-1634	29	11	protein	protein	NOUN
ajcp-1634	29	12	is	be	AUX
ajcp-1634	29	13	given	give	VERB
ajcp-1634	29	14	focus	focus	NOUN
ajcp-1634	29	15	in	in	ADP
ajcp-1634	29	16	vaccine	vaccine	NOUN
ajcp-1634	29	17	development	development	NOUN
ajcp-1634	29	18	.	.	PUNCT
ajcp-1634	30	1	by	by	ADP
ajcp-1634	30	2	doing	do	VERB
ajcp-1634	30	3	so	so	ADV
ajcp-1634	30	4	,	,	PUNCT
ajcp-1634	30	5	this	this	DET
ajcp-1634	30	6	paper	paper	NOUN
ajcp-1634	30	7	can	can	AUX
ajcp-1634	30	8	yield	yield	VERB
ajcp-1634	30	9	implications	implication	NOUN
ajcp-1634	30	10	for	for	ADP
ajcp-1634	30	11	future	future	ADJ
ajcp-1634	30	12	studies	study	NOUN
ajcp-1634	30	13	.	.	PUNCT
ajcp-1634	31	1	literature	literature	NOUN
ajcp-1634	31	2	review	review	PROPN
ajcp-1634	31	3	structure	structure	NOUN
ajcp-1634	31	4	the	the	DET
ajcp-1634	31	5	s	s	NOUN
ajcp-1634	31	6	protein	protein	NOUN
ajcp-1634	31	7	is	be	AUX
ajcp-1634	31	8	a	a	DET
ajcp-1634	31	9	class	class	NOUN
ajcp-1634	31	10	i	i	PRON
ajcp-1634	31	11	fusion	fusion	NOUN
ajcp-1634	31	12	protein	protein	NOUN
ajcp-1634	31	13	that	that	PRON
ajcp-1634	31	14	helps	help	VERB
ajcp-1634	31	15	the	the	DET
ajcp-1634	31	16	virus	virus	NOUN
ajcp-1634	31	17	connect	connect	VERB
ajcp-1634	31	18	to	to	ADP
ajcp-1634	31	19	the	the	DET
ajcp-1634	31	20	angiotensin	angiotensin	NOUN
ajcp-1634	31	21	-	-	PUNCT
ajcp-1634	31	22	converting	convert	VERB
ajcp-1634	31	23	enzyme	enzyme	NOUN
ajcp-1634	31	24	2	2	NUM
ajcp-1634	31	25	https://doi.org/10.54536/ajcp.v2i2.1634	https://doi.org/10.54536/ajcp.v2i2.1634	NOUN
ajcp-1634	31	26	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	31	27	mailto	mailto	NOUN
ajcp-1634	31	28	:	:	PUNCT
ajcp-1634	31	29	leonel.mendoza%40minsu.edu.ph?subject=	leonel.mendoza%40minsu.edu.ph?subject=	ADJ
ajcp-1634	31	30	pa	pa	PROPN
ajcp-1634	31	31	ge	ge	PROPN
ajcp-1634	31	32	67	67	NUM
ajcp-1634	31	33	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	31	34	am	be	AUX
ajcp-1634	31	35	.	.	PUNCT
ajcp-1634	32	1	j.	j.	PROPN
ajcp-1634	32	2	chem	chem	PROPN
ajcp-1634	32	3	.	.	PUNCT
ajcp-1634	33	1	pharm	pharm	PROPN
ajcp-1634	33	2	.	.	PUNCT
ajcp-1634	34	1	2(2	2(2	NUM
ajcp-1634	34	2	)	)	PUNCT
ajcp-1634	35	1	66	66	NUM
ajcp-1634	35	2	-	-	SYM
ajcp-1634	35	3	73	73	NUM
ajcp-1634	35	4	,	,	PUNCT
ajcp-1634	35	5	2023	2023	NUM
ajcp-1634	35	6	(	(	PUNCT
ajcp-1634	35	7	ace2	ace2	NOUN
ajcp-1634	35	8	)	)	PUNCT
ajcp-1634	35	9	receptor	receptor	NOUN
ajcp-1634	35	10	on	on	ADP
ajcp-1634	35	11	the	the	DET
ajcp-1634	35	12	host	host	NOUN
ajcp-1634	35	13	cell	cell	NOUN
ajcp-1634	35	14	surface	surface	NOUN
ajcp-1634	35	15	,	,	PUNCT
ajcp-1634	35	16	causing	cause	VERB
ajcp-1634	35	17	the	the	DET
ajcp-1634	35	18	virus	virus	NOUN
ajcp-1634	35	19	and	and	CCONJ
ajcp-1634	35	20	cell	cell	NOUN
ajcp-1634	35	21	membrane	membrane	NOUN
ajcp-1634	35	22	to	to	ADP
ajcp-1634	35	23	fuse	fuse	NOUN
ajcp-1634	35	24	(	(	PUNCT
ajcp-1634	35	25	pardi	pardi	PROPN
ajcp-1634	35	26	et	et	PROPN
ajcp-1634	35	27	al	al	PROPN
ajcp-1634	35	28	.	.	PROPN
ajcp-1634	35	29	,	,	PUNCT
ajcp-1634	35	30	2015	2015	NUM
ajcp-1634	35	31	;	;	PUNCT
ajcp-1634	35	32	hoffman	hoffman	PROPN
ajcp-1634	35	33	et	et	PROPN
ajcp-1634	35	34	al	al	PROPN
ajcp-1634	35	35	.	.	PROPN
ajcp-1634	35	36	,	,	PUNCT
ajcp-1634	35	37	2020	2020	NUM
ajcp-1634	35	38	;	;	PUNCT
ajcp-1634	35	39	rauch	rauch	PROPN
ajcp-1634	35	40	et	et	PROPN
ajcp-1634	35	41	al	al	PROPN
ajcp-1634	35	42	.	.	PROPN
ajcp-1634	35	43	,	,	PUNCT
ajcp-1634	35	44	2018	2018	NUM
ajcp-1634	35	45	)	)	PUNCT
ajcp-1634	35	46	.	.	PUNCT
ajcp-1634	36	1	the	the	DET
ajcp-1634	36	2	overall	overall	ADJ
ajcp-1634	36	3	length	length	NOUN
ajcp-1634	36	4	of	of	ADP
ajcp-1634	36	5	s	s	NOUN
ajcp-1634	36	6	protein	protein	NOUN
ajcp-1634	36	7	in	in	ADP
ajcp-1634	36	8	sars	sar	NOUN
ajcp-1634	36	9	-	-	PUNCT
ajcp-1634	36	10	cov-2	cov-2	NUM
ajcp-1634	36	11	is	be	AUX
ajcp-1634	36	12	1,273	1,273	NUM
ajcp-1634	36	13	amino	amino	ADJ
ajcp-1634	36	14	acids	acid	NOUN
ajcp-1634	36	15	,	,	PUNCT
ajcp-1634	36	16	including	include	VERB
ajcp-1634	36	17	a	a	DET
ajcp-1634	36	18	signal	signal	ADJ
ajcp-1634	36	19	peptide	peptide	NOUN
ajcp-1634	36	20	at	at	ADP
ajcp-1634	36	21	the	the	DET
ajcp-1634	36	22	n	n	CCONJ
ajcp-1634	36	23	-	-	PUNCT
ajcp-1634	36	24	terminus	terminus	NOUN
ajcp-1634	36	25	(	(	PUNCT
ajcp-1634	36	26	zhao	zhao	PROPN
ajcp-1634	36	27	et	et	PROPN
ajcp-1634	36	28	al	al	PROPN
ajcp-1634	36	29	.	.	PROPN
ajcp-1634	36	30	,	,	PUNCT
ajcp-1634	36	31	2021	2021	NUM
ajcp-1634	36	32	)	)	PUNCT
ajcp-1634	36	33	.	.	PUNCT
ajcp-1634	37	1	two	two	NUM
ajcp-1634	37	2	subunits	subunit	NOUN
ajcp-1634	37	3	,	,	PUNCT
ajcp-1634	37	4	namely	namely	ADV
ajcp-1634	37	5	,	,	PUNCT
ajcp-1634	37	6	s1	s1	NOUN
ajcp-1634	37	7	and	and	CCONJ
ajcp-1634	37	8	s2	s2	PROPN
ajcp-1634	37	9	,	,	PUNCT
ajcp-1634	37	10	composed	compose	VERB
ajcp-1634	37	11	the	the	DET
ajcp-1634	37	12	s	s	NOUN
ajcp-1634	37	13	protein	protein	NOUN
ajcp-1634	37	14	of	of	ADP
ajcp-1634	37	15	sars	sar	NOUN
ajcp-1634	37	16	-	-	PUNCT
ajcp-1634	37	17	cov-2	cov-2	NOUN
ajcp-1634	37	18	.	.	PUNCT
ajcp-1634	38	1	these	these	DET
ajcp-1634	38	2	subunits	subunit	NOUN
ajcp-1634	38	3	are	be	AUX
ajcp-1634	38	4	cleaved	cleave	VERB
ajcp-1634	38	5	from	from	ADP
ajcp-1634	38	6	a	a	DET
ajcp-1634	38	7	furin	furin	NOUN
ajcp-1634	38	8	site	site	NOUN
ajcp-1634	38	9	in	in	ADP
ajcp-1634	38	10	the	the	DET
ajcp-1634	38	11	virus	virus	NOUN
ajcp-1634	38	12	’	'	PUNCT
ajcp-1634	38	13	s	s	PART
ajcp-1634	38	14	protein	protein	NOUN
ajcp-1634	38	15	,	,	PUNCT
ajcp-1634	38	16	containing	contain	VERB
ajcp-1634	38	17	multiple	multiple	ADJ
ajcp-1634	38	18	essential	essential	ADJ
ajcp-1634	38	19	amino	amino	NOUN
ajcp-1634	38	20	acids	acid	NOUN
ajcp-1634	38	21	.	.	PUNCT
ajcp-1634	39	1	the	the	DET
ajcp-1634	39	2	s1	s1	PROPN
ajcp-1634	39	3	subunit	subunit	NOUN
ajcp-1634	39	4	is	be	AUX
ajcp-1634	39	5	apical	apical	ADJ
ajcp-1634	39	6	v	v	ADV
ajcp-1634	39	7	-	-	PUNCT
ajcp-1634	39	8	shaped	shape	VERB
ajcp-1634	39	9	and	and	CCONJ
ajcp-1634	39	10	harbors	harbor	VERB
ajcp-1634	39	11	one	one	NUM
ajcp-1634	39	12	ace2	ace2	NOUN
ajcp-1634	39	13	-	-	PUNCT
ajcp-1634	39	14	recognition	recognition	NOUN
ajcp-1634	39	15	motif	motif	NOUN
ajcp-1634	39	16	per	per	ADP
ajcp-1634	39	17	monomer	monomer	NOUN
ajcp-1634	39	18	,	,	PUNCT
ajcp-1634	39	19	the	the	DET
ajcp-1634	39	20	receptorbinding	receptorbinde	VERB
ajcp-1634	39	21	domain	domain	NOUN
ajcp-1634	39	22	(	(	PUNCT
ajcp-1634	39	23	rbd	rbd	NOUN
ajcp-1634	39	24	)	)	PUNCT
ajcp-1634	39	25	(	(	PUNCT
ajcp-1634	39	26	sterberg	sterberg	PROPN
ajcp-1634	39	27	&	&	CCONJ
ajcp-1634	39	28	naujokat	naujokat	PROPN
ajcp-1634	39	29	,	,	PUNCT
ajcp-1634	39	30	2020	2020	NUM
ajcp-1634	39	31	)	)	PUNCT
ajcp-1634	39	32	.	.	PUNCT
ajcp-1634	40	1	sars	sar	NOUN
ajcp-1634	40	2	-	-	PUNCT
ajcp-1634	40	3	cov-2	cov-2	NOUN
ajcp-1634	40	4	uses	use	VERB
ajcp-1634	40	5	a	a	DET
ajcp-1634	40	6	spike	spike	ADJ
ajcp-1634	40	7	(	(	PUNCT
ajcp-1634	40	8	s	s	NOUN
ajcp-1634	40	9	)	)	PUNCT
ajcp-1634	40	10	protein	protein	NOUN
ajcp-1634	40	11	that	that	PRON
ajcp-1634	40	12	is	be	AUX
ajcp-1634	40	13	highly	highly	ADV
ajcp-1634	40	14	glycosylated	glycosylated	ADJ
ajcp-1634	40	15	to	to	PART
ajcp-1634	40	16	gain	gain	VERB
ajcp-1634	40	17	entry	entry	NOUN
ajcp-1634	40	18	to	to	ADP
ajcp-1634	40	19	host	host	NOUN
ajcp-1634	40	20	cells	cell	NOUN
ajcp-1634	40	21	,	,	PUNCT
ajcp-1634	40	22	as	as	SCONJ
ajcp-1634	40	23	previously	previously	ADV
ajcp-1634	40	24	stated	state	VERB
ajcp-1634	40	25	(	(	PUNCT
ajcp-1634	40	26	wrapp	wrapp	PROPN
ajcp-1634	40	27	et	et	PROPN
ajcp-1634	40	28	al	al	PROPN
ajcp-1634	40	29	.	.	PROPN
ajcp-1634	40	30	,	,	PUNCT
ajcp-1634	40	31	2020	2020	NUM
ajcp-1634	40	32	)	)	PUNCT
ajcp-1634	40	33	.	.	PUNCT
ajcp-1634	41	1	the	the	DET
ajcp-1634	41	2	s	s	NOUN
ajcp-1634	41	3	protein	protein	NOUN
ajcp-1634	41	4	is	be	AUX
ajcp-1634	41	5	glycosylated	glycosylate	VERB
ajcp-1634	41	6	through	through	ADP
ajcp-1634	41	7	the	the	DET
ajcp-1634	41	8	secretory	secretory	ADJ
ajcp-1634	41	9	pathway	pathway	NOUN
ajcp-1634	41	10	and	and	CCONJ
ajcp-1634	41	11	is	be	AUX
ajcp-1634	41	12	glycosylated	glycosylate	VERB
ajcp-1634	41	13	by	by	ADP
ajcp-1634	41	14	the	the	DET
ajcp-1634	41	15	host	host	NOUN
ajcp-1634	41	16	cellular	cellular	ADJ
ajcp-1634	41	17	glycosylation	glycosylation	NOUN
ajcp-1634	41	18	mechanism	mechanism	NOUN
ajcp-1634	41	19	(	(	PUNCT
ajcp-1634	41	20	zhao	zhao	PROPN
ajcp-1634	41	21	et	et	PROPN
ajcp-1634	41	22	al	al	PROPN
ajcp-1634	41	23	.	.	PROPN
ajcp-1634	41	24	,	,	PUNCT
ajcp-1634	41	25	2021	2021	NUM
ajcp-1634	41	26	)	)	PUNCT
ajcp-1634	41	27	.	.	PUNCT
ajcp-1634	42	1	with	with	ADP
ajcp-1634	42	2	this	this	DET
ajcp-1634	42	3	process	process	NOUN
ajcp-1634	42	4	comes	come	VERB
ajcp-1634	42	5	two	two	NUM
ajcp-1634	42	6	benefits	benefit	NOUN
ajcp-1634	42	7	for	for	ADP
ajcp-1634	42	8	the	the	DET
ajcp-1634	42	9	virus	virus	NOUN
ajcp-1634	42	10	itself	itself	PRON
ajcp-1634	42	11	.	.	PUNCT
ajcp-1634	43	1	to	to	PART
ajcp-1634	43	2	begin	begin	VERB
ajcp-1634	43	3	with	with	ADP
ajcp-1634	43	4	,	,	PUNCT
ajcp-1634	43	5	the	the	DET
ajcp-1634	43	6	mannose	mannose	NOUN
ajcp-1634	43	7	residues	residue	NOUN
ajcp-1634	43	8	within	within	ADP
ajcp-1634	43	9	these	these	DET
ajcp-1634	43	10	glycans	glycan	NOUN
ajcp-1634	43	11	are	be	AUX
ajcp-1634	43	12	crucial	crucial	ADJ
ajcp-1634	43	13	components	component	NOUN
ajcp-1634	43	14	in	in	ADP
ajcp-1634	43	15	interacting	interact	VERB
ajcp-1634	43	16	with	with	ADP
ajcp-1634	43	17	cell	cell	NOUN
ajcp-1634	43	18	surface	surface	NOUN
ajcp-1634	43	19	attachment	attachment	NOUN
ajcp-1634	43	20	proteins	protein	NOUN
ajcp-1634	43	21	(	(	PUNCT
ajcp-1634	43	22	li	li	PROPN
ajcp-1634	43	23	et	et	PROPN
ajcp-1634	43	24	al	al	PROPN
ajcp-1634	43	25	.	.	PROPN
ajcp-1634	43	26	,	,	PUNCT
ajcp-1634	43	27	2017	2017	NUM
ajcp-1634	43	28	;	;	PUNCT
ajcp-1634	43	29	tortorici	tortorici	PROPN
ajcp-1634	43	30	et	et	PROPN
ajcp-1634	43	31	al	al	PROPN
ajcp-1634	43	32	.	.	PROPN
ajcp-1634	43	33	,	,	PUNCT
ajcp-1634	43	34	2019	2019	NUM
ajcp-1634	43	35	;	;	PUNCT
ajcp-1634	43	36	robson	robson	NOUN
ajcp-1634	43	37	,	,	PUNCT
ajcp-1634	43	38	2020	2020	NUM
ajcp-1634	43	39	)	)	PUNCT
ajcp-1634	43	40	before	before	ADP
ajcp-1634	43	41	attaching	attach	VERB
ajcp-1634	43	42	to	to	ADP
ajcp-1634	43	43	ace2	ace2	PROPN
ajcp-1634	43	44	.	.	PUNCT
ajcp-1634	44	1	second	second	ADJ
ajcp-1634	44	2	,	,	PUNCT
ajcp-1634	44	3	it	it	PRON
ajcp-1634	44	4	helps	help	VERB
ajcp-1634	44	5	protect	protect	VERB
ajcp-1634	44	6	the	the	DET
ajcp-1634	44	7	virus	virus	NOUN
ajcp-1634	44	8	from	from	ADP
ajcp-1634	44	9	host	host	NOUN
ajcp-1634	44	10	antibodies	antibody	NOUN
ajcp-1634	44	11	by	by	ADP
ajcp-1634	44	12	hiding	hide	VERB
ajcp-1634	44	13	the	the	DET
ajcp-1634	44	14	underlying	underlie	VERB
ajcp-1634	44	15	polypeptide	polypeptide	ADJ
ajcp-1634	44	16	epitopes	epitope	NOUN
ajcp-1634	44	17	(	(	PUNCT
ajcp-1634	44	18	doores	doore	NOUN
ajcp-1634	44	19	,	,	PUNCT
ajcp-1634	44	20	2015	2015	NUM
ajcp-1634	44	21	;	;	PUNCT
ajcp-1634	44	22	bagdonaite	bagdonaite	PROPN
ajcp-1634	44	23	&	&	CCONJ
ajcp-1634	44	24	wandall	wandall	PROPN
ajcp-1634	44	25	,	,	PUNCT
ajcp-1634	44	26	2018	2018	NUM
ajcp-1634	44	27	)	)	PUNCT
ajcp-1634	44	28	.	.	PUNCT
ajcp-1634	45	1	function	function	NOUN
ajcp-1634	45	2	as	as	SCONJ
ajcp-1634	45	3	mentioned	mention	VERB
ajcp-1634	45	4	,	,	PUNCT
ajcp-1634	45	5	the	the	DET
ajcp-1634	45	6	s	s	NOUN
ajcp-1634	45	7	protein	protein	NOUN
ajcp-1634	45	8	in	in	ADP
ajcp-1634	45	9	sars	sar	NOUN
ajcp-1634	45	10	-	-	PUNCT
ajcp-1634	45	11	cov-2	cov-2	NOUN
ajcp-1634	45	12	is	be	AUX
ajcp-1634	45	13	responsible	responsible	ADJ
ajcp-1634	45	14	for	for	ADP
ajcp-1634	45	15	receptor	receptor	NOUN
ajcp-1634	45	16	identification	identification	NOUN
ajcp-1634	45	17	and	and	CCONJ
ajcp-1634	45	18	membrane	membrane	NOUN
ajcp-1634	45	19	fusion	fusion	NOUN
ajcp-1634	45	20	(	(	PUNCT
ajcp-1634	45	21	gallagher	gallagher	PROPN
ajcp-1634	45	22	&	&	CCONJ
ajcp-1634	45	23	buchmeier	buchmeier	PROPN
ajcp-1634	45	24	,	,	PUNCT
ajcp-1634	45	25	2001	2001	NUM
ajcp-1634	45	26	)	)	PUNCT
ajcp-1634	45	27	,	,	PUNCT
ajcp-1634	45	28	which	which	PRON
ajcp-1634	45	29	are	be	AUX
ajcp-1634	45	30	carried	carry	VERB
ajcp-1634	45	31	out	out	ADP
ajcp-1634	45	32	by	by	ADP
ajcp-1634	45	33	functional	functional	ADJ
ajcp-1634	45	34	domains	domain	NOUN
ajcp-1634	45	35	near	near	ADP
ajcp-1634	45	36	the	the	DET
ajcp-1634	45	37	s1	s1	PROPN
ajcp-1634	45	38	and	and	CCONJ
ajcp-1634	45	39	s2	s2	PROPN
ajcp-1634	45	40	termini	termini	NOUN
ajcp-1634	45	41	(	(	PUNCT
ajcp-1634	45	42	hasöksüz	hasöksüz	PROPN
ajcp-1634	45	43	et	et	PROPN
ajcp-1634	45	44	al	al	PROPN
ajcp-1634	45	45	.	.	PROPN
ajcp-1634	45	46	,	,	PUNCT
ajcp-1634	45	47	2020	2020	NUM
ajcp-1634	45	48	)	)	PUNCT
ajcp-1634	45	49	.	.	PUNCT
ajcp-1634	46	1	the	the	DET
ajcp-1634	46	2	s2	s2	NOUN
ajcp-1634	46	3	subunit	subunit	NOUN
ajcp-1634	46	4	is	be	AUX
ajcp-1634	46	5	in	in	ADP
ajcp-1634	46	6	charge	charge	NOUN
ajcp-1634	46	7	of	of	ADP
ajcp-1634	46	8	transmembrane	transmembrane	ADJ
ajcp-1634	46	9	fusion	fusion	NOUN
ajcp-1634	46	10	,	,	PUNCT
ajcp-1634	46	11	whereas	whereas	SCONJ
ajcp-1634	46	12	the	the	DET
ajcp-1634	46	13	s1	s1	NOUN
ajcp-1634	46	14	subunit	subunit	NOUN
ajcp-1634	46	15	controls	control	VERB
ajcp-1634	46	16	receptor	receptor	NOUN
ajcp-1634	46	17	binding	bind	VERB
ajcp-1634	46	18	(	(	PUNCT
ajcp-1634	46	19	chen	chen	PROPN
ajcp-1634	46	20	&	&	CCONJ
ajcp-1634	46	21	guo	guo	PROPN
ajcp-1634	46	22	,	,	PUNCT
ajcp-1634	46	23	2020	2020	NUM
ajcp-1634	46	24	;	;	PUNCT
ajcp-1634	46	25	hasoksuz	hasoksuz	X
ajcp-1634	46	26	et	et	PROPN
ajcp-1634	46	27	al	al	PROPN
ajcp-1634	46	28	.	.	PROPN
ajcp-1634	46	29	,	,	PUNCT
ajcp-1634	46	30	2002	2002	NUM
ajcp-1634	46	31	)	)	PUNCT
ajcp-1634	46	32	.	.	PUNCT
ajcp-1634	47	1	the	the	DET
ajcp-1634	47	2	trimeric	trimeric	PROPN
ajcp-1634	47	3	s	s	PART
ajcp-1634	47	4	protein	protein	NOUN
ajcp-1634	47	5	is	be	AUX
ajcp-1634	47	6	cleaved	cleave	VERB
ajcp-1634	47	7	into	into	ADP
ajcp-1634	47	8	s1	s1	NOUN
ajcp-1634	47	9	and	and	CCONJ
ajcp-1634	47	10	s2	s2	NOUN
ajcp-1634	47	11	subunits	subunit	NOUN
ajcp-1634	47	12	after	after	ADP
ajcp-1634	47	13	viral	viral	ADJ
ajcp-1634	47	14	infection	infection	NOUN
ajcp-1634	47	15	and	and	CCONJ
ajcp-1634	47	16	s1	s1	NOUN
ajcp-1634	47	17	subunits	subunit	NOUN
ajcp-1634	47	18	are	be	AUX
ajcp-1634	47	19	released	release	VERB
ajcp-1634	47	20	during	during	ADP
ajcp-1634	47	21	the	the	DET
ajcp-1634	47	22	transition	transition	NOUN
ajcp-1634	47	23	to	to	ADP
ajcp-1634	47	24	the	the	DET
ajcp-1634	47	25	postfusion	postfusion	NOUN
ajcp-1634	47	26	conformation	conformation	NOUN
ajcp-1634	47	27	(	(	PUNCT
ajcp-1634	47	28	song	song	NOUN
ajcp-1634	47	29	et	et	PROPN
ajcp-1634	47	30	al	al	PROPN
ajcp-1634	47	31	.	.	PROPN
ajcp-1634	47	32	,	,	PUNCT
ajcp-1634	47	33	2018	2018	NUM
ajcp-1634	47	34	;	;	PUNCT
ajcp-1634	47	35	simmons	simmon	NOUN
ajcp-1634	47	36	et	et	PROPN
ajcp-1634	47	37	al	al	PROPN
ajcp-1634	47	38	.	.	PROPN
ajcp-1634	47	39	,	,	PUNCT
ajcp-1634	47	40	2013	2013	NUM
ajcp-1634	47	41	;	;	PUNCT
ajcp-1634	47	42	belouzard	belouzard	NOUN
ajcp-1634	47	43	et	et	PROPN
ajcp-1634	47	44	al	al	PROPN
ajcp-1634	47	45	.	.	PROPN
ajcp-1634	47	46	,	,	PUNCT
ajcp-1634	47	47	2009	2009	NUM
ajcp-1634	47	48	;	;	PUNCT
ajcp-1634	47	49	simmons	simmon	NOUN
ajcp-1634	47	50	et	et	PROPN
ajcp-1634	47	51	al	al	PROPN
ajcp-1634	47	52	.	.	PROPN
ajcp-1634	47	53	,	,	PUNCT
ajcp-1634	47	54	2004	2004	NUM
ajcp-1634	47	55	)	)	PUNCT
ajcp-1634	47	56	.	.	PUNCT
ajcp-1634	48	1	because	because	SCONJ
ajcp-1634	48	2	it	it	PRON
ajcp-1634	48	3	contains	contain	VERB
ajcp-1634	48	4	the	the	DET
ajcp-1634	48	5	receptor	receptor	NOUN
ajcp-1634	48	6	-	-	PUNCT
ajcp-1634	48	7	binding	bind	VERB
ajcp-1634	48	8	domain	domain	NOUN
ajcp-1634	48	9	(	(	PUNCT
ajcp-1634	48	10	rbd	rbd	NOUN
ajcp-1634	48	11	)	)	PUNCT
ajcp-1634	48	12	,	,	PUNCT
ajcp-1634	48	13	which	which	PRON
ajcp-1634	48	14	directly	directly	ADV
ajcp-1634	48	15	connects	connect	VERB
ajcp-1634	48	16	with	with	ADP
ajcp-1634	48	17	ace2	ace2	NOUN
ajcp-1634	48	18	,	,	PUNCT
ajcp-1634	48	19	a	a	DET
ajcp-1634	48	20	peptidase	peptidase	NOUN
ajcp-1634	48	21	domain	domain	NOUN
ajcp-1634	48	22	,	,	PUNCT
ajcp-1634	48	23	the	the	DET
ajcp-1634	48	24	s1	s1	NOUN
ajcp-1634	48	25	subunit	subunit	NOUN
ajcp-1634	48	26	can	can	AUX
ajcp-1634	48	27	bind	bind	VERB
ajcp-1634	48	28	to	to	ADP
ajcp-1634	48	29	receptors	receptor	NOUN
ajcp-1634	48	30	(	(	PUNCT
ajcp-1634	48	31	li	li	PROPN
ajcp-1634	48	32	et	et	PROPN
ajcp-1634	48	33	al	al	PROPN
ajcp-1634	48	34	.	.	PROPN
ajcp-1634	48	35	,	,	PUNCT
ajcp-1634	48	36	2005	2005	NUM
ajcp-1634	48	37	)	)	PUNCT
ajcp-1634	48	38	.	.	PUNCT
ajcp-1634	49	1	to	to	PART
ajcp-1634	49	2	engage	engage	VERB
ajcp-1634	49	3	a	a	DET
ajcp-1634	49	4	host	host	NOUN
ajcp-1634	49	5	cell	cell	NOUN
ajcp-1634	49	6	receptor	receptor	NOUN
ajcp-1634	49	7	,	,	PUNCT
ajcp-1634	49	8	s1	s1	NOUN
ajcp-1634	49	9	’s	’s	PART
ajcp-1634	49	10	receptor	receptor	NOUN
ajcp-1634	49	11	-	-	PUNCT
ajcp-1634	49	12	binding	bind	VERB
ajcp-1634	49	13	domain	domain	NOUN
ajcp-1634	49	14	(	(	PUNCT
ajcp-1634	49	15	rbd	rbd	NOUN
ajcp-1634	49	16	)	)	PUNCT
ajcp-1634	49	17	undergoes	undergo	VERB
ajcp-1634	49	18	hinge	hinge	ADJ
ajcp-1634	49	19	-	-	PUNCT
ajcp-1634	49	20	like	like	ADJ
ajcp-1634	49	21	conformational	conformational	ADJ
ajcp-1634	49	22	movements	movement	NOUN
ajcp-1634	49	23	,	,	PUNCT
ajcp-1634	49	24	briefly	briefly	ADV
ajcp-1634	49	25	hiding	hide	VERB
ajcp-1634	49	26	or	or	CCONJ
ajcp-1634	49	27	exposing	expose	VERB
ajcp-1634	49	28	the	the	DET
ajcp-1634	49	29	receptor	receptor	NOUN
ajcp-1634	49	30	binding	bind	VERB
ajcp-1634	49	31	determinants	determinant	NOUN
ajcp-1634	49	32	(	(	PUNCT
ajcp-1634	49	33	wrapp	wrapp	X
ajcp-1634	49	34	et	et	PROPN
ajcp-1634	49	35	al	al	PROPN
ajcp-1634	49	36	.	.	PROPN
ajcp-1634	49	37	,	,	PUNCT
ajcp-1634	49	38	2020	2020	NUM
ajcp-1634	49	39	)	)	PUNCT
ajcp-1634	49	40	.	.	PUNCT
ajcp-1634	50	1	when	when	SCONJ
ajcp-1634	50	2	s1	s1	NOUN
ajcp-1634	50	3	connects	connect	VERB
ajcp-1634	50	4	to	to	ADP
ajcp-1634	50	5	the	the	DET
ajcp-1634	50	6	ace2	ace2	NOUN
ajcp-1634	50	7	receptor	receptor	NOUN
ajcp-1634	50	8	on	on	ADP
ajcp-1634	50	9	the	the	DET
ajcp-1634	50	10	host	host	NOUN
ajcp-1634	50	11	,	,	PUNCT
ajcp-1634	50	12	another	another	DET
ajcp-1634	50	13	cleavage	cleavage	NOUN
ajcp-1634	50	14	site	site	NOUN
ajcp-1634	50	15	on	on	ADP
ajcp-1634	50	16	s2	s2	PROPN
ajcp-1634	50	17	is	be	AUX
ajcp-1634	50	18	revealed	reveal	VERB
ajcp-1634	50	19	and	and	CCONJ
ajcp-1634	50	20	cleaved	cleave	VERB
ajcp-1634	50	21	by	by	ADP
ajcp-1634	50	22	host	host	NOUN
ajcp-1634	50	23	proteases	protease	NOUN
ajcp-1634	50	24	,	,	PUNCT
ajcp-1634	50	25	a	a	DET
ajcp-1634	50	26	step	step	NOUN
ajcp-1634	50	27	that	that	PRON
ajcp-1634	50	28	is	be	AUX
ajcp-1634	50	29	essential	essential	ADJ
ajcp-1634	50	30	for	for	ADP
ajcp-1634	50	31	viral	viral	ADJ
ajcp-1634	50	32	infection	infection	NOUN
ajcp-1634	50	33	(	(	PUNCT
ajcp-1634	50	34	belouzard	belouzard	NOUN
ajcp-1634	50	35	et	et	PROPN
ajcp-1634	50	36	al	al	PROPN
ajcp-1634	50	37	.	.	PROPN
ajcp-1634	50	38	,	,	PUNCT
ajcp-1634	50	39	2009	2009	NUM
ajcp-1634	50	40	;	;	PUNCT
ajcp-1634	50	41	millet	millet	PROPN
ajcp-1634	50	42	&	&	CCONJ
ajcp-1634	50	43	whittaker	whittaker	PROPN
ajcp-1634	50	44	,	,	PUNCT
ajcp-1634	50	45	2015	2015	NUM
ajcp-1634	50	46	;	;	PUNCT
ajcp-1634	50	47	simmons	simmon	NOUN
ajcp-1634	50	48	et	et	PROPN
ajcp-1634	50	49	al	al	PROPN
ajcp-1634	50	50	.	.	PROPN
ajcp-1634	50	51	,	,	PUNCT
ajcp-1634	50	52	2005	2005	NUM
ajcp-1634	50	53	)	)	PUNCT
ajcp-1634	50	54	.	.	PUNCT
ajcp-1634	51	1	the	the	DET
ajcp-1634	51	2	polybasic	polybasic	ADJ
ajcp-1634	51	3	cleavage	cleavage	NOUN
ajcp-1634	51	4	site	site	NOUN
ajcp-1634	51	5	of	of	ADP
ajcp-1634	51	6	s	s	PRON
ajcp-1634	51	7	may	may	AUX
ajcp-1634	51	8	contribute	contribute	VERB
ajcp-1634	51	9	to	to	ADP
ajcp-1634	51	10	sars	sar	NOUN
ajcp-1634	51	11	-	-	PUNCT
ajcp-1634	51	12	cov-2	cov-2	NOUN
ajcp-1634	51	13	’s	’s	ADJ
ajcp-1634	51	14	high	high	ADJ
ajcp-1634	51	15	virulence	virulence	NOUN
ajcp-1634	51	16	,	,	PUNCT
ajcp-1634	51	17	as	as	SCONJ
ajcp-1634	51	18	furin	furin	NOUN
ajcp-1634	51	19	and	and	CCONJ
ajcp-1634	51	20	furin	furin	NOUN
ajcp-1634	51	21	-	-	PUNCT
ajcp-1634	51	22	like	like	ADJ
ajcp-1634	51	23	proteases	protease	NOUN
ajcp-1634	51	24	,	,	PUNCT
ajcp-1634	51	25	which	which	PRON
ajcp-1634	51	26	are	be	AUX
ajcp-1634	51	27	necessary	necessary	ADJ
ajcp-1634	51	28	for	for	SCONJ
ajcp-1634	51	29	s	s	PROPN
ajcp-1634	51	30	’s	’s	ADJ
ajcp-1634	51	31	proteolytic	proteolytic	ADJ
ajcp-1634	51	32	activation	activation	NOUN
ajcp-1634	51	33	,	,	PUNCT
ajcp-1634	51	34	are	be	AUX
ajcp-1634	51	35	widely	widely	ADV
ajcp-1634	51	36	expressed	express	VERB
ajcp-1634	51	37	in	in	ADP
ajcp-1634	51	38	humans	human	NOUN
ajcp-1634	51	39	,	,	PUNCT
ajcp-1634	51	40	allowing	allow	VERB
ajcp-1634	51	41	sars	sar	NOUN
ajcp-1634	51	42	-	-	PUNCT
ajcp-1634	51	43	cov-2	cov-2	NUM
ajcp-1634	51	44	to	to	PART
ajcp-1634	51	45	infect	infect	VERB
ajcp-1634	51	46	a	a	DET
ajcp-1634	51	47	broader	broad	ADJ
ajcp-1634	51	48	range	range	NOUN
ajcp-1634	51	49	of	of	ADP
ajcp-1634	51	50	tissues	tissue	NOUN
ajcp-1634	51	51	.	.	PUNCT
ajcp-1634	52	1	furthermore	furthermore	ADV
ajcp-1634	52	2	,	,	PUNCT
ajcp-1634	52	3	multiple	multiple	ADJ
ajcp-1634	52	4	investigations	investigation	NOUN
ajcp-1634	52	5	have	have	AUX
ajcp-1634	52	6	suggested	suggest	VERB
ajcp-1634	52	7	that	that	SCONJ
ajcp-1634	52	8	the	the	DET
ajcp-1634	52	9	s	s	PROPN
ajcp-1634	52	10	protein	protein	NOUN
ajcp-1634	52	11	of	of	ADP
ajcp-1634	52	12	sars	sar	NOUN
ajcp-1634	52	13	-	-	PUNCT
ajcp-1634	52	14	cov-2	cov-2	NUM
ajcp-1634	52	15	may	may	AUX
ajcp-1634	52	16	employ	employ	VERB
ajcp-1634	52	17	ace2	ace2	NOUN
ajcp-1634	52	18	to	to	PART
ajcp-1634	52	19	infect	infect	VERB
ajcp-1634	52	20	the	the	DET
ajcp-1634	52	21	host	host	NOUN
ajcp-1634	52	22	(	(	PUNCT
ajcp-1634	52	23	zhou	zhou	X
ajcp-1634	52	24	et	et	PROPN
ajcp-1634	52	25	al	al	PROPN
ajcp-1634	52	26	.	.	PROPN
ajcp-1634	52	27	,	,	PUNCT
ajcp-1634	52	28	2020	2020	NUM
ajcp-1634	52	29	;	;	PUNCT
ajcp-1634	52	30	hoffman	hoffman	PROPN
ajcp-1634	52	31	et	et	PROPN
ajcp-1634	52	32	al	al	PROPN
ajcp-1634	52	33	.	.	PROPN
ajcp-1634	52	34	,	,	PUNCT
ajcp-1634	52	35	2020	2020	NUM
ajcp-1634	52	36	;	;	PUNCT
ajcp-1634	53	1	kuba	kuba	PROPN
ajcp-1634	53	2	et	et	PROPN
ajcp-1634	53	3	al	al	PROPN
ajcp-1634	53	4	.	.	PROPN
ajcp-1634	53	5	,	,	PUNCT
ajcp-1634	53	6	2005	2005	NUM
ajcp-1634	53	7	;	;	PUNCT
ajcp-1634	53	8	li	li	PROPN
ajcp-1634	53	9	et	et	PROPN
ajcp-1634	53	10	al	al	PROPN
ajcp-1634	53	11	.	.	PROPN
ajcp-1634	53	12	,	,	PUNCT
ajcp-1634	53	13	2003	2003	NUM
ajcp-1634	53	14	)	)	PUNCT
ajcp-1634	53	15	.	.	PUNCT
ajcp-1634	54	1	ace2	ace2	PROPN
ajcp-1634	54	2	is	be	AUX
ajcp-1634	54	3	important	important	ADJ
ajcp-1634	54	4	because	because	SCONJ
ajcp-1634	54	5	it	it	PRON
ajcp-1634	54	6	aids	aid	VERB
ajcp-1634	54	7	in	in	ADP
ajcp-1634	54	8	the	the	DET
ajcp-1634	54	9	maturation	maturation	NOUN
ajcp-1634	54	10	of	of	ADP
ajcp-1634	54	11	angiotensin	angiotensin	NOUN
ajcp-1634	54	12	,	,	PUNCT
ajcp-1634	54	13	a	a	DET
ajcp-1634	54	14	hormone	hormone	NOUN
ajcp-1634	54	15	that	that	PRON
ajcp-1634	54	16	regulates	regulate	VERB
ajcp-1634	54	17	blood	blood	NOUN
ajcp-1634	54	18	pressure	pressure	NOUN
ajcp-1634	54	19	and	and	CCONJ
ajcp-1634	54	20	vasoconstriction	vasoconstriction	NOUN
ajcp-1634	54	21	(	(	PUNCT
ajcp-1634	54	22	yan	yan	PROPN
ajcp-1634	54	23	et	et	PROPN
ajcp-1634	54	24	al	al	PROPN
ajcp-1634	54	25	.	.	PROPN
ajcp-1634	54	26	,	,	PUNCT
ajcp-1634	54	27	2020	2020	NUM
ajcp-1634	54	28	)	)	PUNCT
ajcp-1634	54	29	.	.	PUNCT
ajcp-1634	55	1	cardiovascular	cardiovascular	ADJ
ajcp-1634	55	2	illnesses	illness	NOUN
ajcp-1634	55	3	are	be	AUX
ajcp-1634	55	4	very	very	ADV
ajcp-1634	55	5	likely	likely	ADJ
ajcp-1634	55	6	when	when	SCONJ
ajcp-1634	55	7	ace2	ace2	NOUN
ajcp-1634	55	8	expression	expression	NOUN
ajcp-1634	55	9	in	in	ADP
ajcp-1634	55	10	the	the	DET
ajcp-1634	55	11	lungs	lung	NOUN
ajcp-1634	55	12	,	,	PUNCT
ajcp-1634	55	13	heart	heart	NOUN
ajcp-1634	55	14	,	,	PUNCT
ajcp-1634	55	15	kidneys	kidney	NOUN
ajcp-1634	55	16	,	,	PUNCT
ajcp-1634	55	17	and	and	CCONJ
ajcp-1634	55	18	intestines	intestine	NOUN
ajcp-1634	55	19	is	be	AUX
ajcp-1634	55	20	reduced	reduce	VERB
ajcp-1634	55	21	(	(	PUNCT
ajcp-1634	55	22	crackower	crackower	NOUN
ajcp-1634	55	23	et	et	PROPN
ajcp-1634	55	24	al	al	PROPN
ajcp-1634	55	25	.	.	PROPN
ajcp-1634	55	26	,	,	PUNCT
ajcp-1634	55	27	2002	2002	NUM
ajcp-1634	55	28	;	;	PUNCT
ajcp-1634	55	29	zisman	zisman	NOUN
ajcp-1634	55	30	et	et	PROPN
ajcp-1634	55	31	al	al	PROPN
ajcp-1634	55	32	.	.	PROPN
ajcp-1634	55	33	,	,	PUNCT
ajcp-1634	55	34	2002	2002	NUM
ajcp-1634	55	35	;	;	PUNCT
ajcp-1634	55	36	raizada	raizada	PROPN
ajcp-1634	55	37	et	et	PROPN
ajcp-1634	55	38	al	al	PROPN
ajcp-1634	55	39	.	.	PROPN
ajcp-1634	55	40	,	,	PUNCT
ajcp-1634	55	41	2007	2007	NUM
ajcp-1634	55	42	)	)	PUNCT
ajcp-1634	55	43	.	.	PUNCT
ajcp-1634	56	1	the	the	DET
ajcp-1634	56	2	s	s	NOUN
ajcp-1634	56	3	protein	protein	NOUN
ajcp-1634	56	4	is	be	AUX
ajcp-1634	56	5	a	a	DET
ajcp-1634	56	6	target	target	NOUN
ajcp-1634	56	7	for	for	ADP
ajcp-1634	56	8	antibodymediated	antibodymediate	VERB
ajcp-1634	56	9	neutralization	neutralization	NOUN
ajcp-1634	56	10	because	because	SCONJ
ajcp-1634	56	11	of	of	ADP
ajcp-1634	56	12	its	its	PRON
ajcp-1634	56	13	essential	essential	ADJ
ajcp-1634	56	14	function	function	NOUN
ajcp-1634	56	15	.	.	PUNCT
ajcp-1634	57	1	furthermore	furthermore	ADV
ajcp-1634	57	2	,	,	PUNCT
ajcp-1634	57	3	studying	study	VERB
ajcp-1634	57	4	the	the	DET
ajcp-1634	57	5	prefusion	prefusion	NOUN
ajcp-1634	57	6	s	s	PART
ajcp-1634	57	7	structure	structure	NOUN
ajcp-1634	57	8	can	can	AUX
ajcp-1634	57	9	help	help	VERB
ajcp-1634	57	10	with	with	ADP
ajcp-1634	57	11	vaccine	vaccine	NOUN
ajcp-1634	57	12	development	development	NOUN
ajcp-1634	57	13	.	.	PUNCT
ajcp-1634	58	1	materials	material	NOUN
ajcp-1634	58	2	and	and	CCONJ
ajcp-1634	58	3	methods	method	NOUN
ajcp-1634	58	4	the	the	DET
ajcp-1634	58	5	review	review	NOUN
ajcp-1634	58	6	was	be	AUX
ajcp-1634	58	7	carried	carry	VERB
ajcp-1634	58	8	out	out	ADP
ajcp-1634	58	9	through	through	ADP
ajcp-1634	58	10	a	a	DET
ajcp-1634	58	11	deductive	deductive	ADJ
ajcp-1634	58	12	search	search	NOUN
ajcp-1634	58	13	strategy	strategy	NOUN
ajcp-1634	58	14	with	with	ADP
ajcp-1634	58	15	keywords	keyword	NOUN
ajcp-1634	58	16	:	:	PUNCT
ajcp-1634	58	17	covid-19	covid-19	PROPN
ajcp-1634	58	18	vaccines	vaccine	NOUN
ajcp-1634	58	19	,	,	PUNCT
ajcp-1634	58	20	ncov-2019	ncov-2019	ADJ
ajcp-1634	58	21	vaccines	vaccine	NOUN
ajcp-1634	58	22	,	,	PUNCT
ajcp-1634	58	23	coronavirus	coronavirus	NOUN
ajcp-1634	58	24	,	,	PUNCT
ajcp-1634	58	25	covid-19	covid-19	PROPN
ajcp-1634	58	26	vaccine	vaccine	NOUN
ajcp-1634	58	27	development	development	NOUN
ajcp-1634	58	28	,	,	PUNCT
ajcp-1634	58	29	s	s	VERB
ajcp-1634	58	30	protein	protein	NOUN
ajcp-1634	58	31	,	,	PUNCT
ajcp-1634	58	32	and	and	CCONJ
ajcp-1634	58	33	protein	protein	NOUN
ajcp-1634	58	34	glycosylation	glycosylation	NOUN
ajcp-1634	58	35	using	use	VERB
ajcp-1634	58	36	google	google	PROPN
ajcp-1634	58	37	scholar	scholar	NOUN
ajcp-1634	58	38	.	.	PUNCT
ajcp-1634	59	1	articles	article	NOUN
ajcp-1634	59	2	were	be	AUX
ajcp-1634	59	3	included	include	VERB
ajcp-1634	59	4	if	if	SCONJ
ajcp-1634	59	5	they	they	PRON
ajcp-1634	59	6	were	be	AUX
ajcp-1634	59	7	published	publish	VERB
ajcp-1634	59	8	in	in	ADP
ajcp-1634	59	9	english	english	PROPN
ajcp-1634	59	10	,	,	PUNCT
ajcp-1634	59	11	appeared	appear	VERB
ajcp-1634	59	12	in	in	ADP
ajcp-1634	59	13	peer	peer	NOUN
ajcp-1634	59	14	-	-	PUNCT
ajcp-1634	59	15	reviewed	review	VERB
ajcp-1634	59	16	publications	publication	NOUN
ajcp-1634	59	17	,	,	PUNCT
ajcp-1634	59	18	and	and	CCONJ
ajcp-1634	59	19	were	be	AUX
ajcp-1634	59	20	related	relate	VERB
ajcp-1634	59	21	to	to	ADP
ajcp-1634	59	22	the	the	DET
ajcp-1634	59	23	issue	issue	NOUN
ajcp-1634	59	24	of	of	ADP
ajcp-1634	59	25	the	the	DET
ajcp-1634	59	26	sars	sar	NOUN
ajcp-1634	59	27	-	-	PUNCT
ajcp-1634	59	28	cov-2	cov-2	PART
ajcp-1634	59	29	virus	virus	NOUN
ajcp-1634	59	30	and	and	CCONJ
ajcp-1634	59	31	vaccine	vaccine	NOUN
ajcp-1634	59	32	development	development	NOUN
ajcp-1634	59	33	.	.	PUNCT
ajcp-1634	60	1	statistics	statistic	NOUN
ajcp-1634	60	2	from	from	ADP
ajcp-1634	60	3	the	the	DET
ajcp-1634	60	4	world	world	PROPN
ajcp-1634	60	5	health	health	NOUN
ajcp-1634	60	6	organization	organization	NOUN
ajcp-1634	60	7	were	be	AUX
ajcp-1634	60	8	also	also	ADV
ajcp-1634	60	9	included	include	VERB
ajcp-1634	60	10	.	.	PUNCT
ajcp-1634	61	1	the	the	DET
ajcp-1634	61	2	flowchart	flowchart	NOUN
ajcp-1634	61	3	outlining	outline	VERB
ajcp-1634	61	4	the	the	DET
ajcp-1634	61	5	search	search	NOUN
ajcp-1634	61	6	technique	technique	NOUN
ajcp-1634	61	7	is	be	AUX
ajcp-1634	61	8	presented	present	VERB
ajcp-1634	61	9	in	in	ADP
ajcp-1634	61	10	the	the	DET
ajcp-1634	61	11	figure	figure	NOUN
ajcp-1634	61	12	below	below	ADV
ajcp-1634	61	13	.	.	PUNCT
ajcp-1634	62	1	figure	figure	VERB
ajcp-1634	62	2	1	1	NUM
ajcp-1634	62	3	:	:	PUNCT
ajcp-1634	62	4	search	search	NOUN
ajcp-1634	62	5	strategy	strategy	NOUN
ajcp-1634	62	6	employed	employ	VERB
ajcp-1634	62	7	results	result	NOUN
ajcp-1634	62	8	and	and	CCONJ
ajcp-1634	62	9	discussion	discussion	NOUN
ajcp-1634	62	10	glycosylation	glycosylation	NOUN
ajcp-1634	62	11	of	of	ADP
ajcp-1634	62	12	sars	sar	NOUN
ajcp-1634	62	13	-	-	PUNCT
ajcp-1634	62	14	cov-2	cov-2	NOUN
ajcp-1634	62	15	s	s	PART
ajcp-1634	62	16	protein	protein	NOUN
ajcp-1634	62	17	viral	viral	ADJ
ajcp-1634	62	18	protein	protein	NOUN
ajcp-1634	62	19	glycosylation	glycosylation	NOUN
ajcp-1634	62	20	is	be	AUX
ajcp-1634	62	21	a	a	DET
ajcp-1634	62	22	successful	successful	ADJ
ajcp-1634	62	23	virus	virus	NOUN
ajcp-1634	62	24	strategy	strategy	NOUN
ajcp-1634	62	25	for	for	ADP
ajcp-1634	62	26	modifying	modify	VERB
ajcp-1634	62	27	its	its	PRON
ajcp-1634	62	28	proteins	protein	NOUN
ajcp-1634	62	29	using	use	VERB
ajcp-1634	62	30	the	the	DET
ajcp-1634	62	31	host	host	NOUN
ajcp-1634	62	32	-	-	PUNCT
ajcp-1634	62	33	cell	cell	NOUN
ajcp-1634	62	34	machinery	machinery	NOUN
ajcp-1634	62	35	.	.	PUNCT
ajcp-1634	63	1	as	as	ADP
ajcp-1634	63	2	a	a	DET
ajcp-1634	63	3	result	result	NOUN
ajcp-1634	63	4	,	,	PUNCT
ajcp-1634	63	5	glycans	glycan	NOUN
ajcp-1634	63	6	play	play	VERB
ajcp-1634	63	7	critical	critical	ADJ
ajcp-1634	63	8	roles	role	NOUN
ajcp-1634	63	9	in	in	ADP
ajcp-1634	63	10	viral	viral	ADJ
ajcp-1634	63	11	infection	infection	NOUN
ajcp-1634	63	12	and	and	CCONJ
ajcp-1634	63	13	immune	immune	ADJ
ajcp-1634	63	14	response	response	NOUN
ajcp-1634	63	15	(	(	PUNCT
ajcp-1634	63	16	zhao	zhao	PROPN
ajcp-1634	63	17	et	et	PROPN
ajcp-1634	63	18	al	al	PROPN
ajcp-1634	63	19	.	.	PROPN
ajcp-1634	63	20	,	,	PUNCT
ajcp-1634	63	21	2021	2021	NUM
ajcp-1634	63	22	)	)	PUNCT
ajcp-1634	63	23	.	.	PUNCT
ajcp-1634	64	1	glycans	glycan	NOUN
ajcp-1634	64	2	on	on	ADP
ajcp-1634	64	3	viral	viral	ADJ
ajcp-1634	64	4	surface	surface	NOUN
ajcp-1634	64	5	proteins	protein	NOUN
ajcp-1634	64	6	play	play	VERB
ajcp-1634	64	7	a	a	DET
ajcp-1634	64	8	role	role	NOUN
ajcp-1634	64	9	in	in	ADP
ajcp-1634	64	10	viral	viral	ADJ
ajcp-1634	64	11	entry	entry	NOUN
ajcp-1634	64	12	,	,	PUNCT
ajcp-1634	64	13	fusion	fusion	NOUN
ajcp-1634	64	14	,	,	PUNCT
ajcp-1634	64	15	epitope	epitope	NOUN
ajcp-1634	64	16	shielding	shielding	NOUN
ajcp-1634	64	17	,	,	PUNCT
ajcp-1634	64	18	viral	viral	ADJ
ajcp-1634	64	19	protein	protein	NOUN
ajcp-1634	64	20	folding	folding	NOUN
ajcp-1634	64	21	,	,	PUNCT
ajcp-1634	64	22	stability	stability	NOUN
ajcp-1634	64	23	,	,	PUNCT
ajcp-1634	64	24	and	and	CCONJ
ajcp-1634	64	25	protection	protection	NOUN
ajcp-1634	64	26	.	.	PUNCT
ajcp-1634	65	1	for	for	ADP
ajcp-1634	65	2	instance	instance	NOUN
ajcp-1634	65	3	,	,	PUNCT
ajcp-1634	65	4	by	by	ADP
ajcp-1634	65	5	shielding	shield	VERB
ajcp-1634	65	6	surface	surface	NOUN
ajcp-1634	65	7	antigens	antigen	NOUN
ajcp-1634	65	8	with	with	ADP
ajcp-1634	65	9	glycan	glycan	NOUN
ajcp-1634	65	10	envelopes	envelope	NOUN
ajcp-1634	65	11	,	,	PUNCT
ajcp-1634	65	12	glycosylation	glycosylation	NOUN
ajcp-1634	65	13	on	on	ADP
ajcp-1634	65	14	the	the	DET
ajcp-1634	65	15	surface	surface	NOUN
ajcp-1634	65	16	proteins	protein	NOUN
ajcp-1634	65	17	of	of	ADP
ajcp-1634	65	18	viruses	virus	NOUN
ajcp-1634	65	19	can	can	AUX
ajcp-1634	65	20	prevent	prevent	VERB
ajcp-1634	65	21	antibodies	antibody	NOUN
ajcp-1634	65	22	from	from	ADP
ajcp-1634	65	23	binding	bind	VERB
ajcp-1634	65	24	,	,	PUNCT
ajcp-1634	65	25	which	which	PRON
ajcp-1634	65	26	plays	play	VERB
ajcp-1634	65	27	a	a	DET
ajcp-1634	65	28	significant	significant	ADJ
ajcp-1634	65	29	role	role	NOUN
ajcp-1634	65	30	in	in	ADP
ajcp-1634	65	31	viral	viral	ADJ
ajcp-1634	65	32	infection	infection	NOUN
ajcp-1634	65	33	(	(	PUNCT
ajcp-1634	65	34	shajahan	shajahan	PROPN
ajcp-1634	65	35	et	et	PROPN
ajcp-1634	65	36	al	al	PROPN
ajcp-1634	65	37	.	.	PROPN
ajcp-1634	65	38	,	,	PUNCT
ajcp-1634	65	39	2021	2021	NUM
ajcp-1634	65	40	)	)	PUNCT
ajcp-1634	65	41	.	.	PUNCT
ajcp-1634	66	1	as	as	SCONJ
ajcp-1634	66	2	mentioned	mention	VERB
ajcp-1634	66	3	,	,	PUNCT
ajcp-1634	66	4	the	the	DET
ajcp-1634	66	5	s	s	NOUN
ajcp-1634	66	6	protein	protein	NOUN
ajcp-1634	66	7	of	of	ADP
ajcp-1634	66	8	sars	sar	NOUN
ajcp-1634	66	9	-	-	PUNCT
ajcp-1634	66	10	cov-2	cov-2	NUM
ajcp-1634	66	11	is	be	AUX
ajcp-1634	66	12	highly	highly	ADV
ajcp-1634	66	13	glycosylated	glycosylated	ADJ
ajcp-1634	66	14	.	.	PUNCT
ajcp-1634	67	1	sars	sar	NOUN
ajcp-1634	67	2	-	-	PUNCT
ajcp-1634	67	3	cov-2	cov-2	NUM
ajcp-1634	67	4	has	have	VERB
ajcp-1634	67	5	22	22	NUM
ajcp-1634	67	6	n	n	CCONJ
ajcp-1634	67	7	-	-	PUNCT
ajcp-1634	67	8	glycosylation	glycosylation	NOUN
ajcp-1634	67	9	sites	site	NOUN
ajcp-1634	67	10	and	and	CCONJ
ajcp-1634	67	11	several	several	ADJ
ajcp-1634	67	12	o	o	ADJ
ajcp-1634	67	13	-	-	NOUN
ajcp-1634	67	14	glycosylation	glycosylation	NOUN
ajcp-1634	67	15	sites	site	NOUN
ajcp-1634	67	16	on	on	ADP
ajcp-1634	67	17	each	each	DET
ajcp-1634	67	18	protomer	protomer	NOUN
ajcp-1634	67	19	of	of	ADP
ajcp-1634	67	20	the	the	DET
ajcp-1634	67	21	transmembrane	transmembrane	NOUN
ajcp-1634	67	22	homotrimeric	homotrimeric	ADJ
ajcp-1634	67	23	protein	protein	NOUN
ajcp-1634	67	24	(	(	PUNCT
ajcp-1634	67	25	watanabe	watanabe	PROPN
ajcp-1634	67	26	et	et	PROPN
ajcp-1634	67	27	al	al	PROPN
ajcp-1634	67	28	.	.	PROPN
ajcp-1634	67	29	,	,	PUNCT
ajcp-1634	67	30	2020	2020	NUM
ajcp-1634	67	31	)	)	PUNCT
ajcp-1634	67	32	.	.	PUNCT
ajcp-1634	68	1	sars	sar	NOUN
ajcp-1634	68	2	-	-	PUNCT
ajcp-1634	68	3	cov-2	cov-2	PART
ajcp-1634	68	4	infection	infection	NOUN
ajcp-1634	68	5	is	be	AUX
ajcp-1634	68	6	influenced	influence	VERB
ajcp-1634	68	7	by	by	ADP
ajcp-1634	68	8	the	the	DET
ajcp-1634	68	9	glycosylation	glycosylation	NOUN
ajcp-1634	68	10	process	process	NOUN
ajcp-1634	68	11	of	of	ADP
ajcp-1634	68	12	both	both	CCONJ
ajcp-1634	68	13	the	the	DET
ajcp-1634	68	14	virus	virus	NOUN
ajcp-1634	68	15	and	and	CCONJ
ajcp-1634	68	16	the	the	DET
ajcp-1634	68	17	target	target	NOUN
ajcp-1634	68	18	cells	cell	NOUN
ajcp-1634	68	19	on	on	ADP
ajcp-1634	68	20	several	several	ADJ
ajcp-1634	68	21	levels	level	NOUN
ajcp-1634	68	22	,	,	PUNCT
ajcp-1634	68	23	according	accord	VERB
ajcp-1634	68	24	to	to	ADP
ajcp-1634	68	25	recent	recent	ADJ
ajcp-1634	68	26	reports	report	NOUN
ajcp-1634	68	27	(	(	PUNCT
ajcp-1634	68	28	reis	reis	NOUN
ajcp-1634	68	29	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	68	30	pa	pa	PROPN
ajcp-1634	68	31	ge	ge	PROPN
ajcp-1634	68	32	68	68	NUM
ajcp-1634	68	33	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	68	34	am	be	AUX
ajcp-1634	68	35	.	.	PUNCT
ajcp-1634	69	1	j.	j.	PROPN
ajcp-1634	69	2	chem	chem	PROPN
ajcp-1634	69	3	.	.	PUNCT
ajcp-1634	70	1	pharm	pharm	PROPN
ajcp-1634	70	2	.	.	PUNCT
ajcp-1634	71	1	2(2	2(2	NUM
ajcp-1634	71	2	)	)	PUNCT
ajcp-1634	72	1	66	66	NUM
ajcp-1634	72	2	-	-	SYM
ajcp-1634	72	3	73	73	NUM
ajcp-1634	72	4	,	,	PUNCT
ajcp-1634	72	5	2023	2023	NUM
ajcp-1634	72	6	et	et	NOUN
ajcp-1634	72	7	al	al	PROPN
ajcp-1634	72	8	.	.	PROPN
ajcp-1634	72	9	,	,	PUNCT
ajcp-1634	72	10	2020	2020	NUM
ajcp-1634	72	11	)	)	PUNCT
ajcp-1634	72	12	.	.	PUNCT
ajcp-1634	73	1	given	give	VERB
ajcp-1634	73	2	this	this	PRON
ajcp-1634	73	3	,	,	PUNCT
ajcp-1634	73	4	it	it	PRON
ajcp-1634	73	5	’s	’	VERB
ajcp-1634	73	6	worth	worth	ADJ
ajcp-1634	73	7	examining	examine	VERB
ajcp-1634	73	8	how	how	SCONJ
ajcp-1634	73	9	this	this	DET
ajcp-1634	73	10	process	process	NOUN
ajcp-1634	73	11	works	work	VERB
ajcp-1634	73	12	and	and	CCONJ
ajcp-1634	73	13	how	how	SCONJ
ajcp-1634	73	14	it	it	PRON
ajcp-1634	73	15	affects	affect	VERB
ajcp-1634	73	16	sars	sar	NOUN
ajcp-1634	73	17	-	-	PUNCT
ajcp-1634	73	18	cov-2	cov-2	NOUN
ajcp-1634	73	19	because	because	SCONJ
ajcp-1634	73	20	it	it	PRON
ajcp-1634	73	21	could	could	AUX
ajcp-1634	73	22	lead	lead	VERB
ajcp-1634	73	23	to	to	ADP
ajcp-1634	73	24	vaccine	vaccine	NOUN
ajcp-1634	73	25	development	development	NOUN
ajcp-1634	73	26	breakthroughs	breakthrough	NOUN
ajcp-1634	73	27	.	.	PUNCT
ajcp-1634	74	1	for	for	ADP
ajcp-1634	74	2	replication	replication	NOUN
ajcp-1634	74	3	and	and	CCONJ
ajcp-1634	74	4	protein	protein	NOUN
ajcp-1634	74	5	glycosylation	glycosylation	NOUN
ajcp-1634	74	6	,	,	PUNCT
ajcp-1634	74	7	sars	sar	NOUN
ajcp-1634	74	8	-	-	PUNCT
ajcp-1634	74	9	cov-2	cov-2	PART
ajcp-1634	74	10	uses	use	VERB
ajcp-1634	74	11	the	the	DET
ajcp-1634	74	12	machinery	machinery	NOUN
ajcp-1634	74	13	of	of	ADP
ajcp-1634	74	14	the	the	DET
ajcp-1634	74	15	host	host	NOUN
ajcp-1634	74	16	cell	cell	NOUN
ajcp-1634	74	17	.	.	PUNCT
ajcp-1634	75	1	as	as	ADP
ajcp-1634	75	2	a	a	DET
ajcp-1634	75	3	result	result	NOUN
ajcp-1634	75	4	,	,	PUNCT
ajcp-1634	75	5	the	the	DET
ajcp-1634	75	6	viral	viral	ADJ
ajcp-1634	75	7	surface	surface	NOUN
ajcp-1634	75	8	glycans	glycan	NOUN
ajcp-1634	75	9	are	be	AUX
ajcp-1634	75	10	composed	compose	VERB
ajcp-1634	75	11	of	of	ADP
ajcp-1634	75	12	host	host	NOUN
ajcp-1634	75	13	glycans	glycan	NOUN
ajcp-1634	75	14	that	that	SCONJ
ajcp-1634	75	15	the	the	DET
ajcp-1634	75	16	immune	immune	ADJ
ajcp-1634	75	17	system	system	NOUN
ajcp-1634	75	18	recognizes	recognize	VERB
ajcp-1634	75	19	as	as	ADP
ajcp-1634	75	20	self	self	NOUN
ajcp-1634	75	21	,	,	PUNCT
ajcp-1634	75	22	suppressing	suppress	VERB
ajcp-1634	75	23	the	the	DET
ajcp-1634	75	24	anticarbohydrate	anticarbohydrate	ADJ
ajcp-1634	75	25	immune	immune	ADJ
ajcp-1634	75	26	response	response	NOUN
ajcp-1634	75	27	(	(	PUNCT
ajcp-1634	75	28	crispin	crispin	PROPN
ajcp-1634	75	29	et	et	PROPN
ajcp-1634	75	30	al	al	PROPN
ajcp-1634	75	31	.	.	PROPN
ajcp-1634	75	32	,	,	PUNCT
ajcp-1634	75	33	2015	2015	NUM
ajcp-1634	75	34	)	)	PUNCT
ajcp-1634	75	35	.	.	PUNCT
ajcp-1634	76	1	moreover	moreover	ADV
ajcp-1634	76	2	,	,	PUNCT
ajcp-1634	76	3	t	t	NOUN
ajcp-1634	76	4	cell	cell	NOUN
ajcp-1634	76	5	activation	activation	NOUN
ajcp-1634	76	6	and	and	CCONJ
ajcp-1634	76	7	cytokine	cytokine	ADJ
ajcp-1634	76	8	production	production	NOUN
ajcp-1634	76	9	are	be	AUX
ajcp-1634	76	10	affected	affect	VERB
ajcp-1634	76	11	by	by	ADP
ajcp-1634	76	12	differential	differential	ADJ
ajcp-1634	76	13	hemagglutinin	hemagglutinin	ADJ
ajcp-1634	76	14	n	n	CCONJ
ajcp-1634	76	15	-	-	PUNCT
ajcp-1634	76	16	glycosylation	glycosylation	NOUN
ajcp-1634	76	17	,	,	PUNCT
ajcp-1634	76	18	which	which	PRON
ajcp-1634	76	19	poses	pose	VERB
ajcp-1634	76	20	a	a	DET
ajcp-1634	76	21	challenge	challenge	NOUN
ajcp-1634	76	22	for	for	ADP
ajcp-1634	76	23	vaccine	vaccine	NOUN
ajcp-1634	76	24	development	development	NOUN
ajcp-1634	76	25	(	(	PUNCT
ajcp-1634	76	26	hütter	hütter	NOUN
ajcp-1634	76	27	et	et	PROPN
ajcp-1634	76	28	al	al	PROPN
ajcp-1634	76	29	.	.	PROPN
ajcp-1634	76	30	,	,	PUNCT
ajcp-1634	76	31	2013	2013	NUM
ajcp-1634	76	32	)	)	PUNCT
ajcp-1634	76	33	.	.	PUNCT
ajcp-1634	77	1	furthermore	furthermore	ADV
ajcp-1634	77	2	,	,	PUNCT
ajcp-1634	77	3	as	as	SCONJ
ajcp-1634	77	4	shown	show	VERB
ajcp-1634	77	5	in	in	ADP
ajcp-1634	77	6	the	the	DET
ajcp-1634	77	7	case	case	NOUN
ajcp-1634	77	8	of	of	ADP
ajcp-1634	77	9	influenza	influenza	NOUN
ajcp-1634	77	10	viruses	virus	NOUN
ajcp-1634	77	11	,	,	PUNCT
ajcp-1634	77	12	mutations	mutation	NOUN
ajcp-1634	77	13	in	in	ADP
ajcp-1634	77	14	protein	protein	NOUN
ajcp-1634	77	15	sequences	sequence	NOUN
ajcp-1634	77	16	can	can	AUX
ajcp-1634	77	17	alter	alter	VERB
ajcp-1634	77	18	glycosylation	glycosylation	NOUN
ajcp-1634	77	19	by	by	ADP
ajcp-1634	77	20	generating	generate	VERB
ajcp-1634	77	21	new	new	ADJ
ajcp-1634	77	22	or	or	CCONJ
ajcp-1634	77	23	removing	remove	VERB
ajcp-1634	77	24	existing	exist	VERB
ajcp-1634	77	25	glycosylation	glycosylation	NOUN
ajcp-1634	77	26	sites	site	NOUN
ajcp-1634	77	27	(	(	PUNCT
ajcp-1634	77	28	altman	altman	NOUN
ajcp-1634	77	29	et	et	PROPN
ajcp-1634	77	30	al	al	PROPN
ajcp-1634	77	31	.	.	PROPN
ajcp-1634	77	32	,	,	PUNCT
ajcp-1634	77	33	2019	2019	NUM
ajcp-1634	77	34	;	;	PUNCT
ajcp-1634	77	35	zost	zost	X
ajcp-1634	77	36	et	et	NOUN
ajcp-1634	77	37	al	al	PROPN
ajcp-1634	77	38	.	.	PROPN
ajcp-1634	77	39	,	,	PUNCT
ajcp-1634	77	40	2017	2017	NUM
ajcp-1634	77	41	)	)	PUNCT
ajcp-1634	77	42	.	.	PUNCT
ajcp-1634	78	1	this	this	PRON
ajcp-1634	78	2	could	could	AUX
ajcp-1634	78	3	lead	lead	VERB
ajcp-1634	78	4	to	to	ADP
ajcp-1634	78	5	the	the	DET
ajcp-1634	78	6	emergence	emergence	NOUN
ajcp-1634	78	7	of	of	ADP
ajcp-1634	78	8	new	new	ADJ
ajcp-1634	78	9	virus	virus	NOUN
ajcp-1634	78	10	strains	strain	VERB
ajcp-1634	78	11	(	(	PUNCT
ajcp-1634	78	12	altman	altman	NOUN
ajcp-1634	78	13	et	et	PROPN
ajcp-1634	78	14	al	al	PROPN
ajcp-1634	78	15	.	.	PROPN
ajcp-1634	78	16	,	,	PUNCT
ajcp-1634	78	17	2019	2019	NUM
ajcp-1634	78	18	)	)	PUNCT
ajcp-1634	78	19	.	.	PUNCT
ajcp-1634	79	1	this	this	DET
ajcp-1634	79	2	paper	paper	NOUN
ajcp-1634	79	3	summarizes	summarize	NOUN
ajcp-1634	79	4	how	how	SCONJ
ajcp-1634	79	5	protein	protein	NOUN
ajcp-1634	79	6	glycosylation	glycosylation	NOUN
ajcp-1634	79	7	plays	play	VERB
ajcp-1634	79	8	a	a	DET
ajcp-1634	79	9	role	role	NOUN
ajcp-1634	79	10	in	in	ADP
ajcp-1634	79	11	sars	sar	NOUN
ajcp-1634	79	12	-	-	PUNCT
ajcp-1634	79	13	cov-2	cov-2	PART
ajcp-1634	79	14	virus	virus	NOUN
ajcp-1634	79	15	replication	replication	NOUN
ajcp-1634	79	16	,	,	PUNCT
ajcp-1634	79	17	binding	binding	NOUN
ajcp-1634	79	18	and	and	CCONJ
ajcp-1634	79	19	entry	entry	NOUN
ajcp-1634	79	20	,	,	PUNCT
ajcp-1634	79	21	immune	immune	ADJ
ajcp-1634	79	22	response	response	NOUN
ajcp-1634	79	23	,	,	PUNCT
ajcp-1634	79	24	therapy	therapy	NOUN
ajcp-1634	79	25	,	,	PUNCT
ajcp-1634	79	26	and	and	CCONJ
ajcp-1634	79	27	vaccine	vaccine	NOUN
ajcp-1634	79	28	development	development	NOUN
ajcp-1634	79	29	in	in	ADP
ajcp-1634	79	30	the	the	DET
ajcp-1634	79	31	table	table	NOUN
ajcp-1634	79	32	below	below	ADV
ajcp-1634	79	33	.	.	PUNCT
ajcp-1634	80	1	table	table	NOUN
ajcp-1634	80	2	1	1	NUM
ajcp-1634	80	3	:	:	PUNCT
ajcp-1634	80	4	biologic	biologic	ADJ
ajcp-1634	80	5	and	and	CCONJ
ajcp-1634	80	6	pathologic	pathologic	ADJ
ajcp-1634	80	7	effects	effect	NOUN
ajcp-1634	80	8	of	of	ADP
ajcp-1634	80	9	glycosylation	glycosylation	NOUN
ajcp-1634	80	10	of	of	ADP
ajcp-1634	80	11	sars	sar	NOUN
ajcp-1634	80	12	-	-	PUNCT
ajcp-1634	80	13	cov-2	cov-2	NOUN
ajcp-1634	80	14	s	s	NOUN
ajcp-1634	80	15	protein	protein	NOUN
ajcp-1634	80	16	and	and	CCONJ
ajcp-1634	80	17	other	other	ADJ
ajcp-1634	80	18	insights	insight	NOUN
ajcp-1634	80	19	from	from	ADP
ajcp-1634	80	20	literature	literature	NOUN
ajcp-1634	80	21	aspect	aspect	NOUN
ajcp-1634	80	22	role	role	NOUN
ajcp-1634	80	23	of	of	ADP
ajcp-1634	80	24	glycosylation	glycosylation	NOUN
ajcp-1634	80	25	in	in	ADP
ajcp-1634	80	26	biology	biology	NOUN
ajcp-1634	80	27	and	and	CCONJ
ajcp-1634	80	28	pathogenesis	pathogenesis	NOUN
ajcp-1634	80	29	of	of	ADP
ajcp-1634	80	30	sars	sar	NOUN
ajcp-1634	80	31	-	-	PUNCT
ajcp-1634	80	32	cov-2	cov-2	NOUN
ajcp-1634	80	33	s	s	NOUN
ajcp-1634	80	34	protein	protein	NOUN
ajcp-1634	80	35	and	and	CCONJ
ajcp-1634	80	36	additional	additional	ADJ
ajcp-1634	80	37	insights	insight	NOUN
ajcp-1634	80	38	reference	reference	VERB
ajcp-1634	80	39	/	/	SYM
ajcp-1634	80	40	s	s	PART
ajcp-1634	80	41	viral	viral	ADJ
ajcp-1634	80	42	entry	entry	NOUN
ajcp-1634	80	43	glycosaminoglycan	glycosaminoglycan	ADJ
ajcp-1634	80	44	heparan	heparan	ADJ
ajcp-1634	80	45	sulfate	sulfate	NOUN
ajcp-1634	80	46	of	of	ADP
ajcp-1634	80	47	the	the	DET
ajcp-1634	80	48	cellular	cellular	ADJ
ajcp-1634	80	49	glycocalyx	glycocalyx	NOUN
ajcp-1634	80	50	is	be	AUX
ajcp-1634	80	51	required	require	VERB
ajcp-1634	80	52	for	for	ADP
ajcp-1634	80	53	sars	sar	NOUN
ajcp-1634	80	54	-	-	PUNCT
ajcp-1634	80	55	cov-2	cov-2	PART
ajcp-1634	80	56	infection	infection	NOUN
ajcp-1634	80	57	of	of	ADP
ajcp-1634	80	58	these	these	DET
ajcp-1634	80	59	target	target	NOUN
ajcp-1634	80	60	cells	cell	NOUN
ajcp-1634	80	61	.	.	PUNCT
ajcp-1634	81	1	heparan	heparan	ADJ
ajcp-1634	81	2	sulfate	sulfate	NOUN
ajcp-1634	81	3	was	be	AUX
ajcp-1634	81	4	found	find	VERB
ajcp-1634	81	5	to	to	PART
ajcp-1634	81	6	interact	interact	VERB
ajcp-1634	81	7	with	with	ADP
ajcp-1634	81	8	the	the	DET
ajcp-1634	81	9	receptor	receptor	NOUN
ajcp-1634	81	10	-	-	PUNCT
ajcp-1634	81	11	binding	bind	VERB
ajcp-1634	81	12	domain	domain	NOUN
ajcp-1634	81	13	of	of	ADP
ajcp-1634	81	14	the	the	DET
ajcp-1634	81	15	sars	sar	NOUN
ajcp-1634	81	16	-	-	PUNCT
ajcp-1634	81	17	cov-2	cov-2	NOUN
ajcp-1634	81	18	spike	spike	ADJ
ajcp-1634	81	19	glycoprotein	glycoprotein	NOUN
ajcp-1634	81	20	,	,	PUNCT
ajcp-1634	81	21	which	which	PRON
ajcp-1634	81	22	is	be	AUX
ajcp-1634	81	23	located	locate	VERB
ajcp-1634	81	24	next	next	ADV
ajcp-1634	81	25	to	to	ADP
ajcp-1634	81	26	ace-2	ace-2	NUM
ajcp-1634	81	27	,	,	PUNCT
ajcp-1634	81	28	causing	cause	VERB
ajcp-1634	81	29	the	the	DET
ajcp-1634	81	30	spike	spike	ADJ
ajcp-1634	81	31	structure	structure	NOUN
ajcp-1634	81	32	to	to	PART
ajcp-1634	81	33	open	open	VERB
ajcp-1634	81	34	up	up	ADP
ajcp-1634	81	35	and	and	CCONJ
ajcp-1634	81	36	allow	allow	VERB
ajcp-1634	81	37	ace-2	ace-2	PUNCT
ajcp-1634	81	38	to	to	PART
ajcp-1634	81	39	bind	bind	VERB
ajcp-1634	81	40	to	to	ADP
ajcp-1634	81	41	it	it	PRON
ajcp-1634	81	42	.	.	PUNCT
ajcp-1634	82	1	clausen	clausen	PROPN
ajcp-1634	82	2	et	et	PROPN
ajcp-1634	82	3	al	al	PROPN
ajcp-1634	82	4	.	.	PROPN
ajcp-1634	82	5	(	(	PUNCT
ajcp-1634	82	6	2020	2020	NUM
ajcp-1634	82	7	)	)	PUNCT
ajcp-1634	82	8	the	the	DET
ajcp-1634	82	9	conformation	conformation	NOUN
ajcp-1634	82	10	of	of	ADP
ajcp-1634	82	11	the	the	DET
ajcp-1634	82	12	s	s	PROPN
ajcp-1634	82	13	protein	protein	NOUN
ajcp-1634	82	14	’s	’s	PART
ajcp-1634	82	15	receptor	receptor	NOUN
ajcp-1634	82	16	-	-	PUNCT
ajcp-1634	82	17	binding	bind	VERB
ajcp-1634	82	18	domain	domain	NOUN
ajcp-1634	82	19	has	have	AUX
ajcp-1634	82	20	been	be	AUX
ajcp-1634	82	21	shown	show	VERB
ajcp-1634	82	22	to	to	PART
ajcp-1634	82	23	be	be	AUX
ajcp-1634	82	24	modulated	modulate	VERB
ajcp-1634	82	25	by	by	ADP
ajcp-1634	82	26	glycans	glycan	NOUN
ajcp-1634	82	27	at	at	ADP
ajcp-1634	82	28	n165	n165	PROPN
ajcp-1634	82	29	and	and	CCONJ
ajcp-1634	82	30	n234	n234	PROPN
ajcp-1634	82	31	of	of	ADP
ajcp-1634	82	32	the	the	DET
ajcp-1634	82	33	protein	protein	NOUN
ajcp-1634	82	34	.	.	PUNCT
ajcp-1634	83	1	casalino	casalino	PROPN
ajcp-1634	83	2	et	et	PROPN
ajcp-1634	83	3	al	al	PROPN
ajcp-1634	83	4	.	.	PROPN
ajcp-1634	84	1	(	(	PUNCT
ajcp-1634	84	2	2020	2020	NUM
ajcp-1634	84	3	)	)	PUNCT
ajcp-1634	84	4	a	a	DET
ajcp-1634	84	5	sialic	sialic	ADJ
ajcp-1634	84	6	acid	acid	NOUN
ajcp-1634	84	7	-	-	PUNCT
ajcp-1634	84	8	binding	bind	VERB
ajcp-1634	84	9	pocket	pocket	NOUN
ajcp-1634	84	10	was	be	AUX
ajcp-1634	84	11	discovered	discover	VERB
ajcp-1634	84	12	at	at	ADP
ajcp-1634	84	13	the	the	DET
ajcp-1634	84	14	n	n	CCONJ
ajcp-1634	84	15	-	-	PUNCT
ajcp-1634	84	16	terminus	terminus	NOUN
ajcp-1634	84	17	of	of	ADP
ajcp-1634	84	18	the	the	DET
ajcp-1634	84	19	s	s	NOUN
ajcp-1634	84	20	protein	protein	NOUN
ajcp-1634	84	21	from	from	ADP
ajcp-1634	84	22	sars	sar	NOUN
ajcp-1634	84	23	-	-	PUNCT
ajcp-1634	84	24	cov-2	cov-2	NOUN
ajcp-1634	84	25	,	,	PUNCT
ajcp-1634	84	26	suggesting	suggest	VERB
ajcp-1634	84	27	that	that	SCONJ
ajcp-1634	84	28	it	it	PRON
ajcp-1634	84	29	may	may	AUX
ajcp-1634	84	30	play	play	VERB
ajcp-1634	84	31	a	a	DET
ajcp-1634	84	32	role	role	NOUN
ajcp-1634	84	33	in	in	ADP
ajcp-1634	84	34	viral	viral	ADJ
ajcp-1634	84	35	binding	binding	NOUN
ajcp-1634	84	36	.	.	PUNCT
ajcp-1634	85	1	verma	verma	PROPN
ajcp-1634	85	2	(	(	PUNCT
ajcp-1634	85	3	2020	2020	NUM
ajcp-1634	85	4	)	)	PUNCT
ajcp-1634	85	5	human	human	ADJ
ajcp-1634	85	6	lectins	lectin	NOUN
ajcp-1634	85	7	galectin-3	galectin-3	PROPN
ajcp-1634	85	8	,	,	PUNCT
ajcp-1634	85	9	7	7	NUM
ajcp-1634	85	10	and	and	CCONJ
ajcp-1634	85	11	8	8	NUM
ajcp-1634	85	12	,	,	PUNCT
ajcp-1634	85	13	siglec-10	siglec-10	ADJ
ajcp-1634	85	14	,	,	PUNCT
ajcp-1634	85	15	macrophage	macrophage	ADJ
ajcp-1634	85	16	galactose	galactose	ADJ
ajcp-1634	85	17	lectin	lectin	NOUN
ajcp-1634	85	18	(	(	PUNCT
ajcp-1634	85	19	mgl	mgl	PROPN
ajcp-1634	85	20	)	)	PUNCT
ajcp-1634	85	21	,	,	PUNCT
ajcp-1634	85	22	and	and	CCONJ
ajcp-1634	85	23	dendritic	dendritic	ADJ
ajcp-1634	85	24	cell	cell	NOUN
ajcp-1634	85	25	-	-	PUNCT
ajcp-1634	85	26	specific	specific	ADJ
ajcp-1634	85	27	intercellular	intercellular	ADJ
ajcp-1634	85	28	adhesion	adhesion	NOUN
ajcp-1634	85	29	molecule-3	molecule-3	NOUN
ajcp-1634	85	30	-	-	PUNCT
ajcp-1634	85	31	grabbing	grab	VERB
ajcp-1634	85	32	non	non	ADJ
ajcp-1634	85	33	-	-	NOUN
ajcp-1634	85	34	integrin	integrin	ADJ
ajcp-1634	85	35	(	(	PUNCT
ajcp-1634	85	36	dc	dc	PROPN
ajcp-1634	85	37	-	-	PUNCT
ajcp-1634	85	38	sign	sign	NOUN
ajcp-1634	85	39	)	)	PUNCT
ajcp-1634	85	40	bind	bind	VERB
ajcp-1634	85	41	to	to	ADP
ajcp-1634	85	42	two	two	NUM
ajcp-1634	85	43	n	n	CCONJ
ajcp-1634	85	44	-	-	PUNCT
ajcp-1634	85	45	glycans	glycan	NOUN
ajcp-1634	85	46	of	of	ADP
ajcp-1634	85	47	the	the	DET
ajcp-1634	85	48	rbd	rbd	NOUN
ajcp-1634	85	49	of	of	ADP
ajcp-1634	85	50	the	the	DET
ajcp-1634	85	51	s	s	NOUN
ajcp-1634	85	52	protein	protein	NOUN
ajcp-1634	85	53	at	at	ADP
ajcp-1634	85	54	n331	n331	PROPN
ajcp-1634	85	55	and	and	CCONJ
ajcp-1634	85	56	n343	n343	PROPN
ajcp-1634	85	57	,	,	PUNCT
ajcp-1634	85	58	which	which	PRON
ajcp-1634	85	59	may	may	AUX
ajcp-1634	85	60	provide	provide	VERB
ajcp-1634	85	61	insight	insight	NOUN
ajcp-1634	85	62	into	into	ADP
ajcp-1634	85	63	sars	sar	NOUN
ajcp-1634	85	64	-	-	PUNCT
ajcp-1634	85	65	cov-2	cov-2	NOUN
ajcp-1634	85	66	tropism	tropism	NOUN
ajcp-1634	85	67	and	and	CCONJ
ajcp-1634	85	68	binding	binding	ADJ
ajcp-1634	85	69	.	.	PUNCT
ajcp-1634	86	1	lenza	lenza	PROPN
ajcp-1634	86	2	et	et	PROPN
ajcp-1634	86	3	al	al	PROPN
ajcp-1634	86	4	.	.	PROPN
ajcp-1634	87	1	(	(	PUNCT
ajcp-1634	87	2	2020	2020	NUM
ajcp-1634	87	3	)	)	PUNCT
ajcp-1634	87	4	adaptive	adaptive	ADJ
ajcp-1634	87	5	immunity	immunity	NOUN
ajcp-1634	87	6	when	when	SCONJ
ajcp-1634	87	7	compared	compare	VERB
ajcp-1634	87	8	to	to	ADP
ajcp-1634	87	9	other	other	ADJ
ajcp-1634	87	10	blood	blood	NOUN
ajcp-1634	87	11	groups	group	NOUN
ajcp-1634	87	12	,	,	PUNCT
ajcp-1634	87	13	the	the	DET
ajcp-1634	87	14	proportion	proportion	NOUN
ajcp-1634	87	15	of	of	ADP
ajcp-1634	87	16	seropositives	seropositive	NOUN
ajcp-1634	87	17	in	in	ADP
ajcp-1634	87	18	group	group	NOUN
ajcp-1634	87	19	o	o	NOUN
ajcp-1634	87	20	individuals	individual	NOUN
ajcp-1634	87	21	was	be	AUX
ajcp-1634	87	22	significantly	significantly	ADV
ajcp-1634	87	23	lower	low	ADJ
ajcp-1634	87	24	,	,	PUNCT
ajcp-1634	87	25	implying	imply	VERB
ajcp-1634	87	26	that	that	DET
ajcp-1634	87	27	group	group	NOUN
ajcp-1634	87	28	o	o	NOUN
ajcp-1634	87	29	individuals	individual	NOUN
ajcp-1634	87	30	have	have	VERB
ajcp-1634	87	31	a	a	DET
ajcp-1634	87	32	lower	low	ADJ
ajcp-1634	87	33	risk	risk	NOUN
ajcp-1634	87	34	of	of	ADP
ajcp-1634	87	35	infection	infection	NOUN
ajcp-1634	87	36	.	.	PUNCT
ajcp-1634	88	1	gallian	gallian	PROPN
ajcp-1634	88	2	et	et	PROPN
ajcp-1634	88	3	al	al	PROPN
ajcp-1634	88	4	.	.	PROPN
ajcp-1634	89	1	(	(	PUNCT
ajcp-1634	89	2	2020	2020	NUM
ajcp-1634	89	3	)	)	PUNCT
ajcp-1634	89	4	sulfate	sulfate	NOUN
ajcp-1634	89	5	glycans	glycan	NOUN
ajcp-1634	89	6	on	on	ADP
ajcp-1634	89	7	the	the	DET
ajcp-1634	89	8	sars	sar	NOUN
ajcp-1634	89	9	-	-	PUNCT
ajcp-1634	89	10	cov-2	cov-2	NOUN
ajcp-1634	89	11	s	s	PART
ajcp-1634	89	12	protein	protein	NOUN
ajcp-1634	89	13	could	could	AUX
ajcp-1634	89	14	act	act	VERB
ajcp-1634	89	15	as	as	ADP
ajcp-1634	89	16	selectin	selectin	ADJ
ajcp-1634	89	17	ligands	ligand	NOUN
ajcp-1634	89	18	and	and	CCONJ
ajcp-1634	89	19	play	play	VERB
ajcp-1634	89	20	a	a	DET
ajcp-1634	89	21	role	role	NOUN
ajcp-1634	89	22	in	in	ADP
ajcp-1634	89	23	immune	immune	ADJ
ajcp-1634	89	24	regulation	regulation	NOUN
ajcp-1634	89	25	.	.	PUNCT
ajcp-1634	90	1	lowe	lowe	PROPN
ajcp-1634	90	2	(	(	PUNCT
ajcp-1634	90	3	2002	2002	NUM
ajcp-1634	90	4	)	)	PUNCT
ajcp-1634	90	5	variations	variation	NOUN
ajcp-1634	90	6	in	in	ADP
ajcp-1634	90	7	virus	virus	NOUN
ajcp-1634	90	8	and	and	CCONJ
ajcp-1634	90	9	host	host	NOUN
ajcp-1634	90	10	glycosylation	glycosylation	NOUN
ajcp-1634	90	11	are	be	AUX
ajcp-1634	90	12	likely	likely	ADJ
ajcp-1634	90	13	to	to	PART
ajcp-1634	90	14	influence	influence	VERB
ajcp-1634	90	15	tissue	tissue	NOUN
ajcp-1634	90	16	tropism	tropism	NOUN
ajcp-1634	90	17	and	and	CCONJ
ajcp-1634	90	18	individual	individual	ADJ
ajcp-1634	90	19	infection	infection	NOUN
ajcp-1634	90	20	susceptibility	susceptibility	NOUN
ajcp-1634	90	21	;	;	PUNCT
ajcp-1634	90	22	differences	difference	NOUN
ajcp-1634	90	23	in	in	ADP
ajcp-1634	90	24	virus	virus	NOUN
ajcp-1634	90	25	infectivity	infectivity	NOUN
ajcp-1634	90	26	and	and	CCONJ
ajcp-1634	90	27	patient	patient	ADJ
ajcp-1634	90	28	susceptibility	susceptibility	NOUN
ajcp-1634	90	29	may	may	AUX
ajcp-1634	90	30	be	be	AUX
ajcp-1634	90	31	caused	cause	VERB
ajcp-1634	90	32	by	by	ADP
ajcp-1634	90	33	sars	sar	NOUN
ajcp-1634	90	34	-	-	PUNCT
ajcp-1634	90	35	cov-2	cov-2	PART
ajcp-1634	90	36	and	and	CCONJ
ajcp-1634	90	37	ace	ace	VERB
ajcp-1634	90	38	2	2	NUM
ajcp-1634	90	39	mutations	mutation	NOUN
ajcp-1634	90	40	that	that	PRON
ajcp-1634	90	41	alter	alter	VERB
ajcp-1634	90	42	n	n	CCONJ
ajcp-1634	90	43	-	-	PUNCT
ajcp-1634	90	44	glycosylation	glycosylation	NOUN
ajcp-1634	90	45	sites	site	NOUN
ajcp-1634	90	46	.	.	PUNCT
ajcp-1634	91	1	reis	reis	NOUN
ajcp-1634	91	2	et	et	PROPN
ajcp-1634	91	3	al	al	PROPN
ajcp-1634	91	4	.	.	PROPN
ajcp-1634	92	1	(	(	PUNCT
ajcp-1634	92	2	2021	2021	NUM
ajcp-1634	92	3	)	)	PUNCT
ajcp-1634	92	4	vaccine	vaccine	NOUN
ajcp-1634	92	5	development	development	NOUN
ajcp-1634	92	6	sars	sar	NOUN
ajcp-1634	92	7	-	-	PUNCT
ajcp-1634	92	8	cov-2	cov-2	PART
ajcp-1634	92	9	glycosylation	glycosylation	NOUN
ajcp-1634	92	10	can	can	AUX
ajcp-1634	92	11	affect	affect	VERB
ajcp-1634	92	12	each	each	PRON
ajcp-1634	92	13	of	of	ADP
ajcp-1634	92	14	the	the	DET
ajcp-1634	92	15	current	current	ADJ
ajcp-1634	92	16	vaccine	vaccine	NOUN
ajcp-1634	92	17	strategies	strategy	NOUN
ajcp-1634	92	18	in	in	ADP
ajcp-1634	92	19	different	different	ADJ
ajcp-1634	92	20	ways	way	NOUN
ajcp-1634	92	21	(	(	PUNCT
ajcp-1634	92	22	i.e.	i.e.	X
ajcp-1634	92	23	,	,	PUNCT
ajcp-1634	92	24	vector	vector	NOUN
ajcp-1634	92	25	-	-	PUNCT
ajcp-1634	92	26	based	base	VERB
ajcp-1634	92	27	vaccine	vaccine	NOUN
ajcp-1634	92	28	,	,	PUNCT
ajcp-1634	92	29	mrna	mrna	NOUN
ajcp-1634	92	30	-	-	PUNCT
ajcp-1634	92	31	based	base	VERB
ajcp-1634	92	32	vaccines	vaccine	NOUN
ajcp-1634	92	33	)	)	PUNCT
ajcp-1634	92	34	.	.	PUNCT
ajcp-1634	93	1	reis	reis	NOUN
ajcp-1634	93	2	et	et	PROPN
ajcp-1634	93	3	al	al	PROPN
ajcp-1634	93	4	.	.	PROPN
ajcp-1634	94	1	(	(	PUNCT
ajcp-1634	94	2	2021	2021	NUM
ajcp-1634	94	3	)	)	PUNCT
ajcp-1634	94	4	suitable	suitable	ADJ
ajcp-1634	94	5	glycosylation	glycosylation	NOUN
ajcp-1634	94	6	of	of	ADP
ajcp-1634	94	7	the	the	DET
ajcp-1634	94	8	recombinant	recombinant	ADJ
ajcp-1634	94	9	protein	protein	NOUN
ajcp-1634	94	10	will	will	AUX
ajcp-1634	94	11	at	at	ADV
ajcp-1634	94	12	least	least	ADJ
ajcp-1634	94	13	partly	partly	ADV
ajcp-1634	94	14	determine	determine	VERB
ajcp-1634	94	15	how	how	SCONJ
ajcp-1634	94	16	immunogenic	immunogenic	ADJ
ajcp-1634	94	17	polypeptide	polypeptide	ADJ
ajcp-1634	94	18	epitopes	epitope	NOUN
ajcp-1634	94	19	of	of	ADP
ajcp-1634	94	20	vaccine	vaccine	NOUN
ajcp-1634	94	21	glycoproteins	glycoprotein	NOUN
ajcp-1634	94	22	fold	fold	VERB
ajcp-1634	94	23	.	.	PUNCT
ajcp-1634	95	1	reis	reis	NOUN
ajcp-1634	95	2	et	et	PROPN
ajcp-1634	95	3	al	al	PROPN
ajcp-1634	95	4	.	.	PROPN
ajcp-1634	96	1	(	(	PUNCT
ajcp-1634	96	2	2020	2020	NUM
ajcp-1634	96	3	)	)	PUNCT
ajcp-1634	96	4	the	the	DET
ajcp-1634	96	5	presence	presence	NOUN
ajcp-1634	96	6	of	of	ADP
ajcp-1634	96	7	glycans	glycan	NOUN
ajcp-1634	96	8	on	on	ADP
ajcp-1634	96	9	protein	protein	NOUN
ajcp-1634	96	10	antigens	antigen	NOUN
ajcp-1634	96	11	influences	influence	VERB
ajcp-1634	96	12	cellular	cellular	ADJ
ajcp-1634	96	13	uptake	uptake	NOUN
ajcp-1634	96	14	,	,	PUNCT
ajcp-1634	96	15	proteolytic	proteolytic	ADJ
ajcp-1634	96	16	processing	processing	NOUN
ajcp-1634	96	17	,	,	PUNCT
ajcp-1634	96	18	mhc	mhc	PROPN
ajcp-1634	96	19	presentation	presentation	NOUN
ajcp-1634	96	20	,	,	PUNCT
ajcp-1634	96	21	and	and	CCONJ
ajcp-1634	96	22	subsequent	subsequent	ADJ
ajcp-1634	96	23	t	t	PROPN
ajcp-1634	96	24	-	-	PUNCT
ajcp-1634	96	25	cell	cell	NOUN
ajcp-1634	96	26	priming	priming	NOUN
ajcp-1634	96	27	,	,	PUNCT
ajcp-1634	96	28	providing	provide	VERB
ajcp-1634	96	29	insight	insight	NOUN
ajcp-1634	96	30	into	into	ADP
ajcp-1634	96	31	how	how	SCONJ
ajcp-1634	96	32	proper	proper	ADJ
ajcp-1634	96	33	folding	folding	NOUN
ajcp-1634	96	34	of	of	ADP
ajcp-1634	96	35	recombinant	recombinant	ADJ
ajcp-1634	96	36	vaccine	vaccine	NOUN
ajcp-1634	96	37	glycoprotein	glycoprotein	NOUN
ajcp-1634	96	38	can	can	AUX
ajcp-1634	96	39	affect	affect	VERB
ajcp-1634	96	40	the	the	DET
ajcp-1634	96	41	development	development	NOUN
ajcp-1634	96	42	of	of	ADP
ajcp-1634	96	43	an	an	DET
ajcp-1634	96	44	adaptive	adaptive	ADJ
ajcp-1634	96	45	immune	immune	ADJ
ajcp-1634	96	46	response	response	NOUN
ajcp-1634	96	47	wolfert	wolfert	PROPN
ajcp-1634	96	48	&	&	CCONJ
ajcp-1634	96	49	boons	boon	NOUN
ajcp-1634	96	50	(	(	PUNCT
ajcp-1634	96	51	2013	2013	NUM
ajcp-1634	96	52	)	)	PUNCT
ajcp-1634	96	53	the	the	DET
ajcp-1634	96	54	presence	presence	NOUN
ajcp-1634	96	55	of	of	ADP
ajcp-1634	96	56	non	non	ADJ
ajcp-1634	96	57	-	-	ADJ
ajcp-1634	96	58	human	human	ADJ
ajcp-1634	96	59	glycans	glycan	NOUN
ajcp-1634	96	60	on	on	ADP
ajcp-1634	96	61	recombinant	recombinant	ADJ
ajcp-1634	96	62	therapeutic	therapeutic	ADJ
ajcp-1634	96	63	glycoproteins	glycoprotein	NOUN
ajcp-1634	96	64	may	may	AUX
ajcp-1634	96	65	induce	induce	VERB
ajcp-1634	96	66	antibodies	antibody	NOUN
ajcp-1634	96	67	directed	direct	VERB
ajcp-1634	96	68	against	against	ADP
ajcp-1634	96	69	non	non	ADJ
ajcp-1634	96	70	-	-	ADJ
ajcp-1634	96	71	human	human	ADJ
ajcp-1634	96	72	glycan	glycan	NOUN
ajcp-1634	96	73	epitopes	epitope	NOUN
ajcp-1634	96	74	.	.	PUNCT
ajcp-1634	97	1	zhou	zhou	PROPN
ajcp-1634	97	2	&	&	CCONJ
ajcp-1634	97	3	qiu	qiu	PROPN
ajcp-1634	97	4	(	(	PUNCT
ajcp-1634	97	5	2019	2019	NUM
ajcp-1634	97	6	)	)	PUNCT
ajcp-1634	97	7	vaccines	vaccine	NOUN
ajcp-1634	97	8	based	base	VERB
ajcp-1634	97	9	on	on	ADP
ajcp-1634	97	10	the	the	DET
ajcp-1634	97	11	sars	sar	NOUN
ajcp-1634	97	12	-	-	PUNCT
ajcp-1634	97	13	cov-2	cov-2	NOUN
ajcp-1634	97	14	s	s	NOUN
ajcp-1634	97	15	protein	protein	NOUN
ajcp-1634	97	16	because	because	SCONJ
ajcp-1634	97	17	the	the	DET
ajcp-1634	97	18	s	s	NOUN
ajcp-1634	97	19	protein	protein	NOUN
ajcp-1634	97	20	is	be	AUX
ajcp-1634	97	21	involved	involve	VERB
ajcp-1634	97	22	in	in	ADP
ajcp-1634	97	23	receptor	receptor	NOUN
ajcp-1634	97	24	binding	bind	VERB
ajcp-1634	97	25	and	and	CCONJ
ajcp-1634	97	26	membrane	membrane	NOUN
ajcp-1634	97	27	fusion	fusion	NOUN
ajcp-1634	97	28	,	,	PUNCT
ajcp-1634	97	29	vaccinations	vaccination	NOUN
ajcp-1634	97	30	may	may	AUX
ajcp-1634	97	31	induce	induce	VERB
ajcp-1634	97	32	antibodies	antibody	NOUN
ajcp-1634	97	33	that	that	PRON
ajcp-1634	97	34	prevent	prevent	VERB
ajcp-1634	97	35	virus	virus	NOUN
ajcp-1634	97	36	binding	bind	VERB
ajcp-1634	97	37	and	and	CCONJ
ajcp-1634	97	38	fusion	fusion	NOUN
ajcp-1634	97	39	or	or	CCONJ
ajcp-1634	97	40	neutralize	neutralize	VERB
ajcp-1634	97	41	virus	virus	NOUN
ajcp-1634	97	42	infection	infection	NOUN
ajcp-1634	97	43	.	.	PUNCT
ajcp-1634	98	1	s	s	VERB
ajcp-1634	99	1	protein	protein	NOUN
ajcp-1634	99	2	is	be	AUX
ajcp-1634	99	3	the	the	DET
ajcp-1634	99	4	major	major	ADJ
ajcp-1634	99	5	antigenic	antigenic	ADJ
ajcp-1634	99	6	component	component	NOUN
ajcp-1634	99	7	of	of	ADP
ajcp-1634	99	8	sars	sars	PROPN
ajcp-1634	99	9	-	-	PUNCT
ajcp-1634	99	10	cov	cov	NOUN
ajcp-1634	99	11	.	.	PUNCT
ajcp-1634	100	1	it	it	PRON
ajcp-1634	100	2	is	be	AUX
ajcp-1634	100	3	essential	essential	ADJ
ajcp-1634	100	4	to	to	PART
ajcp-1634	100	5	generate	generate	VERB
ajcp-1634	100	6	host	host	NOUN
ajcp-1634	100	7	immunological	immunological	ADJ
ajcp-1634	100	8	responses	response	NOUN
ajcp-1634	100	9	,	,	PUNCT
ajcp-1634	100	10	neutralizing	neutralize	VERB
ajcp-1634	100	11	antibodies	antibody	NOUN
ajcp-1634	100	12	,	,	PUNCT
ajcp-1634	100	13	and	and	CCONJ
ajcp-1634	100	14	protective	protective	ADJ
ajcp-1634	100	15	immunity	immunity	NOUN
ajcp-1634	100	16	against	against	ADP
ajcp-1634	100	17	virus	virus	NOUN
ajcp-1634	100	18	infection	infection	NOUN
ajcp-1634	100	19	among	among	ADP
ajcp-1634	100	20	all	all	DET
ajcp-1634	100	21	structural	structural	ADJ
ajcp-1634	100	22	proteins	protein	NOUN
ajcp-1634	100	23	(	(	PUNCT
ajcp-1634	100	24	du	du	X
ajcp-1634	100	25	et	et	PROPN
ajcp-1634	100	26	al	al	PROPN
ajcp-1634	100	27	.	.	PROPN
ajcp-1634	100	28	,	,	PUNCT
ajcp-1634	100	29	2009	2009	NUM
ajcp-1634	100	30	)	)	PUNCT
ajcp-1634	100	31	.	.	PUNCT
ajcp-1634	101	1	this	this	DET
ajcp-1634	101	2	paper	paper	NOUN
ajcp-1634	101	3	reviewed	review	VERB
ajcp-1634	101	4	and	and	CCONJ
ajcp-1634	101	5	compared	compare	VERB
ajcp-1634	101	6	each	each	DET
ajcp-1634	101	7	approach	approach	NOUN
ajcp-1634	101	8	on	on	ADP
ajcp-1634	101	9	which	which	PRON
ajcp-1634	101	10	s	s	VERB
ajcp-1634	101	11	protein	protein	NOUN
ajcp-1634	101	12	is	be	AUX
ajcp-1634	101	13	given	give	VERB
ajcp-1634	101	14	focus	focus	NOUN
ajcp-1634	101	15	in	in	ADP
ajcp-1634	101	16	vaccine	vaccine	NOUN
ajcp-1634	101	17	development	development	NOUN
ajcp-1634	101	18	.	.	PUNCT
ajcp-1634	102	1	some	some	PRON
ajcp-1634	102	2	of	of	ADP
ajcp-1634	102	3	these	these	DET
ajcp-1634	102	4	vaccines	vaccine	NOUN
ajcp-1634	102	5	are	be	AUX
ajcp-1634	102	6	already	already	ADV
ajcp-1634	102	7	being	be	AUX
ajcp-1634	102	8	used	use	VERB
ajcp-1634	102	9	and	and	CCONJ
ajcp-1634	102	10	distributed	distribute	VERB
ajcp-1634	102	11	worldwide	worldwide	ADV
ajcp-1634	102	12	.	.	PUNCT
ajcp-1634	103	1	table	table	NOUN
ajcp-1634	103	2	1	1	NUM
ajcp-1634	103	3	summarizes	summarize	NOUN
ajcp-1634	103	4	the	the	DET
ajcp-1634	103	5	findings	finding	NOUN
ajcp-1634	103	6	.	.	PUNCT
ajcp-1634	104	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	104	2	pa	pa	PROPN
ajcp-1634	104	3	ge	ge	PROPN
ajcp-1634	104	4	69	69	NUM
ajcp-1634	104	5	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	104	6	am	be	AUX
ajcp-1634	104	7	.	.	PUNCT
ajcp-1634	105	1	j.	j.	PROPN
ajcp-1634	105	2	chem	chem	PROPN
ajcp-1634	105	3	.	.	PUNCT
ajcp-1634	106	1	pharm	pharm	PROPN
ajcp-1634	106	2	.	.	PUNCT
ajcp-1634	107	1	2(2	2(2	NUM
ajcp-1634	107	2	)	)	PUNCT
ajcp-1634	107	3	66	66	NUM
ajcp-1634	107	4	-	-	SYM
ajcp-1634	107	5	73	73	NUM
ajcp-1634	107	6	,	,	PUNCT
ajcp-1634	108	1	2023	2023	NUM
ajcp-1634	108	2	mrna	mrna	PROPN
ajcp-1634	108	3	-	-	PUNCT
ajcp-1634	108	4	based	base	VERB
ajcp-1634	108	5	three	three	NUM
ajcp-1634	108	6	mrna	mrna	NOUN
ajcp-1634	108	7	-	-	PUNCT
ajcp-1634	108	8	based	base	VERB
ajcp-1634	108	9	vaccines	vaccine	NOUN
ajcp-1634	108	10	,	,	PUNCT
ajcp-1634	108	11	biontech	biontech	NOUN
ajcp-1634	108	12	/	/	SYM
ajcp-1634	108	13	pfizer	pfizer	NOUN
ajcp-1634	108	14	(	(	PUNCT
ajcp-1634	108	15	bnt162b2	bnt162b2	NOUN
ajcp-1634	108	16	mrna	mrna	PROPN
ajcp-1634	108	17	)	)	PUNCT
ajcp-1634	108	18	,	,	PUNCT
ajcp-1634	108	19	moderna	moderna	PROPN
ajcp-1634	108	20	(	(	PUNCT
ajcp-1634	108	21	mrna-1273	mrna-1273	ADJ
ajcp-1634	108	22	)	)	PUNCT
ajcp-1634	108	23	,	,	PUNCT
ajcp-1634	108	24	and	and	CCONJ
ajcp-1634	108	25	curevac	curevac	NOUN
ajcp-1634	108	26	(	(	PUNCT
ajcp-1634	108	27	cvncov	cvncov	ADJ
ajcp-1634	108	28	)	)	PUNCT
ajcp-1634	108	29	,	,	PUNCT
ajcp-1634	108	30	have	have	AUX
ajcp-1634	108	31	been	be	AUX
ajcp-1634	108	32	reported	report	VERB
ajcp-1634	108	33	(	(	PUNCT
ajcp-1634	108	34	sadarangani	sadarangani	PROPN
ajcp-1634	108	35	et	et	PROPN
ajcp-1634	108	36	al	al	PROPN
ajcp-1634	108	37	.	.	PROPN
ajcp-1634	108	38	,	,	PUNCT
ajcp-1634	108	39	2021	2021	NUM
ajcp-1634	108	40	;	;	PUNCT
ajcp-1634	108	41	kowalzik	kowalzik	PROPN
ajcp-1634	108	42	et	et	PROPN
ajcp-1634	108	43	al	al	PROPN
ajcp-1634	108	44	.	.	PROPN
ajcp-1634	108	45	,	,	PUNCT
ajcp-1634	108	46	2021	2021	NUM
ajcp-1634	108	47	)	)	PUNCT
ajcp-1634	108	48	.	.	PUNCT
ajcp-1634	109	1	this	this	DET
ajcp-1634	109	2	type	type	NOUN
ajcp-1634	109	3	of	of	ADP
ajcp-1634	109	4	vaccine	vaccine	NOUN
ajcp-1634	109	5	is	be	AUX
ajcp-1634	109	6	said	say	VERB
ajcp-1634	109	7	to	to	PART
ajcp-1634	109	8	be	be	AUX
ajcp-1634	109	9	different	different	ADJ
ajcp-1634	109	10	from	from	ADP
ajcp-1634	109	11	the	the	DET
ajcp-1634	109	12	traditional	traditional	ADJ
ajcp-1634	109	13	kind	kind	NOUN
ajcp-1634	109	14	of	of	ADP
ajcp-1634	109	15	vaccine	vaccine	NOUN
ajcp-1634	109	16	.	.	PUNCT
ajcp-1634	110	1	in	in	ADP
ajcp-1634	110	2	an	an	DET
ajcp-1634	110	3	mrna	mrna	NOUN
ajcp-1634	110	4	vaccine	vaccine	NOUN
ajcp-1634	110	5	,	,	PUNCT
ajcp-1634	110	6	a	a	DET
ajcp-1634	110	7	transcript	transcript	NOUN
ajcp-1634	110	8	encoding	encode	VERB
ajcp-1634	110	9	one	one	NUM
ajcp-1634	110	10	or	or	CCONJ
ajcp-1634	110	11	more	more	ADJ
ajcp-1634	110	12	immunogens	immunogen	NOUN
ajcp-1634	110	13	is	be	AUX
ajcp-1634	110	14	delivered	deliver	VERB
ajcp-1634	110	15	into	into	ADP
ajcp-1634	110	16	the	the	DET
ajcp-1634	110	17	host	host	NOUN
ajcp-1634	110	18	cell	cell	NOUN
ajcp-1634	110	19	’s	’s	PART
ajcp-1634	110	20	cytoplasm	cytoplasm	NOUN
ajcp-1634	110	21	,	,	PUNCT
ajcp-1634	110	22	which	which	PRON
ajcp-1634	110	23	is	be	AUX
ajcp-1634	110	24	translated	translate	VERB
ajcp-1634	110	25	into	into	ADP
ajcp-1634	110	26	immunogenic	immunogenic	ADJ
ajcp-1634	110	27	proteins	protein	NOUN
ajcp-1634	110	28	(	(	PUNCT
ajcp-1634	110	29	kowalzik	kowalzik	NOUN
ajcp-1634	110	30	et	et	PROPN
ajcp-1634	110	31	al	al	PROPN
ajcp-1634	110	32	.	.	PROPN
ajcp-1634	110	33	,	,	PUNCT
ajcp-1634	110	34	2021	2021	NUM
ajcp-1634	110	35	)	)	PUNCT
ajcp-1634	110	36	.	.	PUNCT
ajcp-1634	111	1	mrna	mrna	PROPN
ajcp-1634	111	2	vaccine	vaccine	NOUN
ajcp-1634	111	3	manufacture	manufacture	NOUN
ajcp-1634	111	4	does	do	AUX
ajcp-1634	111	5	not	not	PART
ajcp-1634	111	6	entail	entail	VERB
ajcp-1634	111	7	infectious	infectious	ADJ
ajcp-1634	111	8	elements	element	NOUN
ajcp-1634	111	9	or	or	CCONJ
ajcp-1634	111	10	the	the	DET
ajcp-1634	111	11	risk	risk	NOUN
ajcp-1634	111	12	of	of	ADP
ajcp-1634	111	13	stable	stable	ADJ
ajcp-1634	111	14	integration	integration	NOUN
ajcp-1634	111	15	into	into	ADP
ajcp-1634	111	16	the	the	DET
ajcp-1634	111	17	host	host	NOUN
ajcp-1634	111	18	cell	cell	NOUN
ajcp-1634	111	19	genome	genome	NOUN
ajcp-1634	111	20	;	;	PUNCT
ajcp-1634	111	21	instead	instead	ADV
ajcp-1634	111	22	,	,	PUNCT
ajcp-1634	111	23	the	the	DET
ajcp-1634	111	24	vaccine	vaccine	NOUN
ajcp-1634	111	25	rna	rna	NOUN
ajcp-1634	111	26	strand	strand	NOUN
ajcp-1634	111	27	is	be	AUX
ajcp-1634	111	28	destroyed	destroy	VERB
ajcp-1634	111	29	(	(	PUNCT
ajcp-1634	111	30	sadarangani	sadarangani	PROPN
ajcp-1634	111	31	et	et	PROPN
ajcp-1634	111	32	al	al	PROPN
ajcp-1634	111	33	.	.	PROPN
ajcp-1634	111	34	,	,	PUNCT
ajcp-1634	111	35	2021	2021	NUM
ajcp-1634	111	36	)	)	PUNCT
ajcp-1634	111	37	.	.	PUNCT
ajcp-1634	112	1	because	because	SCONJ
ajcp-1634	112	2	of	of	ADP
ajcp-1634	112	3	this	this	PRON
ajcp-1634	112	4	,	,	PUNCT
ajcp-1634	112	5	this	this	DET
ajcp-1634	112	6	type	type	NOUN
ajcp-1634	112	7	of	of	ADP
ajcp-1634	112	8	vaccine	vaccine	NOUN
ajcp-1634	112	9	is	be	AUX
ajcp-1634	112	10	safer	safe	ADJ
ajcp-1634	112	11	.	.	PUNCT
ajcp-1634	113	1	in	in	ADP
ajcp-1634	113	2	the	the	DET
ajcp-1634	113	3	case	case	NOUN
ajcp-1634	113	4	of	of	ADP
ajcp-1634	113	5	biontech	biontech	NOUN
ajcp-1634	113	6	/	/	SYM
ajcp-1634	113	7	pfizer	pfizer	NOUN
ajcp-1634	113	8	,	,	PUNCT
ajcp-1634	113	9	a	a	DET
ajcp-1634	113	10	prefusion	prefusion	NOUN
ajcp-1634	113	11	stabilized	stabilize	VERB
ajcp-1634	113	12	,	,	PUNCT
ajcp-1634	113	13	membrane	membrane	NOUN
ajcp-1634	113	14	-	-	PUNCT
ajcp-1634	113	15	anchored	anchor	VERB
ajcp-1634	113	16	sarscov-2	sarscov-2	NUM
ajcp-1634	113	17	full	full	ADJ
ajcp-1634	113	18	-	-	PUNCT
ajcp-1634	113	19	length	length	NOUN
ajcp-1634	113	20	spike	spike	ADJ
ajcp-1634	113	21	protein	protein	NOUN
ajcp-1634	113	22	is	be	AUX
ajcp-1634	113	23	encoded	encode	VERB
ajcp-1634	113	24	(	(	PUNCT
ajcp-1634	113	25	polack	polack	PROPN
ajcp-1634	113	26	et	et	PROPN
ajcp-1634	113	27	al	al	PROPN
ajcp-1634	113	28	.	.	PROPN
ajcp-1634	113	29	,	,	PUNCT
ajcp-1634	113	30	2020	2020	NUM
ajcp-1634	113	31	;	;	PUNCT
ajcp-1634	113	32	walsh	walsh	PROPN
ajcp-1634	113	33	et	et	PROPN
ajcp-1634	113	34	al	al	PROPN
ajcp-1634	113	35	.	.	PROPN
ajcp-1634	113	36	,	,	PUNCT
ajcp-1634	113	37	2020	2020	NUM
ajcp-1634	113	38	)	)	PUNCT
ajcp-1634	113	39	.	.	PUNCT
ajcp-1634	114	1	two	two	NUM
ajcp-1634	114	2	proline	proline	NOUN
ajcp-1634	114	3	mutations	mutation	NOUN
ajcp-1634	114	4	modify	modify	VERB
ajcp-1634	114	5	this	this	DET
ajcp-1634	114	6	encoding	encoding	NOUN
ajcp-1634	114	7	s	s	PART
ajcp-1634	114	8	protein	protein	NOUN
ajcp-1634	114	9	to	to	PART
ajcp-1634	114	10	lock	lock	VERB
ajcp-1634	114	11	protein	protein	NOUN
ajcp-1634	114	12	in	in	ADP
ajcp-1634	114	13	the	the	DET
ajcp-1634	114	14	pre	pre	ADJ
ajcp-1634	114	15	-	-	ADJ
ajcp-1634	114	16	fusion	fusion	ADJ
ajcp-1634	114	17	conformation	conformation	NOUN
ajcp-1634	114	18	(	(	PUNCT
ajcp-1634	114	19	pardi	pardi	PROPN
ajcp-1634	114	20	et	et	PROPN
ajcp-1634	114	21	al	al	PROPN
ajcp-1634	114	22	.	.	PROPN
ajcp-1634	114	23	,	,	PUNCT
ajcp-1634	114	24	2015	2015	NUM
ajcp-1634	114	25	;	;	PUNCT
ajcp-1634	114	26	kariko	kariko	NOUN
ajcp-1634	114	27	et	et	PROPN
ajcp-1634	114	28	al	al	PROPN
ajcp-1634	114	29	.	.	PROPN
ajcp-1634	114	30	,	,	PUNCT
ajcp-1634	114	31	2005	2005	NUM
ajcp-1634	114	32	;	;	PUNCT
ajcp-1634	114	33	wrapp	wrapp	PROPN
ajcp-1634	114	34	et	et	PROPN
ajcp-1634	114	35	al	al	PROPN
ajcp-1634	114	36	.	.	PROPN
ajcp-1634	114	37	,	,	PUNCT
ajcp-1634	114	38	2020	2020	NUM
ajcp-1634	114	39	)	)	PUNCT
ajcp-1634	114	40	.	.	PUNCT
ajcp-1634	115	1	mrnabased	mrnabase	VERB
ajcp-1634	115	2	vaccines	vaccine	NOUN
ajcp-1634	115	3	,	,	PUNCT
ajcp-1634	115	4	particularly	particularly	ADV
ajcp-1634	115	5	the	the	DET
ajcp-1634	115	6	biontech	biontech	NOUN
ajcp-1634	115	7	/	/	SYM
ajcp-1634	115	8	pfizer	pfizer	NOUN
ajcp-1634	115	9	vaccine	vaccine	NOUN
ajcp-1634	115	10	,	,	PUNCT
ajcp-1634	115	11	elicit	elicit	VERB
ajcp-1634	115	12	high	high	ADJ
ajcp-1634	115	13	sars	sar	NOUN
ajcp-1634	115	14	-	-	PUNCT
ajcp-1634	115	15	cov-2	cov-2	NOUN
ajcp-1634	115	16	neutralizing	neutralize	VERB
ajcp-1634	115	17	antibody	antibody	NOUN
ajcp-1634	115	18	titers	titer	NOUN
ajcp-1634	115	19	and	and	CCONJ
ajcp-1634	115	20	robust	robust	ADJ
ajcp-1634	115	21	antigen	antigen	NOUN
ajcp-1634	115	22	-	-	PUNCT
ajcp-1634	115	23	specific	specific	ADJ
ajcp-1634	115	24	th1	th1	NOUN
ajcp-1634	115	25	-	-	PUNCT
ajcp-1634	115	26	type	type	NOUN
ajcp-1634	115	27	cd4	cd4	PROPN
ajcp-1634	115	28	+	+	PROPN
ajcp-1634	115	29	and	and	CCONJ
ajcp-1634	115	30	cd8	cd8	PROPN
ajcp-1634	115	31	+	+	PROPN
ajcp-1634	115	32	t	t	PROPN
ajcp-1634	115	33	-	-	PUNCT
ajcp-1634	115	34	cell	cell	NOUN
ajcp-1634	115	35	responses	response	NOUN
ajcp-1634	115	36	,	,	PUNCT
ajcp-1634	115	37	similar	similar	ADJ
ajcp-1634	115	38	to	to	ADP
ajcp-1634	115	39	dna	dna	NOUN
ajcp-1634	115	40	-	-	PUNCT
ajcp-1634	115	41	based	base	VERB
ajcp-1634	115	42	vaccines	vaccine	NOUN
ajcp-1634	115	43	developed	develop	VERB
ajcp-1634	115	44	for	for	ADP
ajcp-1634	115	45	sars	sar	NOUN
ajcp-1634	115	46	-	-	PUNCT
ajcp-1634	115	47	cov	cov	NOUN
ajcp-1634	115	48	,	,	PUNCT
ajcp-1634	115	49	which	which	PRON
ajcp-1634	115	50	induce	induce	VERB
ajcp-1634	115	51	neutralizing	neutralize	VERB
ajcp-1634	115	52	antibody	antibody	NOUN
ajcp-1634	115	53	and	and	CCONJ
ajcp-1634	115	54	t	t	NOUN
ajcp-1634	115	55	-	-	PUNCT
ajcp-1634	115	56	cell	cell	NOUN
ajcp-1634	115	57	responses	response	NOUN
ajcp-1634	115	58	and	and	CCONJ
ajcp-1634	115	59	protective	protective	ADJ
ajcp-1634	115	60	immunity	immunity	NOUN
ajcp-1634	115	61	(	(	PUNCT
ajcp-1634	115	62	wang	wang	PROPN
ajcp-1634	115	63	et	et	PROPN
ajcp-1634	115	64	al	al	PROPN
ajcp-1634	115	65	.	.	PROPN
ajcp-1634	115	66	,	,	PUNCT
ajcp-1634	115	67	2005	2005	NUM
ajcp-1634	115	68	;	;	PUNCT
ajcp-1634	115	69	huang	huang	PROPN
ajcp-1634	115	70	et	et	PROPN
ajcp-1634	115	71	al	al	PROPN
ajcp-1634	115	72	.	.	PROPN
ajcp-1634	115	73	,	,	PUNCT
ajcp-1634	115	74	2007	2007	NUM
ajcp-1634	115	75	;	;	PUNCT
ajcp-1634	115	76	liu	liu	PROPN
ajcp-1634	115	77	et	et	PROPN
ajcp-1634	115	78	(	(	PUNCT
ajcp-1634	115	79	sadarangani	sadarangani	PROPN
ajcp-1634	115	80	et	et	PROPN
ajcp-1634	115	81	al	al	PROPN
ajcp-1634	115	82	.	.	PROPN
ajcp-1634	115	83	,	,	PUNCT
ajcp-1634	115	84	2021	2021	NUM
ajcp-1634	115	85	)	)	PUNCT
ajcp-1634	115	86	.	.	PUNCT
ajcp-1634	116	1	the	the	DET
ajcp-1634	116	2	s1	s1	NOUN
ajcp-1634	116	3	-	-	PUNCT
ajcp-1634	116	4	binding	bind	VERB
ajcp-1634	116	5	antibody	antibody	NOUN
ajcp-1634	116	6	is	be	AUX
ajcp-1634	116	7	also	also	ADV
ajcp-1634	116	8	present	present	ADJ
ajcp-1634	116	9	after	after	ADP
ajcp-1634	116	10	the	the	DET
ajcp-1634	116	11	first	first	ADJ
ajcp-1634	116	12	of	of	ADP
ajcp-1634	116	13	table	table	NOUN
ajcp-1634	116	14	2	2	NUM
ajcp-1634	116	15	:	:	PUNCT
ajcp-1634	116	16	summary	summary	NOUN
ajcp-1634	116	17	of	of	ADP
ajcp-1634	116	18	key	key	ADJ
ajcp-1634	116	19	findings	finding	NOUN
ajcp-1634	116	20	vaccine	vaccine	NOUN
ajcp-1634	116	21	developer	developer	NOUN
ajcp-1634	116	22	nature	nature	NOUN
ajcp-1634	116	23	of	of	ADP
ajcp-1634	116	24	the	the	DET
ajcp-1634	116	25	vaccine	vaccine	NOUN
ajcp-1634	116	26	s	s	PART
ajcp-1634	116	27	protein	protein	NOUN
ajcp-1634	116	28	utilization	utilization	NOUN
ajcp-1634	116	29	approach	approach	NOUN
ajcp-1634	116	30	reference	reference	NOUN
ajcp-1634	116	31	/	/	SYM
ajcp-1634	116	32	s	s	PART
ajcp-1634	116	33	biontech/	biontech/	NUM
ajcp-1634	116	34	pfizer	pfizer	NOUN
ajcp-1634	116	35	mrna	mrna	NOUN
ajcp-1634	116	36	-	-	PUNCT
ajcp-1634	116	37	based	base	VERB
ajcp-1634	116	38	prefusion	prefusion	NOUN
ajcp-1634	116	39	stabilized	stabilize	VERB
ajcp-1634	116	40	,	,	PUNCT
ajcp-1634	116	41	membrane	membrane	NOUN
ajcp-1634	116	42	-	-	PUNCT
ajcp-1634	116	43	anchored	anchor	VERB
ajcp-1634	116	44	sarscov-2	sarscov-2	NUM
ajcp-1634	116	45	full	full	ADJ
ajcp-1634	116	46	-	-	PUNCT
ajcp-1634	116	47	length	length	NOUN
ajcp-1634	116	48	spike	spike	ADJ
ajcp-1634	116	49	protein	protein	NOUN
ajcp-1634	116	50	is	be	AUX
ajcp-1634	116	51	encoded	encode	VERB
ajcp-1634	116	52	polack	polack	PROPN
ajcp-1634	116	53	et	et	PROPN
ajcp-1634	116	54	al	al	PROPN
ajcp-1634	116	55	.	.	PROPN
ajcp-1634	116	56	,	,	PUNCT
ajcp-1634	116	57	2020	2020	NUM
ajcp-1634	116	58	;	;	PUNCT
ajcp-1634	116	59	walsh	walsh	PROPN
ajcp-1634	116	60	et	et	PROPN
ajcp-1634	116	61	al	al	PROPN
ajcp-1634	116	62	.	.	PROPN
ajcp-1634	116	63	,	,	PUNCT
ajcp-1634	116	64	2020	2020	NUM
ajcp-1634	116	65	moderna	moderna	PROPN
ajcp-1634	116	66	mrna	mrna	PROPN
ajcp-1634	116	67	-	-	PUNCT
ajcp-1634	116	68	based	base	VERB
ajcp-1634	116	69	encodes	encode	NOUN
ajcp-1634	116	70	the	the	PRON
ajcp-1634	116	71	sars	sar	NOUN
ajcp-1634	116	72	-	-	PUNCT
ajcp-1634	116	73	cov-2	cov-2	NOUN
ajcp-1634	116	74	stabilized	stabilize	VERB
ajcp-1634	116	75	prefusion	prefusion	NOUN
ajcp-1634	116	76	spike	spike	ADJ
ajcp-1634	116	77	glycoprotein	glycoprotein	NOUN
ajcp-1634	116	78	trimer	trimer	NOUN
ajcp-1634	116	79	baden	baden	PROPN
ajcp-1634	116	80	et	et	PROPN
ajcp-1634	116	81	al	al	PROPN
ajcp-1634	116	82	.	.	PROPN
ajcp-1634	116	83	,	,	PUNCT
ajcp-1634	116	84	2021	2021	NUM
ajcp-1634	116	85	university	university	NOUN
ajcp-1634	116	86	of	of	ADP
ajcp-1634	116	87	oxford/	oxford/	NUM
ajcp-1634	116	88	astra	astra	PROPN
ajcp-1634	116	89	-	-	PROPN
ajcp-1634	116	90	zeneca	zeneca	PROPN
ajcp-1634	116	91	viral	viral	ADJ
ajcp-1634	116	92	vector	vector	NOUN
ajcp-1634	116	93	-	-	PUNCT
ajcp-1634	116	94	based	base	VERB
ajcp-1634	116	95	formulated	formulate	VERB
ajcp-1634	116	96	with	with	ADP
ajcp-1634	116	97	simian	simian	ADJ
ajcp-1634	116	98	adenovirus	adenovirus	NOUN
ajcp-1634	116	99	vector	vector	NOUN
ajcp-1634	116	100	encoding	encode	VERB
ajcp-1634	116	101	the	the	DET
ajcp-1634	116	102	full	full	ADJ
ajcp-1634	116	103	-	-	PUNCT
ajcp-1634	116	104	length	length	NOUN
ajcp-1634	116	105	s	s	NOUN
ajcp-1634	116	106	protein	protein	NOUN
ajcp-1634	116	107	with	with	ADP
ajcp-1634	116	108	a	a	DET
ajcp-1634	116	109	tpa	tpa	NOUN
ajcp-1634	116	110	leader	leader	NOUN
ajcp-1634	116	111	sequence	sequence	NOUN
ajcp-1634	116	112	that	that	PRON
ajcp-1634	116	113	is	be	AUX
ajcp-1634	116	114	recombinant	recombinant	ADJ
ajcp-1634	116	115	and	and	CCONJ
ajcp-1634	116	116	replication	replication	NOUN
ajcp-1634	116	117	-	-	PUNCT
ajcp-1634	116	118	deficient	deficient	ADJ
ajcp-1634	116	119	folegatti	folegatti	NOUN
ajcp-1634	116	120	et	et	PROPN
ajcp-1634	116	121	al	al	PROPN
ajcp-1634	116	122	.	.	PROPN
ajcp-1634	116	123	,	,	PUNCT
ajcp-1634	116	124	2020	2020	NUM
ajcp-1634	116	125	gamaleya	gamaleya	PROPN
ajcp-1634	116	126	research	research	PROPN
ajcp-1634	116	127	institute	institute	PROPN
ajcp-1634	116	128	viral	viral	ADJ
ajcp-1634	116	129	vector	vector	NOUN
ajcp-1634	116	130	-	-	PUNCT
ajcp-1634	116	131	based	base	VERB
ajcp-1634	116	132	made	make	VERB
ajcp-1634	116	133	up	up	ADP
ajcp-1634	116	134	of	of	ADP
ajcp-1634	116	135	full	full	ADJ
ajcp-1634	116	136	-	-	PUNCT
ajcp-1634	116	137	length	length	NOUN
ajcp-1634	116	138	s	s	PART
ajcp-1634	116	139	protein	protein	NOUN
ajcp-1634	116	140	-	-	PUNCT
ajcp-1634	116	141	expressing	express	VERB
ajcp-1634	116	142	recombinant	recombinant	ADJ
ajcp-1634	116	143	and	and	CCONJ
ajcp-1634	116	144	replication	replication	NOUN
ajcp-1634	116	145	-	-	PUNCT
ajcp-1634	116	146	deficient	deficient	ADJ
ajcp-1634	116	147	human	human	ADJ
ajcp-1634	116	148	adenovirus	adenovirus	NOUN
ajcp-1634	116	149	26	26	NUM
ajcp-1634	116	150	(	(	PUNCT
ajcp-1634	116	151	dose	dose	NOUN
ajcp-1634	116	152	1	1	NUM
ajcp-1634	116	153	)	)	PUNCT
ajcp-1634	116	154	and	and	CCONJ
ajcp-1634	116	155	human	human	ADJ
ajcp-1634	116	156	adenovirus	adenovirus	NOUN
ajcp-1634	116	157	5	5	NUM
ajcp-1634	116	158	(	(	PUNCT
ajcp-1634	116	159	dose	dose	NOUN
ajcp-1634	116	160	2	2	NUM
ajcp-1634	116	161	)	)	PUNCT
ajcp-1634	116	162	logunov	logunov	NOUN
ajcp-1634	116	163	et	et	PROPN
ajcp-1634	116	164	al	al	PROPN
ajcp-1634	116	165	.	.	PROPN
ajcp-1634	116	166	,	,	PUNCT
ajcp-1634	116	167	2020	2020	NUM
ajcp-1634	116	168	janssen	janssen	PROPN
ajcp-1634	116	169	viral	viral	ADJ
ajcp-1634	116	170	vector	vector	NOUN
ajcp-1634	116	171	-	-	PUNCT
ajcp-1634	116	172	based	base	VERB
ajcp-1634	116	173	formulation	formulation	NOUN
ajcp-1634	116	174	was	be	AUX
ajcp-1634	116	175	characterized	characterize	VERB
ajcp-1634	116	176	by	by	ADP
ajcp-1634	116	177	a	a	DET
ajcp-1634	116	178	recombinant	recombinant	ADJ
ajcp-1634	116	179	,	,	PUNCT
ajcp-1634	116	180	replication	replication	NOUN
ajcp-1634	116	181	-	-	PUNCT
ajcp-1634	116	182	deficient	deficient	ADJ
ajcp-1634	116	183	human	human	ADJ
ajcp-1634	116	184	adenovirus	adenovirus	NOUN
ajcp-1634	116	185	26	26	NUM
ajcp-1634	116	186	producing	produce	VERB
ajcp-1634	116	187	full	full	ADJ
ajcp-1634	116	188	-	-	PUNCT
ajcp-1634	116	189	length	length	NOUN
ajcp-1634	116	190	s	s	NOUN
ajcp-1634	116	191	protein	protein	NOUN
ajcp-1634	116	192	with	with	ADP
ajcp-1634	116	193	two	two	NUM
ajcp-1634	116	194	amino	amino	NOUN
ajcp-1634	116	195	acid	acid	NOUN
ajcp-1634	116	196	alterations	alteration	NOUN
ajcp-1634	116	197	in	in	ADP
ajcp-1634	116	198	the	the	DET
ajcp-1634	116	199	s1	s1	NOUN
ajcp-1634	116	200	/	/	SYM
ajcp-1634	116	201	s2	s2	NOUN
ajcp-1634	116	202	junction	junction	NOUN
ajcp-1634	116	203	that	that	PRON
ajcp-1634	116	204	eliminate	eliminate	VERB
ajcp-1634	116	205	the	the	DET
ajcp-1634	116	206	furin	furin	NOUN
ajcp-1634	116	207	cleavage	cleavage	NOUN
ajcp-1634	116	208	site	site	NOUN
ajcp-1634	116	209	and	and	CCONJ
ajcp-1634	116	210	two	two	NUM
ajcp-1634	116	211	proline	proline	NOUN
ajcp-1634	116	212	substitutions	substitution	NOUN
ajcp-1634	116	213	in	in	ADP
ajcp-1634	116	214	the	the	DET
ajcp-1634	116	215	hinge	hinge	NOUN
ajcp-1634	116	216	region	region	NOUN
ajcp-1634	116	217	that	that	PRON
ajcp-1634	116	218	keep	keep	VERB
ajcp-1634	116	219	the	the	DET
ajcp-1634	116	220	protein	protein	NOUN
ajcp-1634	116	221	in	in	ADP
ajcp-1634	116	222	the	the	DET
ajcp-1634	116	223	pre	pre	ADJ
ajcp-1634	116	224	-	-	ADJ
ajcp-1634	116	225	fusion	fusion	ADJ
ajcp-1634	116	226	conformation	conformation	NOUN
ajcp-1634	116	227	bos	bo	NOUN
ajcp-1634	116	228	et	et	NOUN
ajcp-1634	116	229	al	al	PROPN
ajcp-1634	116	230	.	.	PROPN
ajcp-1634	116	231	,	,	PUNCT
ajcp-1634	116	232	2020	2020	NUM
ajcp-1634	116	233	novavax	novavax	NOUN
ajcp-1634	116	234	protein	protein	NOUN
ajcp-1634	116	235	subunit	subunit	NOUN
ajcp-1634	116	236	uses	use	VERB
ajcp-1634	116	237	a	a	DET
ajcp-1634	116	238	recombinant	recombinant	ADJ
ajcp-1634	116	239	nanoparticle	nanoparticle	NOUN
ajcp-1634	116	240	of	of	ADP
ajcp-1634	116	241	full	full	ADJ
ajcp-1634	116	242	-	-	PUNCT
ajcp-1634	116	243	length	length	NOUN
ajcp-1634	116	244	s	s	NOUN
ajcp-1634	116	245	protein	protein	NOUN
ajcp-1634	116	246	with	with	ADP
ajcp-1634	116	247	protease	protease	NOUN
ajcp-1634	116	248	resistance	resistance	NOUN
ajcp-1634	116	249	mutations	mutation	NOUN
ajcp-1634	116	250	at	at	ADP
ajcp-1634	116	251	the	the	DET
ajcp-1634	116	252	s1	s1	PROPN
ajcp-1634	116	253	/	/	SYM
ajcp-1634	116	254	s2	s2	NOUN
ajcp-1634	116	255	cleavage	cleavage	NOUN
ajcp-1634	116	256	sites	site	NOUN
ajcp-1634	116	257	and	and	CCONJ
ajcp-1634	116	258	two	two	NUM
ajcp-1634	116	259	proline	proline	NOUN
ajcp-1634	116	260	substitutions	substitution	NOUN
ajcp-1634	116	261	to	to	PART
ajcp-1634	116	262	stabilize	stabilize	VERB
ajcp-1634	116	263	protein	protein	NOUN
ajcp-1634	116	264	in	in	ADP
ajcp-1634	116	265	a	a	DET
ajcp-1634	116	266	pre	pre	ADJ
ajcp-1634	116	267	-	-	ADJ
ajcp-1634	116	268	fusion	fusion	ADJ
ajcp-1634	116	269	conformation	conformation	NOUN
ajcp-1634	116	270	,	,	PUNCT
ajcp-1634	116	271	together	together	ADV
ajcp-1634	116	272	with	with	ADP
ajcp-1634	116	273	a	a	DET
ajcp-1634	116	274	saponinbased	saponinbase	VERB
ajcp-1634	116	275	adjuvant	adjuvant	NOUN
ajcp-1634	116	276	(	(	PUNCT
ajcp-1634	116	277	matrixm1	matrixm1	NOUN
ajcp-1634	116	278	)	)	PUNCT
ajcp-1634	116	279	keech	keech	NOUN
ajcp-1634	116	280	et	et	PROPN
ajcp-1634	116	281	al	al	PROPN
ajcp-1634	116	282	.	.	PROPN
ajcp-1634	116	283	,	,	PUNCT
ajcp-1634	116	284	2020	2020	NUM
ajcp-1634	116	285	sinovac	sinovac	PROPN
ajcp-1634	116	286	biotech	biotech	ADJ
ajcp-1634	116	287	whole	whole	ADJ
ajcp-1634	116	288	cell	cell	NOUN
ajcp-1634	116	289	inactivated	inactivate	VERB
ajcp-1634	116	290	virus	virus	NOUN
ajcp-1634	116	291	the	the	DET
ajcp-1634	116	292	attenuated	attenuated	ADJ
ajcp-1634	116	293	or	or	CCONJ
ajcp-1634	116	294	inactivated	inactivated	ADJ
ajcp-1634	116	295	whole	whole	ADJ
ajcp-1634	116	296	sars	sar	NOUN
ajcp-1634	116	297	-	-	PUNCT
ajcp-1634	116	298	cov-2	cov-2	PART
ajcp-1634	116	299	virus	virus	NOUN
ajcp-1634	116	300	is	be	AUX
ajcp-1634	116	301	administered	administer	VERB
ajcp-1634	116	302	to	to	ADP
ajcp-1634	116	303	individuals	individual	NOUN
ajcp-1634	116	304	to	to	PART
ajcp-1634	116	305	elicit	elicit	VERB
ajcp-1634	116	306	the	the	DET
ajcp-1634	116	307	immune	immune	ADJ
ajcp-1634	116	308	responses	response	NOUN
ajcp-1634	116	309	,	,	PUNCT
ajcp-1634	116	310	which	which	PRON
ajcp-1634	116	311	target	target	VERB
ajcp-1634	116	312	the	the	DET
ajcp-1634	116	313	sars	sar	NOUN
ajcp-1634	116	314	-	-	PUNCT
ajcp-1634	116	315	cov-2	cov-2	NOUN
ajcp-1634	116	316	s	s	PART
ajcp-1634	116	317	protein	protein	NOUN
ajcp-1634	116	318	.	.	PUNCT
ajcp-1634	117	1	li	li	PROPN
ajcp-1634	117	2	et	et	PROPN
ajcp-1634	117	3	al	al	PROPN
ajcp-1634	117	4	.	.	PROPN
ajcp-1634	117	5	,	,	PUNCT
ajcp-1634	117	6	2021	2021	NUM
ajcp-1634	117	7	two	two	NUM
ajcp-1634	117	8	doses	dose	NOUN
ajcp-1634	117	9	(	(	PUNCT
ajcp-1634	117	10	walsh	walsh	PROPN
ajcp-1634	117	11	et	et	PROPN
ajcp-1634	117	12	al	al	PROPN
ajcp-1634	117	13	.	.	PROPN
ajcp-1634	117	14	,	,	PUNCT
ajcp-1634	117	15	2020	2020	NUM
ajcp-1634	117	16	)	)	PUNCT
ajcp-1634	117	17	.	.	PUNCT
ajcp-1634	118	1	like	like	ADP
ajcp-1634	118	2	biontech	biontech	PROPN
ajcp-1634	118	3	/	/	SYM
ajcp-1634	118	4	pfizer	pfizer	NOUN
ajcp-1634	118	5	’s	’s	PART
ajcp-1634	118	6	the	the	DET
ajcp-1634	118	7	moderna	moderna	PROPN
ajcp-1634	118	8	vaccine	vaccine	NOUN
ajcp-1634	118	9	encodes	encode	VERB
ajcp-1634	118	10	the	the	DET
ajcp-1634	118	11	sars	sar	NOUN
ajcp-1634	118	12	-	-	PUNCT
ajcp-1634	118	13	cov-2	cov-2	NOUN
ajcp-1634	118	14	stabilized	stabilize	VERB
ajcp-1634	118	15	prefusion	prefusion	NOUN
ajcp-1634	118	16	spike	spike	ADJ
ajcp-1634	118	17	glycoprotein	glycoprotein	NOUN
ajcp-1634	118	18	trimer	trimer	NOUN
ajcp-1634	118	19	,	,	PUNCT
ajcp-1634	118	20	which	which	PRON
ajcp-1634	118	21	is	be	AUX
ajcp-1634	118	22	necessary	necessary	ADJ
ajcp-1634	118	23	for	for	ADP
ajcp-1634	118	24	host	host	NOUN
ajcp-1634	118	25	cell	cell	NOUN
ajcp-1634	118	26	attachment	attachment	NOUN
ajcp-1634	118	27	and	and	CCONJ
ajcp-1634	118	28	viral	viral	ADJ
ajcp-1634	118	29	entry	entry	NOUN
ajcp-1634	118	30	(	(	PUNCT
ajcp-1634	118	31	baden	baden	PROPN
ajcp-1634	118	32	et	et	PROPN
ajcp-1634	118	33	al	al	PROPN
ajcp-1634	118	34	.	.	PROPN
ajcp-1634	118	35	,	,	PUNCT
ajcp-1634	118	36	2021	2021	NUM
ajcp-1634	118	37	)	)	PUNCT
ajcp-1634	118	38	.	.	PUNCT
ajcp-1634	119	1	s	s	X
ajcp-1634	119	2	-	-	PUNCT
ajcp-1634	119	3	binding	bind	VERB
ajcp-1634	119	4	antibody	antibody	NOUN
ajcp-1634	119	5	was	be	AUX
ajcp-1634	119	6	also	also	ADV
ajcp-1634	119	7	detected	detect	VERB
ajcp-1634	119	8	14	14	NUM
ajcp-1634	119	9	days	day	NOUN
ajcp-1634	119	10	after	after	ADP
ajcp-1634	119	11	the	the	DET
ajcp-1634	119	12	first	first	ADJ
ajcp-1634	119	13	dose	dose	NOUN
ajcp-1634	119	14	,	,	PUNCT
ajcp-1634	119	15	with	with	ADP
ajcp-1634	119	16	levels	level	NOUN
ajcp-1634	119	17	increasing	increase	VERB
ajcp-1634	119	18	marginally	marginally	ADV
ajcp-1634	119	19	by	by	ADP
ajcp-1634	119	20	28	28	NUM
ajcp-1634	119	21	days	day	NOUN
ajcp-1634	119	22	and	and	CCONJ
ajcp-1634	119	23	significantly	significantly	ADV
ajcp-1634	119	24	after	after	ADP
ajcp-1634	119	25	the	the	DET
ajcp-1634	119	26	second	second	ADJ
ajcp-1634	119	27	dose	dose	PROPN
ajcp-1634	119	28	(	(	PUNCT
ajcp-1634	119	29	jackson	jackson	PROPN
ajcp-1634	119	30	et	et	PROPN
ajcp-1634	119	31	al	al	PROPN
ajcp-1634	119	32	.	.	PROPN
ajcp-1634	119	33	,	,	PUNCT
ajcp-1634	119	34	2020	2020	NUM
ajcp-1634	119	35	)	)	PUNCT
ajcp-1634	119	36	.	.	PUNCT
ajcp-1634	120	1	after	after	ADP
ajcp-1634	120	2	the	the	DET
ajcp-1634	120	3	second	second	ADJ
ajcp-1634	120	4	treatment	treatment	NOUN
ajcp-1634	120	5	,	,	PUNCT
ajcp-1634	120	6	cd4	cd4	PROPN
ajcp-1634	120	7	+	+	PROPN
ajcp-1634	120	8	t	t	NOUN
ajcp-1634	120	9	cells	cell	NOUN
ajcp-1634	120	10	secreting	secrete	VERB
ajcp-1634	120	11	th1	th1	NOUN
ajcp-1634	120	12	cytokines	cytokine	NOUN
ajcp-1634	120	13	(	(	PUNCT
ajcp-1634	120	14	tnf	tnf	PROPN
ajcp-1634	120	15	>	>	X
ajcp-1634	120	16	il-2	il-2	PROPN
ajcp-1634	120	17	>	>	X
ajcp-1634	120	18	ifnγ	ifnγ	NOUN
ajcp-1634	120	19	)	)	PUNCT
ajcp-1634	120	20	increased	increase	VERB
ajcp-1634	120	21	significantly	significantly	ADV
ajcp-1634	120	22	(	(	PUNCT
ajcp-1634	120	23	jackson	jackson	PROPN
ajcp-1634	120	24	et	et	PROPN
ajcp-1634	120	25	al	al	PROPN
ajcp-1634	120	26	.	.	PROPN
ajcp-1634	120	27	,	,	PUNCT
ajcp-1634	120	28	2020	2020	NUM
ajcp-1634	120	29	)	)	PUNCT
ajcp-1634	120	30	.	.	PUNCT
ajcp-1634	121	1	viral	viral	ADJ
ajcp-1634	121	2	vector	vector	NOUN
ajcp-1634	121	3	-	-	PUNCT
ajcp-1634	121	4	based	base	VERB
ajcp-1634	121	5	incorporating	incorporate	VERB
ajcp-1634	121	6	immunogenic	immunogenic	ADJ
ajcp-1634	121	7	full	full	ADJ
ajcp-1634	121	8	-	-	PUNCT
ajcp-1634	121	9	length	length	NOUN
ajcp-1634	121	10	or	or	CCONJ
ajcp-1634	121	11	truncated	truncate	VERB
ajcp-1634	121	12	viral	viral	ADJ
ajcp-1634	121	13	surface	surface	NOUN
ajcp-1634	121	14	proteins	protein	NOUN
ajcp-1634	121	15	into	into	ADP
ajcp-1634	121	16	viral	viral	ADJ
ajcp-1634	121	17	expression	expression	NOUN
ajcp-1634	121	18	has	have	AUX
ajcp-1634	121	19	been	be	AUX
ajcp-1634	121	20	a	a	DET
ajcp-1634	121	21	common	common	ADJ
ajcp-1634	121	22	strategy	strategy	NOUN
ajcp-1634	121	23	for	for	ADP
ajcp-1634	121	24	vaccine	vaccine	NOUN
ajcp-1634	121	25	development	development	NOUN
ajcp-1634	121	26	against	against	ADP
ajcp-1634	121	27	infectious	infectious	ADJ
ajcp-1634	121	28	agents	agent	NOUN
ajcp-1634	121	29	,	,	PUNCT
ajcp-1634	121	30	primarily	primarily	ADV
ajcp-1634	121	31	viruses	virus	NOUN
ajcp-1634	121	32	(	(	PUNCT
ajcp-1634	121	33	lundstrom	lundstrom	NOUN
ajcp-1634	121	34	,	,	PUNCT
ajcp-1634	121	35	2020	2020	NUM
ajcp-1634	121	36	)	)	PUNCT
ajcp-1634	121	37	.	.	PUNCT
ajcp-1634	122	1	various	various	ADJ
ajcp-1634	122	2	viral	viral	ADJ
ajcp-1634	122	3	vector	vector	NOUN
ajcp-1634	122	4	expression	expression	NOUN
ajcp-1634	122	5	techniques	technique	NOUN
ajcp-1634	122	6	have	have	AUX
ajcp-1634	122	7	been	be	AUX
ajcp-1634	122	8	used	use	VERB
ajcp-1634	122	9	to	to	PART
ajcp-1634	122	10	target	target	VERB
ajcp-1634	122	11	viral	viral	ADJ
ajcp-1634	122	12	surface	surface	NOUN
ajcp-1634	122	13	proteins	protein	NOUN
ajcp-1634	122	14	.	.	PUNCT
ajcp-1634	123	1	adenoviruses	adenovirus	NOUN
ajcp-1634	123	2	(	(	PUNCT
ajcp-1634	123	3	ads	ad	NOUN
ajcp-1634	123	4	)	)	PUNCT
ajcp-1634	123	5	,	,	PUNCT
ajcp-1634	123	6	alphaviruses	alphavirus	NOUN
ajcp-1634	123	7	,	,	PUNCT
ajcp-1634	123	8	flaviviruses	flavivirus	NOUN
ajcp-1634	123	9	,	,	PUNCT
ajcp-1634	123	10	measles	measle	NOUN
ajcp-1634	123	11	viruses	virus	NOUN
ajcp-1634	123	12	(	(	PUNCT
ajcp-1634	123	13	mvs	mvs	PROPN
ajcp-1634	123	14	)	)	PUNCT
ajcp-1634	123	15	,	,	PUNCT
ajcp-1634	123	16	rhabdoviruses	rhabdovirus	NOUN
ajcp-1634	123	17	,	,	PUNCT
ajcp-1634	123	18	retroviruses	retrovirus	NOUN
ajcp-1634	123	19	(	(	PUNCT
ajcp-1634	123	20	rvs	rvs	NOUN
ajcp-1634	123	21	)	)	PUNCT
ajcp-1634	123	22	,	,	PUNCT
ajcp-1634	123	23	lentiviruses	lentiviruse	NOUN
ajcp-1634	123	24	(	(	PUNCT
ajcp-1634	123	25	lvs	lvs	NOUN
ajcp-1634	123	26	)	)	PUNCT
ajcp-1634	123	27	,	,	PUNCT
ajcp-1634	123	28	and	and	CCONJ
ajcp-1634	123	29	poxviruses	poxvirus	NOUN
ajcp-1634	123	30	are	be	AUX
ajcp-1634	123	31	all	all	PRON
ajcp-1634	123	32	examples	example	NOUN
ajcp-1634	123	33	of	of	ADP
ajcp-1634	123	34	expression	expression	NOUN
ajcp-1634	123	35	vectors	vector	NOUN
ajcp-1634	123	36	(	(	PUNCT
ajcp-1634	123	37	sm	sm	PROPN
ajcp-1634	123	38	wold	wold	PROPN
ajcp-1634	123	39	&	&	CCONJ
ajcp-1634	123	40	toth	toth	PROPN
ajcp-1634	123	41	,	,	PUNCT
ajcp-1634	123	42	2013	2013	NUM
ajcp-1634	123	43	;	;	PUNCT
ajcp-1634	123	44	lundstrom	lundstrom	NOUN
ajcp-1634	123	45	,	,	PUNCT
ajcp-1634	123	46	2019	2019	NUM
ajcp-1634	123	47	)	)	PUNCT
ajcp-1634	123	48	.	.	PUNCT
ajcp-1634	124	1	four	four	NUM
ajcp-1634	124	2	viral	viral	ADJ
ajcp-1634	124	3	vector	vector	NOUN
ajcp-1634	124	4	-	-	PUNCT
ajcp-1634	124	5	based	base	VERB
ajcp-1634	124	6	vaccines	vaccine	NOUN
ajcp-1634	124	7	,	,	PUNCT
ajcp-1634	124	8	namely	namely	ADV
ajcp-1634	124	9	,	,	PUNCT
ajcp-1634	124	10	university	university	NOUN
ajcp-1634	124	11	of	of	ADP
ajcp-1634	124	12	oxford	oxford	PROPN
ajcp-1634	124	13	/	/	SYM
ajcp-1634	124	14	astra	astra	PROPN
ajcp-1634	124	15	-	-	PROPN
ajcp-1634	124	16	zeneca	zeneca	PROPN
ajcp-1634	124	17	(	(	PUNCT
ajcp-1634	124	18	chadox1	chadox1	NOUN
ajcp-1634	124	19	ncov-19	ncov-19	PROPN
ajcp-1634	124	20	)	)	PUNCT
ajcp-1634	124	21	,	,	PUNCT
ajcp-1634	124	22	gamaleya	gamaleya	PROPN
ajcp-1634	124	23	research	research	PROPN
ajcp-1634	124	24	institute	institute	PROPN
ajcp-1634	124	25	(	(	PUNCT
ajcp-1634	124	26	gam	gam	NOUN
ajcp-1634	124	27	-	-	NOUN
ajcp-1634	124	28	covidvac	covidvac	NOUN
ajcp-1634	124	29	)	)	PUNCT
ajcp-1634	124	30	,	,	PUNCT
ajcp-1634	124	31	janssen	janssen	PROPN
ajcp-1634	124	32	(	(	PUNCT
ajcp-1634	124	33	ad26.cov2.s	ad26.cov2.s	NUM
ajcp-1634	124	34	)	)	PUNCT
ajcp-1634	124	35	,	,	PUNCT
ajcp-1634	124	36	and	and	CCONJ
ajcp-1634	124	37	cansino	cansino	NOUN
ajcp-1634	124	38	biologics	biologic	NOUN
ajcp-1634	124	39	(	(	PUNCT
ajcp-1634	124	40	ad5ncov	ad5ncov	NOUN
ajcp-1634	124	41	)	)	PUNCT
ajcp-1634	124	42	,	,	PUNCT
ajcp-1634	124	43	have	have	AUX
ajcp-1634	124	44	been	be	AUX
ajcp-1634	124	45	reported	report	VERB
ajcp-1634	124	46	(	(	PUNCT
ajcp-1634	124	47	sadarangani	sadarangani	PROPN
ajcp-1634	124	48	et	et	PROPN
ajcp-1634	124	49	al	al	PROPN
ajcp-1634	124	50	.	.	PROPN
ajcp-1634	124	51	,	,	PUNCT
ajcp-1634	124	52	2021	2021	NUM
ajcp-1634	124	53	;	;	PUNCT
ajcp-1634	124	54	knoll	knoll	NOUN
ajcp-1634	124	55	&	&	CCONJ
ajcp-1634	124	56	wonodi	wonodi	PROPN
ajcp-1634	124	57	,	,	PUNCT
ajcp-1634	124	58	2021	2021	NUM
ajcp-1634	124	59	)	)	PUNCT
ajcp-1634	124	60	.	.	PUNCT
ajcp-1634	125	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	125	2	pa	pa	PROPN
ajcp-1634	125	3	ge	ge	PROPN
ajcp-1634	125	4	70	70	NUM
ajcp-1634	126	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	126	2	am	be	AUX
ajcp-1634	126	3	.	.	PUNCT
ajcp-1634	127	1	j.	j.	PROPN
ajcp-1634	127	2	chem	chem	PROPN
ajcp-1634	127	3	.	.	PUNCT
ajcp-1634	128	1	pharm	pharm	PROPN
ajcp-1634	128	2	.	.	PUNCT
ajcp-1634	129	1	2(2	2(2	NUM
ajcp-1634	129	2	)	)	PUNCT
ajcp-1634	130	1	66	66	NUM
ajcp-1634	130	2	-	-	SYM
ajcp-1634	130	3	73	73	NUM
ajcp-1634	130	4	,	,	PUNCT
ajcp-1634	130	5	2023	2023	NUM
ajcp-1634	130	6	the	the	DET
ajcp-1634	130	7	university	university	NOUN
ajcp-1634	130	8	of	of	ADP
ajcp-1634	130	9	oxford	oxford	PROPN
ajcp-1634	130	10	/	/	SYM
ajcp-1634	130	11	astra	astra	PROPN
ajcp-1634	130	12	-	-	PUNCT
ajcp-1634	130	13	zeneca	zeneca	PROPN
ajcp-1634	130	14	vaccine	vaccine	NOUN
ajcp-1634	130	15	is	be	AUX
ajcp-1634	130	16	formulated	formulate	VERB
ajcp-1634	130	17	with	with	ADP
ajcp-1634	130	18	a	a	DET
ajcp-1634	130	19	simian	simian	ADJ
ajcp-1634	130	20	adenovirus	adenovirus	NOUN
ajcp-1634	130	21	vector	vector	NOUN
ajcp-1634	130	22	encoding	encode	VERB
ajcp-1634	130	23	the	the	DET
ajcp-1634	130	24	full	full	ADJ
ajcp-1634	130	25	-	-	PUNCT
ajcp-1634	130	26	length	length	NOUN
ajcp-1634	130	27	s	s	NOUN
ajcp-1634	130	28	protein	protein	NOUN
ajcp-1634	130	29	with	with	ADP
ajcp-1634	130	30	a	a	DET
ajcp-1634	130	31	tpa	tpa	NOUN
ajcp-1634	130	32	leader	leader	NOUN
ajcp-1634	130	33	sequence	sequence	NOUN
ajcp-1634	130	34	that	that	PRON
ajcp-1634	130	35	is	be	AUX
ajcp-1634	130	36	recombinant	recombinant	ADJ
ajcp-1634	130	37	and	and	CCONJ
ajcp-1634	130	38	replication	replication	NOUN
ajcp-1634	130	39	-	-	PUNCT
ajcp-1634	130	40	deficient	deficient	ADJ
ajcp-1634	130	41	(	(	PUNCT
ajcp-1634	130	42	folegatti	folegatti	PROPN
ajcp-1634	130	43	et	et	PROPN
ajcp-1634	130	44	al	al	PROPN
ajcp-1634	130	45	.	.	PROPN
ajcp-1634	130	46	,	,	PUNCT
ajcp-1634	130	47	2020	2020	NUM
ajcp-1634	130	48	)	)	PUNCT
ajcp-1634	130	49	.	.	PUNCT
ajcp-1634	131	1	when	when	SCONJ
ajcp-1634	131	2	mice	mouse	NOUN
ajcp-1634	131	3	and	and	CCONJ
ajcp-1634	131	4	rhesus	rhesus	NOUN
ajcp-1634	131	5	macaques	macaque	NOUN
ajcp-1634	131	6	were	be	AUX
ajcp-1634	131	7	immunized	immunize	VERB
ajcp-1634	131	8	with	with	ADP
ajcp-1634	131	9	the	the	DET
ajcp-1634	131	10	chimpanzee	chimpanzee	NOUN
ajcp-1634	131	11	ad	ad	NOUN
ajcp-1634	131	12	vector	vector	NOUN
ajcp-1634	131	13	chadox1	chadox1	NOUN
ajcp-1634	131	14	ncov-19	ncov-19	PROPN
ajcp-1634	131	15	,	,	PUNCT
ajcp-1634	131	16	which	which	PRON
ajcp-1634	131	17	was	be	AUX
ajcp-1634	131	18	designed	design	VERB
ajcp-1634	131	19	to	to	PART
ajcp-1634	131	20	produce	produce	VERB
ajcp-1634	131	21	the	the	DET
ajcp-1634	131	22	sars	sar	NOUN
ajcp-1634	131	23	-	-	PUNCT
ajcp-1634	131	24	cov-2	cov-2	NOUN
ajcp-1634	131	25	s	s	PART
ajcp-1634	131	26	protein	protein	NOUN
ajcp-1634	131	27	,	,	PUNCT
ajcp-1634	131	28	it	it	PRON
ajcp-1634	131	29	induced	induce	VERB
ajcp-1634	131	30	robust	robust	ADJ
ajcp-1634	131	31	humoral	humoral	ADJ
ajcp-1634	131	32	and	and	CCONJ
ajcp-1634	131	33	cellular	cellular	ADJ
ajcp-1634	131	34	immune	immune	ADJ
ajcp-1634	131	35	responses	response	NOUN
ajcp-1634	131	36	and	and	CCONJ
ajcp-1634	131	37	prevented	prevent	VERB
ajcp-1634	131	38	pneumonia	pneumonia	NOUN
ajcp-1634	131	39	in	in	ADP
ajcp-1634	131	40	macaques	macaque	NOUN
ajcp-1634	131	41	(	(	PUNCT
ajcp-1634	131	42	van	van	PROPN
ajcp-1634	131	43	doremalen	doremalen	PROPN
ajcp-1634	131	44	et	et	PROPN
ajcp-1634	131	45	al	al	PROPN
ajcp-1634	131	46	.	.	PROPN
ajcp-1634	131	47	,	,	PUNCT
ajcp-1634	131	48	2020	2020	NUM
ajcp-1634	131	49	;	;	PUNCT
ajcp-1634	131	50	folegatti	folegatti	PROPN
ajcp-1634	131	51	et	et	PROPN
ajcp-1634	131	52	al	al	PROPN
ajcp-1634	131	53	.	.	PROPN
ajcp-1634	131	54	,	,	PUNCT
ajcp-1634	131	55	2020	2020	NUM
ajcp-1634	131	56	)	)	PUNCT
ajcp-1634	131	57	.	.	PUNCT
ajcp-1634	132	1	in	in	ADP
ajcp-1634	132	2	humans	human	NOUN
ajcp-1634	132	3	,	,	PUNCT
ajcp-1634	132	4	s	s	NOUN
ajcp-1634	132	5	-	-	PUNCT
ajcp-1634	132	6	binding	bind	VERB
ajcp-1634	132	7	antibody	antibody	NOUN
ajcp-1634	132	8	was	be	AUX
ajcp-1634	132	9	detected	detect	VERB
ajcp-1634	132	10	14	14	NUM
ajcp-1634	132	11	days	day	NOUN
ajcp-1634	132	12	after	after	ADP
ajcp-1634	132	13	the	the	DET
ajcp-1634	132	14	first	first	ADJ
ajcp-1634	132	15	dosage	dosage	NOUN
ajcp-1634	132	16	,	,	PUNCT
ajcp-1634	132	17	and	and	CCONJ
ajcp-1634	132	18	levels	level	NOUN
ajcp-1634	132	19	increased	increase	VERB
ajcp-1634	132	20	by	by	ADP
ajcp-1634	132	21	28	28	NUM
ajcp-1634	132	22	days	day	NOUN
ajcp-1634	132	23	;	;	PUNCT
ajcp-1634	132	24	there	there	PRON
ajcp-1634	132	25	was	be	VERB
ajcp-1634	132	26	a	a	DET
ajcp-1634	132	27	significant	significant	ADJ
ajcp-1634	132	28	rise	rise	NOUN
ajcp-1634	132	29	after	after	ADP
ajcp-1634	132	30	the	the	DET
ajcp-1634	132	31	second	second	ADJ
ajcp-1634	132	32	dose	dose	NOUN
ajcp-1634	132	33	,	,	PUNCT
ajcp-1634	132	34	with	with	ADP
ajcp-1634	132	35	a	a	DET
ajcp-1634	132	36	peak	peak	NOUN
ajcp-1634	132	37	at	at	ADP
ajcp-1634	132	38	14	14	NUM
ajcp-1634	132	39	days	day	NOUN
ajcp-1634	132	40	.	.	PUNCT
ajcp-1634	133	1	also	also	ADV
ajcp-1634	133	2	,	,	PUNCT
ajcp-1634	133	3	t	t	PROPN
ajcp-1634	133	4	cell	cell	NOUN
ajcp-1634	133	5	responses	response	NOUN
ajcp-1634	133	6	peaked	peak	VERB
ajcp-1634	133	7	14	14	NUM
ajcp-1634	133	8	days	day	NOUN
ajcp-1634	133	9	following	follow	VERB
ajcp-1634	133	10	the	the	DET
ajcp-1634	133	11	first	first	ADJ
ajcp-1634	133	12	dosage	dosage	NOUN
ajcp-1634	133	13	but	but	CCONJ
ajcp-1634	133	14	were	be	AUX
ajcp-1634	133	15	slightly	slightly	ADV
ajcp-1634	133	16	greater	great	ADJ
ajcp-1634	133	17	28	28	NUM
ajcp-1634	133	18	days	day	NOUN
ajcp-1634	133	19	later	later	ADV
ajcp-1634	133	20	(	(	PUNCT
ajcp-1634	133	21	folegatti	folegatti	NOUN
ajcp-1634	133	22	et	et	PROPN
ajcp-1634	133	23	al	al	PROPN
ajcp-1634	133	24	.	.	PROPN
ajcp-1634	133	25	,	,	PUNCT
ajcp-1634	133	26	2020	2020	NUM
ajcp-1634	133	27	)	)	PUNCT
ajcp-1634	133	28	.	.	PUNCT
ajcp-1634	134	1	meanwhile	meanwhile	ADV
ajcp-1634	134	2	,	,	PUNCT
ajcp-1634	134	3	the	the	DET
ajcp-1634	134	4	gamaleya	gamaleya	PROPN
ajcp-1634	134	5	research	research	PROPN
ajcp-1634	134	6	institute	institute	PROPN
ajcp-1634	134	7	vaccine	vaccine	NOUN
ajcp-1634	134	8	is	be	AUX
ajcp-1634	134	9	made	make	VERB
ajcp-1634	134	10	up	up	ADP
ajcp-1634	134	11	of	of	ADP
ajcp-1634	134	12	full	full	ADJ
ajcp-1634	134	13	-	-	PUNCT
ajcp-1634	134	14	length	length	NOUN
ajcp-1634	134	15	s	s	PART
ajcp-1634	134	16	protein	protein	NOUN
ajcp-1634	134	17	-	-	PUNCT
ajcp-1634	134	18	expressing	express	VERB
ajcp-1634	134	19	recombinant	recombinant	ADJ
ajcp-1634	134	20	and	and	CCONJ
ajcp-1634	134	21	replication	replication	NOUN
ajcp-1634	134	22	-	-	PUNCT
ajcp-1634	134	23	deficient	deficient	ADJ
ajcp-1634	134	24	human	human	ADJ
ajcp-1634	134	25	adenovirus	adenovirus	NOUN
ajcp-1634	134	26	26	26	NUM
ajcp-1634	134	27	(	(	PUNCT
ajcp-1634	134	28	dose	dose	NOUN
ajcp-1634	134	29	1	1	NUM
ajcp-1634	134	30	)	)	PUNCT
ajcp-1634	134	31	and	and	CCONJ
ajcp-1634	134	32	human	human	ADJ
ajcp-1634	134	33	adenovirus	adenovirus	NOUN
ajcp-1634	134	34	5	5	NUM
ajcp-1634	134	35	(	(	PUNCT
ajcp-1634	134	36	dose	dose	NOUN
ajcp-1634	134	37	2	2	NUM
ajcp-1634	134	38	)	)	PUNCT
ajcp-1634	134	39	(	(	PUNCT
ajcp-1634	134	40	logunov	logunov	NOUN
ajcp-1634	134	41	et	et	PROPN
ajcp-1634	134	42	al	al	PROPN
ajcp-1634	134	43	.	.	PROPN
ajcp-1634	134	44	,	,	PUNCT
ajcp-1634	134	45	2020	2020	NUM
ajcp-1634	134	46	)	)	PUNCT
ajcp-1634	134	47	.	.	PUNCT
ajcp-1634	135	1	s	s	X
ajcp-1634	135	2	-	-	PUNCT
ajcp-1634	135	3	binding	bind	VERB
ajcp-1634	135	4	antibody	antibody	NOUN
ajcp-1634	135	5	was	be	AUX
ajcp-1634	135	6	found	find	VERB
ajcp-1634	135	7	in	in	ADP
ajcp-1634	135	8	85–89	85–89	NUM
ajcp-1634	135	9	%	%	NOUN
ajcp-1634	135	10	of	of	ADP
ajcp-1634	135	11	people	people	NOUN
ajcp-1634	135	12	14	14	NUM
ajcp-1634	135	13	days	day	NOUN
ajcp-1634	135	14	after	after	ADP
ajcp-1634	135	15	the	the	DET
ajcp-1634	135	16	initial	initial	ADJ
ajcp-1634	135	17	dose	dose	NOUN
ajcp-1634	135	18	(	(	PUNCT
ajcp-1634	135	19	logunov	logunov	PROPN
ajcp-1634	135	20	et	et	PROPN
ajcp-1634	135	21	al	al	PROPN
ajcp-1634	135	22	.	.	PROPN
ajcp-1634	135	23	,	,	PUNCT
ajcp-1634	135	24	2020	2020	NUM
ajcp-1634	135	25	)	)	PUNCT
ajcp-1634	135	26	.	.	PUNCT
ajcp-1634	136	1	fourteen	fourteen	NUM
ajcp-1634	136	2	days	day	NOUN
ajcp-1634	136	3	after	after	ADP
ajcp-1634	136	4	the	the	DET
ajcp-1634	136	5	second	second	ADJ
ajcp-1634	136	6	dose	dose	NOUN
ajcp-1634	136	7	,	,	PUNCT
ajcp-1634	136	8	s	s	VERB
ajcp-1634	136	9	antibody	antibody	NOUN
ajcp-1634	136	10	levels	level	NOUN
ajcp-1634	136	11	are	be	AUX
ajcp-1634	136	12	boosted	boost	VERB
ajcp-1634	136	13	(	(	PUNCT
ajcp-1634	136	14	logunov	logunov	NOUN
ajcp-1634	136	15	et	et	PROPN
ajcp-1634	136	16	al	al	PROPN
ajcp-1634	136	17	.	.	PROPN
ajcp-1634	136	18	,	,	PUNCT
ajcp-1634	136	19	2021	2021	NUM
ajcp-1634	136	20	)	)	PUNCT
ajcp-1634	136	21	.	.	PUNCT
ajcp-1634	137	1	based	base	VERB
ajcp-1634	137	2	on	on	ADP
ajcp-1634	137	3	proliferation	proliferation	NOUN
ajcp-1634	137	4	assays	assay	NOUN
ajcp-1634	137	5	and	and	CCONJ
ajcp-1634	137	6	antigen	antigen	NOUN
ajcp-1634	137	7	-	-	PUNCT
ajcp-1634	137	8	specific	specific	ADJ
ajcp-1634	137	9	ifn	ifn	NOUN
ajcp-1634	137	10	production	production	NOUN
ajcp-1634	137	11	,	,	PUNCT
ajcp-1634	137	12	cd4	cd4	PROPN
ajcp-1634	137	13	+	+	PROPN
ajcp-1634	137	14	and	and	CCONJ
ajcp-1634	137	15	cd8	cd8	PROPN
ajcp-1634	137	16	+	+	PROPN
ajcp-1634	137	17	t	t	NOUN
ajcp-1634	137	18	cell	cell	NOUN
ajcp-1634	137	19	responses	response	NOUN
ajcp-1634	137	20	were	be	AUX
ajcp-1634	137	21	seen	see	VERB
ajcp-1634	137	22	14	14	NUM
ajcp-1634	137	23	days	day	NOUN
ajcp-1634	137	24	after	after	ADP
ajcp-1634	137	25	the	the	DET
ajcp-1634	137	26	initial	initial	ADJ
ajcp-1634	137	27	dosage	dosage	NOUN
ajcp-1634	137	28	(	(	PUNCT
ajcp-1634	137	29	lugonov	lugonov	NOUN
ajcp-1634	137	30	et	et	PROPN
ajcp-1634	137	31	al	al	PROPN
ajcp-1634	137	32	.	.	PROPN
ajcp-1634	137	33	,	,	PUNCT
ajcp-1634	137	34	2021	2021	NUM
ajcp-1634	137	35	)	)	PUNCT
ajcp-1634	137	36	.	.	PUNCT
ajcp-1634	138	1	for	for	ADP
ajcp-1634	138	2	the	the	DET
ajcp-1634	138	3	janssen	janssen	PROPN
ajcp-1634	138	4	vaccine	vaccine	NOUN
ajcp-1634	138	5	,	,	PUNCT
ajcp-1634	138	6	the	the	DET
ajcp-1634	138	7	formulation	formulation	NOUN
ajcp-1634	138	8	was	be	AUX
ajcp-1634	138	9	characterized	characterize	VERB
ajcp-1634	138	10	by	by	ADP
ajcp-1634	138	11	a	a	DET
ajcp-1634	138	12	recombinant	recombinant	ADJ
ajcp-1634	138	13	,	,	PUNCT
ajcp-1634	138	14	replication	replication	NOUN
ajcp-1634	138	15	-	-	PUNCT
ajcp-1634	138	16	deficient	deficient	ADJ
ajcp-1634	138	17	human	human	ADJ
ajcp-1634	138	18	adenovirus	adenovirus	NOUN
ajcp-1634	138	19	26	26	NUM
ajcp-1634	138	20	producing	produce	VERB
ajcp-1634	138	21	full	full	ADJ
ajcp-1634	138	22	-	-	PUNCT
ajcp-1634	138	23	length	length	NOUN
ajcp-1634	138	24	s	s	NOUN
ajcp-1634	138	25	protein	protein	NOUN
ajcp-1634	138	26	with	with	ADP
ajcp-1634	138	27	two	two	NUM
ajcp-1634	138	28	amino	amino	NOUN
ajcp-1634	138	29	acid	acid	NOUN
ajcp-1634	138	30	alterations	alteration	NOUN
ajcp-1634	138	31	in	in	ADP
ajcp-1634	138	32	the	the	DET
ajcp-1634	138	33	s1	s1	NOUN
ajcp-1634	138	34	/	/	SYM
ajcp-1634	138	35	s2	s2	NOUN
ajcp-1634	138	36	junction	junction	NOUN
ajcp-1634	138	37	that	that	PRON
ajcp-1634	138	38	eliminate	eliminate	VERB
ajcp-1634	138	39	the	the	DET
ajcp-1634	138	40	furin	furin	NOUN
ajcp-1634	138	41	cleavage	cleavage	NOUN
ajcp-1634	138	42	site	site	NOUN
ajcp-1634	138	43	and	and	CCONJ
ajcp-1634	138	44	two	two	NUM
ajcp-1634	138	45	proline	proline	NOUN
ajcp-1634	138	46	substitutions	substitution	NOUN
ajcp-1634	138	47	in	in	ADP
ajcp-1634	138	48	the	the	DET
ajcp-1634	138	49	hinge	hinge	NOUN
ajcp-1634	138	50	region	region	NOUN
ajcp-1634	138	51	that	that	PRON
ajcp-1634	138	52	keep	keep	VERB
ajcp-1634	138	53	the	the	DET
ajcp-1634	138	54	protein	protein	NOUN
ajcp-1634	138	55	in	in	ADP
ajcp-1634	138	56	the	the	DET
ajcp-1634	138	57	prefusion	prefusion	NOUN
ajcp-1634	138	58	conformation	conformation	NOUN
ajcp-1634	138	59	(	(	PUNCT
ajcp-1634	138	60	bos	bos	NOUN
ajcp-1634	138	61	et	et	NOUN
ajcp-1634	138	62	al	al	PROPN
ajcp-1634	138	63	.	.	PROPN
ajcp-1634	138	64	,	,	PUNCT
ajcp-1634	138	65	2020	2020	NUM
ajcp-1634	138	66	)	)	PUNCT
ajcp-1634	138	67	.	.	PUNCT
ajcp-1634	139	1	after	after	SCONJ
ajcp-1634	139	2	stabilizing	stabilize	VERB
ajcp-1634	139	3	substitutions	substitution	NOUN
ajcp-1634	139	4	were	be	AUX
ajcp-1634	139	5	inserted	insert	VERB
ajcp-1634	139	6	,	,	PUNCT
ajcp-1634	139	7	the	the	DET
ajcp-1634	139	8	ratio	ratio	NOUN
ajcp-1634	139	9	of	of	ADP
ajcp-1634	139	10	neutralizing	neutralize	VERB
ajcp-1634	139	11	vs.	vs.	CCONJ
ajcp-1634	139	12	non	non	ADJ
ajcp-1634	139	13	-	-	ADJ
ajcp-1634	139	14	neutralizing	neutralizing	ADJ
ajcp-1634	139	15	antibody	antibody	NOUN
ajcp-1634	139	16	binding	bind	VERB
ajcp-1634	139	17	increased	increase	VERB
ajcp-1634	139	18	,	,	PUNCT
ajcp-1634	139	19	indicating	indicate	VERB
ajcp-1634	139	20	that	that	SCONJ
ajcp-1634	139	21	the	the	DET
ajcp-1634	139	22	s	s	NOUN
ajcp-1634	139	23	protein	protein	NOUN
ajcp-1634	139	24	was	be	AUX
ajcp-1634	139	25	in	in	ADP
ajcp-1634	139	26	a	a	DET
ajcp-1634	139	27	prefusion	prefusion	NOUN
ajcp-1634	139	28	conformation	conformation	NOUN
ajcp-1634	139	29	,	,	PUNCT
ajcp-1634	139	30	as	as	SCONJ
ajcp-1634	139	31	observed	observe	VERB
ajcp-1634	139	32	in	in	ADP
ajcp-1634	139	33	its	its	PRON
ajcp-1634	139	34	experimental	experimental	ADJ
ajcp-1634	139	35	stages	stage	NOUN
ajcp-1634	139	36	.	.	PUNCT
ajcp-1634	140	1	s	s	X
ajcp-1634	140	2	-	-	PUNCT
ajcp-1634	140	3	binding	bind	VERB
ajcp-1634	140	4	and	and	CCONJ
ajcp-1634	140	5	neutralizing	neutralize	VERB
ajcp-1634	140	6	antibodies	antibody	NOUN
ajcp-1634	140	7	were	be	AUX
ajcp-1634	140	8	detectable	detectable	ADJ
ajcp-1634	140	9	in	in	ADP
ajcp-1634	140	10	99	99	NUM
ajcp-1634	140	11	percent	percent	NOUN
ajcp-1634	140	12	of	of	ADP
ajcp-1634	140	13	people	people	NOUN
ajcp-1634	140	14	28	28	NUM
ajcp-1634	140	15	days	day	NOUN
ajcp-1634	140	16	after	after	ADP
ajcp-1634	140	17	immunization	immunization	NOUN
ajcp-1634	140	18	,	,	PUNCT
ajcp-1634	140	19	and	and	CCONJ
ajcp-1634	140	20	antibody	antibody	NOUN
ajcp-1634	140	21	levels	level	NOUN
ajcp-1634	140	22	were	be	AUX
ajcp-1634	140	23	maintained	maintain	VERB
ajcp-1634	140	24	for	for	ADP
ajcp-1634	140	25	at	at	ADV
ajcp-1634	140	26	least	least	ADV
ajcp-1634	140	27	84	84	NUM
ajcp-1634	140	28	days	day	NOUN
ajcp-1634	140	29	(	(	PUNCT
ajcp-1634	140	30	janssen	janssen	PROPN
ajcp-1634	140	31	biotech	biotech	NOUN
ajcp-1634	140	32	,	,	PUNCT
ajcp-1634	140	33	2021	2021	NUM
ajcp-1634	140	34	;	;	PUNCT
ajcp-1634	140	35	sadoff	sadoff	NOUN
ajcp-1634	140	36	et	et	PROPN
ajcp-1634	140	37	al	al	PROPN
ajcp-1634	140	38	.	.	PROPN
ajcp-1634	140	39	,	,	PUNCT
ajcp-1634	140	40	2021	2021	NUM
ajcp-1634	140	41	)	)	PUNCT
ajcp-1634	140	42	.	.	PUNCT
ajcp-1634	141	1	protein	protein	NOUN
ajcp-1634	141	2	subunit	subunit	NOUN
ajcp-1634	141	3	to	to	PART
ajcp-1634	141	4	elicit	elicit	VERB
ajcp-1634	141	5	an	an	DET
ajcp-1634	141	6	immune	immune	ADJ
ajcp-1634	141	7	response	response	NOUN
ajcp-1634	141	8	,	,	PUNCT
ajcp-1634	141	9	protein	protein	NOUN
ajcp-1634	141	10	subunit	subunit	NOUN
ajcp-1634	141	11	-	-	PUNCT
ajcp-1634	141	12	based	base	VERB
ajcp-1634	141	13	vaccinations	vaccination	NOUN
ajcp-1634	141	14	combine	combine	VERB
ajcp-1634	141	15	a	a	DET
ajcp-1634	141	16	protein	protein	NOUN
ajcp-1634	141	17	(	(	PUNCT
ajcp-1634	141	18	or	or	CCONJ
ajcp-1634	141	19	part	part	NOUN
ajcp-1634	141	20	of	of	ADP
ajcp-1634	141	21	a	a	DET
ajcp-1634	141	22	protein	protein	NOUN
ajcp-1634	141	23	)	)	PUNCT
ajcp-1634	141	24	from	from	ADP
ajcp-1634	141	25	the	the	DET
ajcp-1634	141	26	targeted	target	VERB
ajcp-1634	141	27	virus	virus	NOUN
ajcp-1634	141	28	with	with	ADP
ajcp-1634	141	29	an	an	DET
ajcp-1634	141	30	immune	immune	NOUN
ajcp-1634	141	31	-	-	PUNCT
ajcp-1634	141	32	boosting	boost	VERB
ajcp-1634	141	33	chemical	chemical	NOUN
ajcp-1634	141	34	termed	term	VERB
ajcp-1634	141	35	an	an	DET
ajcp-1634	141	36	adjuvant	adjuvant	NOUN
ajcp-1634	141	37	(	(	PUNCT
ajcp-1634	141	38	wadman	wadman	ADJ
ajcp-1634	141	39	,	,	PUNCT
ajcp-1634	141	40	2020	2020	NUM
ajcp-1634	141	41	)	)	PUNCT
ajcp-1634	141	42	.	.	PUNCT
ajcp-1634	142	1	adjuvants	adjuvant	NOUN
ajcp-1634	142	2	are	be	AUX
ajcp-1634	142	3	frequently	frequently	ADV
ajcp-1634	142	4	required	require	VERB
ajcp-1634	142	5	for	for	ADP
ajcp-1634	142	6	this	this	DET
ajcp-1634	142	7	type	type	NOUN
ajcp-1634	142	8	of	of	ADP
ajcp-1634	142	9	vaccine	vaccine	NOUN
ajcp-1634	142	10	to	to	PART
ajcp-1634	142	11	increase	increase	VERB
ajcp-1634	142	12	the	the	DET
ajcp-1634	142	13	immune	immune	ADJ
ajcp-1634	142	14	response	response	NOUN
ajcp-1634	142	15	and	and	CCONJ
ajcp-1634	142	16	improve	improve	VERB
ajcp-1634	142	17	vaccine	vaccine	NOUN
ajcp-1634	142	18	efficacy	efficacy	NOUN
ajcp-1634	142	19	(	(	PUNCT
ajcp-1634	142	20	brito	brito	PROPN
ajcp-1634	142	21	et	et	PROPN
ajcp-1634	142	22	al	al	PROPN
ajcp-1634	142	23	.	.	PROPN
ajcp-1634	142	24	,	,	PUNCT
ajcp-1634	142	25	2013	2013	NUM
ajcp-1634	142	26	)	)	PUNCT
ajcp-1634	142	27	.	.	PUNCT
ajcp-1634	143	1	when	when	SCONJ
ajcp-1634	143	2	a	a	DET
ajcp-1634	143	3	protein	protein	NOUN
ajcp-1634	143	4	-	-	PUNCT
ajcp-1634	143	5	based	base	VERB
ajcp-1634	143	6	vaccination	vaccination	NOUN
ajcp-1634	143	7	is	be	AUX
ajcp-1634	143	8	taken	take	VERB
ajcp-1634	143	9	up	up	ADP
ajcp-1634	143	10	and	and	CCONJ
ajcp-1634	143	11	processed	process	VERB
ajcp-1634	143	12	into	into	ADP
ajcp-1634	143	13	several	several	ADJ
ajcp-1634	143	14	epitopes	epitope	NOUN
ajcp-1634	143	15	by	by	ADP
ajcp-1634	143	16	cells	cell	NOUN
ajcp-1634	143	17	,	,	PUNCT
ajcp-1634	143	18	it	it	PRON
ajcp-1634	143	19	provides	provide	VERB
ajcp-1634	143	20	a	a	DET
ajcp-1634	143	21	more	more	ADV
ajcp-1634	143	22	focused	focused	ADJ
ajcp-1634	143	23	response	response	NOUN
ajcp-1634	143	24	to	to	ADP
ajcp-1634	143	25	a	a	DET
ajcp-1634	143	26	particular	particular	ADJ
ajcp-1634	143	27	antigen	antigen	NOUN
ajcp-1634	143	28	(	(	PUNCT
ajcp-1634	143	29	li	li	PROPN
ajcp-1634	143	30	et	et	PROPN
ajcp-1634	143	31	al	al	PROPN
ajcp-1634	143	32	.	.	PROPN
ajcp-1634	143	33	,	,	PUNCT
ajcp-1634	143	34	2021	2021	NUM
ajcp-1634	143	35	)	)	PUNCT
ajcp-1634	143	36	.	.	PUNCT
ajcp-1634	144	1	the	the	DET
ajcp-1634	144	2	antigen	antigen	NOUN
ajcp-1634	144	3	in	in	ADP
ajcp-1634	144	4	most	most	ADJ
ajcp-1634	144	5	of	of	ADP
ajcp-1634	144	6	these	these	DET
ajcp-1634	144	7	vaccinations	vaccination	NOUN
ajcp-1634	144	8	is	be	AUX
ajcp-1634	144	9	either	either	CCONJ
ajcp-1634	144	10	the	the	DET
ajcp-1634	144	11	s	s	NOUN
ajcp-1634	144	12	protein	protein	NOUN
ajcp-1634	144	13	or	or	CCONJ
ajcp-1634	144	14	its	its	PRON
ajcp-1634	144	15	receptor	receptor	NOUN
ajcp-1634	144	16	-	-	PUNCT
ajcp-1634	144	17	binding	bind	VERB
ajcp-1634	144	18	domain	domain	NOUN
ajcp-1634	144	19	(	(	PUNCT
ajcp-1634	144	20	rbd	rbd	NOUN
ajcp-1634	144	21	)	)	PUNCT
ajcp-1634	144	22	.	.	PUNCT
ajcp-1634	145	1	the	the	DET
ajcp-1634	145	2	novavax	novavax	NOUN
ajcp-1634	145	3	vaccine	vaccine	NOUN
ajcp-1634	145	4	,	,	PUNCT
ajcp-1634	145	5	one	one	NUM
ajcp-1634	145	6	of	of	ADP
ajcp-1634	145	7	the	the	DET
ajcp-1634	145	8	vaccines	vaccine	NOUN
ajcp-1634	145	9	that	that	PRON
ajcp-1634	145	10	utilize	utilize	VERB
ajcp-1634	145	11	protein	protein	NOUN
ajcp-1634	145	12	subunit	subunit	NOUN
ajcp-1634	145	13	,	,	PUNCT
ajcp-1634	145	14	uses	use	VERB
ajcp-1634	145	15	a	a	DET
ajcp-1634	145	16	recombinant	recombinant	ADJ
ajcp-1634	145	17	nanoparticle	nanoparticle	NOUN
ajcp-1634	145	18	of	of	ADP
ajcp-1634	145	19	fulllength	fulllength	NOUN
ajcp-1634	145	20	s	s	PART
ajcp-1634	145	21	protein	protein	NOUN
ajcp-1634	145	22	with	with	ADP
ajcp-1634	145	23	protease	protease	NOUN
ajcp-1634	145	24	resistance	resistance	NOUN
ajcp-1634	145	25	mutations	mutation	NOUN
ajcp-1634	145	26	at	at	ADP
ajcp-1634	145	27	the	the	DET
ajcp-1634	145	28	s1	s1	PROPN
ajcp-1634	145	29	/	/	SYM
ajcp-1634	145	30	s2	s2	NOUN
ajcp-1634	145	31	cleavage	cleavage	NOUN
ajcp-1634	145	32	sites	site	NOUN
ajcp-1634	145	33	and	and	CCONJ
ajcp-1634	145	34	two	two	NUM
ajcp-1634	145	35	proline	proline	NOUN
ajcp-1634	145	36	substitutions	substitution	NOUN
ajcp-1634	145	37	to	to	PART
ajcp-1634	145	38	stabilize	stabilize	VERB
ajcp-1634	145	39	protein	protein	NOUN
ajcp-1634	145	40	in	in	ADP
ajcp-1634	145	41	a	a	DET
ajcp-1634	145	42	pre	pre	ADJ
ajcp-1634	145	43	-	-	ADJ
ajcp-1634	145	44	fusion	fusion	ADJ
ajcp-1634	145	45	conformation	conformation	NOUN
ajcp-1634	145	46	,	,	PUNCT
ajcp-1634	145	47	together	together	ADV
ajcp-1634	145	48	with	with	ADP
ajcp-1634	145	49	a	a	DET
ajcp-1634	145	50	saponin	saponin	NOUN
ajcp-1634	145	51	-	-	PUNCT
ajcp-1634	145	52	based	base	VERB
ajcp-1634	145	53	adjuvant	adjuvant	NOUN
ajcp-1634	145	54	(	(	PUNCT
ajcp-1634	145	55	matrixm1	matrixm1	NOUN
ajcp-1634	145	56	)	)	PUNCT
ajcp-1634	145	57	(	(	PUNCT
ajcp-1634	145	58	keech	keech	NOUN
ajcp-1634	145	59	et	et	PROPN
ajcp-1634	145	60	al	al	PROPN
ajcp-1634	145	61	.	.	PROPN
ajcp-1634	145	62	,	,	PUNCT
ajcp-1634	145	63	2020	2020	NUM
ajcp-1634	145	64	)	)	PUNCT
ajcp-1634	145	65	.	.	PUNCT
ajcp-1634	146	1	antibody	antibody	NOUN
ajcp-1634	146	2	to	to	ADP
ajcp-1634	146	3	s	s	VERB
ajcp-1634	146	4	-	-	PUNCT
ajcp-1634	146	5	binding	binding	ADJ
ajcp-1634	146	6	was	be	AUX
ajcp-1634	146	7	identified	identify	VERB
ajcp-1634	146	8	21	21	NUM
ajcp-1634	146	9	days	day	NOUN
ajcp-1634	146	10	after	after	ADP
ajcp-1634	146	11	the	the	DET
ajcp-1634	146	12	first	first	ADJ
ajcp-1634	146	13	treatment	treatment	NOUN
ajcp-1634	146	14	,	,	PUNCT
ajcp-1634	146	15	and	and	CCONJ
ajcp-1634	146	16	significantly	significantly	ADV
ajcp-1634	146	17	increased	increase	VERB
ajcp-1634	146	18	after	after	ADP
ajcp-1634	146	19	the	the	DET
ajcp-1634	146	20	second	second	ADJ
ajcp-1634	146	21	dose	dose	NOUN
ajcp-1634	146	22	.	.	PUNCT
ajcp-1634	147	1	meanwhile	meanwhile	ADV
ajcp-1634	147	2	,	,	PUNCT
ajcp-1634	147	3	based	base	VERB
ajcp-1634	147	4	on	on	ADP
ajcp-1634	147	5	ifn	ifn	PROPN
ajcp-1634	147	6	,	,	PUNCT
ajcp-1634	147	7	il-2	il-2	PROPN
ajcp-1634	147	8	,	,	PUNCT
ajcp-1634	147	9	and	and	CCONJ
ajcp-1634	147	10	tnf	tnf	PROPN
ajcp-1634	147	11	production	production	NOUN
ajcp-1634	147	12	in	in	ADP
ajcp-1634	147	13	response	response	NOUN
ajcp-1634	147	14	to	to	ADP
ajcp-1634	147	15	s	s	NOUN
ajcp-1634	147	16	protein	protein	NOUN
ajcp-1634	147	17	stimulation	stimulation	NOUN
ajcp-1634	147	18	,	,	PUNCT
ajcp-1634	147	19	cd4	cd4	PROPN
ajcp-1634	147	20	+	+	PROPN
ajcp-1634	147	21	t	t	NOUN
ajcp-1634	147	22	cell	cell	NOUN
ajcp-1634	147	23	responses	response	NOUN
ajcp-1634	147	24	were	be	AUX
ajcp-1634	147	25	detectable	detectable	ADJ
ajcp-1634	147	26	seven	seven	NUM
ajcp-1634	147	27	days	day	NOUN
ajcp-1634	147	28	after	after	ADP
ajcp-1634	147	29	the	the	DET
ajcp-1634	147	30	second	second	ADJ
ajcp-1634	147	31	dosage	dosage	NOUN
ajcp-1634	147	32	,	,	PUNCT
ajcp-1634	147	33	with	with	ADP
ajcp-1634	147	34	a	a	DET
ajcp-1634	147	35	substantial	substantial	ADJ
ajcp-1634	147	36	bias	bias	NOUN
ajcp-1634	147	37	towards	towards	ADP
ajcp-1634	147	38	a	a	DET
ajcp-1634	147	39	th1	th1	NOUN
ajcp-1634	147	40	cell	cell	NOUN
ajcp-1634	147	41	phenotype	phenotype	NOUN
ajcp-1634	147	42	(	(	PUNCT
ajcp-1634	147	43	keech	keech	PROPN
ajcp-1634	147	44	et	et	PROPN
ajcp-1634	147	45	a.	a.	PROPN
ajcp-1634	147	46	,	,	PUNCT
ajcp-1634	147	47	2020	2020	NUM
ajcp-1634	147	48	)	)	PUNCT
ajcp-1634	147	49	.	.	PUNCT
ajcp-1634	148	1	whole	whole	ADJ
ajcp-1634	148	2	cell	cell	NOUN
ajcp-1634	148	3	inactivated	inactivate	VERB
ajcp-1634	148	4	virus	virus	NOUN
ajcp-1634	148	5	sinovac	sinovac	PROPN
ajcp-1634	148	6	biotech	biotech	NOUN
ajcp-1634	148	7	(	(	PUNCT
ajcp-1634	148	8	coronavac	coronavac	PROPN
ajcp-1634	148	9	)	)	PUNCT
ajcp-1634	148	10	,	,	PUNCT
ajcp-1634	148	11	sinoparm	sinoparm	NOUN
ajcp-1634	148	12	(	(	PUNCT
ajcp-1634	148	13	bbibpcorv	bbibpcorv	NOUN
ajcp-1634	148	14	;	;	PUNCT
ajcp-1634	148	15	wibpcorv	wibpcorv	NOUN
ajcp-1634	148	16	)	)	PUNCT
ajcp-1634	148	17	,	,	PUNCT
ajcp-1634	148	18	and	and	CCONJ
ajcp-1634	148	19	bharat	bharat	PROPN
ajcp-1634	148	20	biotech	biotech	NOUN
ajcp-1634	148	21	are	be	AUX
ajcp-1634	148	22	three	three	NUM
ajcp-1634	148	23	sarscov-2	sarscov-2	NUM
ajcp-1634	148	24	vaccines	vaccine	NOUN
ajcp-1634	148	25	that	that	PRON
ajcp-1634	148	26	use	use	VERB
ajcp-1634	148	27	the	the	DET
ajcp-1634	148	28	whole	whole	ADJ
ajcp-1634	148	29	-	-	PUNCT
ajcp-1634	148	30	cell	cell	NOUN
ajcp-1634	148	31	inactivated	inactivated	ADJ
ajcp-1634	148	32	virus	virus	NOUN
ajcp-1634	148	33	method	method	NOUN
ajcp-1634	148	34	(	(	PUNCT
ajcp-1634	148	35	bbv152	bbv152	PROPN
ajcp-1634	148	36	)	)	PUNCT
ajcp-1634	148	37	(	(	PUNCT
ajcp-1634	148	38	sadarangani	sadarangani	PROPN
ajcp-1634	148	39	et	et	PROPN
ajcp-1634	148	40	al	al	PROPN
ajcp-1634	148	41	.	.	PROPN
ajcp-1634	148	42	,	,	PUNCT
ajcp-1634	148	43	2021	2021	NUM
ajcp-1634	148	44	)	)	PUNCT
ajcp-1634	148	45	.	.	PUNCT
ajcp-1634	149	1	inactivated	inactivated	ADJ
ajcp-1634	149	2	vaccines	vaccine	NOUN
ajcp-1634	149	3	,	,	PUNCT
ajcp-1634	149	4	also	also	ADV
ajcp-1634	149	5	known	know	VERB
ajcp-1634	149	6	as	as	ADP
ajcp-1634	149	7	killed	kill	VERB
ajcp-1634	149	8	vaccines	vaccine	NOUN
ajcp-1634	149	9	,	,	PUNCT
ajcp-1634	149	10	are	be	AUX
ajcp-1634	149	11	made	make	VERB
ajcp-1634	149	12	by	by	ADP
ajcp-1634	149	13	growing	grow	VERB
ajcp-1634	149	14	the	the	DET
ajcp-1634	149	15	virus	virus	NOUN
ajcp-1634	149	16	in	in	ADP
ajcp-1634	149	17	a	a	DET
ajcp-1634	149	18	culture	culture	NOUN
ajcp-1634	149	19	medium	medium	NOUN
ajcp-1634	149	20	and	and	CCONJ
ajcp-1634	149	21	then	then	ADV
ajcp-1634	149	22	treating	treat	VERB
ajcp-1634	149	23	it	it	PRON
ajcp-1634	149	24	with	with	ADP
ajcp-1634	149	25	chemicals	chemical	NOUN
ajcp-1634	149	26	,	,	PUNCT
ajcp-1634	149	27	heat	heat	NOUN
ajcp-1634	149	28	,	,	PUNCT
ajcp-1634	149	29	or	or	CCONJ
ajcp-1634	149	30	radiation	radiation	NOUN
ajcp-1634	149	31	to	to	PART
ajcp-1634	149	32	inactivate	inactivate	VERB
ajcp-1634	149	33	it	it	PRON
ajcp-1634	149	34	(	(	PUNCT
ajcp-1634	149	35	li	li	PROPN
ajcp-1634	149	36	et	et	PROPN
ajcp-1634	149	37	al	al	PROPN
ajcp-1634	149	38	.	.	PROPN
ajcp-1634	149	39	,	,	PUNCT
ajcp-1634	149	40	2021	2021	NUM
ajcp-1634	149	41	)	)	PUNCT
ajcp-1634	149	42	.	.	PUNCT
ajcp-1634	150	1	the	the	DET
ajcp-1634	150	2	majority	majority	NOUN
ajcp-1634	150	3	of	of	ADP
ajcp-1634	150	4	these	these	DET
ajcp-1634	150	5	vaccines	vaccine	NOUN
ajcp-1634	150	6	contain	contain	VERB
ajcp-1634	150	7	aluminum	aluminum	NOUN
ajcp-1634	150	8	hydroxide	hydroxide	NOUN
ajcp-1634	150	9	(	(	PUNCT
ajcp-1634	150	10	flanagan	flanagan	NOUN
ajcp-1634	150	11	et	et	PROPN
ajcp-1634	150	12	al	al	PROPN
ajcp-1634	150	13	.	.	PROPN
ajcp-1634	150	14	,	,	PUNCT
ajcp-1634	150	15	2020	2020	NUM
ajcp-1634	150	16	;	;	PUNCT
ajcp-1634	150	17	who	who	PRON
ajcp-1634	150	18	,	,	PUNCT
ajcp-1634	150	19	2021	2021	NUM
ajcp-1634	150	20	)	)	PUNCT
ajcp-1634	150	21	.	.	PUNCT
ajcp-1634	151	1	the	the	DET
ajcp-1634	151	2	sinovac	sinovac	ADJ
ajcp-1634	151	3	biotech	biotech	ADJ
ajcp-1634	151	4	vaccine	vaccine	NOUN
ajcp-1634	151	5	,	,	PUNCT
ajcp-1634	151	6	for	for	ADP
ajcp-1634	151	7	example	example	NOUN
ajcp-1634	151	8	,	,	PUNCT
ajcp-1634	151	9	is	be	AUX
ajcp-1634	151	10	made	make	VERB
ajcp-1634	151	11	from	from	ADP
ajcp-1634	151	12	sars	sar	NOUN
ajcp-1634	151	13	-	-	PUNCT
ajcp-1634	151	14	cov-2	cov-2	NOUN
ajcp-1634	151	15	produced	produce	VERB
ajcp-1634	151	16	in	in	ADP
ajcp-1634	151	17	vero	vero	PROPN
ajcp-1634	151	18	cells	cell	NOUN
ajcp-1634	151	19	,	,	PUNCT
ajcp-1634	151	20	inactivated	inactivated	ADJ
ajcp-1634	151	21	using	use	VERB
ajcp-1634	151	22	β	β	NOUN
ajcp-1634	151	23	-	-	NOUN
ajcp-1634	151	24	propiolactone	propiolactone	ADJ
ajcp-1634	151	25	,	,	PUNCT
ajcp-1634	151	26	and	and	CCONJ
ajcp-1634	151	27	adsorbed	adsorb	VERB
ajcp-1634	151	28	onto	onto	ADP
ajcp-1634	151	29	aluminum	aluminum	NOUN
ajcp-1634	151	30	hydroxide	hydroxide	NOUN
ajcp-1634	151	31	.	.	PUNCT
ajcp-1634	152	1	in	in	ADP
ajcp-1634	152	2	the	the	DET
ajcp-1634	152	3	case	case	NOUN
ajcp-1634	152	4	of	of	ADP
ajcp-1634	152	5	vaccines	vaccine	NOUN
ajcp-1634	152	6	developed	develop	VERB
ajcp-1634	152	7	against	against	ADP
ajcp-1634	152	8	covid-19	covid-19	PROPN
ajcp-1634	152	9	,	,	PUNCT
ajcp-1634	152	10	the	the	DET
ajcp-1634	152	11	attenuated	attenuated	ADJ
ajcp-1634	152	12	or	or	CCONJ
ajcp-1634	152	13	inactivated	inactivated	ADJ
ajcp-1634	152	14	whole	whole	ADJ
ajcp-1634	152	15	sars	sar	NOUN
ajcp-1634	152	16	-	-	PUNCT
ajcp-1634	152	17	cov-2	cov-2	PART
ajcp-1634	152	18	virus	virus	NOUN
ajcp-1634	152	19	is	be	AUX
ajcp-1634	152	20	administered	administer	VERB
ajcp-1634	152	21	to	to	ADP
ajcp-1634	152	22	individuals	individual	NOUN
ajcp-1634	152	23	to	to	PART
ajcp-1634	152	24	elicit	elicit	VERB
ajcp-1634	152	25	immune	immune	ADJ
ajcp-1634	152	26	responses	response	NOUN
ajcp-1634	152	27	(	(	PUNCT
ajcp-1634	152	28	li	li	PROPN
ajcp-1634	152	29	et	et	PROPN
ajcp-1634	152	30	al	al	PROPN
ajcp-1634	152	31	.	.	PROPN
ajcp-1634	152	32	,	,	PUNCT
ajcp-1634	152	33	2021	2021	NUM
ajcp-1634	152	34	)	)	PUNCT
ajcp-1634	152	35	.	.	PUNCT
ajcp-1634	153	1	these	these	DET
ajcp-1634	153	2	immune	immune	ADJ
ajcp-1634	153	3	responses	response	NOUN
ajcp-1634	153	4	target	target	VERB
ajcp-1634	153	5	the	the	DET
ajcp-1634	153	6	sars	sar	NOUN
ajcp-1634	153	7	-	-	PUNCT
ajcp-1634	153	8	cov-2	cov-2	NOUN
ajcp-1634	153	9	s	s	PART
ajcp-1634	153	10	protein	protein	NOUN
ajcp-1634	153	11	.	.	PUNCT
ajcp-1634	154	1	inactivated	inactivated	ADJ
ajcp-1634	154	2	vaccines	vaccine	NOUN
ajcp-1634	154	3	have	have	VERB
ajcp-1634	154	4	a	a	DET
ajcp-1634	154	5	long	long	ADJ
ajcp-1634	154	6	history	history	NOUN
ajcp-1634	154	7	of	of	ADP
ajcp-1634	154	8	use	use	NOUN
ajcp-1634	154	9	and	and	CCONJ
ajcp-1634	154	10	can	can	AUX
ajcp-1634	154	11	benefit	benefit	VERB
ajcp-1634	154	12	many	many	ADJ
ajcp-1634	154	13	people	people	NOUN
ajcp-1634	154	14	,	,	PUNCT
ajcp-1634	154	15	even	even	ADV
ajcp-1634	154	16	individuals	individual	NOUN
ajcp-1634	154	17	with	with	ADP
ajcp-1634	154	18	advanced	advanced	ADJ
ajcp-1634	154	19	immunological	immunological	ADJ
ajcp-1634	154	20	senescence	senescence	NOUN
ajcp-1634	154	21	(	(	PUNCT
ajcp-1634	154	22	iversen	iversen	NOUN
ajcp-1634	154	23	&	&	CCONJ
ajcp-1634	154	24	bavari	bavari	PROPN
ajcp-1634	154	25	,	,	PUNCT
ajcp-1634	154	26	2021	2021	NUM
ajcp-1634	154	27	)	)	PUNCT
ajcp-1634	154	28	.	.	PUNCT
ajcp-1634	155	1	conclusion	conclusion	NOUN
ajcp-1634	155	2	sars	sar	NOUN
ajcp-1634	155	3	-	-	PUNCT
ajcp-1634	155	4	cov-2	cov-2	PART
ajcp-1634	155	5	mutations	mutation	NOUN
ajcp-1634	155	6	have	have	AUX
ajcp-1634	155	7	been	be	AUX
ajcp-1634	155	8	on	on	ADP
ajcp-1634	155	9	the	the	DET
ajcp-1634	155	10	rise	rise	NOUN
ajcp-1634	155	11	recently	recently	ADV
ajcp-1634	155	12	.	.	PUNCT
ajcp-1634	156	1	the	the	DET
ajcp-1634	156	2	delta	delta	NOUN
ajcp-1634	156	3	variant	variant	NOUN
ajcp-1634	156	4	,	,	PUNCT
ajcp-1634	156	5	for	for	ADP
ajcp-1634	156	6	example	example	NOUN
ajcp-1634	156	7	,	,	PUNCT
ajcp-1634	156	8	has	have	AUX
ajcp-1634	156	9	been	be	AUX
ajcp-1634	156	10	linked	link	VERB
ajcp-1634	156	11	to	to	ADP
ajcp-1634	156	12	a	a	DET
ajcp-1634	156	13	surge	surge	NOUN
ajcp-1634	156	14	in	in	ADP
ajcp-1634	156	15	cases	case	NOUN
ajcp-1634	156	16	in	in	ADP
ajcp-1634	156	17	india	india	PROPN
ajcp-1634	156	18	and	and	CCONJ
ajcp-1634	156	19	has	have	AUX
ajcp-1634	156	20	now	now	ADV
ajcp-1634	156	21	been	be	AUX
ajcp-1634	156	22	found	find	VERB
ajcp-1634	156	23	worldwide	worldwide	ADV
ajcp-1634	156	24	,	,	PUNCT
ajcp-1634	156	25	including	include	VERB
ajcp-1634	156	26	a	a	DET
ajcp-1634	156	27	significant	significant	ADJ
ajcp-1634	156	28	increase	increase	NOUN
ajcp-1634	156	29	in	in	ADP
ajcp-1634	156	30	cases	case	NOUN
ajcp-1634	156	31	in	in	ADP
ajcp-1634	156	32	the	the	DET
ajcp-1634	156	33	united	united	ADJ
ajcp-1634	156	34	kingdom	kingdom	PROPN
ajcp-1634	156	35	(	(	PUNCT
ajcp-1634	156	36	bernal	bernal	PROPN
ajcp-1634	156	37	et	et	PROPN
ajcp-1634	156	38	al	al	PROPN
ajcp-1634	156	39	.	.	PROPN
ajcp-1634	156	40	,	,	PUNCT
ajcp-1634	156	41	2021	2021	NUM
ajcp-1634	156	42	)	)	PUNCT
ajcp-1634	156	43	.	.	PUNCT
ajcp-1634	157	1	the	the	DET
ajcp-1634	157	2	spike	spike	ADJ
ajcp-1634	157	3	protein	protein	NOUN
ajcp-1634	157	4	mutations	mutation	NOUN
ajcp-1634	157	5	t19r	t19r	ADJ
ajcp-1634	157	6	,	,	PUNCT
ajcp-1634	157	7	157	157	NUM
ajcp-1634	157	8	-	-	SYM
ajcp-1634	157	9	158	158	NUM
ajcp-1634	157	10	,	,	PUNCT
ajcp-1634	157	11	l452r	l452r	PROPN
ajcp-1634	157	12	,	,	PUNCT
ajcp-1634	157	13	t478k	t478k	PROPN
ajcp-1634	157	14	,	,	PUNCT
ajcp-1634	157	15	d614	d614	PROPN
ajcp-1634	157	16	g	g	NOUN
ajcp-1634	157	17	,	,	PUNCT
ajcp-1634	157	18	p681r	p681r	PROPN
ajcp-1634	157	19	,	,	PUNCT
ajcp-1634	157	20	and	and	CCONJ
ajcp-1634	157	21	d950n	d950n	PROPN
ajcp-1634	157	22	distinguish	distinguish	VERB
ajcp-1634	157	23	the	the	DET
ajcp-1634	157	24	delta	delta	NOUN
ajcp-1634	157	25	variant	variant	NOUN
ajcp-1634	157	26	(	(	PUNCT
ajcp-1634	157	27	ecdpc	ecdpc	NOUN
ajcp-1634	157	28	,	,	PUNCT
ajcp-1634	157	29	2021	2021	NUM
ajcp-1634	157	30	)	)	PUNCT
ajcp-1634	157	31	.	.	PUNCT
ajcp-1634	158	1	several	several	ADJ
ajcp-1634	158	2	of	of	ADP
ajcp-1634	158	3	these	these	DET
ajcp-1634	158	4	mutations	mutation	NOUN
ajcp-1634	158	5	may	may	AUX
ajcp-1634	158	6	affect	affect	VERB
ajcp-1634	158	7	immune	immune	ADJ
ajcp-1634	158	8	responses	response	NOUN
ajcp-1634	158	9	directed	direct	VERB
ajcp-1634	158	10	at	at	ADP
ajcp-1634	158	11	the	the	DET
ajcp-1634	158	12	receptor	receptor	NOUN
ajcp-1634	158	13	-	-	PUNCT
ajcp-1634	158	14	binding	bind	VERB
ajcp-1634	158	15	protein	protein	NOUN
ajcp-1634	158	16	’s	’s	PART
ajcp-1634	158	17	key	key	ADJ
ajcp-1634	158	18	antigenic	antigenic	ADJ
ajcp-1634	158	19	regions	region	NOUN
ajcp-1634	158	20	(	(	PUNCT
ajcp-1634	158	21	452	452	NUM
ajcp-1634	158	22	and	and	CCONJ
ajcp-1634	158	23	478	478	NUM
ajcp-1634	158	24	)	)	PUNCT
ajcp-1634	158	25	and	and	CCONJ
ajcp-1634	158	26	the	the	DET
ajcp-1634	158	27	deletion	deletion	NOUN
ajcp-1634	158	28	of	of	ADP
ajcp-1634	158	29	a	a	DET
ajcp-1634	158	30	portion	portion	NOUN
ajcp-1634	158	31	of	of	ADP
ajcp-1634	158	32	the	the	DET
ajcp-1634	158	33	n	n	CCONJ
ajcp-1634	158	34	-	-	PUNCT
ajcp-1634	158	35	terminal	terminal	ADJ
ajcp-1634	158	36	domain	domain	NOUN
ajcp-1634	158	37	(	(	PUNCT
ajcp-1634	158	38	li	li	PROPN
ajcp-1634	158	39	et	et	PROPN
ajcp-1634	158	40	a.	a.	PROPN
ajcp-1634	158	41	,	,	PUNCT
ajcp-1634	158	42	2020	2020	NUM
ajcp-1634	158	43	)	)	PUNCT
ajcp-1634	158	44	.	.	PUNCT
ajcp-1634	159	1	p681r	p681r	PROPN
ajcp-1634	159	2	is	be	AUX
ajcp-1634	159	3	located	locate	VERB
ajcp-1634	159	4	at	at	ADP
ajcp-1634	159	5	the	the	DET
ajcp-1634	159	6	s1	s1	NOUN
ajcp-1634	159	7	–	–	PUNCT
ajcp-1634	159	8	s2	s2	NOUN
ajcp-1634	159	9	cleavage	cleavage	NOUN
ajcp-1634	159	10	site	site	NOUN
ajcp-1634	159	11	,	,	PUNCT
ajcp-1634	159	12	and	and	CCONJ
ajcp-1634	159	13	it	it	PRON
ajcp-1634	159	14	appears	appear	VERB
ajcp-1634	159	15	that	that	SCONJ
ajcp-1634	159	16	strains	strain	VERB
ajcp-1634	159	17	with	with	ADP
ajcp-1634	159	18	mutations	mutation	NOUN
ajcp-1634	159	19	there	there	ADV
ajcp-1634	159	20	has	have	VERB
ajcp-1634	159	21	greater	great	ADJ
ajcp-1634	159	22	replication	replication	NOUN
ajcp-1634	159	23	,	,	PUNCT
ajcp-1634	159	24	resulting	result	VERB
ajcp-1634	159	25	in	in	ADP
ajcp-1634	159	26	higher	high	ADJ
ajcp-1634	159	27	viral	viral	ADJ
ajcp-1634	159	28	loads	load	NOUN
ajcp-1634	159	29	and	and	CCONJ
ajcp-1634	159	30	transmission	transmission	NOUN
ajcp-1634	159	31	(	(	PUNCT
ajcp-1634	159	32	johnson	johnson	PROPN
ajcp-1634	159	33	et	et	PROPN
ajcp-1634	159	34	al	al	PROPN
ajcp-1634	159	35	.	.	PROPN
ajcp-1634	159	36	,	,	PUNCT
ajcp-1634	159	37	2020	2020	NUM
ajcp-1634	159	38	)	)	PUNCT
ajcp-1634	159	39	.	.	PUNCT
ajcp-1634	160	1	this	this	DET
ajcp-1634	160	2	advent	advent	NOUN
ajcp-1634	160	3	of	of	ADP
ajcp-1634	160	4	more	more	ADJ
ajcp-1634	160	5	lethal	lethal	ADJ
ajcp-1634	160	6	sars	sar	NOUN
ajcp-1634	160	7	-	-	PUNCT
ajcp-1634	160	8	cov-2	cov-2	NOUN
ajcp-1634	160	9	variations	variation	NOUN
ajcp-1634	160	10	raised	raise	VERB
ajcp-1634	160	11	questions	question	NOUN
ajcp-1634	160	12	about	about	ADP
ajcp-1634	160	13	the	the	DET
ajcp-1634	160	14	efficiency	efficiency	NOUN
ajcp-1634	160	15	of	of	ADP
ajcp-1634	160	16	existing	exist	VERB
ajcp-1634	160	17	vaccines	vaccine	NOUN
ajcp-1634	160	18	,	,	PUNCT
ajcp-1634	160	19	which	which	PRON
ajcp-1634	160	20	were	be	AUX
ajcp-1634	160	21	meant	mean	VERB
ajcp-1634	160	22	to	to	PART
ajcp-1634	160	23	combat	combat	VERB
ajcp-1634	160	24	the	the	DET
ajcp-1634	160	25	initial	initial	ADJ
ajcp-1634	160	26	sars	sar	NOUN
ajcp-1634	160	27	-	-	PUNCT
ajcp-1634	160	28	cov-2	cov-2	PART
ajcp-1634	160	29	strain	strain	NOUN
ajcp-1634	160	30	.	.	PUNCT
ajcp-1634	161	1	as	as	ADP
ajcp-1634	161	2	a	a	DET
ajcp-1634	161	3	result	result	NOUN
ajcp-1634	161	4	,	,	PUNCT
ajcp-1634	161	5	future	future	ADJ
ajcp-1634	161	6	vaccine	vaccine	NOUN
ajcp-1634	161	7	development	development	NOUN
ajcp-1634	161	8	research	research	NOUN
ajcp-1634	161	9	must	must	AUX
ajcp-1634	161	10	focus	focus	VERB
ajcp-1634	161	11	on	on	ADP
ajcp-1634	161	12	how	how	SCONJ
ajcp-1634	161	13	vaccines	vaccine	NOUN
ajcp-1634	161	14	can	can	AUX
ajcp-1634	161	15	effectively	effectively	ADV
ajcp-1634	161	16	battle	battle	VERB
ajcp-1634	161	17	these	these	DET
ajcp-1634	161	18	developing	develop	VERB
ajcp-1634	161	19	strains	strain	NOUN
ajcp-1634	161	20	,	,	PUNCT
ajcp-1634	161	21	focusing	focus	VERB
ajcp-1634	161	22	on	on	ADP
ajcp-1634	161	23	the	the	DET
ajcp-1634	161	24	mechanism	mechanism	NOUN
ajcp-1634	161	25	of	of	ADP
ajcp-1634	161	26	the	the	DET
ajcp-1634	161	27	sars	sar	NOUN
ajcp-1634	161	28	-	-	PUNCT
ajcp-1634	161	29	cov-2	cov-2	NOUN
ajcp-1634	161	30	s	s	NOUN
ajcp-1634	161	31	proteins	protein	NOUN
ajcp-1634	161	32	,	,	PUNCT
ajcp-1634	161	33	which	which	PRON
ajcp-1634	161	34	is	be	AUX
ajcp-1634	161	35	the	the	DET
ajcp-1634	161	36	site	site	NOUN
ajcp-1634	161	37	of	of	ADP
ajcp-1634	161	38	mutations	mutation	NOUN
ajcp-1634	161	39	in	in	ADP
ajcp-1634	161	40	the	the	DET
ajcp-1634	161	41	delta	delta	NOUN
ajcp-1634	161	42	variant	variant	NOUN
ajcp-1634	161	43	.	.	PUNCT
ajcp-1634	162	1	references	reference	NOUN
ajcp-1634	162	2	altman	altman	PROPN
ajcp-1634	162	3	,	,	PUNCT
ajcp-1634	162	4	m.	m.	PROPN
ajcp-1634	162	5	o.	o.	PROPN
ajcp-1634	162	6	,	,	PUNCT
ajcp-1634	162	7	angel	angel	NOUN
ajcp-1634	162	8	,	,	PUNCT
ajcp-1634	162	9	m.	m.	NOUN
ajcp-1634	162	10	,	,	PUNCT
ajcp-1634	162	11	košík	košík	PROPN
ajcp-1634	162	12	,	,	PUNCT
ajcp-1634	162	13	i.	i.	PROPN
ajcp-1634	162	14	,	,	PUNCT
ajcp-1634	162	15	trovão	trovão	NOUN
ajcp-1634	162	16	,	,	PUNCT
ajcp-1634	162	17	n.	n.	PROPN
ajcp-1634	162	18	s.	s.	PROPN
ajcp-1634	162	19	,	,	PUNCT
ajcp-1634	162	20	zost	zost	PROPN
ajcp-1634	162	21	,	,	PUNCT
ajcp-1634	162	22	s.	s.	PROPN
ajcp-1634	162	23	j.	j.	PROPN
ajcp-1634	162	24	,	,	PUNCT
ajcp-1634	162	25	gibbs	gibbs	PROPN
ajcp-1634	162	26	,	,	PUNCT
ajcp-1634	162	27	j.	j.	PROPN
ajcp-1634	162	28	s.	s.	PROPN
ajcp-1634	162	29	,	,	PUNCT
ajcp-1634	162	30	...	...	PUNCT
ajcp-1634	162	31	&	&	CCONJ
ajcp-1634	162	32	yewdell	yewdell	PROPN
ajcp-1634	162	33	,	,	PUNCT
ajcp-1634	162	34	j.	j.	PROPN
ajcp-1634	162	35	w.	w.	PROPN
ajcp-1634	162	36	(	(	PUNCT
ajcp-1634	162	37	2019	2019	NUM
ajcp-1634	162	38	)	)	PUNCT
ajcp-1634	162	39	.	.	PUNCT
ajcp-1634	163	1	human	human	ADJ
ajcp-1634	163	2	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	163	3	pa	pa	PROPN
ajcp-1634	163	4	ge	ge	PROPN
ajcp-1634	163	5	71	71	NUM
ajcp-1634	163	6	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	163	7	am	be	AUX
ajcp-1634	163	8	.	.	PUNCT
ajcp-1634	164	1	j.	j.	PROPN
ajcp-1634	164	2	chem	chem	PROPN
ajcp-1634	164	3	.	.	PUNCT
ajcp-1634	165	1	pharm	pharm	PROPN
ajcp-1634	165	2	.	.	PUNCT
ajcp-1634	166	1	2(2	2(2	NUM
ajcp-1634	166	2	)	)	PUNCT
ajcp-1634	167	1	66	66	NUM
ajcp-1634	167	2	-	-	SYM
ajcp-1634	167	3	73	73	NUM
ajcp-1634	167	4	,	,	PUNCT
ajcp-1634	167	5	2023	2023	NUM
ajcp-1634	167	6	influenza	influenza	NOUN
ajcp-1634	167	7	a	a	DET
ajcp-1634	167	8	virus	virus	NOUN
ajcp-1634	167	9	hemagglutinin	hemagglutinin	ADJ
ajcp-1634	167	10	glycan	glycan	PROPN
ajcp-1634	167	11	evolution	evolution	PROPN
ajcp-1634	167	12	follows	follow	VERB
ajcp-1634	167	13	a	a	DET
ajcp-1634	167	14	temporal	temporal	ADJ
ajcp-1634	167	15	pattern	pattern	NOUN
ajcp-1634	167	16	to	to	ADP
ajcp-1634	167	17	a	a	DET
ajcp-1634	167	18	glycan	glycan	NOUN
ajcp-1634	167	19	limit	limit	NOUN
ajcp-1634	167	20	.	.	PUNCT
ajcp-1634	168	1	mbio	mbio	PROPN
ajcp-1634	168	2	,	,	PUNCT
ajcp-1634	168	3	10(2	10(2	NUM
ajcp-1634	168	4	)	)	PUNCT
ajcp-1634	168	5	,	,	PUNCT
ajcp-1634	168	6	e00204	e00204	NUM
ajcp-1634	168	7	-	-	SYM
ajcp-1634	168	8	19	19	NUM
ajcp-1634	168	9	.	.	PUNCT
ajcp-1634	169	1	baden	baden	PROPN
ajcp-1634	169	2	,	,	PUNCT
ajcp-1634	169	3	l.	l.	PROPN
ajcp-1634	169	4	r.	r.	PROPN
ajcp-1634	169	5	,	,	PUNCT
ajcp-1634	169	6	el	el	PROPN
ajcp-1634	169	7	sahly	sahly	PROPN
ajcp-1634	169	8	,	,	PUNCT
ajcp-1634	169	9	h.	h.	PROPN
ajcp-1634	169	10	m.	m.	PROPN
ajcp-1634	169	11	,	,	PUNCT
ajcp-1634	169	12	essink	essink	PROPN
ajcp-1634	169	13	,	,	PUNCT
ajcp-1634	169	14	b.	b.	PROPN
ajcp-1634	169	15	,	,	PUNCT
ajcp-1634	169	16	kotloff	kotloff	PROPN
ajcp-1634	169	17	,	,	PUNCT
ajcp-1634	169	18	k.	k.	PROPN
ajcp-1634	169	19	,	,	PUNCT
ajcp-1634	169	20	frey	frey	PROPN
ajcp-1634	169	21	,	,	PUNCT
ajcp-1634	169	22	s.	s.	PROPN
ajcp-1634	169	23	,	,	PUNCT
ajcp-1634	169	24	novak	novak	PROPN
ajcp-1634	169	25	,	,	PUNCT
ajcp-1634	169	26	r.	r.	PROPN
ajcp-1634	169	27	,	,	PUNCT
ajcp-1634	169	28	...	...	PUNCT
ajcp-1634	169	29	&	&	CCONJ
ajcp-1634	169	30	zaks	zak	NOUN
ajcp-1634	169	31	,	,	PUNCT
ajcp-1634	169	32	t.	t.	NOUN
ajcp-1634	169	33	(	(	PUNCT
ajcp-1634	169	34	2021	2021	NUM
ajcp-1634	169	35	)	)	PUNCT
ajcp-1634	169	36	.	.	PUNCT
ajcp-1634	170	1	efficacy	efficacy	NOUN
ajcp-1634	170	2	and	and	CCONJ
ajcp-1634	170	3	safety	safety	NOUN
ajcp-1634	170	4	of	of	ADP
ajcp-1634	170	5	the	the	DET
ajcp-1634	170	6	mrna-1273	mrna-1273	ADJ
ajcp-1634	170	7	sars	sar	NOUN
ajcp-1634	170	8	-	-	PUNCT
ajcp-1634	170	9	cov-2	cov-2	PART
ajcp-1634	170	10	vaccine	vaccine	NOUN
ajcp-1634	170	11	.	.	PUNCT
ajcp-1634	171	1	new	new	PROPN
ajcp-1634	171	2	england	england	PROPN
ajcp-1634	171	3	journal	journal	PROPN
ajcp-1634	171	4	of	of	ADP
ajcp-1634	171	5	medicine	medicine	NOUN
ajcp-1634	171	6	,	,	PUNCT
ajcp-1634	171	7	384(5	384(5	NUM
ajcp-1634	171	8	)	)	PUNCT
ajcp-1634	171	9	,	,	PUNCT
ajcp-1634	171	10	403	403	NUM
ajcp-1634	171	11	-	-	SYM
ajcp-1634	171	12	416	416	NUM
ajcp-1634	171	13	.	.	PUNCT
ajcp-1634	172	1	bagdonaite	bagdonaite	PROPN
ajcp-1634	172	2	,	,	PUNCT
ajcp-1634	172	3	i.	i.	PROPN
ajcp-1634	172	4	,	,	PUNCT
ajcp-1634	172	5	&	&	CCONJ
ajcp-1634	172	6	wandall	wandall	PROPN
ajcp-1634	172	7	,	,	PUNCT
ajcp-1634	172	8	h.	h.	PROPN
ajcp-1634	172	9	h.	h.	PROPN
ajcp-1634	172	10	(	(	PUNCT
ajcp-1634	172	11	2018	2018	NUM
ajcp-1634	172	12	)	)	PUNCT
ajcp-1634	172	13	.	.	PUNCT
ajcp-1634	173	1	global	global	ADJ
ajcp-1634	173	2	aspects	aspect	NOUN
ajcp-1634	173	3	of	of	ADP
ajcp-1634	173	4	viral	viral	ADJ
ajcp-1634	173	5	glycosylation	glycosylation	NOUN
ajcp-1634	173	6	.	.	PUNCT
ajcp-1634	174	1	glycobiology	glycobiology	NOUN
ajcp-1634	174	2	,	,	PUNCT
ajcp-1634	174	3	28(7	28(7	NUM
ajcp-1634	174	4	)	)	PUNCT
ajcp-1634	174	5	,	,	PUNCT
ajcp-1634	174	6	443	443	NUM
ajcp-1634	174	7	-	-	SYM
ajcp-1634	174	8	467	467	NUM
ajcp-1634	174	9	.	.	PUNCT
ajcp-1634	174	10	belouzard	belouzard	PROPN
ajcp-1634	174	11	,	,	PUNCT
ajcp-1634	174	12	s.	s.	PROPN
ajcp-1634	174	13	,	,	PUNCT
ajcp-1634	174	14	chu	chu	PROPN
ajcp-1634	174	15	,	,	PUNCT
ajcp-1634	174	16	v.	v.	PROPN
ajcp-1634	174	17	c.	c.	PROPN
ajcp-1634	174	18	,	,	PUNCT
ajcp-1634	174	19	&	&	CCONJ
ajcp-1634	174	20	whittaker	whittaker	PROPN
ajcp-1634	174	21	,	,	PUNCT
ajcp-1634	174	22	g.	g.	PROPN
ajcp-1634	174	23	r.	r.	PROPN
ajcp-1634	174	24	(	(	PUNCT
ajcp-1634	174	25	2009	2009	NUM
ajcp-1634	174	26	)	)	PUNCT
ajcp-1634	174	27	.	.	PUNCT
ajcp-1634	175	1	activation	activation	NOUN
ajcp-1634	175	2	of	of	ADP
ajcp-1634	175	3	the	the	DET
ajcp-1634	175	4	sars	sars	PROPN
ajcp-1634	175	5	coronavirus	coronavirus	PROPN
ajcp-1634	175	6	spike	spike	ADJ
ajcp-1634	175	7	protein	protein	NOUN
ajcp-1634	175	8	via	via	ADP
ajcp-1634	175	9	sequential	sequential	ADJ
ajcp-1634	175	10	proteolytic	proteolytic	ADJ
ajcp-1634	175	11	cleavage	cleavage	NOUN
ajcp-1634	175	12	at	at	ADP
ajcp-1634	175	13	two	two	NUM
ajcp-1634	175	14	distinct	distinct	ADJ
ajcp-1634	175	15	sites	site	NOUN
ajcp-1634	175	16	.	.	PUNCT
ajcp-1634	176	1	proceedings	proceeding	NOUN
ajcp-1634	176	2	of	of	ADP
ajcp-1634	176	3	the	the	DET
ajcp-1634	176	4	national	national	PROPN
ajcp-1634	176	5	academy	academy	PROPN
ajcp-1634	176	6	of	of	ADP
ajcp-1634	176	7	sciences	sciences	PROPN
ajcp-1634	176	8	,	,	PUNCT
ajcp-1634	176	9	106(14	106(14	NUM
ajcp-1634	176	10	)	)	PUNCT
ajcp-1634	176	11	,	,	PUNCT
ajcp-1634	176	12	5871	5871	NUM
ajcp-1634	176	13	-	-	SYM
ajcp-1634	176	14	5876	5876	NUM
ajcp-1634	176	15	.	.	PUNCT
ajcp-1634	177	1	bernal	bernal	PROPN
ajcp-1634	177	2	,	,	PUNCT
ajcp-1634	177	3	j.	j.	PROPN
ajcp-1634	177	4	l.	l.	PROPN
ajcp-1634	177	5	,	,	PUNCT
ajcp-1634	177	6	andrews	andrews	PROPN
ajcp-1634	177	7	,	,	PUNCT
ajcp-1634	177	8	n.	n.	PROPN
ajcp-1634	177	9	,	,	PUNCT
ajcp-1634	177	10	gower	gower	PROPN
ajcp-1634	177	11	,	,	PUNCT
ajcp-1634	177	12	c.	c.	PROPN
ajcp-1634	177	13	,	,	PUNCT
ajcp-1634	177	14	gallagher	gallagher	PROPN
ajcp-1634	177	15	,	,	PUNCT
ajcp-1634	177	16	e.	e.	PROPN
ajcp-1634	177	17	,	,	PUNCT
ajcp-1634	177	18	simmons	simmons	PROPN
ajcp-1634	177	19	,	,	PUNCT
ajcp-1634	177	20	r.	r.	PROPN
ajcp-1634	177	21	,	,	PUNCT
ajcp-1634	177	22	thelwall	thelwall	PROPN
ajcp-1634	177	23	,	,	PUNCT
ajcp-1634	177	24	s.	s.	PROPN
ajcp-1634	177	25	,	,	PUNCT
ajcp-1634	177	26	...	...	PUNCT
ajcp-1634	177	27	&	&	CCONJ
ajcp-1634	177	28	ramsay	ramsay	PROPN
ajcp-1634	177	29	,	,	PUNCT
ajcp-1634	177	30	m.	m.	NOUN
ajcp-1634	177	31	(	(	PUNCT
ajcp-1634	177	32	2021	2021	NUM
ajcp-1634	177	33	)	)	PUNCT
ajcp-1634	177	34	.	.	PUNCT
ajcp-1634	178	1	effectiveness	effectiveness	NOUN
ajcp-1634	178	2	of	of	ADP
ajcp-1634	178	3	covid-19	covid-19	PROPN
ajcp-1634	178	4	vaccines	vaccine	NOUN
ajcp-1634	178	5	against	against	ADP
ajcp-1634	178	6	the	the	DET
ajcp-1634	178	7	b.	b.	PROPN
ajcp-1634	178	8	1.617	1.617	NUM
ajcp-1634	178	9	.	.	PUNCT
ajcp-1634	179	1	2	2	NUM
ajcp-1634	179	2	(	(	PUNCT
ajcp-1634	179	3	delta	delta	NOUN
ajcp-1634	179	4	)	)	PUNCT
ajcp-1634	179	5	variant	variant	NOUN
ajcp-1634	179	6	.	.	PUNCT
ajcp-1634	180	1	new	new	PROPN
ajcp-1634	180	2	england	england	PROPN
ajcp-1634	180	3	journal	journal	PROPN
ajcp-1634	180	4	of	of	ADP
ajcp-1634	180	5	medicine	medicine	NOUN
ajcp-1634	180	6	.	.	PUNCT
ajcp-1634	181	1	385(7	385(7	NUM
ajcp-1634	181	2	)	)	PUNCT
ajcp-1634	181	3	,	,	PUNCT
ajcp-1634	181	4	585	585	NUM
ajcp-1634	181	5	-	-	SYM
ajcp-1634	181	6	594	594	NUM
ajcp-1634	181	7	.	.	PUNCT
ajcp-1634	182	1	casalino	casalino	PROPN
ajcp-1634	182	2	,	,	PUNCT
ajcp-1634	182	3	l.	l.	PROPN
ajcp-1634	182	4	,	,	PUNCT
ajcp-1634	182	5	gaieb	gaieb	PROPN
ajcp-1634	182	6	,	,	PUNCT
ajcp-1634	182	7	z.	z.	PROPN
ajcp-1634	182	8	,	,	PUNCT
ajcp-1634	182	9	dommer	dommer	PROPN
ajcp-1634	182	10	,	,	PUNCT
ajcp-1634	182	11	a.	a.	PROPN
ajcp-1634	182	12	c.	c.	PROPN
ajcp-1634	182	13	,	,	PUNCT
ajcp-1634	182	14	harbison	harbison	PROPN
ajcp-1634	182	15	,	,	PUNCT
ajcp-1634	182	16	a.	a.	NOUN
ajcp-1634	182	17	m.	m.	PROPN
ajcp-1634	182	18	,	,	PUNCT
ajcp-1634	182	19	fogarty	fogarty	PROPN
ajcp-1634	182	20	,	,	PUNCT
ajcp-1634	182	21	c.	c.	PROPN
ajcp-1634	182	22	a.	a.	PROPN
ajcp-1634	182	23	,	,	PUNCT
ajcp-1634	182	24	barros	barros	PROPN
ajcp-1634	182	25	,	,	PUNCT
ajcp-1634	182	26	e.	e.	PROPN
ajcp-1634	182	27	p.	p.	PROPN
ajcp-1634	182	28	,	,	PUNCT
ajcp-1634	182	29	...	...	PUNCT
ajcp-1634	182	30	&	&	CCONJ
ajcp-1634	182	31	amaro	amaro	PROPN
ajcp-1634	182	32	,	,	PUNCT
ajcp-1634	182	33	r.	r.	PROPN
ajcp-1634	182	34	e.	e.	PROPN
ajcp-1634	182	35	(	(	PUNCT
ajcp-1634	182	36	2020	2020	NUM
ajcp-1634	182	37	)	)	PUNCT
ajcp-1634	182	38	.	.	PUNCT
ajcp-1634	183	1	shielding	shielding	NOUN
ajcp-1634	183	2	and	and	CCONJ
ajcp-1634	183	3	beyond	beyond	ADP
ajcp-1634	183	4	:	:	PUNCT
ajcp-1634	183	5	the	the	DET
ajcp-1634	183	6	roles	role	NOUN
ajcp-1634	183	7	of	of	ADP
ajcp-1634	183	8	glycans	glycan	NOUN
ajcp-1634	183	9	in	in	ADP
ajcp-1634	183	10	sarscov-2	sarscov-2	NUM
ajcp-1634	183	11	spike	spike	ADJ
ajcp-1634	183	12	protein	protein	NOUN
ajcp-1634	183	13	.	.	PUNCT
ajcp-1634	184	1	biorxiv	biorxiv	NOUN
ajcp-1634	184	2	.	.	PUNCT
ajcp-1634	185	1	chen	chen	PROPN
ajcp-1634	185	2	,	,	PUNCT
ajcp-1634	185	3	y.	y.	PROPN
ajcp-1634	185	4	l.	l.	PROPN
ajcp-1634	185	5	q.	q.	PROPN
ajcp-1634	185	6	,	,	PUNCT
ajcp-1634	185	7	guo	guo	PROPN
ajcp-1634	185	8	,	,	PUNCT
ajcp-1634	185	9	d.(2020	d.(2020	PROPN
ajcp-1634	185	10	)	)	PUNCT
ajcp-1634	185	11	emerging	emerge	VERB
ajcp-1634	185	12	coronaviruses	coronaviruse	NOUN
ajcp-1634	185	13	:	:	PUNCT
ajcp-1634	185	14	genome	genome	NOUN
ajcp-1634	185	15	structure	structure	NOUN
ajcp-1634	185	16	,	,	PUNCT
ajcp-1634	185	17	replication	replication	NOUN
ajcp-1634	185	18	,	,	PUNCT
ajcp-1634	185	19	parthenogenesis	parthenogenesis	ADJ
ajcp-1634	185	20	.	.	PUNCT
ajcp-1634	186	1	journal	journal	PROPN
ajcp-1634	186	2	of	of	ADP
ajcp-1634	186	3	virology	virology	NOUN
ajcp-1634	186	4	,	,	PUNCT
ajcp-1634	186	5	92	92	NUM
ajcp-1634	186	6	,	,	PUNCT
ajcp-1634	186	7	418423	418423	NUM
ajcp-1634	186	8	.	.	PUNCT
ajcp-1634	187	1	clausen	clausen	PROPN
ajcp-1634	187	2	,	,	PUNCT
ajcp-1634	187	3	t.	t.	PROPN
ajcp-1634	187	4	m.	m.	PROPN
ajcp-1634	187	5	,	,	PUNCT
ajcp-1634	187	6	sandoval	sandoval	PROPN
ajcp-1634	187	7	,	,	PUNCT
ajcp-1634	187	8	d.	d.	PROPN
ajcp-1634	187	9	r.	r.	PROPN
ajcp-1634	187	10	,	,	PUNCT
ajcp-1634	187	11	spliid	spliid	PROPN
ajcp-1634	187	12	,	,	PUNCT
ajcp-1634	187	13	c.	c.	PROPN
ajcp-1634	187	14	b.	b.	PROPN
ajcp-1634	187	15	,	,	PUNCT
ajcp-1634	187	16	pihl	pihl	PROPN
ajcp-1634	187	17	,	,	PUNCT
ajcp-1634	187	18	j.	j.	PROPN
ajcp-1634	187	19	,	,	PUNCT
ajcp-1634	187	20	perrett	perrett	NOUN
ajcp-1634	187	21	,	,	PUNCT
ajcp-1634	187	22	h.	h.	PROPN
ajcp-1634	187	23	r.	r.	PROPN
ajcp-1634	187	24	,	,	PUNCT
ajcp-1634	187	25	painter	painter	NOUN
ajcp-1634	187	26	,	,	PUNCT
ajcp-1634	187	27	c.	c.	PROPN
ajcp-1634	187	28	d.	d.	PROPN
ajcp-1634	187	29	,	,	PUNCT
ajcp-1634	187	30	...	...	PUNCT
ajcp-1634	187	31	&	&	CCONJ
ajcp-1634	187	32	esko	esko	PROPN
ajcp-1634	187	33	,	,	PUNCT
ajcp-1634	187	34	j.	j.	PROPN
ajcp-1634	187	35	d.	d.	PROPN
ajcp-1634	187	36	(	(	PUNCT
ajcp-1634	187	37	2020	2020	NUM
ajcp-1634	187	38	)	)	PUNCT
ajcp-1634	187	39	.	.	PUNCT
ajcp-1634	188	1	sarscov-2	sarscov-2	NUM
ajcp-1634	188	2	infection	infection	NOUN
ajcp-1634	188	3	depends	depend	VERB
ajcp-1634	188	4	on	on	ADP
ajcp-1634	188	5	cellular	cellular	ADJ
ajcp-1634	188	6	heparan	heparan	ADJ
ajcp-1634	188	7	sulfate	sulfate	NOUN
ajcp-1634	188	8	and	and	CCONJ
ajcp-1634	188	9	ace2	ace2	PROPN
ajcp-1634	188	10	.	.	PUNCT
ajcp-1634	189	1	cell	cell	NOUN
ajcp-1634	189	2	,	,	PUNCT
ajcp-1634	189	3	183(4	183(4	NUM
ajcp-1634	189	4	)	)	PUNCT
ajcp-1634	189	5	,	,	PUNCT
ajcp-1634	189	6	1043	1043	NUM
ajcp-1634	189	7	-	-	SYM
ajcp-1634	189	8	1057	1057	NUM
ajcp-1634	189	9	.	.	PUNCT
ajcp-1634	190	1	crackower	crackower	NOUN
ajcp-1634	190	2	,	,	PUNCT
ajcp-1634	190	3	m.	m.	NOUN
ajcp-1634	190	4	a.	a.	PROPN
ajcp-1634	190	5	,	,	PUNCT
ajcp-1634	190	6	sarao	sarao	PROPN
ajcp-1634	190	7	,	,	PUNCT
ajcp-1634	190	8	r.	r.	PROPN
ajcp-1634	190	9	,	,	PUNCT
ajcp-1634	190	10	oudit	oudit	NOUN
ajcp-1634	190	11	,	,	PUNCT
ajcp-1634	190	12	g.	g.	PROPN
ajcp-1634	190	13	y.	y.	PROPN
ajcp-1634	190	14	,	,	PUNCT
ajcp-1634	190	15	yagil	yagil	PROPN
ajcp-1634	190	16	,	,	PUNCT
ajcp-1634	190	17	c.	c.	NOUN
ajcp-1634	190	18	,	,	PUNCT
ajcp-1634	190	19	kozieradzki	kozieradzki	PROPN
ajcp-1634	190	20	,	,	PUNCT
ajcp-1634	190	21	i.	i.	NOUN
ajcp-1634	190	22	,	,	PUNCT
ajcp-1634	190	23	scanga	scanga	PROPN
ajcp-1634	190	24	,	,	PUNCT
ajcp-1634	190	25	s.	s.	PROPN
ajcp-1634	190	26	e.	e.	PROPN
ajcp-1634	190	27	,	,	PUNCT
ajcp-1634	190	28	...	...	PUNCT
ajcp-1634	190	29	&	&	CCONJ
ajcp-1634	190	30	penninger	penninger	PROPN
ajcp-1634	190	31	,	,	PUNCT
ajcp-1634	190	32	j.	j.	PROPN
ajcp-1634	190	33	m.	m.	PROPN
ajcp-1634	190	34	(	(	PUNCT
ajcp-1634	190	35	2002	2002	NUM
ajcp-1634	190	36	)	)	PUNCT
ajcp-1634	190	37	.	.	PUNCT
ajcp-1634	191	1	angiotensin	angiotensin	NOUN
ajcp-1634	191	2	-	-	PUNCT
ajcp-1634	191	3	converting	convert	VERB
ajcp-1634	191	4	enzyme	enzyme	NOUN
ajcp-1634	191	5	2	2	NUM
ajcp-1634	191	6	is	be	AUX
ajcp-1634	191	7	an	an	DET
ajcp-1634	191	8	essential	essential	ADJ
ajcp-1634	191	9	regulator	regulator	NOUN
ajcp-1634	191	10	of	of	ADP
ajcp-1634	191	11	heart	heart	NOUN
ajcp-1634	191	12	function	function	NOUN
ajcp-1634	191	13	.	.	PUNCT
ajcp-1634	192	1	nature	nature	NOUN
ajcp-1634	192	2	,	,	PUNCT
ajcp-1634	192	3	417(6891	417(6891	NUM
ajcp-1634	192	4	)	)	PUNCT
ajcp-1634	192	5	,	,	PUNCT
ajcp-1634	192	6	822	822	NUM
ajcp-1634	192	7	-	-	SYM
ajcp-1634	192	8	828	828	NUM
ajcp-1634	192	9	.	.	PUNCT
ajcp-1634	193	1	crispin	crispin	NOUN
ajcp-1634	193	2	,	,	PUNCT
ajcp-1634	193	3	m.	m.	NOUN
ajcp-1634	193	4	,	,	PUNCT
ajcp-1634	193	5	&	&	CCONJ
ajcp-1634	193	6	doores	doore	NOUN
ajcp-1634	193	7	,	,	PUNCT
ajcp-1634	193	8	k.	k.	PROPN
ajcp-1634	193	9	j.	j.	PROPN
ajcp-1634	193	10	(	(	PUNCT
ajcp-1634	193	11	2015	2015	NUM
ajcp-1634	193	12	)	)	PUNCT
ajcp-1634	193	13	.	.	PUNCT
ajcp-1634	194	1	targeting	target	VERB
ajcp-1634	194	2	host	host	NOUN
ajcp-1634	194	3	-	-	PUNCT
ajcp-1634	194	4	derived	derive	VERB
ajcp-1634	194	5	glycans	glycan	NOUN
ajcp-1634	194	6	on	on	ADP
ajcp-1634	194	7	enveloped	envelop	VERB
ajcp-1634	194	8	viruses	virus	NOUN
ajcp-1634	194	9	for	for	ADP
ajcp-1634	194	10	antibody	antibody	NOUN
ajcp-1634	194	11	-	-	PUNCT
ajcp-1634	194	12	based	base	VERB
ajcp-1634	194	13	vaccine	vaccine	NOUN
ajcp-1634	194	14	design	design	NOUN
ajcp-1634	194	15	.	.	PUNCT
ajcp-1634	195	1	current	current	ADJ
ajcp-1634	195	2	opinion	opinion	NOUN
ajcp-1634	195	3	in	in	ADP
ajcp-1634	195	4	virology	virology	NOUN
ajcp-1634	195	5	,	,	PUNCT
ajcp-1634	195	6	11	11	NUM
ajcp-1634	195	7	,	,	PUNCT
ajcp-1634	195	8	63	63	NUM
ajcp-1634	195	9	-	-	SYM
ajcp-1634	195	10	69	69	NUM
ajcp-1634	195	11	.	.	PUNCT
ajcp-1634	196	1	doores	doore	NOUN
ajcp-1634	196	2	,	,	PUNCT
ajcp-1634	196	3	k.	k.	PROPN
ajcp-1634	196	4	j.	j.	PROPN
ajcp-1634	196	5	(	(	PUNCT
ajcp-1634	196	6	2015	2015	NUM
ajcp-1634	196	7	)	)	PUNCT
ajcp-1634	196	8	.	.	PUNCT
ajcp-1634	197	1	the	the	DET
ajcp-1634	197	2	hiv	hiv	PROPN
ajcp-1634	197	3	glycan	glycan	NOUN
ajcp-1634	197	4	shield	shield	VERB
ajcp-1634	197	5	as	as	ADP
ajcp-1634	197	6	a	a	DET
ajcp-1634	197	7	target	target	NOUN
ajcp-1634	197	8	for	for	ADP
ajcp-1634	197	9	broadly	broadly	ADV
ajcp-1634	197	10	neutralizing	neutralize	VERB
ajcp-1634	197	11	antibodies	antibody	NOUN
ajcp-1634	197	12	.	.	PUNCT
ajcp-1634	198	1	the	the	DET
ajcp-1634	198	2	febs	febs	NOUN
ajcp-1634	198	3	journal	journal	NOUN
ajcp-1634	198	4	,	,	PUNCT
ajcp-1634	198	5	282(24	282(24	NUM
ajcp-1634	198	6	)	)	PUNCT
ajcp-1634	198	7	,	,	PUNCT
ajcp-1634	198	8	4679	4679	NUM
ajcp-1634	198	9	-	-	SYM
ajcp-1634	198	10	4691	4691	NUM
ajcp-1634	198	11	.	.	PUNCT
ajcp-1634	199	1	du	du	PROPN
ajcp-1634	199	2	,	,	PUNCT
ajcp-1634	199	3	l.	l.	PROPN
ajcp-1634	199	4	,	,	PUNCT
ajcp-1634	199	5	he	he	PRON
ajcp-1634	199	6	,	,	PUNCT
ajcp-1634	199	7	y.	y.	PROPN
ajcp-1634	199	8	,	,	PUNCT
ajcp-1634	199	9	zhou	zhou	PROPN
ajcp-1634	199	10	,	,	PUNCT
ajcp-1634	199	11	y.	y.	PROPN
ajcp-1634	199	12	,	,	PUNCT
ajcp-1634	199	13	liu	liu	PROPN
ajcp-1634	199	14	,	,	PUNCT
ajcp-1634	199	15	s.	s.	PROPN
ajcp-1634	199	16	,	,	PUNCT
ajcp-1634	199	17	zheng	zheng	PROPN
ajcp-1634	199	18	,	,	PUNCT
ajcp-1634	199	19	b.	b.	PROPN
ajcp-1634	199	20	j.	j.	PROPN
ajcp-1634	199	21	,	,	PUNCT
ajcp-1634	199	22	&	&	CCONJ
ajcp-1634	199	23	jiang	jiang	PROPN
ajcp-1634	199	24	,	,	PUNCT
ajcp-1634	199	25	s.	s.	PROPN
ajcp-1634	199	26	(	(	PUNCT
ajcp-1634	199	27	2009	2009	NUM
ajcp-1634	199	28	)	)	PUNCT
ajcp-1634	199	29	.	.	PUNCT
ajcp-1634	200	1	the	the	DET
ajcp-1634	200	2	spike	spike	ADJ
ajcp-1634	200	3	protein	protein	NOUN
ajcp-1634	200	4	of	of	ADP
ajcp-1634	200	5	sars	sars	PROPN
ajcp-1634	200	6	-	-	PUNCT
ajcp-1634	200	7	cov	cov	NOUN
ajcp-1634	200	8	—	—	PUNCT
ajcp-1634	200	9	a	a	DET
ajcp-1634	200	10	target	target	NOUN
ajcp-1634	200	11	for	for	ADP
ajcp-1634	200	12	vaccine	vaccine	NOUN
ajcp-1634	200	13	and	and	CCONJ
ajcp-1634	200	14	therapeutic	therapeutic	ADJ
ajcp-1634	200	15	development	development	NOUN
ajcp-1634	200	16	.	.	PUNCT
ajcp-1634	201	1	nature	nature	NOUN
ajcp-1634	201	2	reviews	review	VERB
ajcp-1634	201	3	microbiology	microbiology	NOUN
ajcp-1634	201	4	,	,	PUNCT
ajcp-1634	201	5	7(3	7(3	NUM
ajcp-1634	201	6	)	)	PUNCT
ajcp-1634	201	7	,	,	PUNCT
ajcp-1634	201	8	226	226	NUM
ajcp-1634	201	9	-	-	SYM
ajcp-1634	201	10	236	236	NUM
ajcp-1634	201	11	.	.	PUNCT
ajcp-1634	202	1	european	european	ADJ
ajcp-1634	202	2	centre	centre	PROPN
ajcp-1634	202	3	for	for	ADP
ajcp-1634	202	4	disease	disease	NOUN
ajcp-1634	202	5	prevention	prevention	NOUN
ajcp-1634	202	6	and	and	CCONJ
ajcp-1634	202	7	control	control	NOUN
ajcp-1634	202	8	.	.	PUNCT
ajcp-1634	203	1	(	(	PUNCT
ajcp-1634	203	2	2021	2021	NUM
ajcp-1634	203	3	)	)	PUNCT
ajcp-1634	203	4	.	.	PUNCT
ajcp-1634	204	1	threat	threat	NOUN
ajcp-1634	204	2	assessment	assessment	NOUN
ajcp-1634	204	3	brief	brief	NOUN
ajcp-1634	204	4	:	:	PUNCT
ajcp-1634	204	5	emergence	emergence	NOUN
ajcp-1634	204	6	of	of	ADP
ajcp-1634	204	7	sarscov-2	sarscov-2	NUM
ajcp-1634	204	8	b.	b.	PROPN
ajcp-1634	204	9	1.617	1.617	NUM
ajcp-1634	204	10	variants	variant	NOUN
ajcp-1634	204	11	in	in	ADP
ajcp-1634	204	12	india	india	PROPN
ajcp-1634	204	13	and	and	CCONJ
ajcp-1634	204	14	situation	situation	NOUN
ajcp-1634	204	15	in	in	ADP
ajcp-1634	204	16	the	the	DET
ajcp-1634	204	17	eu	eu	PROPN
ajcp-1634	204	18	/	/	PROPN
ajcp-1634	204	19	eea	eea	PROPN
ajcp-1634	204	20	.	.	PUNCT
ajcp-1634	204	21	fehr	fehr	PROPN
ajcp-1634	204	22	,	,	PUNCT
ajcp-1634	204	23	a.	a.	PROPN
ajcp-1634	204	24	r.	r.	PROPN
ajcp-1634	204	25	,	,	PUNCT
ajcp-1634	204	26	perlman	perlman	NOUN
ajcp-1634	204	27	,	,	PUNCT
ajcp-1634	204	28	s.	s.	PROPN
ajcp-1634	204	29	,	,	PUNCT
ajcp-1634	204	30	maier	maier	PROPN
ajcp-1634	204	31	,	,	PUNCT
ajcp-1634	204	32	h.	h.	PROPN
ajcp-1634	204	33	j.	j.	PROPN
ajcp-1634	204	34	,	,	PUNCT
ajcp-1634	204	35	bickerton	bickerton	PROPN
ajcp-1634	204	36	,	,	PUNCT
ajcp-1634	204	37	e.	e.	PROPN
ajcp-1634	204	38	,	,	PUNCT
ajcp-1634	204	39	&	&	CCONJ
ajcp-1634	204	40	britton	britton	PROPN
ajcp-1634	204	41	,	,	PUNCT
ajcp-1634	205	1	p.	p.	NOUN
ajcp-1634	205	2	(	(	PUNCT
ajcp-1634	205	3	2015	2015	NUM
ajcp-1634	205	4	)	)	PUNCT
ajcp-1634	205	5	.	.	PUNCT
ajcp-1634	206	1	an	an	DET
ajcp-1634	206	2	overview	overview	NOUN
ajcp-1634	206	3	of	of	ADP
ajcp-1634	206	4	their	their	PRON
ajcp-1634	206	5	replication	replication	NOUN
ajcp-1634	206	6	and	and	CCONJ
ajcp-1634	206	7	pathogenesis	pathogenesis	NOUN
ajcp-1634	206	8	;	;	PUNCT
ajcp-1634	206	9	section	section	NOUN
ajcp-1634	206	10	2	2	NUM
ajcp-1634	206	11	genomic	genomic	NOUN
ajcp-1634	206	12	organization	organization	NOUN
ajcp-1634	206	13	.	.	PUNCT
ajcp-1634	207	1	methods	method	NOUN
ajcp-1634	207	2	in	in	ADP
ajcp-1634	207	3	molecular	molecular	ADJ
ajcp-1634	207	4	biology	biology	NOUN
ajcp-1634	207	5	,	,	PUNCT
ajcp-1634	207	6	1282	1282	NUM
ajcp-1634	207	7	,	,	PUNCT
ajcp-1634	207	8	1	1	NUM
ajcp-1634	207	9	-	-	SYM
ajcp-1634	207	10	23	23	NUM
ajcp-1634	207	11	.	.	PUNCT
ajcp-1634	208	1	flanagan	flanagan	PROPN
ajcp-1634	208	2	,	,	PUNCT
ajcp-1634	208	3	k.	k.	PROPN
ajcp-1634	208	4	l.	l.	PROPN
ajcp-1634	208	5	,	,	PUNCT
ajcp-1634	208	6	best	well	ADV
ajcp-1634	208	7	,	,	PUNCT
ajcp-1634	208	8	e.	e.	PROPN
ajcp-1634	208	9	,	,	PUNCT
ajcp-1634	208	10	crawford	crawford	PROPN
ajcp-1634	208	11	,	,	PUNCT
ajcp-1634	208	12	n.	n.	PROPN
ajcp-1634	208	13	w.	w.	PROPN
ajcp-1634	208	14	,	,	PUNCT
ajcp-1634	208	15	giles	gile	NOUN
ajcp-1634	208	16	,	,	PUNCT
ajcp-1634	208	17	m.	m.	NOUN
ajcp-1634	208	18	,	,	PUNCT
ajcp-1634	208	19	koirala	koirala	PROPN
ajcp-1634	208	20	,	,	PUNCT
ajcp-1634	208	21	a.	a.	PROPN
ajcp-1634	208	22	,	,	PUNCT
ajcp-1634	208	23	macartney	macartney	PROPN
ajcp-1634	208	24	,	,	PUNCT
ajcp-1634	208	25	k.	k.	PROPN
ajcp-1634	208	26	,	,	PUNCT
ajcp-1634	208	27	...	...	PUNCT
ajcp-1634	208	28	&	&	CCONJ
ajcp-1634	208	29	wen	wen	PROPN
ajcp-1634	208	30	,	,	PUNCT
ajcp-1634	208	31	s.	s.	PROPN
ajcp-1634	208	32	c.	c.	PROPN
ajcp-1634	208	33	(	(	PUNCT
ajcp-1634	208	34	2020	2020	NUM
ajcp-1634	208	35	)	)	PUNCT
ajcp-1634	208	36	.	.	PUNCT
ajcp-1634	209	1	progress	progress	NOUN
ajcp-1634	209	2	and	and	CCONJ
ajcp-1634	209	3	pitfalls	pitfall	NOUN
ajcp-1634	209	4	in	in	ADP
ajcp-1634	209	5	the	the	DET
ajcp-1634	209	6	quest	quest	NOUN
ajcp-1634	209	7	for	for	ADP
ajcp-1634	209	8	effective	effective	ADJ
ajcp-1634	209	9	sarscov-2	sarscov-2	NUM
ajcp-1634	209	10	(	(	PUNCT
ajcp-1634	209	11	covid-19	covid-19	PROPN
ajcp-1634	209	12	)	)	PUNCT
ajcp-1634	209	13	vaccines	vaccine	NOUN
ajcp-1634	209	14	.	.	PUNCT
ajcp-1634	210	1	frontiers	frontier	NOUN
ajcp-1634	210	2	in	in	ADP
ajcp-1634	210	3	immunology	immunology	NOUN
ajcp-1634	210	4	,	,	PUNCT
ajcp-1634	210	5	11	11	NUM
ajcp-1634	210	6	,	,	PUNCT
ajcp-1634	210	7	2410	2410	NUM
ajcp-1634	210	8	.	.	PUNCT
ajcp-1634	211	1	folegatti	folegatti	PROPN
ajcp-1634	211	2	,	,	PUNCT
ajcp-1634	211	3	p.	p.	NOUN
ajcp-1634	211	4	m.	m.	NOUN
ajcp-1634	211	5	,	,	PUNCT
ajcp-1634	211	6	ewer	ewer	NOUN
ajcp-1634	211	7	,	,	PUNCT
ajcp-1634	211	8	k.	k.	PROPN
ajcp-1634	211	9	j.	j.	PROPN
ajcp-1634	211	10	,	,	PUNCT
ajcp-1634	211	11	aley	aley	PROPN
ajcp-1634	211	12	,	,	PUNCT
ajcp-1634	211	13	p.	p.	PROPN
ajcp-1634	211	14	k.	k.	PROPN
ajcp-1634	211	15	,	,	PUNCT
ajcp-1634	211	16	angus	angus	PROPN
ajcp-1634	211	17	,	,	PUNCT
ajcp-1634	211	18	b.	b.	PROPN
ajcp-1634	211	19	,	,	PUNCT
ajcp-1634	211	20	becker	becker	PROPN
ajcp-1634	211	21	,	,	PUNCT
ajcp-1634	211	22	s.	s.	PROPN
ajcp-1634	211	23	,	,	PUNCT
ajcp-1634	211	24	belij	belij	NOUN
ajcp-1634	211	25	-	-	PUNCT
ajcp-1634	211	26	rammerstorfer	rammerstorfer	NOUN
ajcp-1634	211	27	,	,	PUNCT
ajcp-1634	211	28	s.	s.	PROPN
ajcp-1634	211	29	,	,	PUNCT
ajcp-1634	211	30	...	...	PUNCT
ajcp-1634	211	31	&	&	CCONJ
ajcp-1634	211	32	hamlyn	hamlyn	PROPN
ajcp-1634	211	33	,	,	PUNCT
ajcp-1634	211	34	j.	j.	PROPN
ajcp-1634	211	35	(	(	PUNCT
ajcp-1634	211	36	2020	2020	NUM
ajcp-1634	211	37	)	)	PUNCT
ajcp-1634	211	38	.	.	PUNCT
ajcp-1634	212	1	safety	safety	NOUN
ajcp-1634	212	2	and	and	CCONJ
ajcp-1634	212	3	immunogenicity	immunogenicity	NOUN
ajcp-1634	212	4	of	of	ADP
ajcp-1634	212	5	the	the	DET
ajcp-1634	212	6	chadox1	chadox1	ADJ
ajcp-1634	212	7	ncov-19	ncov-19	ADJ
ajcp-1634	212	8	vaccine	vaccine	NOUN
ajcp-1634	212	9	against	against	ADP
ajcp-1634	212	10	sars	sar	NOUN
ajcp-1634	212	11	-	-	PUNCT
ajcp-1634	212	12	cov-2	cov-2	NOUN
ajcp-1634	212	13	:	:	PUNCT
ajcp-1634	212	14	a	a	DET
ajcp-1634	212	15	preliminary	preliminary	ADJ
ajcp-1634	212	16	report	report	NOUN
ajcp-1634	212	17	of	of	ADP
ajcp-1634	212	18	a	a	DET
ajcp-1634	212	19	phase	phase	NOUN
ajcp-1634	212	20	1/2	1/2	NUM
ajcp-1634	212	21	,	,	PUNCT
ajcp-1634	212	22	single	single	ADJ
ajcp-1634	212	23	-	-	PUNCT
ajcp-1634	212	24	blind	blind	ADJ
ajcp-1634	212	25	,	,	PUNCT
ajcp-1634	212	26	randomised	randomise	VERB
ajcp-1634	212	27	controlled	control	VERB
ajcp-1634	212	28	trial	trial	NOUN
ajcp-1634	212	29	.	.	PUNCT
ajcp-1634	213	1	the	the	DET
ajcp-1634	213	2	lancet	lancet	NOUN
ajcp-1634	213	3	,	,	PUNCT
ajcp-1634	213	4	396(10249	396(10249	NUM
ajcp-1634	213	5	)	)	PUNCT
ajcp-1634	213	6	,	,	PUNCT
ajcp-1634	213	7	467	467	NUM
ajcp-1634	213	8	-	-	SYM
ajcp-1634	213	9	478	478	NUM
ajcp-1634	213	10	.	.	PUNCT
ajcp-1634	213	11	gallagher	gallagher	PROPN
ajcp-1634	213	12	,	,	PUNCT
ajcp-1634	213	13	t.	t.	NOUN
ajcp-1634	213	14	m.	m.	NOUN
ajcp-1634	213	15	,	,	PUNCT
ajcp-1634	213	16	&	&	CCONJ
ajcp-1634	213	17	buchmeier	buchmeier	PROPN
ajcp-1634	213	18	,	,	PUNCT
ajcp-1634	213	19	m.	m.	NOUN
ajcp-1634	213	20	j.	j.	PROPN
ajcp-1634	213	21	(	(	PUNCT
ajcp-1634	213	22	2001	2001	NUM
ajcp-1634	213	23	)	)	PUNCT
ajcp-1634	213	24	.	.	PUNCT
ajcp-1634	214	1	coronavirus	coronavirus	NOUN
ajcp-1634	214	2	spike	spike	ADJ
ajcp-1634	214	3	proteins	protein	NOUN
ajcp-1634	214	4	in	in	ADP
ajcp-1634	214	5	viral	viral	ADJ
ajcp-1634	214	6	entry	entry	NOUN
ajcp-1634	214	7	and	and	CCONJ
ajcp-1634	214	8	pathogenesis	pathogenesis	NOUN
ajcp-1634	214	9	.	.	PUNCT
ajcp-1634	215	1	virology	virology	NOUN
ajcp-1634	215	2	,	,	PUNCT
ajcp-1634	215	3	279(2	279(2	NUM
ajcp-1634	215	4	)	)	PUNCT
ajcp-1634	215	5	,	,	PUNCT
ajcp-1634	215	6	371	371	NUM
ajcp-1634	215	7	-	-	SYM
ajcp-1634	215	8	374	374	NUM
ajcp-1634	215	9	.	.	PUNCT
ajcp-1634	216	1	gallian	gallian	ADJ
ajcp-1634	216	2	,	,	PUNCT
ajcp-1634	216	3	p.	p.	NOUN
ajcp-1634	216	4	,	,	PUNCT
ajcp-1634	216	5	pastorino	pastorino	PROPN
ajcp-1634	216	6	,	,	PUNCT
ajcp-1634	216	7	b.	b.	PROPN
ajcp-1634	216	8	,	,	PUNCT
ajcp-1634	216	9	morel	morel	PROPN
ajcp-1634	216	10	,	,	PUNCT
ajcp-1634	216	11	p.	p.	NOUN
ajcp-1634	216	12	,	,	PUNCT
ajcp-1634	216	13	chiaroni	chiaroni	PROPN
ajcp-1634	216	14	,	,	PUNCT
ajcp-1634	216	15	j.	j.	PROPN
ajcp-1634	216	16	,	,	PUNCT
ajcp-1634	216	17	ninove	ninove	NOUN
ajcp-1634	216	18	,	,	PUNCT
ajcp-1634	216	19	l.	l.	PROPN
ajcp-1634	216	20	,	,	PUNCT
ajcp-1634	216	21	&	&	CCONJ
ajcp-1634	216	22	de	de	X
ajcp-1634	216	23	lamballerie	lamballerie	PROPN
ajcp-1634	216	24	,	,	PUNCT
ajcp-1634	216	25	x.	x.	NOUN
ajcp-1634	216	26	(	(	PUNCT
ajcp-1634	216	27	2020	2020	NUM
ajcp-1634	216	28	)	)	PUNCT
ajcp-1634	216	29	.	.	PUNCT
ajcp-1634	217	1	lower	low	ADJ
ajcp-1634	217	2	prevalence	prevalence	NOUN
ajcp-1634	217	3	of	of	ADP
ajcp-1634	217	4	antibodies	antibody	NOUN
ajcp-1634	217	5	neutralizing	neutralize	VERB
ajcp-1634	217	6	sars	sar	NOUN
ajcp-1634	217	7	-	-	PUNCT
ajcp-1634	217	8	cov-2	cov-2	NOUN
ajcp-1634	217	9	in	in	ADP
ajcp-1634	217	10	group	group	NOUN
ajcp-1634	217	11	o	o	PROPN
ajcp-1634	217	12	french	french	ADJ
ajcp-1634	217	13	blood	blood	NOUN
ajcp-1634	217	14	donors	donor	NOUN
ajcp-1634	217	15	.	.	PUNCT
ajcp-1634	218	1	antiviral	antiviral	ADJ
ajcp-1634	218	2	research	research	NOUN
ajcp-1634	218	3	,	,	PUNCT
ajcp-1634	218	4	181	181	NUM
ajcp-1634	218	5	,	,	PUNCT
ajcp-1634	218	6	104880	104880	NUM
ajcp-1634	218	7	.	.	PUNCT
ajcp-1634	219	1	hasoksuz	hasoksuz	NOUN
ajcp-1634	219	2	,	,	PUNCT
ajcp-1634	219	3	m.	m.	NOUN
ajcp-1634	219	4	,	,	PUNCT
ajcp-1634	219	5	sreevatsan	sreevatsan	ADJ
ajcp-1634	219	6	,	,	PUNCT
ajcp-1634	219	7	s.	s.	PROPN
ajcp-1634	219	8	,	,	PUNCT
ajcp-1634	219	9	cho	cho	PROPN
ajcp-1634	219	10	,	,	PUNCT
ajcp-1634	219	11	k.	k.	PROPN
ajcp-1634	219	12	o.	o.	PROPN
ajcp-1634	219	13	,	,	PUNCT
ajcp-1634	219	14	hoet	hoet	VERB
ajcp-1634	219	15	,	,	PUNCT
ajcp-1634	219	16	a.	a.	PROPN
ajcp-1634	219	17	e.	e.	PROPN
ajcp-1634	219	18	,	,	PUNCT
ajcp-1634	219	19	&	&	CCONJ
ajcp-1634	219	20	saif	saif	PROPN
ajcp-1634	219	21	,	,	PUNCT
ajcp-1634	219	22	l.	l.	PROPN
ajcp-1634	219	23	j.	j.	PROPN
ajcp-1634	219	24	(	(	PUNCT
ajcp-1634	219	25	2002	2002	NUM
ajcp-1634	219	26	)	)	PUNCT
ajcp-1634	219	27	.	.	PUNCT
ajcp-1634	220	1	molecular	molecular	ADJ
ajcp-1634	220	2	analysis	analysis	NOUN
ajcp-1634	220	3	of	of	ADP
ajcp-1634	220	4	the	the	DET
ajcp-1634	220	5	s1	s1	NOUN
ajcp-1634	220	6	subunit	subunit	NOUN
ajcp-1634	220	7	of	of	ADP
ajcp-1634	220	8	the	the	DET
ajcp-1634	220	9	spike	spike	ADJ
ajcp-1634	220	10	glycoprotein	glycoprotein	NOUN
ajcp-1634	220	11	of	of	ADP
ajcp-1634	220	12	respiratory	respiratory	ADJ
ajcp-1634	220	13	and	and	CCONJ
ajcp-1634	220	14	enteric	enteric	ADJ
ajcp-1634	220	15	bovine	bovine	NOUN
ajcp-1634	220	16	coronavirus	coronavirus	NOUN
ajcp-1634	220	17	isolates	isolate	NOUN
ajcp-1634	220	18	.	.	PUNCT
ajcp-1634	221	1	virus	virus	NOUN
ajcp-1634	221	2	research	research	NOUN
ajcp-1634	221	3	,	,	PUNCT
ajcp-1634	221	4	84(1	84(1	NUM
ajcp-1634	221	5	-	-	SYM
ajcp-1634	221	6	2	2	NUM
ajcp-1634	221	7	)	)	PUNCT
ajcp-1634	221	8	,	,	PUNCT
ajcp-1634	221	9	101109	101109	NUM
ajcp-1634	221	10	.	.	PUNCT
ajcp-1634	222	1	hasöksüz	hasöksüz	PROPN
ajcp-1634	222	2	,	,	PUNCT
ajcp-1634	222	3	m.	m.	NOUN
ajcp-1634	222	4	,	,	PUNCT
ajcp-1634	222	5	kiliç	kiliç	PROPN
ajcp-1634	222	6	,	,	PUNCT
ajcp-1634	222	7	s.	s.	PROPN
ajcp-1634	222	8	,	,	PUNCT
ajcp-1634	222	9	&	&	CCONJ
ajcp-1634	222	10	saraç	saraç	PROPN
ajcp-1634	222	11	,	,	PUNCT
ajcp-1634	222	12	f.	f.	PROPN
ajcp-1634	222	13	(	(	PUNCT
ajcp-1634	222	14	2020	2020	NUM
ajcp-1634	222	15	)	)	PUNCT
ajcp-1634	222	16	.	.	PUNCT
ajcp-1634	223	1	coronaviruses	coronaviruse	NOUN
ajcp-1634	223	2	and	and	CCONJ
ajcp-1634	223	3	sars	sar	NOUN
ajcp-1634	223	4	-	-	PUNCT
ajcp-1634	223	5	cov-2	cov-2	NOUN
ajcp-1634	223	6	.	.	PUNCT
ajcp-1634	224	1	turkish	turkish	ADJ
ajcp-1634	224	2	journal	journal	PROPN
ajcp-1634	224	3	of	of	ADP
ajcp-1634	224	4	medical	medical	ADJ
ajcp-1634	224	5	sciences	science	NOUN
ajcp-1634	224	6	,	,	PUNCT
ajcp-1634	224	7	50(si1	50(si1	NUM
ajcp-1634	224	8	)	)	PUNCT
ajcp-1634	224	9	,	,	PUNCT
ajcp-1634	224	10	549	549	NUM
ajcp-1634	224	11	-	-	SYM
ajcp-1634	224	12	556	556	NUM
ajcp-1634	224	13	.	.	PUNCT
ajcp-1634	225	1	hoffmann	hoffmann	PROPN
ajcp-1634	225	2	,	,	PUNCT
ajcp-1634	225	3	m.	m.	NOUN
ajcp-1634	225	4	,	,	PUNCT
ajcp-1634	225	5	kleine	kleine	PROPN
ajcp-1634	225	6	-	-	PUNCT
ajcp-1634	225	7	weber	weber	PROPN
ajcp-1634	225	8	,	,	PUNCT
ajcp-1634	225	9	h.	h.	PROPN
ajcp-1634	225	10	,	,	PUNCT
ajcp-1634	225	11	krüger	krüger	PROPN
ajcp-1634	225	12	,	,	PUNCT
ajcp-1634	225	13	n.	n.	NOUN
ajcp-1634	225	14	,	,	PUNCT
ajcp-1634	225	15	müller	müller	PROPN
ajcp-1634	225	16	,	,	PUNCT
ajcp-1634	225	17	m.	m.	NOUN
ajcp-1634	225	18	,	,	PUNCT
ajcp-1634	225	19	&	&	CCONJ
ajcp-1634	225	20	drosten	drosten	PROPN
ajcp-1634	225	21	,	,	PUNCT
ajcp-1634	225	22	c.	c.	PROPN
ajcp-1634	225	23	pöhlmann	pöhlmann	PROPN
ajcp-1634	225	24	,	,	PUNCT
ajcp-1634	225	25	vop	vop	PROPN
ajcp-1634	225	26	(	(	PUNCT
ajcp-1634	225	27	2020	2020	NUM
ajcp-1634	225	28	)	)	PUNCT
ajcp-1634	225	29	.	.	PUNCT
ajcp-1634	226	1	the	the	DET
ajcp-1634	226	2	novel	novel	ADJ
ajcp-1634	226	3	coronavirus	coronavirus	NOUN
ajcp-1634	226	4	(	(	PUNCT
ajcp-1634	226	5	2019	2019	NUM
ajcp-1634	226	6	-	-	PUNCT
ajcp-1634	226	7	ncov	ncov	NOUN
ajcp-1634	226	8	)	)	PUNCT
ajcp-1634	226	9	uses	use	VERB
ajcp-1634	226	10	the	the	DET
ajcp-1634	226	11	sars	sar	NOUN
ajcp-1634	226	12	-	-	PUNCT
ajcp-1634	226	13	coronavirus	coronavirus	NOUN
ajcp-1634	226	14	receptor	receptor	NOUN
ajcp-1634	226	15	ace2	ace2	NOUN
ajcp-1634	226	16	and	and	CCONJ
ajcp-1634	226	17	the	the	DET
ajcp-1634	226	18	cellular	cellular	ADJ
ajcp-1634	226	19	protease	protease	NOUN
ajcp-1634	226	20	tmprss2	tmprss2	VERB
ajcp-1634	226	21	for	for	ADP
ajcp-1634	226	22	entry	entry	NOUN
ajcp-1634	226	23	into	into	ADP
ajcp-1634	226	24	target	target	NOUN
ajcp-1634	226	25	cells	cell	NOUN
ajcp-1634	226	26	.	.	PUNCT
ajcp-1634	227	1	biorxiv	biorxiv	NOUN
ajcp-1634	227	2	.	.	PUNCT
ajcp-1634	228	1	hoffmann	hoffmann	PROPN
ajcp-1634	228	2	,	,	PUNCT
ajcp-1634	228	3	m.	m.	NOUN
ajcp-1634	228	4	,	,	PUNCT
ajcp-1634	228	5	kleine	kleine	PROPN
ajcp-1634	228	6	-	-	PUNCT
ajcp-1634	228	7	weber	weber	PROPN
ajcp-1634	228	8	,	,	PUNCT
ajcp-1634	228	9	h.	h.	PROPN
ajcp-1634	228	10	,	,	PUNCT
ajcp-1634	228	11	schroeder	schroeder	PROPN
ajcp-1634	228	12	,	,	PUNCT
ajcp-1634	228	13	s.	s.	PROPN
ajcp-1634	228	14	,	,	PUNCT
ajcp-1634	228	15	krüger	krüger	PROPN
ajcp-1634	228	16	,	,	PUNCT
ajcp-1634	228	17	n.	n.	NOUN
ajcp-1634	228	18	,	,	PUNCT
ajcp-1634	228	19	herrler	herrler	NOUN
ajcp-1634	228	20	,	,	PUNCT
ajcp-1634	228	21	t.	t.	PROPN
ajcp-1634	228	22	,	,	PUNCT
ajcp-1634	228	23	erichsen	erichsen	ADJ
ajcp-1634	228	24	,	,	PUNCT
ajcp-1634	228	25	s.	s.	PROPN
ajcp-1634	228	26	,	,	PUNCT
ajcp-1634	228	27	...	...	PUNCT
ajcp-1634	228	28	&	&	CCONJ
ajcp-1634	228	29	pöhlmann	pöhlmann	PROPN
ajcp-1634	228	30	,	,	PUNCT
ajcp-1634	228	31	s.	s.	PROPN
ajcp-1634	228	32	(	(	PUNCT
ajcp-1634	228	33	2020	2020	NUM
ajcp-1634	228	34	)	)	PUNCT
ajcp-1634	228	35	.	.	PUNCT
ajcp-1634	229	1	sars	sars	PROPN
ajcp-1634	229	2	-	-	PUNCT
ajcp-1634	229	3	cov-2	cov-2	PART
ajcp-1634	229	4	cell	cell	NOUN
ajcp-1634	229	5	entry	entry	NOUN
ajcp-1634	229	6	depends	depend	VERB
ajcp-1634	229	7	on	on	ADP
ajcp-1634	229	8	ace2	ace2	NOUN
ajcp-1634	229	9	and	and	CCONJ
ajcp-1634	229	10	tmprss2	tmprss2	ADV
ajcp-1634	229	11	and	and	CCONJ
ajcp-1634	229	12	is	be	AUX
ajcp-1634	229	13	blocked	block	VERB
ajcp-1634	229	14	by	by	ADP
ajcp-1634	229	15	a	a	DET
ajcp-1634	229	16	clinically	clinically	ADV
ajcp-1634	229	17	proven	prove	VERB
ajcp-1634	229	18	protease	protease	NOUN
ajcp-1634	229	19	inhibitor	inhibitor	NOUN
ajcp-1634	229	20	.	.	PUNCT
ajcp-1634	230	1	cell	cell	NOUN
ajcp-1634	230	2	,	,	PUNCT
ajcp-1634	230	3	181(2	181(2	NUM
ajcp-1634	230	4	)	)	PUNCT
ajcp-1634	230	5	,	,	PUNCT
ajcp-1634	230	6	271	271	NUM
ajcp-1634	230	7	-	-	SYM
ajcp-1634	230	8	280	280	NUM
ajcp-1634	230	9	.	.	PUNCT
ajcp-1634	231	1	huang	huang	PROPN
ajcp-1634	231	2	,	,	PUNCT
ajcp-1634	231	3	j.	j.	PROPN
ajcp-1634	231	4	,	,	PUNCT
ajcp-1634	231	5	cao	cao	PROPN
ajcp-1634	231	6	,	,	PUNCT
ajcp-1634	231	7	y.	y.	PROPN
ajcp-1634	231	8	,	,	PUNCT
ajcp-1634	231	9	du	du	PROPN
ajcp-1634	231	10	,	,	PUNCT
ajcp-1634	231	11	j.	j.	PROPN
ajcp-1634	231	12	,	,	PUNCT
ajcp-1634	231	13	bu	bu	PROPN
ajcp-1634	231	14	,	,	PUNCT
ajcp-1634	231	15	x.	x.	PROPN
ajcp-1634	231	16	,	,	PUNCT
ajcp-1634	231	17	ma	ma	PROPN
ajcp-1634	231	18	,	,	PUNCT
ajcp-1634	231	19	r.	r.	PROPN
ajcp-1634	231	20	,	,	PUNCT
ajcp-1634	231	21	&	&	CCONJ
ajcp-1634	231	22	wu	wu	PROPN
ajcp-1634	231	23	,	,	PUNCT
ajcp-1634	231	24	c.	c.	PROPN
ajcp-1634	231	25	(	(	PUNCT
ajcp-1634	231	26	2007	2007	NUM
ajcp-1634	231	27	)	)	PUNCT
ajcp-1634	231	28	.	.	PUNCT
ajcp-1634	232	1	priming	prime	VERB
ajcp-1634	232	2	with	with	ADP
ajcp-1634	232	3	sars	sars	PROPN
ajcp-1634	232	4	cov	cov	PROPN
ajcp-1634	232	5	s	s	PART
ajcp-1634	232	6	dna	dna	PROPN
ajcp-1634	232	7	and	and	CCONJ
ajcp-1634	232	8	boosting	boost	VERB
ajcp-1634	232	9	with	with	ADP
ajcp-1634	232	10	sars	sars	PROPN
ajcp-1634	232	11	cov	cov	PROPN
ajcp-1634	232	12	s	s	PART
ajcp-1634	232	13	epitopes	epitope	NOUN
ajcp-1634	232	14	specific	specific	ADJ
ajcp-1634	232	15	for	for	ADP
ajcp-1634	232	16	cd4	cd4	PROPN
ajcp-1634	232	17	+	+	PROPN
ajcp-1634	232	18	and	and	CCONJ
ajcp-1634	232	19	cd8	cd8	PROPN
ajcp-1634	232	20	+	+	PROPN
ajcp-1634	232	21	t	t	PROPN
ajcp-1634	232	22	cells	cell	NOUN
ajcp-1634	232	23	promote	promote	VERB
ajcp-1634	232	24	cellular	cellular	ADJ
ajcp-1634	232	25	immune	immune	ADJ
ajcp-1634	232	26	responses	response	NOUN
ajcp-1634	232	27	.	.	PUNCT
ajcp-1634	233	1	vaccine	vaccine	NOUN
ajcp-1634	233	2	,	,	PUNCT
ajcp-1634	233	3	25(39	25(39	NUM
ajcp-1634	233	4	-	-	SYM
ajcp-1634	233	5	40	40	NUM
ajcp-1634	233	6	)	)	PUNCT
ajcp-1634	233	7	,	,	PUNCT
ajcp-1634	233	8	6981	6981	NUM
ajcp-1634	233	9	-	-	SYM
ajcp-1634	233	10	6991	6991	NUM
ajcp-1634	233	11	.	.	PUNCT
ajcp-1634	234	1	hütter	hütter	PROPN
ajcp-1634	234	2	,	,	PUNCT
ajcp-1634	234	3	j.	j.	PROPN
ajcp-1634	234	4	,	,	PUNCT
ajcp-1634	234	5	rödig	rödig	PROPN
ajcp-1634	234	6	,	,	PUNCT
ajcp-1634	234	7	j.	j.	PROPN
ajcp-1634	234	8	v.	v.	PROPN
ajcp-1634	234	9	,	,	PUNCT
ajcp-1634	234	10	höper	höper	PROPN
ajcp-1634	234	11	,	,	PUNCT
ajcp-1634	234	12	d.	d.	PROPN
ajcp-1634	234	13	,	,	PUNCT
ajcp-1634	234	14	seeberger	seeberger	NOUN
ajcp-1634	234	15	,	,	PUNCT
ajcp-1634	234	16	p.	p.	PROPN
ajcp-1634	234	17	h.	h.	PROPN
ajcp-1634	234	18	,	,	PUNCT
ajcp-1634	234	19	reichl	reichl	NOUN
ajcp-1634	234	20	,	,	PUNCT
ajcp-1634	234	21	u.	u.	PROPN
ajcp-1634	234	22	,	,	PUNCT
ajcp-1634	234	23	rapp	rapp	PROPN
ajcp-1634	234	24	,	,	PUNCT
ajcp-1634	234	25	e.	e.	PROPN
ajcp-1634	234	26	,	,	PUNCT
ajcp-1634	234	27	&	&	CCONJ
ajcp-1634	234	28	lepenies	lepenies	PROPN
ajcp-1634	234	29	,	,	PUNCT
ajcp-1634	234	30	b.	b.	PROPN
ajcp-1634	234	31	(	(	PUNCT
ajcp-1634	234	32	2013	2013	NUM
ajcp-1634	234	33	)	)	PUNCT
ajcp-1634	234	34	.	.	PUNCT
ajcp-1634	235	1	toward	toward	ADP
ajcp-1634	235	2	animal	animal	NOUN
ajcp-1634	235	3	cell	cell	NOUN
ajcp-1634	235	4	culture	culture	NOUN
ajcp-1634	235	5	–	–	PUNCT
ajcp-1634	235	6	based	base	VERB
ajcp-1634	235	7	influenza	influenza	NOUN
ajcp-1634	235	8	vaccine	vaccine	NOUN
ajcp-1634	235	9	design	design	VERB
ajcp-1634	235	10	:	:	PUNCT
ajcp-1634	235	11	viral	viral	ADJ
ajcp-1634	235	12	hemagglutinin	hemagglutinin	ADJ
ajcp-1634	235	13	n	n	CCONJ
ajcp-1634	235	14	-	-	PUNCT
ajcp-1634	235	15	glycosylation	glycosylation	NOUN
ajcp-1634	235	16	markedly	markedly	ADJ
ajcp-1634	235	17	impacts	impact	NOUN
ajcp-1634	235	18	immunogenicity	immunogenicity	NOUN
ajcp-1634	235	19	.	.	PUNCT
ajcp-1634	236	1	the	the	DET
ajcp-1634	236	2	journal	journal	NOUN
ajcp-1634	236	3	of	of	ADP
ajcp-1634	236	4	immunology	immunology	NOUN
ajcp-1634	236	5	,	,	PUNCT
ajcp-1634	236	6	190(1	190(1	NUM
ajcp-1634	236	7	)	)	PUNCT
ajcp-1634	236	8	,	,	PUNCT
ajcp-1634	236	9	220230	220230	NUM
ajcp-1634	236	10	.	.	PUNCT
ajcp-1634	237	1	iversen	iversen	PROPN
ajcp-1634	237	2	,	,	PUNCT
ajcp-1634	237	3	p.	p.	PROPN
ajcp-1634	237	4	l.	l.	PROPN
ajcp-1634	237	5	,	,	PUNCT
ajcp-1634	237	6	&	&	CCONJ
ajcp-1634	237	7	bavari	bavari	PROPN
ajcp-1634	237	8	,	,	PUNCT
ajcp-1634	237	9	s.	s.	PROPN
ajcp-1634	237	10	(	(	PUNCT
ajcp-1634	237	11	2021	2021	NUM
ajcp-1634	237	12	)	)	PUNCT
ajcp-1634	237	13	.	.	PUNCT
ajcp-1634	238	1	inactivated	inactivated	ADJ
ajcp-1634	238	2	covid-19	covid-19	PROPN
ajcp-1634	238	3	vaccines	vaccine	NOUN
ajcp-1634	238	4	to	to	PART
ajcp-1634	238	5	make	make	VERB
ajcp-1634	238	6	a	a	DET
ajcp-1634	238	7	global	global	ADJ
ajcp-1634	238	8	impact	impact	NOUN
ajcp-1634	238	9	.	.	PUNCT
ajcp-1634	239	1	the	the	DET
ajcp-1634	239	2	lancet	lancet	ADJ
ajcp-1634	239	3	infectious	infectious	ADJ
ajcp-1634	239	4	diseases	disease	NOUN
ajcp-1634	239	5	,	,	PUNCT
ajcp-1634	239	6	21(6	21(6	NOUN
ajcp-1634	239	7	)	)	PUNCT
ajcp-1634	239	8	,	,	PUNCT
ajcp-1634	239	9	746	746	NUM
ajcp-1634	239	10	-	-	SYM
ajcp-1634	239	11	748	748	NUM
ajcp-1634	239	12	.	.	PUNCT
ajcp-1634	239	13	jackson	jackson	PROPN
ajcp-1634	239	14	,	,	PUNCT
ajcp-1634	239	15	l.	l.	PROPN
ajcp-1634	239	16	a.	a.	PROPN
ajcp-1634	239	17	,	,	PUNCT
ajcp-1634	239	18	anderson	anderson	PROPN
ajcp-1634	239	19	,	,	PUNCT
ajcp-1634	239	20	e.	e.	PROPN
ajcp-1634	239	21	j.	j.	PROPN
ajcp-1634	239	22	,	,	PUNCT
ajcp-1634	239	23	rouphael	rouphael	PROPN
ajcp-1634	239	24	,	,	PUNCT
ajcp-1634	239	25	n.	n.	PROPN
ajcp-1634	239	26	g.	g.	PROPN
ajcp-1634	239	27	,	,	PUNCT
ajcp-1634	239	28	roberts	roberts	PROPN
ajcp-1634	239	29	,	,	PUNCT
ajcp-1634	239	30	p.	p.	PROPN
ajcp-1634	239	31	c.	c.	PROPN
ajcp-1634	239	32	,	,	PUNCT
ajcp-1634	239	33	makhene	makhene	NOUN
ajcp-1634	239	34	,	,	PUNCT
ajcp-1634	239	35	m.	m.	NOUN
ajcp-1634	239	36	,	,	PUNCT
ajcp-1634	239	37	coler	coler	PROPN
ajcp-1634	239	38	,	,	PUNCT
ajcp-1634	239	39	r.	r.	PROPN
ajcp-1634	239	40	n.	n.	PROPN
ajcp-1634	239	41	,	,	PUNCT
ajcp-1634	239	42	...	...	PUNCT
ajcp-1634	239	43	&	&	CCONJ
ajcp-1634	239	44	beigel	beigel	NOUN
ajcp-1634	239	45	,	,	PUNCT
ajcp-1634	239	46	j.	j.	PROPN
ajcp-1634	239	47	h.	h.	PROPN
ajcp-1634	239	48	(	(	PUNCT
ajcp-1634	239	49	2020	2020	NUM
ajcp-1634	239	50	)	)	PUNCT
ajcp-1634	239	51	.	.	PUNCT
ajcp-1634	240	1	an	an	DET
ajcp-1634	240	2	mrna	mrna	NOUN
ajcp-1634	240	3	vaccine	vaccine	NOUN
ajcp-1634	240	4	against	against	ADP
ajcp-1634	240	5	sars	sar	NOUN
ajcp-1634	240	6	-	-	PUNCT
ajcp-1634	240	7	cov-2	cov-2	NOUN
ajcp-1634	240	8	—	—	PUNCT
ajcp-1634	240	9	preliminary	preliminary	ADJ
ajcp-1634	240	10	report	report	NOUN
ajcp-1634	240	11	.	.	PUNCT
ajcp-1634	241	1	new	new	PROPN
ajcp-1634	241	2	england	england	PROPN
ajcp-1634	241	3	journal	journal	PROPN
ajcp-1634	241	4	of	of	ADP
ajcp-1634	241	5	medicine	medicine	NOUN
ajcp-1634	241	6	.	.	PUNCT
ajcp-1634	242	1	janssen	janssen	PROPN
ajcp-1634	242	2	biotech	biotech	PROPN
ajcp-1634	242	3	.	.	PUNCT
ajcp-1634	243	1	(	(	PUNCT
ajcp-1634	243	2	2021	2021	NUM
ajcp-1634	243	3	)	)	PUNCT
ajcp-1634	243	4	.	.	PUNCT
ajcp-1634	244	1	covid-19	covid-19	PROPN
ajcp-1634	244	2	vaccine	vaccine	NOUN
ajcp-1634	244	3	ad26	ad26	PROPN
ajcp-1634	244	4	.	.	PUNCT
ajcp-1634	245	1	cov2.s	cov2.s	PROPN
ajcp-1634	245	2	.	.	PUNCT
ajcp-1634	246	1	sponsor	sponsor	NOUN
ajcp-1634	246	2	briefing	briefing	NOUN
ajcp-1634	246	3	document	document	NOUN
ajcp-1634	246	4	(	(	PUNCT
ajcp-1634	246	5	vaccines	vaccine	NOUN
ajcp-1634	246	6	and	and	CCONJ
ajcp-1634	246	7	related	related	ADJ
ajcp-1634	246	8	biological	biological	ADJ
ajcp-1634	246	9	products	product	NOUN
ajcp-1634	246	10	advisory	advisory	ADJ
ajcp-1634	246	11	committee	committee	NOUN
ajcp-1634	246	12	,	,	PUNCT
ajcp-1634	246	13	2021	2021	NUM
ajcp-1634	246	14	)	)	PUNCT
ajcp-1634	246	15	.	.	PUNCT
ajcp-1634	247	1	johnson	johnson	PROPN
ajcp-1634	247	2	,	,	PUNCT
ajcp-1634	247	3	b.	b.	PROPN
ajcp-1634	247	4	a.	a.	PROPN
ajcp-1634	247	5	,	,	PUNCT
ajcp-1634	247	6	xie	xie	PROPN
ajcp-1634	247	7	,	,	PUNCT
ajcp-1634	247	8	x.	x.	PROPN
ajcp-1634	247	9	,	,	PUNCT
ajcp-1634	247	10	kalveram	kalveram	PROPN
ajcp-1634	247	11	,	,	PUNCT
ajcp-1634	247	12	b.	b.	PROPN
ajcp-1634	247	13	,	,	PUNCT
ajcp-1634	247	14	lokugamage	lokugamage	NOUN
ajcp-1634	247	15	,	,	PUNCT
ajcp-1634	247	16	k.	k.	PROPN
ajcp-1634	247	17	g.	g.	PROPN
ajcp-1634	247	18	,	,	PUNCT
ajcp-1634	247	19	muruato	muruato	PROPN
ajcp-1634	247	20	,	,	PUNCT
ajcp-1634	247	21	a.	a.	PROPN
ajcp-1634	247	22	,	,	PUNCT
ajcp-1634	247	23	zou	zou	PROPN
ajcp-1634	247	24	,	,	PUNCT
ajcp-1634	247	25	j.	j.	PROPN
ajcp-1634	247	26	,	,	PUNCT
ajcp-1634	247	27	...	...	PUNCT
ajcp-1634	247	28	&	&	CCONJ
ajcp-1634	247	29	menachery	menachery	PROPN
ajcp-1634	247	30	,	,	PUNCT
ajcp-1634	247	31	v.	v.	ADP
ajcp-1634	247	32	d.	d.	PROPN
ajcp-1634	247	33	(	(	PUNCT
ajcp-1634	247	34	2020	2020	NUM
ajcp-1634	247	35	)	)	PUNCT
ajcp-1634	247	36	.	.	PUNCT
ajcp-1634	248	1	furin	furin	NOUN
ajcp-1634	248	2	cleavage	cleavage	NOUN
ajcp-1634	248	3	site	site	NOUN
ajcp-1634	248	4	is	be	AUX
ajcp-1634	248	5	key	key	ADJ
ajcp-1634	248	6	to	to	ADP
ajcp-1634	248	7	sars	sar	NOUN
ajcp-1634	248	8	-	-	PUNCT
ajcp-1634	248	9	cov-2	cov-2	NOUN
ajcp-1634	248	10	pathogenesis	pathogenesis	NOUN
ajcp-1634	248	11	.	.	PUNCT
ajcp-1634	249	1	biorxiv	biorxiv	PROPN
ajcp-1634	249	2	.	.	PUNCT
ajcp-1634	250	1	karikó	karikó	PROPN
ajcp-1634	250	2	,	,	PUNCT
ajcp-1634	250	3	k.	k.	PROPN
ajcp-1634	250	4	,	,	PUNCT
ajcp-1634	250	5	muramatsu	muramatsu	PROPN
ajcp-1634	250	6	,	,	PUNCT
ajcp-1634	250	7	h.	h.	PROPN
ajcp-1634	250	8	,	,	PUNCT
ajcp-1634	250	9	welsh	welsh	PROPN
ajcp-1634	250	10	,	,	PUNCT
ajcp-1634	250	11	f.	f.	PROPN
ajcp-1634	250	12	a.	a.	PROPN
ajcp-1634	250	13	,	,	PUNCT
ajcp-1634	250	14	ludwig	ludwig	PROPN
ajcp-1634	250	15	,	,	PUNCT
ajcp-1634	250	16	j.	j.	PROPN
ajcp-1634	250	17	,	,	PUNCT
ajcp-1634	250	18	kato	kato	PROPN
ajcp-1634	250	19	,	,	PUNCT
ajcp-1634	250	20	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	250	21	pa	pa	PROPN
ajcp-1634	250	22	ge	ge	PROPN
ajcp-1634	250	23	72	72	NUM
ajcp-1634	250	24	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	250	25	am	be	AUX
ajcp-1634	250	26	.	.	PUNCT
ajcp-1634	251	1	j.	j.	PROPN
ajcp-1634	251	2	chem	chem	PROPN
ajcp-1634	251	3	.	.	PUNCT
ajcp-1634	252	1	pharm	pharm	PROPN
ajcp-1634	252	2	.	.	PUNCT
ajcp-1634	253	1	2(2	2(2	NUM
ajcp-1634	253	2	)	)	PUNCT
ajcp-1634	253	3	66	66	NUM
ajcp-1634	253	4	-	-	SYM
ajcp-1634	253	5	73	73	NUM
ajcp-1634	253	6	,	,	PUNCT
ajcp-1634	253	7	2023	2023	NUM
ajcp-1634	253	8	h.	h.	PROPN
ajcp-1634	253	9	,	,	PUNCT
ajcp-1634	253	10	akira	akira	PROPN
ajcp-1634	253	11	,	,	PUNCT
ajcp-1634	253	12	s.	s.	PROPN
ajcp-1634	253	13	,	,	PUNCT
ajcp-1634	253	14	&	&	CCONJ
ajcp-1634	253	15	weissman	weissman	PROPN
ajcp-1634	253	16	,	,	PUNCT
ajcp-1634	253	17	d.	d.	PROPN
ajcp-1634	253	18	(	(	PUNCT
ajcp-1634	253	19	2008	2008	NUM
ajcp-1634	253	20	)	)	PUNCT
ajcp-1634	253	21	.	.	PUNCT
ajcp-1634	254	1	incorporation	incorporation	NOUN
ajcp-1634	254	2	of	of	ADP
ajcp-1634	254	3	pseudouridine	pseudouridine	NOUN
ajcp-1634	254	4	into	into	ADP
ajcp-1634	254	5	mrna	mrna	PROPN
ajcp-1634	254	6	yields	yield	NOUN
ajcp-1634	254	7	superior	superior	ADJ
ajcp-1634	254	8	nonimmunogenic	nonimmunogenic	ADJ
ajcp-1634	254	9	vector	vector	NOUN
ajcp-1634	254	10	with	with	ADP
ajcp-1634	254	11	increased	increase	VERB
ajcp-1634	254	12	translational	translational	ADJ
ajcp-1634	254	13	capacity	capacity	NOUN
ajcp-1634	254	14	and	and	CCONJ
ajcp-1634	254	15	biological	biological	ADJ
ajcp-1634	254	16	stability	stability	NOUN
ajcp-1634	254	17	.	.	PUNCT
ajcp-1634	255	1	molecular	molecular	ADJ
ajcp-1634	255	2	therapy	therapy	NOUN
ajcp-1634	255	3	,	,	PUNCT
ajcp-1634	255	4	16(11	16(11	NUM
ajcp-1634	255	5	)	)	PUNCT
ajcp-1634	255	6	,	,	PUNCT
ajcp-1634	255	7	1833	1833	NUM
ajcp-1634	255	8	-	-	SYM
ajcp-1634	255	9	1840	1840	NUM
ajcp-1634	255	10	.	.	PUNCT
ajcp-1634	256	1	keech	keech	PROPN
ajcp-1634	256	2	,	,	PUNCT
ajcp-1634	256	3	c.	c.	PROPN
ajcp-1634	256	4	,	,	PUNCT
ajcp-1634	256	5	albert	albert	PROPN
ajcp-1634	256	6	,	,	PUNCT
ajcp-1634	256	7	g.	g.	PROPN
ajcp-1634	256	8	,	,	PUNCT
ajcp-1634	256	9	cho	cho	PROPN
ajcp-1634	256	10	,	,	PUNCT
ajcp-1634	256	11	i.	i.	PROPN
ajcp-1634	256	12	,	,	PUNCT
ajcp-1634	256	13	robertson	robertson	PROPN
ajcp-1634	256	14	,	,	PUNCT
ajcp-1634	256	15	a.	a.	PROPN
ajcp-1634	256	16	,	,	PUNCT
ajcp-1634	256	17	reed	reed	NOUN
ajcp-1634	256	18	,	,	PUNCT
ajcp-1634	256	19	p.	p.	PROPN
ajcp-1634	256	20	,	,	PUNCT
ajcp-1634	256	21	neal	neal	PROPN
ajcp-1634	256	22	,	,	PUNCT
ajcp-1634	256	23	s.	s.	PROPN
ajcp-1634	256	24	,	,	PUNCT
ajcp-1634	256	25	...	...	PUNCT
ajcp-1634	256	26	&	&	CCONJ
ajcp-1634	256	27	glenn	glenn	PROPN
ajcp-1634	256	28	,	,	PUNCT
ajcp-1634	256	29	g.	g.	PROPN
ajcp-1634	256	30	m.	m.	PROPN
ajcp-1634	256	31	(	(	PUNCT
ajcp-1634	256	32	2020	2020	NUM
ajcp-1634	256	33	)	)	PUNCT
ajcp-1634	256	34	.	.	PUNCT
ajcp-1634	257	1	phase	phase	NOUN
ajcp-1634	257	2	1–2	1–2	DET
ajcp-1634	257	3	trial	trial	NOUN
ajcp-1634	257	4	of	of	ADP
ajcp-1634	257	5	a	a	DET
ajcp-1634	257	6	sarscov-2	sarscov-2	NUM
ajcp-1634	257	7	recombinant	recombinant	ADJ
ajcp-1634	257	8	spike	spike	ADJ
ajcp-1634	257	9	protein	protein	NOUN
ajcp-1634	257	10	nanoparticle	nanoparticle	NOUN
ajcp-1634	257	11	vaccine	vaccine	NOUN
ajcp-1634	257	12	.	.	PUNCT
ajcp-1634	258	1	new	new	PROPN
ajcp-1634	258	2	england	england	PROPN
ajcp-1634	258	3	journal	journal	PROPN
ajcp-1634	258	4	of	of	ADP
ajcp-1634	258	5	medicine	medicine	NOUN
ajcp-1634	258	6	,	,	PUNCT
ajcp-1634	258	7	383(24	383(24	NUM
ajcp-1634	258	8	)	)	PUNCT
ajcp-1634	258	9	,	,	PUNCT
ajcp-1634	258	10	2320	2320	NUM
ajcp-1634	258	11	-	-	SYM
ajcp-1634	258	12	2332	2332	NUM
ajcp-1634	258	13	.	.	PUNCT
ajcp-1634	259	1	kowalzik	kowalzik	NOUN
ajcp-1634	259	2	,	,	PUNCT
ajcp-1634	259	3	f.	f.	PROPN
ajcp-1634	259	4	,	,	PUNCT
ajcp-1634	259	5	schreiner	schreiner	PROPN
ajcp-1634	259	6	,	,	PUNCT
ajcp-1634	259	7	d.	d.	PROPN
ajcp-1634	259	8	,	,	PUNCT
ajcp-1634	259	9	jensen	jensen	PROPN
ajcp-1634	259	10	,	,	PUNCT
ajcp-1634	259	11	c.	c.	PROPN
ajcp-1634	259	12	,	,	PUNCT
ajcp-1634	259	13	teschner	teschner	NOUN
ajcp-1634	259	14	,	,	PUNCT
ajcp-1634	259	15	d.	d.	PROPN
ajcp-1634	259	16	,	,	PUNCT
ajcp-1634	259	17	gehring	gehring	PROPN
ajcp-1634	259	18	,	,	PUNCT
ajcp-1634	259	19	s.	s.	PROPN
ajcp-1634	259	20	,	,	PUNCT
ajcp-1634	259	21	&	&	CCONJ
ajcp-1634	259	22	zepp	zepp	PROPN
ajcp-1634	259	23	,	,	PUNCT
ajcp-1634	259	24	f.	f.	PROPN
ajcp-1634	259	25	(	(	PUNCT
ajcp-1634	259	26	2021	2021	NUM
ajcp-1634	259	27	)	)	PUNCT
ajcp-1634	259	28	.	.	PUNCT
ajcp-1634	260	1	mrna	mrna	PROPN
ajcp-1634	260	2	-	-	PUNCT
ajcp-1634	260	3	based	base	VERB
ajcp-1634	260	4	vaccines	vaccine	NOUN
ajcp-1634	260	5	.	.	PUNCT
ajcp-1634	261	1	vaccines	vaccine	NOUN
ajcp-1634	261	2	,	,	PUNCT
ajcp-1634	261	3	9(4	9(4	NUM
ajcp-1634	261	4	)	)	PUNCT
ajcp-1634	261	5	,	,	PUNCT
ajcp-1634	261	6	390	390	NUM
ajcp-1634	261	7	.	.	PUNCT
ajcp-1634	262	1	kuba	kuba	PROPN
ajcp-1634	262	2	,	,	PUNCT
ajcp-1634	262	3	k.	k.	PROPN
ajcp-1634	262	4	,	,	PUNCT
ajcp-1634	262	5	imai	imai	PROPN
ajcp-1634	262	6	,	,	PUNCT
ajcp-1634	262	7	y.	y.	PROPN
ajcp-1634	262	8	,	,	PUNCT
ajcp-1634	262	9	rao	rao	PROPN
ajcp-1634	262	10	,	,	PUNCT
ajcp-1634	262	11	s.	s.	PROPN
ajcp-1634	262	12	,	,	PUNCT
ajcp-1634	262	13	gao	gao	PROPN
ajcp-1634	262	14	,	,	PUNCT
ajcp-1634	262	15	h.	h.	PROPN
ajcp-1634	262	16	,	,	PUNCT
ajcp-1634	262	17	guo	guo	PROPN
ajcp-1634	262	18	,	,	PUNCT
ajcp-1634	262	19	f.	f.	PROPN
ajcp-1634	262	20	,	,	PUNCT
ajcp-1634	262	21	guan	guan	PROPN
ajcp-1634	262	22	,	,	PUNCT
ajcp-1634	262	23	b.	b.	PROPN
ajcp-1634	262	24	,	,	PUNCT
ajcp-1634	262	25	...	...	PUNCT
ajcp-1634	262	26	&	&	CCONJ
ajcp-1634	262	27	penninger	penninger	PROPN
ajcp-1634	262	28	,	,	PUNCT
ajcp-1634	262	29	j.	j.	PROPN
ajcp-1634	262	30	m.	m.	PROPN
ajcp-1634	262	31	(	(	PUNCT
ajcp-1634	262	32	2005	2005	NUM
ajcp-1634	262	33	)	)	PUNCT
ajcp-1634	262	34	.	.	PUNCT
ajcp-1634	263	1	a	a	DET
ajcp-1634	263	2	crucial	crucial	ADJ
ajcp-1634	263	3	role	role	NOUN
ajcp-1634	263	4	of	of	ADP
ajcp-1634	263	5	angiotensin	angiotensin	NOUN
ajcp-1634	263	6	converting	convert	VERB
ajcp-1634	263	7	enzyme	enzyme	NOUN
ajcp-1634	263	8	2	2	NUM
ajcp-1634	263	9	(	(	PUNCT
ajcp-1634	263	10	ace2	ace2	PROPN
ajcp-1634	263	11	)	)	PUNCT
ajcp-1634	263	12	in	in	ADP
ajcp-1634	263	13	sars	sars	PROPN
ajcp-1634	263	14	coronavirus	coronavirus	PROPN
ajcp-1634	263	15	–	–	PUNCT
ajcp-1634	263	16	induced	induce	VERB
ajcp-1634	263	17	lung	lung	NOUN
ajcp-1634	263	18	injury	injury	NOUN
ajcp-1634	263	19	.	.	PUNCT
ajcp-1634	264	1	nature	nature	NOUN
ajcp-1634	264	2	medicine	medicine	PROPN
ajcp-1634	264	3	,	,	PUNCT
ajcp-1634	264	4	11(8	11(8	NUM
ajcp-1634	264	5	)	)	PUNCT
ajcp-1634	264	6	,	,	PUNCT
ajcp-1634	264	7	875	875	NUM
ajcp-1634	264	8	-	-	SYM
ajcp-1634	264	9	879	879	NUM
ajcp-1634	264	10	.	.	PUNCT
ajcp-1634	265	1	lenza	lenza	PROPN
ajcp-1634	265	2	,	,	PUNCT
ajcp-1634	265	3	m.	m.	NOUN
ajcp-1634	265	4	p.	p.	PROPN
ajcp-1634	265	5	,	,	PUNCT
ajcp-1634	265	6	oyenarte	oyenarte	PROPN
ajcp-1634	265	7	,	,	PUNCT
ajcp-1634	265	8	i.	i.	PROPN
ajcp-1634	265	9	,	,	PUNCT
ajcp-1634	265	10	diercks	dierck	NOUN
ajcp-1634	265	11	,	,	PUNCT
ajcp-1634	265	12	t.	t.	PROPN
ajcp-1634	265	13	,	,	PUNCT
ajcp-1634	265	14	quintana	quintana	PROPN
ajcp-1634	265	15	,	,	PUNCT
ajcp-1634	265	16	j.	j.	PROPN
ajcp-1634	265	17	i.	i.	PROPN
ajcp-1634	265	18	,	,	PUNCT
ajcp-1634	265	19	gimeno	gimeno	PROPN
ajcp-1634	265	20	,	,	PUNCT
ajcp-1634	265	21	a.	a.	PROPN
ajcp-1634	265	22	,	,	PUNCT
ajcp-1634	265	23	coelho	coelho	PROPN
ajcp-1634	265	24	,	,	PUNCT
ajcp-1634	265	25	h.	h.	PROPN
ajcp-1634	265	26	,	,	PUNCT
ajcp-1634	265	27	...	...	PUNCT
ajcp-1634	265	28	&	&	CCONJ
ajcp-1634	265	29	ereño	ereño	PROPN
ajcp-1634	265	30	-	-	NOUN
ajcp-1634	265	31	orbea	orbea	PROPN
ajcp-1634	265	32	,	,	PUNCT
ajcp-1634	265	33	j.	j.	PROPN
ajcp-1634	265	34	(	(	PUNCT
ajcp-1634	265	35	2020	2020	NUM
ajcp-1634	265	36	)	)	PUNCT
ajcp-1634	265	37	.	.	PUNCT
ajcp-1634	266	1	structural	structural	ADJ
ajcp-1634	266	2	characterization	characterization	NOUN
ajcp-1634	266	3	of	of	ADP
ajcp-1634	266	4	n	n	ADV
ajcp-1634	266	5	-	-	PUNCT
ajcp-1634	266	6	linked	link	VERB
ajcp-1634	266	7	glycans	glycan	NOUN
ajcp-1634	266	8	in	in	ADP
ajcp-1634	266	9	the	the	DET
ajcp-1634	266	10	receptor	receptor	NOUN
ajcp-1634	266	11	binding	bind	VERB
ajcp-1634	266	12	domain	domain	NOUN
ajcp-1634	266	13	of	of	ADP
ajcp-1634	266	14	the	the	DET
ajcp-1634	266	15	sars	sar	NOUN
ajcp-1634	266	16	-	-	PUNCT
ajcp-1634	266	17	cov-2	cov-2	NOUN
ajcp-1634	266	18	spike	spike	ADJ
ajcp-1634	266	19	protein	protein	NOUN
ajcp-1634	266	20	and	and	CCONJ
ajcp-1634	266	21	their	their	PRON
ajcp-1634	266	22	interactions	interaction	NOUN
ajcp-1634	266	23	with	with	ADP
ajcp-1634	266	24	human	human	ADJ
ajcp-1634	266	25	lectins	lectin	NOUN
ajcp-1634	266	26	.	.	PUNCT
ajcp-1634	267	1	angewandte	angewandte	PROPN
ajcp-1634	267	2	chemie	chemie	PROPN
ajcp-1634	267	3	international	international	PROPN
ajcp-1634	267	4	edition	edition	PROPN
ajcp-1634	267	5	,	,	PUNCT
ajcp-1634	267	6	59(52	59(52	NUM
ajcp-1634	267	7	)	)	PUNCT
ajcp-1634	267	8	,	,	PUNCT
ajcp-1634	267	9	2376323771	2376323771	NUM
ajcp-1634	267	10	.	.	PUNCT
ajcp-1634	268	1	li	li	PROPN
ajcp-1634	268	2	,	,	PUNCT
ajcp-1634	268	3	w.	w.	PROPN
ajcp-1634	268	4	,	,	PUNCT
ajcp-1634	268	5	moore	moore	PROPN
ajcp-1634	268	6	,	,	PUNCT
ajcp-1634	268	7	m.	m.	PROPN
ajcp-1634	268	8	j.	j.	PROPN
ajcp-1634	268	9	,	,	PUNCT
ajcp-1634	268	10	vasilieva	vasilieva	PROPN
ajcp-1634	268	11	,	,	PUNCT
ajcp-1634	268	12	n.	n.	PROPN
ajcp-1634	268	13	,	,	PUNCT
ajcp-1634	268	14	sui	sui	PROPN
ajcp-1634	268	15	,	,	PUNCT
ajcp-1634	268	16	j.	j.	PROPN
ajcp-1634	268	17	,	,	PUNCT
ajcp-1634	268	18	wong	wong	PROPN
ajcp-1634	268	19	,	,	PUNCT
ajcp-1634	268	20	s.	s.	PROPN
ajcp-1634	268	21	k.	k.	PROPN
ajcp-1634	268	22	,	,	PUNCT
ajcp-1634	268	23	berne	berne	PROPN
ajcp-1634	268	24	,	,	PUNCT
ajcp-1634	268	25	m.	m.	NOUN
ajcp-1634	268	26	a.	a.	PROPN
ajcp-1634	268	27	,	,	PUNCT
ajcp-1634	268	28	...	...	PUNCT
ajcp-1634	268	29	&	&	CCONJ
ajcp-1634	268	30	farzan	farzan	PROPN
ajcp-1634	268	31	,	,	PUNCT
ajcp-1634	268	32	m.	m.	NOUN
ajcp-1634	268	33	(	(	PUNCT
ajcp-1634	268	34	2003	2003	NUM
ajcp-1634	268	35	)	)	PUNCT
ajcp-1634	268	36	.	.	PUNCT
ajcp-1634	269	1	angiotensinconverting	angiotensinconverte	VERB
ajcp-1634	269	2	enzyme	enzyme	NOUN
ajcp-1634	269	3	2	2	NUM
ajcp-1634	269	4	is	be	AUX
ajcp-1634	269	5	a	a	DET
ajcp-1634	269	6	functional	functional	ADJ
ajcp-1634	269	7	receptor	receptor	NOUN
ajcp-1634	269	8	for	for	ADP
ajcp-1634	269	9	the	the	DET
ajcp-1634	269	10	sars	sars	PROPN
ajcp-1634	269	11	coronavirus	coronavirus	PROPN
ajcp-1634	269	12	.	.	PUNCT
ajcp-1634	270	1	nature	nature	NOUN
ajcp-1634	270	2	,	,	PUNCT
ajcp-1634	270	3	426(6965	426(6965	NOUN
ajcp-1634	270	4	)	)	PUNCT
ajcp-1634	270	5	,	,	PUNCT
ajcp-1634	270	6	450	450	NUM
ajcp-1634	270	7	-	-	SYM
ajcp-1634	270	8	454	454	NUM
ajcp-1634	270	9	.	.	PUNCT
ajcp-1634	271	1	li	li	PROPN
ajcp-1634	271	2	,	,	PUNCT
ajcp-1634	271	3	f.	f.	PROPN
ajcp-1634	271	4	,	,	PUNCT
ajcp-1634	271	5	li	li	PROPN
ajcp-1634	271	6	,	,	PUNCT
ajcp-1634	271	7	w.	w.	PROPN
ajcp-1634	271	8	,	,	PUNCT
ajcp-1634	271	9	farzan	farzan	PROPN
ajcp-1634	271	10	,	,	PUNCT
ajcp-1634	271	11	m.	m.	NOUN
ajcp-1634	271	12	,	,	PUNCT
ajcp-1634	271	13	&	&	CCONJ
ajcp-1634	271	14	harrison	harrison	PROPN
ajcp-1634	271	15	,	,	PUNCT
ajcp-1634	271	16	s.	s.	PROPN
ajcp-1634	271	17	c.	c.	PROPN
ajcp-1634	271	18	(	(	PUNCT
ajcp-1634	271	19	2005	2005	NUM
ajcp-1634	271	20	)	)	PUNCT
ajcp-1634	271	21	.	.	PUNCT
ajcp-1634	272	1	structure	structure	NOUN
ajcp-1634	272	2	of	of	ADP
ajcp-1634	272	3	sars	sars	PROPN
ajcp-1634	272	4	coronavirus	coronavirus	PROPN
ajcp-1634	272	5	spike	spike	ADJ
ajcp-1634	272	6	receptor	receptor	NOUN
ajcp-1634	272	7	-	-	PUNCT
ajcp-1634	272	8	binding	bind	VERB
ajcp-1634	272	9	domain	domain	NOUN
ajcp-1634	272	10	complexed	complexe	VERB
ajcp-1634	272	11	with	with	ADP
ajcp-1634	272	12	receptor	receptor	NOUN
ajcp-1634	272	13	.	.	PUNCT
ajcp-1634	273	1	science	science	NOUN
ajcp-1634	273	2	,	,	PUNCT
ajcp-1634	273	3	309(5742	309(5742	NUM
ajcp-1634	273	4	)	)	PUNCT
ajcp-1634	273	5	,	,	PUNCT
ajcp-1634	273	6	1864	1864	NUM
ajcp-1634	273	7	-	-	SYM
ajcp-1634	273	8	1868	1868	NUM
ajcp-1634	273	9	.	.	PUNCT
ajcp-1634	274	1	li	li	PROPN
ajcp-1634	274	2	,	,	PUNCT
ajcp-1634	274	3	w.	w.	PROPN
ajcp-1634	274	4	,	,	PUNCT
ajcp-1634	274	5	hulswit	hulswit	PROPN
ajcp-1634	274	6	,	,	PUNCT
ajcp-1634	274	7	r.	r.	PROPN
ajcp-1634	274	8	j.	j.	PROPN
ajcp-1634	274	9	,	,	PUNCT
ajcp-1634	274	10	widjaja	widjaja	PROPN
ajcp-1634	274	11	,	,	PUNCT
ajcp-1634	274	12	i.	i.	PROPN
ajcp-1634	274	13	,	,	PUNCT
ajcp-1634	274	14	raj	raj	PROPN
ajcp-1634	274	15	,	,	PUNCT
ajcp-1634	274	16	v.	v.	PROPN
ajcp-1634	274	17	s.	s.	PROPN
ajcp-1634	274	18	,	,	PUNCT
ajcp-1634	274	19	mcbride	mcbride	PROPN
ajcp-1634	274	20	,	,	PUNCT
ajcp-1634	274	21	r.	r.	PROPN
ajcp-1634	274	22	,	,	PUNCT
ajcp-1634	274	23	peng	peng	PROPN
ajcp-1634	274	24	,	,	PUNCT
ajcp-1634	274	25	w.	w.	PROPN
ajcp-1634	274	26	,	,	PUNCT
ajcp-1634	274	27	...	...	PUNCT
ajcp-1634	274	28	&	&	CCONJ
ajcp-1634	274	29	bosch	bosch	PROPN
ajcp-1634	274	30	,	,	PUNCT
ajcp-1634	274	31	b.	b.	PROPN
ajcp-1634	274	32	j.	j.	PROPN
ajcp-1634	274	33	(	(	PUNCT
ajcp-1634	274	34	2017	2017	NUM
ajcp-1634	274	35	)	)	PUNCT
ajcp-1634	274	36	.	.	PUNCT
ajcp-1634	275	1	identification	identification	NOUN
ajcp-1634	275	2	of	of	ADP
ajcp-1634	275	3	sialic	sialic	ADJ
ajcp-1634	275	4	acid	acid	NOUN
ajcp-1634	275	5	-	-	PUNCT
ajcp-1634	275	6	binding	bind	VERB
ajcp-1634	275	7	function	function	NOUN
ajcp-1634	275	8	for	for	ADP
ajcp-1634	275	9	the	the	DET
ajcp-1634	275	10	middle	middle	PROPN
ajcp-1634	275	11	east	east	PROPN
ajcp-1634	275	12	respiratory	respiratory	ADJ
ajcp-1634	275	13	syndrome	syndrome	PROPN
ajcp-1634	275	14	coronavirus	coronavirus	NOUN
ajcp-1634	275	15	spike	spike	NOUN
ajcp-1634	275	16	glycoprotein	glycoprotein	NOUN
ajcp-1634	275	17	.	.	PUNCT
ajcp-1634	276	1	proceedings	proceeding	NOUN
ajcp-1634	276	2	of	of	ADP
ajcp-1634	276	3	the	the	DET
ajcp-1634	276	4	national	national	PROPN
ajcp-1634	276	5	academy	academy	PROPN
ajcp-1634	276	6	of	of	ADP
ajcp-1634	276	7	sciences	sciences	PROPN
ajcp-1634	276	8	,	,	PUNCT
ajcp-1634	276	9	114(40	114(40	NUM
ajcp-1634	276	10	)	)	PUNCT
ajcp-1634	276	11	,	,	PUNCT
ajcp-1634	276	12	e8508	e8508	NOUN
ajcp-1634	276	13	-	-	PUNCT
ajcp-1634	276	14	e8517	e8517	PROPN
ajcp-1634	276	15	.	.	PUNCT
ajcp-1634	277	1	li	li	PROPN
ajcp-1634	277	2	,	,	PUNCT
ajcp-1634	277	3	q.	q.	PROPN
ajcp-1634	277	4	,	,	PUNCT
ajcp-1634	277	5	guan	guan	PROPN
ajcp-1634	277	6	,	,	PUNCT
ajcp-1634	277	7	x.	x.	PROPN
ajcp-1634	277	8	,	,	PUNCT
ajcp-1634	277	9	wu	wu	PROPN
ajcp-1634	277	10	,	,	PUNCT
ajcp-1634	277	11	p.	p.	PROPN
ajcp-1634	277	12	,	,	PUNCT
ajcp-1634	277	13	wang	wang	PROPN
ajcp-1634	277	14	,	,	PUNCT
ajcp-1634	277	15	x.	x.	PROPN
ajcp-1634	277	16	,	,	PUNCT
ajcp-1634	277	17	zhou	zhou	PROPN
ajcp-1634	277	18	,	,	PUNCT
ajcp-1634	277	19	l.	l.	PROPN
ajcp-1634	277	20	,	,	PUNCT
ajcp-1634	277	21	tong	tong	PROPN
ajcp-1634	277	22	,	,	PUNCT
ajcp-1634	277	23	y.	y.	PROPN
ajcp-1634	277	24	,	,	PUNCT
ajcp-1634	277	25	...	...	PUNCT
ajcp-1634	277	26	&	&	CCONJ
ajcp-1634	277	27	feng	feng	PROPN
ajcp-1634	277	28	,	,	PUNCT
ajcp-1634	277	29	z.	z.	PROPN
ajcp-1634	277	30	(	(	PUNCT
ajcp-1634	277	31	2020	2020	NUM
ajcp-1634	277	32	)	)	PUNCT
ajcp-1634	277	33	.	.	PUNCT
ajcp-1634	278	1	early	early	ADJ
ajcp-1634	278	2	transmission	transmission	NOUN
ajcp-1634	278	3	dynamics	dynamic	NOUN
ajcp-1634	278	4	in	in	ADP
ajcp-1634	278	5	wuhan	wuhan	PROPN
ajcp-1634	278	6	,	,	PUNCT
ajcp-1634	278	7	china	china	PROPN
ajcp-1634	278	8	,	,	PUNCT
ajcp-1634	278	9	of	of	ADP
ajcp-1634	278	10	novel	novel	ADJ
ajcp-1634	278	11	coronavirus	coronavirus	NOUN
ajcp-1634	278	12	–	–	PUNCT
ajcp-1634	278	13	infected	infected	ADJ
ajcp-1634	278	14	pneumonia	pneumonia	NOUN
ajcp-1634	278	15	.	.	PUNCT
ajcp-1634	279	1	new	new	PROPN
ajcp-1634	279	2	england	england	PROPN
ajcp-1634	279	3	journal	journal	PROPN
ajcp-1634	279	4	of	of	ADP
ajcp-1634	279	5	medicine	medicine	NOUN
ajcp-1634	279	6	.	.	PUNCT
ajcp-1634	280	1	li	li	PROPN
ajcp-1634	280	2	,	,	PUNCT
ajcp-1634	280	3	x.	x.	PROPN
ajcp-1634	280	4	,	,	PUNCT
ajcp-1634	280	5	wang	wang	PROPN
ajcp-1634	280	6	,	,	PUNCT
ajcp-1634	280	7	w.	w.	PROPN
ajcp-1634	280	8	,	,	PUNCT
ajcp-1634	280	9	zhao	zhao	PROPN
ajcp-1634	280	10	,	,	PUNCT
ajcp-1634	280	11	x.	x.	PROPN
ajcp-1634	280	12	,	,	PUNCT
ajcp-1634	280	13	zai	zai	PROPN
ajcp-1634	280	14	,	,	PUNCT
ajcp-1634	280	15	j.	j.	PROPN
ajcp-1634	280	16	,	,	PUNCT
ajcp-1634	280	17	zhao	zhao	PROPN
ajcp-1634	280	18	,	,	PUNCT
ajcp-1634	280	19	q.	q.	PROPN
ajcp-1634	280	20	,	,	PUNCT
ajcp-1634	280	21	li	li	PROPN
ajcp-1634	280	22	,	,	PUNCT
ajcp-1634	280	23	y.	y.	PROPN
ajcp-1634	280	24	,	,	PUNCT
ajcp-1634	280	25	&	&	CCONJ
ajcp-1634	280	26	chaillon	chaillon	PROPN
ajcp-1634	280	27	,	,	PUNCT
ajcp-1634	280	28	a.	a.	NOUN
ajcp-1634	280	29	(	(	PUNCT
ajcp-1634	280	30	2020	2020	NUM
ajcp-1634	280	31	)	)	PUNCT
ajcp-1634	280	32	.	.	PUNCT
ajcp-1634	281	1	transmission	transmission	NOUN
ajcp-1634	281	2	dynamics	dynamic	NOUN
ajcp-1634	281	3	and	and	CCONJ
ajcp-1634	281	4	evolutionary	evolutionary	ADJ
ajcp-1634	281	5	history	history	NOUN
ajcp-1634	281	6	of	of	ADP
ajcp-1634	281	7	2019	2019	NUM
ajcp-1634	281	8	-	-	PUNCT
ajcp-1634	281	9	ncov	ncov	NOUN
ajcp-1634	281	10	.	.	PUNCT
ajcp-1634	282	1	journal	journal	PROPN
ajcp-1634	282	2	of	of	ADP
ajcp-1634	282	3	medical	medical	ADJ
ajcp-1634	282	4	virology	virology	NOUN
ajcp-1634	282	5	,	,	PUNCT
ajcp-1634	282	6	92(5	92(5	NOUN
ajcp-1634	282	7	)	)	PUNCT
ajcp-1634	282	8	,	,	PUNCT
ajcp-1634	282	9	501	501	NUM
ajcp-1634	282	10	-	-	SYM
ajcp-1634	282	11	511	511	NUM
ajcp-1634	282	12	.	.	PUNCT
ajcp-1634	283	1	li	li	PROPN
ajcp-1634	283	2	,	,	PUNCT
ajcp-1634	283	3	q.	q.	PROPN
ajcp-1634	283	4	,	,	PUNCT
ajcp-1634	283	5	wu	wu	PROPN
ajcp-1634	283	6	,	,	PUNCT
ajcp-1634	283	7	j.	j.	PROPN
ajcp-1634	283	8	,	,	PUNCT
ajcp-1634	283	9	nie	nie	PROPN
ajcp-1634	283	10	,	,	PUNCT
ajcp-1634	283	11	j.	j.	PROPN
ajcp-1634	283	12	,	,	PUNCT
ajcp-1634	283	13	zhang	zhang	PROPN
ajcp-1634	283	14	,	,	PUNCT
ajcp-1634	283	15	l.	l.	PROPN
ajcp-1634	283	16	,	,	PUNCT
ajcp-1634	283	17	hao	hao	PROPN
ajcp-1634	283	18	,	,	PUNCT
ajcp-1634	283	19	h.	h.	PROPN
ajcp-1634	283	20	,	,	PUNCT
ajcp-1634	283	21	liu	liu	PROPN
ajcp-1634	283	22	,	,	PUNCT
ajcp-1634	283	23	s.	s.	PROPN
ajcp-1634	283	24	,	,	PUNCT
ajcp-1634	283	25	...	...	PUNCT
ajcp-1634	283	26	&	&	CCONJ
ajcp-1634	283	27	wang	wang	PROPN
ajcp-1634	283	28	,	,	PUNCT
ajcp-1634	283	29	y.	y.	PROPN
ajcp-1634	283	30	(	(	PUNCT
ajcp-1634	283	31	2020	2020	NUM
ajcp-1634	283	32	)	)	PUNCT
ajcp-1634	283	33	.	.	PUNCT
ajcp-1634	284	1	the	the	DET
ajcp-1634	284	2	impact	impact	NOUN
ajcp-1634	284	3	of	of	ADP
ajcp-1634	284	4	mutations	mutation	NOUN
ajcp-1634	284	5	in	in	ADP
ajcp-1634	284	6	sars	sar	NOUN
ajcp-1634	284	7	-	-	PUNCT
ajcp-1634	284	8	cov-2	cov-2	NOUN
ajcp-1634	284	9	spike	spike	NOUN
ajcp-1634	284	10	on	on	ADP
ajcp-1634	284	11	viral	viral	ADJ
ajcp-1634	284	12	infectivity	infectivity	NOUN
ajcp-1634	284	13	and	and	CCONJ
ajcp-1634	284	14	antigenicity	antigenicity	NOUN
ajcp-1634	284	15	.	.	PUNCT
ajcp-1634	285	1	cell	cell	NOUN
ajcp-1634	285	2	,	,	PUNCT
ajcp-1634	285	3	182(5	182(5	NUM
ajcp-1634	285	4	)	)	PUNCT
ajcp-1634	285	5	,	,	PUNCT
ajcp-1634	285	6	1284	1284	NUM
ajcp-1634	285	7	-	-	SYM
ajcp-1634	285	8	1294	1294	NUM
ajcp-1634	285	9	.	.	PUNCT
ajcp-1634	286	1	li	li	PROPN
ajcp-1634	286	2	,	,	PUNCT
ajcp-1634	286	3	y.	y.	PROPN
ajcp-1634	286	4	,	,	PUNCT
ajcp-1634	286	5	tenchov	tenchov	PROPN
ajcp-1634	286	6	,	,	PUNCT
ajcp-1634	286	7	r.	r.	PROPN
ajcp-1634	286	8	,	,	PUNCT
ajcp-1634	286	9	smoot	smoot	PROPN
ajcp-1634	286	10	,	,	PUNCT
ajcp-1634	286	11	j.	j.	PROPN
ajcp-1634	286	12	,	,	PUNCT
ajcp-1634	286	13	liu	liu	PROPN
ajcp-1634	286	14	,	,	PUNCT
ajcp-1634	286	15	c.	c.	PROPN
ajcp-1634	286	16	,	,	PUNCT
ajcp-1634	286	17	watkins	watkins	PROPN
ajcp-1634	286	18	,	,	PUNCT
ajcp-1634	286	19	s.	s.	PROPN
ajcp-1634	286	20	,	,	PUNCT
ajcp-1634	286	21	&	&	CCONJ
ajcp-1634	286	22	zhou	zhou	PROPN
ajcp-1634	286	23	,	,	PUNCT
ajcp-1634	286	24	q.	q.	PROPN
ajcp-1634	286	25	(	(	PUNCT
ajcp-1634	286	26	2021	2021	NUM
ajcp-1634	286	27	)	)	PUNCT
ajcp-1634	286	28	.	.	PUNCT
ajcp-1634	287	1	a	a	DET
ajcp-1634	287	2	comprehensive	comprehensive	ADJ
ajcp-1634	287	3	review	review	NOUN
ajcp-1634	287	4	of	of	ADP
ajcp-1634	287	5	the	the	DET
ajcp-1634	287	6	global	global	ADJ
ajcp-1634	287	7	efforts	effort	NOUN
ajcp-1634	287	8	on	on	ADP
ajcp-1634	287	9	covid-19	covid-19	PROPN
ajcp-1634	287	10	vaccine	vaccine	NOUN
ajcp-1634	287	11	development	development	NOUN
ajcp-1634	287	12	.	.	PUNCT
ajcp-1634	288	1	acs	acs	PROPN
ajcp-1634	288	2	central	central	PROPN
ajcp-1634	288	3	science	science	NOUN
ajcp-1634	288	4	,	,	PUNCT
ajcp-1634	288	5	7(4	7(4	NUM
ajcp-1634	288	6	)	)	PUNCT
ajcp-1634	288	7	,	,	PUNCT
ajcp-1634	288	8	512	512	NUM
ajcp-1634	288	9	-	-	SYM
ajcp-1634	288	10	533	533	NUM
ajcp-1634	288	11	.	.	PUNCT
ajcp-1634	289	1	liu	liu	PROPN
ajcp-1634	289	2	,	,	PUNCT
ajcp-1634	289	3	l.	l.	PROPN
ajcp-1634	289	4	,	,	PUNCT
ajcp-1634	289	5	fang	fang	PROPN
ajcp-1634	289	6	,	,	PUNCT
ajcp-1634	289	7	q.	q.	PROPN
ajcp-1634	289	8	,	,	PUNCT
ajcp-1634	289	9	deng	deng	PROPN
ajcp-1634	289	10	,	,	PUNCT
ajcp-1634	289	11	f.	f.	PROPN
ajcp-1634	289	12	,	,	PUNCT
ajcp-1634	289	13	wang	wang	PROPN
ajcp-1634	289	14	,	,	PUNCT
ajcp-1634	289	15	h.	h.	PROPN
ajcp-1634	289	16	,	,	PUNCT
ajcp-1634	289	17	yi	yi	PROPN
ajcp-1634	289	18	,	,	PUNCT
ajcp-1634	289	19	c.	c.	PROPN
ajcp-1634	289	20	e.	e.	PROPN
ajcp-1634	289	21	,	,	PUNCT
ajcp-1634	289	22	ba	ba	PROPN
ajcp-1634	289	23	,	,	PUNCT
ajcp-1634	289	24	l.	l.	PROPN
ajcp-1634	289	25	,	,	PUNCT
ajcp-1634	289	26	...	...	PUNCT
ajcp-1634	289	27	&	&	CCONJ
ajcp-1634	289	28	chen	chen	PROPN
ajcp-1634	289	29	,	,	PUNCT
ajcp-1634	289	30	z.	z.	PROPN
ajcp-1634	289	31	(	(	PUNCT
ajcp-1634	289	32	2007	2007	NUM
ajcp-1634	289	33	)	)	PUNCT
ajcp-1634	289	34	.	.	PUNCT
ajcp-1634	290	1	natural	natural	ADJ
ajcp-1634	290	2	mutations	mutation	NOUN
ajcp-1634	290	3	in	in	ADP
ajcp-1634	290	4	the	the	DET
ajcp-1634	290	5	receptor	receptor	NOUN
ajcp-1634	290	6	binding	bind	VERB
ajcp-1634	290	7	domain	domain	NOUN
ajcp-1634	290	8	of	of	ADP
ajcp-1634	290	9	spike	spike	ADJ
ajcp-1634	290	10	glycoprotein	glycoprotein	NOUN
ajcp-1634	290	11	determine	determine	VERB
ajcp-1634	290	12	the	the	DET
ajcp-1634	290	13	reactivity	reactivity	NOUN
ajcp-1634	290	14	of	of	ADP
ajcp-1634	290	15	cross	cross	NOUN
ajcp-1634	290	16	-	-	NOUN
ajcp-1634	290	17	neutralization	neutralization	NOUN
ajcp-1634	290	18	between	between	ADP
ajcp-1634	290	19	palm	palm	NOUN
ajcp-1634	290	20	civet	civet	NOUN
ajcp-1634	290	21	coronavirus	coronavirus	NOUN
ajcp-1634	290	22	and	and	CCONJ
ajcp-1634	290	23	severe	severe	ADJ
ajcp-1634	290	24	acute	acute	ADJ
ajcp-1634	290	25	respiratory	respiratory	ADJ
ajcp-1634	290	26	syndrome	syndrome	NOUN
ajcp-1634	290	27	coronavirus	coronavirus	NOUN
ajcp-1634	290	28	.	.	PUNCT
ajcp-1634	291	1	journal	journal	PROPN
ajcp-1634	291	2	of	of	ADP
ajcp-1634	291	3	virology	virology	NOUN
ajcp-1634	291	4	,	,	PUNCT
ajcp-1634	291	5	81(9	81(9	NOUN
ajcp-1634	291	6	)	)	PUNCT
ajcp-1634	291	7	,	,	PUNCT
ajcp-1634	291	8	4694	4694	NUM
ajcp-1634	291	9	-	-	SYM
ajcp-1634	291	10	4700	4700	NUM
ajcp-1634	291	11	.	.	PUNCT
ajcp-1634	292	1	logunov	logunov	PROPN
ajcp-1634	292	2	,	,	PUNCT
ajcp-1634	292	3	d.	d.	PROPN
ajcp-1634	292	4	y.	y.	PROPN
ajcp-1634	292	5	,	,	PUNCT
ajcp-1634	292	6	dolzhikova	dolzhikova	PROPN
ajcp-1634	292	7	,	,	PUNCT
ajcp-1634	292	8	i.	i.	PROPN
ajcp-1634	292	9	v.	v.	PROPN
ajcp-1634	292	10	,	,	PUNCT
ajcp-1634	292	11	zubkova	zubkova	PROPN
ajcp-1634	292	12	,	,	PUNCT
ajcp-1634	292	13	o.	o.	PROPN
ajcp-1634	292	14	v.	v.	PROPN
ajcp-1634	292	15	,	,	PUNCT
ajcp-1634	292	16	tukhvatullin	tukhvatullin	NOUN
ajcp-1634	292	17	,	,	PUNCT
ajcp-1634	292	18	a.	a.	NOUN
ajcp-1634	292	19	i.	i.	PROPN
ajcp-1634	292	20	,	,	PUNCT
ajcp-1634	292	21	shcheblyakov	shcheblyakov	PROPN
ajcp-1634	292	22	,	,	PUNCT
ajcp-1634	292	23	d.	d.	PROPN
ajcp-1634	292	24	v.	v.	PROPN
ajcp-1634	292	25	,	,	PUNCT
ajcp-1634	292	26	dzharullaeva	dzharullaeva	PROPN
ajcp-1634	292	27	,	,	PUNCT
ajcp-1634	292	28	a.	a.	PROPN
ajcp-1634	292	29	s.	s.	PROPN
ajcp-1634	292	30	,	,	PUNCT
ajcp-1634	292	31	...	...	PUNCT
ajcp-1634	292	32	&	&	CCONJ
ajcp-1634	292	33	gintsburg	gintsburg	PROPN
ajcp-1634	292	34	,	,	PUNCT
ajcp-1634	292	35	a.	a.	NOUN
ajcp-1634	292	36	l.	l.	PROPN
ajcp-1634	292	37	(	(	PUNCT
ajcp-1634	292	38	2020	2020	NUM
ajcp-1634	292	39	)	)	PUNCT
ajcp-1634	292	40	.	.	PUNCT
ajcp-1634	293	1	safety	safety	NOUN
ajcp-1634	293	2	and	and	CCONJ
ajcp-1634	293	3	immunogenicity	immunogenicity	NOUN
ajcp-1634	293	4	of	of	ADP
ajcp-1634	293	5	an	an	DET
ajcp-1634	293	6	rad26	rad26	PROPN
ajcp-1634	293	7	and	and	CCONJ
ajcp-1634	293	8	rad5	rad5	PROPN
ajcp-1634	293	9	vector	vector	NOUN
ajcp-1634	293	10	-	-	PUNCT
ajcp-1634	293	11	based	base	VERB
ajcp-1634	293	12	heterologous	heterologous	ADJ
ajcp-1634	293	13	prime	prime	ADJ
ajcp-1634	293	14	-	-	PUNCT
ajcp-1634	293	15	boost	boost	NOUN
ajcp-1634	293	16	covid-19	covid-19	PROPN
ajcp-1634	293	17	vaccine	vaccine	NOUN
ajcp-1634	293	18	in	in	ADP
ajcp-1634	293	19	two	two	NUM
ajcp-1634	293	20	formulations	formulation	NOUN
ajcp-1634	293	21	:	:	PUNCT
ajcp-1634	293	22	two	two	NUM
ajcp-1634	293	23	open	open	ADJ
ajcp-1634	293	24	,	,	PUNCT
ajcp-1634	293	25	non	non	ADJ
ajcp-1634	293	26	-	-	ADJ
ajcp-1634	293	27	randomised	randomised	ADJ
ajcp-1634	293	28	phase	phase	NOUN
ajcp-1634	293	29	1/2	1/2	NUM
ajcp-1634	293	30	studies	study	NOUN
ajcp-1634	293	31	from	from	ADP
ajcp-1634	293	32	russia	russia	PROPN
ajcp-1634	293	33	.	.	PUNCT
ajcp-1634	294	1	the	the	DET
ajcp-1634	294	2	lancet	lancet	NOUN
ajcp-1634	294	3	,	,	PUNCT
ajcp-1634	294	4	396(10255	396(10255	NUM
ajcp-1634	294	5	)	)	PUNCT
ajcp-1634	294	6	,	,	PUNCT
ajcp-1634	294	7	887	887	NUM
ajcp-1634	294	8	-	-	SYM
ajcp-1634	294	9	897	897	NUM
ajcp-1634	294	10	.	.	PUNCT
ajcp-1634	295	1	logunov	logunov	PROPN
ajcp-1634	295	2	,	,	PUNCT
ajcp-1634	295	3	d.	d.	PROPN
ajcp-1634	295	4	y.	y.	PROPN
ajcp-1634	295	5	,	,	PUNCT
ajcp-1634	295	6	dolzhikova	dolzhikova	PROPN
ajcp-1634	295	7	,	,	PUNCT
ajcp-1634	295	8	i.	i.	PROPN
ajcp-1634	295	9	v.	v.	PROPN
ajcp-1634	295	10	,	,	PUNCT
ajcp-1634	295	11	shcheblyakov	shcheblyakov	PROPN
ajcp-1634	295	12	,	,	PUNCT
ajcp-1634	295	13	d.	d.	PROPN
ajcp-1634	295	14	v.	v.	PROPN
ajcp-1634	295	15	,	,	PUNCT
ajcp-1634	295	16	tukhvatulin	tukhvatulin	PROPN
ajcp-1634	295	17	,	,	PUNCT
ajcp-1634	295	18	a.	a.	NOUN
ajcp-1634	295	19	i.	i.	PROPN
ajcp-1634	295	20	,	,	PUNCT
ajcp-1634	295	21	zubkova	zubkova	PROPN
ajcp-1634	295	22	,	,	PUNCT
ajcp-1634	295	23	o.	o.	PROPN
ajcp-1634	295	24	v.	v.	PROPN
ajcp-1634	295	25	,	,	PUNCT
ajcp-1634	295	26	dzharullaeva	dzharullaeva	PROPN
ajcp-1634	295	27	,	,	PUNCT
ajcp-1634	295	28	a.	a.	PROPN
ajcp-1634	295	29	s.	s.	PROPN
ajcp-1634	295	30	,	,	PUNCT
ajcp-1634	295	31	...	...	PUNCT
ajcp-1634	295	32	&	&	CCONJ
ajcp-1634	295	33	gam	gam	PROPN
ajcp-1634	295	34	-	-	PUNCT
ajcp-1634	295	35	covid	covid	ADJ
ajcp-1634	295	36	-	-	PUNCT
ajcp-1634	295	37	vac	vac	ADJ
ajcp-1634	295	38	vaccine	vaccine	NOUN
ajcp-1634	295	39	trial	trial	NOUN
ajcp-1634	295	40	group	group	NOUN
ajcp-1634	295	41	.	.	PUNCT
ajcp-1634	296	1	(	(	PUNCT
ajcp-1634	296	2	2021	2021	NUM
ajcp-1634	296	3	)	)	PUNCT
ajcp-1634	296	4	.	.	PUNCT
ajcp-1634	297	1	safety	safety	NOUN
ajcp-1634	297	2	and	and	CCONJ
ajcp-1634	297	3	efficacy	efficacy	NOUN
ajcp-1634	297	4	of	of	ADP
ajcp-1634	297	5	an	an	DET
ajcp-1634	297	6	rad26	rad26	PROPN
ajcp-1634	297	7	and	and	CCONJ
ajcp-1634	297	8	rad5	rad5	PROPN
ajcp-1634	297	9	vectorbased	vectorbase	VERB
ajcp-1634	297	10	heterologous	heterologous	ADJ
ajcp-1634	297	11	prime	prime	ADJ
ajcp-1634	297	12	-	-	PUNCT
ajcp-1634	297	13	boost	boost	NOUN
ajcp-1634	297	14	covid-19	covid-19	PROPN
ajcp-1634	297	15	vaccine	vaccine	NOUN
ajcp-1634	297	16	:	:	PUNCT
ajcp-1634	297	17	an	an	DET
ajcp-1634	297	18	interim	interim	ADJ
ajcp-1634	297	19	analysis	analysis	NOUN
ajcp-1634	297	20	of	of	ADP
ajcp-1634	297	21	a	a	DET
ajcp-1634	297	22	randomised	randomised	ADJ
ajcp-1634	297	23	controlled	control	VERB
ajcp-1634	297	24	phase	phase	NOUN
ajcp-1634	297	25	3	3	NUM
ajcp-1634	297	26	trial	trial	NOUN
ajcp-1634	297	27	in	in	ADP
ajcp-1634	297	28	russia	russia	PROPN
ajcp-1634	297	29	.	.	PUNCT
ajcp-1634	298	1	the	the	DET
ajcp-1634	298	2	lancet	lancet	NOUN
ajcp-1634	298	3	,	,	PUNCT
ajcp-1634	298	4	397(10275	397(10275	NUM
ajcp-1634	298	5	)	)	PUNCT
ajcp-1634	298	6	,	,	PUNCT
ajcp-1634	298	7	671	671	NUM
ajcp-1634	298	8	-	-	SYM
ajcp-1634	298	9	681	681	NUM
ajcp-1634	298	10	.	.	PUNCT
ajcp-1634	299	1	lowe	lowe	PROPN
ajcp-1634	299	2	,	,	PUNCT
ajcp-1634	299	3	j.	j.	PROPN
ajcp-1634	299	4	b.	b.	PROPN
ajcp-1634	299	5	(	(	PUNCT
ajcp-1634	299	6	2002	2002	NUM
ajcp-1634	299	7	)	)	PUNCT
ajcp-1634	299	8	.	.	PUNCT
ajcp-1634	300	1	glycosylation	glycosylation	NOUN
ajcp-1634	300	2	in	in	ADP
ajcp-1634	300	3	the	the	DET
ajcp-1634	300	4	control	control	NOUN
ajcp-1634	300	5	of	of	ADP
ajcp-1634	300	6	selectin	selectin	PROPN
ajcp-1634	300	7	counter	counter	NOUN
ajcp-1634	300	8	-	-	NOUN
ajcp-1634	300	9	receptor	receptor	NOUN
ajcp-1634	300	10	structure	structure	NOUN
ajcp-1634	300	11	and	and	CCONJ
ajcp-1634	300	12	function	function	NOUN
ajcp-1634	300	13	.	.	PUNCT
ajcp-1634	301	1	immunological	immunological	ADJ
ajcp-1634	301	2	reviews	review	NOUN
ajcp-1634	301	3	,	,	PUNCT
ajcp-1634	301	4	186(1	186(1	NUM
ajcp-1634	301	5	)	)	PUNCT
ajcp-1634	301	6	,	,	PUNCT
ajcp-1634	301	7	19	19	NUM
ajcp-1634	301	8	-	-	SYM
ajcp-1634	301	9	36	36	NUM
ajcp-1634	301	10	.	.	PUNCT
ajcp-1634	302	1	lundstrom	lundstrom	PROPN
ajcp-1634	302	2	,	,	PUNCT
ajcp-1634	302	3	k.	k.	PROPN
ajcp-1634	302	4	(	(	PUNCT
ajcp-1634	302	5	2019	2019	NUM
ajcp-1634	302	6	)	)	PUNCT
ajcp-1634	302	7	.	.	PUNCT
ajcp-1634	303	1	rna	rna	NOUN
ajcp-1634	303	2	viruses	virus	NOUN
ajcp-1634	303	3	as	as	ADP
ajcp-1634	303	4	tools	tool	NOUN
ajcp-1634	303	5	in	in	ADP
ajcp-1634	303	6	gene	gene	NOUN
ajcp-1634	303	7	therapy	therapy	NOUN
ajcp-1634	303	8	and	and	CCONJ
ajcp-1634	303	9	vaccine	vaccine	NOUN
ajcp-1634	303	10	development	development	NOUN
ajcp-1634	303	11	.	.	PUNCT
ajcp-1634	304	1	genes	gene	NOUN
ajcp-1634	304	2	,	,	PUNCT
ajcp-1634	304	3	10(3	10(3	NUM
ajcp-1634	304	4	)	)	PUNCT
ajcp-1634	304	5	,	,	PUNCT
ajcp-1634	304	6	189	189	NUM
ajcp-1634	304	7	.	.	PUNCT
ajcp-1634	304	8	lundstrom	lundstrom	PROPN
ajcp-1634	304	9	,	,	PUNCT
ajcp-1634	304	10	k.	k.	PROPN
ajcp-1634	304	11	(	(	PUNCT
ajcp-1634	304	12	2020	2020	NUM
ajcp-1634	304	13	)	)	PUNCT
ajcp-1634	304	14	.	.	PUNCT
ajcp-1634	305	1	application	application	NOUN
ajcp-1634	305	2	of	of	ADP
ajcp-1634	305	3	viral	viral	ADJ
ajcp-1634	305	4	vectors	vector	NOUN
ajcp-1634	305	5	for	for	ADP
ajcp-1634	305	6	vaccine	vaccine	NOUN
ajcp-1634	305	7	development	development	NOUN
ajcp-1634	305	8	with	with	ADP
ajcp-1634	305	9	a	a	DET
ajcp-1634	305	10	special	special	ADJ
ajcp-1634	305	11	emphasis	emphasis	NOUN
ajcp-1634	305	12	on	on	ADP
ajcp-1634	305	13	covid-19	covid-19	PROPN
ajcp-1634	305	14	.	.	PUNCT
ajcp-1634	305	15	viruses	virus	NOUN
ajcp-1634	305	16	,	,	PUNCT
ajcp-1634	305	17	12(11	12(11	NUM
ajcp-1634	305	18	)	)	PUNCT
ajcp-1634	305	19	,	,	PUNCT
ajcp-1634	305	20	1324	1324	NUM
ajcp-1634	305	21	.	.	PUNCT
ajcp-1634	306	1	mcintosh	mcintosh	PROPN
ajcp-1634	306	2	,	,	PUNCT
ajcp-1634	306	3	k.	k.	PROPN
ajcp-1634	306	4	,	,	PUNCT
ajcp-1634	306	5	&	&	CCONJ
ajcp-1634	306	6	peiris	peiris	PROPN
ajcp-1634	306	7	,	,	PUNCT
ajcp-1634	306	8	j.	j.	PROPN
ajcp-1634	306	9	s.	s.	PROPN
ajcp-1634	306	10	m.	m.	PROPN
ajcp-1634	306	11	(	(	PUNCT
ajcp-1634	306	12	2009	2009	NUM
ajcp-1634	306	13	)	)	PUNCT
ajcp-1634	306	14	.	.	PUNCT
ajcp-1634	307	1	coronaviruses	coronaviruse	NOUN
ajcp-1634	307	2	.	.	PUNCT
ajcp-1634	308	1	in	in	ADP
ajcp-1634	308	2	clinical	clinical	ADJ
ajcp-1634	308	3	virology	virology	NOUN
ajcp-1634	308	4	,	,	PUNCT
ajcp-1634	308	5	third	third	ADJ
ajcp-1634	308	6	edition	edition	NOUN
ajcp-1634	308	7	(	(	PUNCT
ajcp-1634	308	8	pp	pp	ADJ
ajcp-1634	308	9	.	.	PUNCT
ajcp-1634	308	10	1155	1155	NUM
ajcp-1634	308	11	-	-	SYM
ajcp-1634	308	12	1171	1171	NUM
ajcp-1634	308	13	)	)	PUNCT
ajcp-1634	308	14	.	.	PUNCT
ajcp-1634	309	1	american	american	ADJ
ajcp-1634	309	2	society	society	NOUN
ajcp-1634	309	3	of	of	ADP
ajcp-1634	309	4	microbiology	microbiology	NOUN
ajcp-1634	309	5	.	.	PUNCT
ajcp-1634	310	1	millet	millet	PROPN
ajcp-1634	310	2	,	,	PUNCT
ajcp-1634	310	3	j.	j.	PROPN
ajcp-1634	310	4	k.	k.	PROPN
ajcp-1634	310	5	,	,	PUNCT
ajcp-1634	310	6	&	&	CCONJ
ajcp-1634	310	7	whittaker	whittaker	PROPN
ajcp-1634	310	8	,	,	PUNCT
ajcp-1634	310	9	g.	g.	PROPN
ajcp-1634	310	10	r.	r.	PROPN
ajcp-1634	310	11	(	(	PUNCT
ajcp-1634	310	12	2015	2015	NUM
ajcp-1634	310	13	)	)	PUNCT
ajcp-1634	310	14	.	.	PUNCT
ajcp-1634	311	1	host	host	NOUN
ajcp-1634	311	2	cell	cell	NOUN
ajcp-1634	311	3	proteases	protease	NOUN
ajcp-1634	311	4	:	:	PUNCT
ajcp-1634	311	5	critical	critical	ADJ
ajcp-1634	311	6	determinants	determinant	NOUN
ajcp-1634	311	7	of	of	ADP
ajcp-1634	311	8	coronavirus	coronavirus	NOUN
ajcp-1634	311	9	tropism	tropism	NOUN
ajcp-1634	311	10	and	and	CCONJ
ajcp-1634	311	11	pathogenesis	pathogenesis	NOUN
ajcp-1634	311	12	.	.	PUNCT
ajcp-1634	312	1	virus	virus	NOUN
ajcp-1634	312	2	research	research	NOUN
ajcp-1634	312	3	,	,	PUNCT
ajcp-1634	312	4	202	202	NUM
ajcp-1634	312	5	,	,	PUNCT
ajcp-1634	312	6	120	120	NUM
ajcp-1634	312	7	-	-	SYM
ajcp-1634	312	8	134	134	NUM
ajcp-1634	312	9	.	.	PUNCT
ajcp-1634	313	1	olson	olson	PROPN
ajcp-1634	313	2	,	,	PUNCT
ajcp-1634	313	3	d.	d.	PROPN
ajcp-1634	313	4	r.	r.	PROPN
ajcp-1634	313	5	,	,	PUNCT
ajcp-1634	313	6	huynh	huynh	PROPN
ajcp-1634	313	7	,	,	PUNCT
ajcp-1634	313	8	m.	m.	NOUN
ajcp-1634	313	9	,	,	PUNCT
ajcp-1634	313	10	fine	fine	INTJ
ajcp-1634	313	11	,	,	PUNCT
ajcp-1634	313	12	a.	a.	NOUN
ajcp-1634	313	13	,	,	PUNCT
ajcp-1634	313	14	baumgartner	baumgartner	PROPN
ajcp-1634	313	15	,	,	PUNCT
ajcp-1634	313	16	j.	j.	PROPN
ajcp-1634	313	17	,	,	PUNCT
ajcp-1634	313	18	castro	castro	PROPN
ajcp-1634	313	19	,	,	PUNCT
ajcp-1634	313	20	a.	a.	PROPN
ajcp-1634	313	21	,	,	PUNCT
ajcp-1634	313	22	chan	chan	PROPN
ajcp-1634	313	23	,	,	PUNCT
ajcp-1634	313	24	h.	h.	PROPN
ajcp-1634	313	25	t.	t.	PROPN
ajcp-1634	313	26	,	,	PUNCT
ajcp-1634	313	27	...	...	PUNCT
ajcp-1634	313	28	&	&	CCONJ
ajcp-1634	313	29	van	van	PROPN
ajcp-1634	313	30	wye	wye	PROPN
ajcp-1634	313	31	,	,	PUNCT
ajcp-1634	313	32	g.	g.	PROPN
ajcp-1634	313	33	(	(	PUNCT
ajcp-1634	313	34	2020	2020	NUM
ajcp-1634	313	35	)	)	PUNCT
ajcp-1634	313	36	.	.	PUNCT
ajcp-1634	314	1	preliminary	preliminary	ADJ
ajcp-1634	314	2	estimate	estimate	NOUN
ajcp-1634	314	3	of	of	ADP
ajcp-1634	314	4	excess	excess	ADJ
ajcp-1634	314	5	mortality	mortality	NOUN
ajcp-1634	314	6	during	during	ADP
ajcp-1634	314	7	the	the	DET
ajcp-1634	314	8	covid-19	covid-19	PROPN
ajcp-1634	314	9	outbreak	outbreak	NOUN
ajcp-1634	314	10	—	—	PUNCT
ajcp-1634	314	11	new	new	PROPN
ajcp-1634	314	12	york	york	PROPN
ajcp-1634	314	13	city	city	PROPN
ajcp-1634	314	14	,	,	PUNCT
ajcp-1634	314	15	march	march	PROPN
ajcp-1634	314	16	11	11	NUM
ajcp-1634	314	17	–	–	PUNCT
ajcp-1634	314	18	may	may	PROPN
ajcp-1634	314	19	2	2	NUM
ajcp-1634	314	20	,	,	PUNCT
ajcp-1634	314	21	2020	2020	NUM
ajcp-1634	314	22	.	.	PUNCT
ajcp-1634	315	1	pardi	pardi	NOUN
ajcp-1634	315	2	,	,	PUNCT
ajcp-1634	315	3	n.	n.	NOUN
ajcp-1634	315	4	,	,	PUNCT
ajcp-1634	315	5	tuyishime	tuyishime	NOUN
ajcp-1634	315	6	,	,	PUNCT
ajcp-1634	315	7	s.	s.	PROPN
ajcp-1634	315	8	,	,	PUNCT
ajcp-1634	315	9	muramatsu	muramatsu	PROPN
ajcp-1634	315	10	,	,	PUNCT
ajcp-1634	315	11	h.	h.	PROPN
ajcp-1634	315	12	,	,	PUNCT
ajcp-1634	315	13	kariko	kariko	NOUN
ajcp-1634	315	14	,	,	PUNCT
ajcp-1634	315	15	k.	k.	PROPN
ajcp-1634	315	16	,	,	PUNCT
ajcp-1634	315	17	mui	mui	PROPN
ajcp-1634	315	18	,	,	PUNCT
ajcp-1634	315	19	b.	b.	PROPN
ajcp-1634	315	20	l.	l.	PROPN
ajcp-1634	315	21	,	,	PUNCT
ajcp-1634	315	22	tam	tam	PROPN
ajcp-1634	315	23	,	,	PUNCT
ajcp-1634	315	24	y.	y.	PROPN
ajcp-1634	315	25	k.	k.	PROPN
ajcp-1634	315	26	,	,	PUNCT
ajcp-1634	315	27	...	...	PUNCT
ajcp-1634	315	28	&	&	CCONJ
ajcp-1634	315	29	weissman	weissman	PROPN
ajcp-1634	315	30	,	,	PUNCT
ajcp-1634	315	31	d.	d.	PROPN
ajcp-1634	315	32	(	(	PUNCT
ajcp-1634	315	33	2015	2015	NUM
ajcp-1634	315	34	)	)	PUNCT
ajcp-1634	315	35	.	.	PUNCT
ajcp-1634	316	1	expression	expression	NOUN
ajcp-1634	316	2	kinetics	kinetic	NOUN
ajcp-1634	316	3	of	of	ADP
ajcp-1634	316	4	nucleoside	nucleoside	NOUN
ajcp-1634	316	5	-	-	PUNCT
ajcp-1634	316	6	modified	modify	VERB
ajcp-1634	316	7	mrna	mrna	NOUN
ajcp-1634	316	8	delivered	deliver	VERB
ajcp-1634	316	9	in	in	ADP
ajcp-1634	316	10	lipid	lipid	ADJ
ajcp-1634	316	11	nanoparticles	nanoparticle	NOUN
ajcp-1634	316	12	to	to	PART
ajcp-1634	316	13	mice	mice	VERB
ajcp-1634	316	14	by	by	ADP
ajcp-1634	316	15	various	various	ADJ
ajcp-1634	316	16	routes	route	NOUN
ajcp-1634	316	17	.	.	PUNCT
ajcp-1634	317	1	journal	journal	PROPN
ajcp-1634	317	2	of	of	ADP
ajcp-1634	317	3	controlled	control	VERB
ajcp-1634	317	4	release	release	NOUN
ajcp-1634	317	5	,	,	PUNCT
ajcp-1634	317	6	217	217	NUM
ajcp-1634	317	7	,	,	PUNCT
ajcp-1634	317	8	345	345	NUM
ajcp-1634	317	9	-	-	SYM
ajcp-1634	317	10	351	351	NUM
ajcp-1634	317	11	.	.	PUNCT
ajcp-1634	318	1	pedersen	pedersen	PROPN
ajcp-1634	318	2	,	,	PUNCT
ajcp-1634	318	3	s.	s.	PROPN
ajcp-1634	318	4	f.	f.	PROPN
ajcp-1634	318	5	,	,	PUNCT
ajcp-1634	318	6	&	&	CCONJ
ajcp-1634	318	7	ho	ho	PROPN
ajcp-1634	318	8	,	,	PUNCT
ajcp-1634	318	9	y.	y.	PROPN
ajcp-1634	318	10	c.	c.	PROPN
ajcp-1634	318	11	(	(	PUNCT
ajcp-1634	318	12	2020	2020	NUM
ajcp-1634	318	13	)	)	PUNCT
ajcp-1634	318	14	.	.	PUNCT
ajcp-1634	319	1	sars	sar	NOUN
ajcp-1634	319	2	-	-	PUNCT
ajcp-1634	319	3	cov-2	cov-2	NUM
ajcp-1634	319	4	:	:	PUNCT
ajcp-1634	319	5	a	a	DET
ajcp-1634	319	6	storm	storm	NOUN
ajcp-1634	319	7	is	be	AUX
ajcp-1634	319	8	raging	rage	VERB
ajcp-1634	319	9	.	.	PUNCT
ajcp-1634	320	1	the	the	DET
ajcp-1634	320	2	journal	journal	NOUN
ajcp-1634	320	3	of	of	ADP
ajcp-1634	320	4	clinical	clinical	ADJ
ajcp-1634	320	5	investigation	investigation	NOUN
ajcp-1634	320	6	,	,	PUNCT
ajcp-1634	320	7	130(5	130(5	NUM
ajcp-1634	320	8	)	)	PUNCT
ajcp-1634	320	9	,	,	PUNCT
ajcp-1634	320	10	22022205	22022205	NUM
ajcp-1634	320	11	.	.	PUNCT
ajcp-1634	321	1	perlman	perlman	NOUN
ajcp-1634	321	2	,	,	PUNCT
ajcp-1634	321	3	s.	s.	PROPN
ajcp-1634	321	4	,	,	PUNCT
ajcp-1634	321	5	&	&	CCONJ
ajcp-1634	321	6	netland	netland	PROPN
ajcp-1634	321	7	,	,	PUNCT
ajcp-1634	321	8	j.	j.	PROPN
ajcp-1634	321	9	(	(	PUNCT
ajcp-1634	321	10	2009	2009	NUM
ajcp-1634	321	11	)	)	PUNCT
ajcp-1634	321	12	.	.	PUNCT
ajcp-1634	322	1	coronaviruses	coronaviruse	NOUN
ajcp-1634	322	2	postsars	postsar	NOUN
ajcp-1634	322	3	:	:	PUNCT
ajcp-1634	322	4	update	update	NOUN
ajcp-1634	322	5	on	on	ADP
ajcp-1634	322	6	coronaviruses	coronaviruse	NOUN
ajcp-1634	322	7	post	post	NOUN
ajcp-1634	322	8	-	-	NOUN
ajcp-1634	322	9	sars	sar	NOUN
ajcp-1634	322	10	:	:	PUNCT
ajcp-1634	322	11	update	update	NOUN
ajcp-1634	322	12	on	on	ADP
ajcp-1634	322	13	.	.	PUNCT
ajcp-1634	323	1	nature	nature	NOUN
ajcp-1634	323	2	reviews	review	VERB
ajcp-1634	323	3	microbiology	microbiology	NOUN
ajcp-1634	323	4	,	,	PUNCT
ajcp-1634	323	5	7(6	7(6	NUM
ajcp-1634	323	6	)	)	PUNCT
ajcp-1634	323	7	,	,	PUNCT
ajcp-1634	323	8	439	439	NUM
ajcp-1634	323	9	-	-	SYM
ajcp-1634	323	10	50	50	NUM
ajcp-1634	323	11	.	.	PUNCT
ajcp-1634	324	1	polack	polack	PROPN
ajcp-1634	324	2	,	,	PUNCT
ajcp-1634	324	3	f.	f.	PROPN
ajcp-1634	324	4	p.	p.	PROPN
ajcp-1634	324	5	,	,	PUNCT
ajcp-1634	324	6	thomas	thomas	PROPN
ajcp-1634	324	7	,	,	PUNCT
ajcp-1634	324	8	s.	s.	PROPN
ajcp-1634	324	9	j.	j.	PROPN
ajcp-1634	324	10	,	,	PUNCT
ajcp-1634	324	11	kitchin	kitchin	PROPN
ajcp-1634	324	12	,	,	PUNCT
ajcp-1634	324	13	n.	n.	NOUN
ajcp-1634	324	14	,	,	PUNCT
ajcp-1634	324	15	absalon	absalon	PROPN
ajcp-1634	324	16	,	,	PUNCT
ajcp-1634	324	17	j.	j.	PROPN
ajcp-1634	324	18	,	,	PUNCT
ajcp-1634	324	19	gurtman	gurtman	NOUN
ajcp-1634	324	20	,	,	PUNCT
ajcp-1634	324	21	a.	a.	NOUN
ajcp-1634	324	22	,	,	PUNCT
ajcp-1634	324	23	lockhart	lockhart	PROPN
ajcp-1634	324	24	,	,	PUNCT
ajcp-1634	324	25	s.	s.	PROPN
ajcp-1634	324	26	,	,	PUNCT
ajcp-1634	324	27	...	...	PUNCT
ajcp-1634	324	28	&	&	CCONJ
ajcp-1634	324	29	gruber	gruber	PROPN
ajcp-1634	324	30	,	,	PUNCT
ajcp-1634	324	31	w.	w.	PROPN
ajcp-1634	324	32	c.	c.	PROPN
ajcp-1634	324	33	(	(	PUNCT
ajcp-1634	324	34	2020	2020	NUM
ajcp-1634	324	35	)	)	PUNCT
ajcp-1634	324	36	.	.	PUNCT
ajcp-1634	325	1	safety	safety	NOUN
ajcp-1634	325	2	and	and	CCONJ
ajcp-1634	325	3	efficacy	efficacy	NOUN
ajcp-1634	325	4	of	of	ADP
ajcp-1634	325	5	the	the	DET
ajcp-1634	325	6	bnt162b2	bnt162b2	PROPN
ajcp-1634	325	7	mrna	mrna	PROPN
ajcp-1634	325	8	covid-19	covid-19	PROPN
ajcp-1634	325	9	vaccine	vaccine	NOUN
ajcp-1634	325	10	.	.	PUNCT
ajcp-1634	326	1	new	new	PROPN
ajcp-1634	326	2	england	england	PROPN
ajcp-1634	326	3	journal	journal	PROPN
ajcp-1634	326	4	of	of	ADP
ajcp-1634	326	5	medicine	medicine	NOUN
ajcp-1634	326	6	.	.	PUNCT
ajcp-1634	327	1	raizada	raizada	PROPN
ajcp-1634	327	2	,	,	PUNCT
ajcp-1634	327	3	m.	m.	PROPN
ajcp-1634	327	4	k.	k.	PROPN
ajcp-1634	327	5	,	,	PUNCT
ajcp-1634	327	6	&	&	CCONJ
ajcp-1634	327	7	ferreira	ferreira	PROPN
ajcp-1634	327	8	,	,	PUNCT
ajcp-1634	327	9	a.	a.	PROPN
ajcp-1634	327	10	j.	j.	PROPN
ajcp-1634	327	11	(	(	PUNCT
ajcp-1634	327	12	2007	2007	NUM
ajcp-1634	327	13	)	)	PUNCT
ajcp-1634	327	14	.	.	PUNCT
ajcp-1634	328	1	ace2	ace2	PROPN
ajcp-1634	328	2	:	:	PUNCT
ajcp-1634	328	3	a	a	DET
ajcp-1634	328	4	new	new	ADJ
ajcp-1634	328	5	target	target	NOUN
ajcp-1634	328	6	for	for	ADP
ajcp-1634	328	7	cardiovascular	cardiovascular	ADJ
ajcp-1634	328	8	disease	disease	NOUN
ajcp-1634	328	9	therapeutics	therapeutic	NOUN
ajcp-1634	328	10	.	.	PUNCT
ajcp-1634	329	1	journal	journal	NOUN
ajcp-1634	329	2	of	of	ADP
ajcp-1634	329	3	cardiovascular	cardiovascular	ADJ
ajcp-1634	329	4	pharmacology	pharmacology	NOUN
ajcp-1634	329	5	,	,	PUNCT
ajcp-1634	329	6	50(2	50(2	NUM
ajcp-1634	329	7	)	)	PUNCT
ajcp-1634	329	8	,	,	PUNCT
ajcp-1634	329	9	112	112	NUM
ajcp-1634	329	10	-	-	SYM
ajcp-1634	329	11	119	119	NUM
ajcp-1634	329	12	.	.	PUNCT
ajcp-1634	330	1	rauch	rauch	PROPN
ajcp-1634	330	2	,	,	PUNCT
ajcp-1634	330	3	s.	s.	PROPN
ajcp-1634	330	4	,	,	PUNCT
ajcp-1634	330	5	jasny	jasny	PROPN
ajcp-1634	330	6	,	,	PUNCT
ajcp-1634	330	7	e.	e.	PROPN
ajcp-1634	330	8	,	,	PUNCT
ajcp-1634	330	9	schmidt	schmidt	PROPN
ajcp-1634	330	10	,	,	PUNCT
ajcp-1634	330	11	k.	k.	PROPN
ajcp-1634	330	12	e.	e.	PROPN
ajcp-1634	330	13	,	,	PUNCT
ajcp-1634	330	14	&	&	CCONJ
ajcp-1634	330	15	petsch	petsch	PROPN
ajcp-1634	330	16	,	,	PUNCT
ajcp-1634	330	17	b.	b.	PROPN
ajcp-1634	330	18	(	(	PUNCT
ajcp-1634	330	19	2018	2018	NUM
ajcp-1634	330	20	)	)	PUNCT
ajcp-1634	330	21	.	.	PUNCT
ajcp-1634	331	1	new	new	ADJ
ajcp-1634	331	2	vaccine	vaccine	NOUN
ajcp-1634	331	3	technologies	technology	NOUN
ajcp-1634	331	4	to	to	PART
ajcp-1634	331	5	combat	combat	VERB
ajcp-1634	331	6	outbreak	outbreak	NOUN
ajcp-1634	331	7	situations	situation	NOUN
ajcp-1634	331	8	.	.	PUNCT
ajcp-1634	332	1	frontiers	frontier	NOUN
ajcp-1634	332	2	in	in	ADP
ajcp-1634	332	3	immunology	immunology	NOUN
ajcp-1634	332	4	,	,	PUNCT
ajcp-1634	332	5	9	9	NUM
ajcp-1634	332	6	,	,	PUNCT
ajcp-1634	332	7	1963	1963	NUM
ajcp-1634	332	8	.	.	PUNCT
ajcp-1634	333	1	reis	reis	NOUN
ajcp-1634	333	2	,	,	PUNCT
ajcp-1634	333	3	c.	c.	PROPN
ajcp-1634	333	4	a.	a.	PROPN
ajcp-1634	333	5	,	,	PUNCT
ajcp-1634	333	6	tauber	tauber	PROPN
ajcp-1634	333	7	,	,	PUNCT
ajcp-1634	333	8	r.	r.	PROPN
ajcp-1634	333	9	,	,	PUNCT
ajcp-1634	333	10	&	&	CCONJ
ajcp-1634	333	11	blanchard	blanchard	PROPN
ajcp-1634	333	12	,	,	PUNCT
ajcp-1634	333	13	v.	v.	PROPN
ajcp-1634	333	14	(	(	PUNCT
ajcp-1634	333	15	2021	2021	NUM
ajcp-1634	333	16	)	)	PUNCT
ajcp-1634	333	17	.	.	PUNCT
ajcp-1634	334	1	glycosylation	glycosylation	NOUN
ajcp-1634	334	2	is	be	AUX
ajcp-1634	334	3	a	a	DET
ajcp-1634	334	4	key	key	NOUN
ajcp-1634	334	5	in	in	ADP
ajcp-1634	334	6	sars	sar	NOUN
ajcp-1634	334	7	-	-	PUNCT
ajcp-1634	334	8	cov-2	cov-2	PART
ajcp-1634	334	9	infection	infection	NOUN
ajcp-1634	334	10	.	.	PUNCT
ajcp-1634	335	1	journal	journal	NOUN
ajcp-1634	335	2	of	of	ADP
ajcp-1634	335	3	molecular	molecular	ADJ
ajcp-1634	335	4	medicine	medicine	NOUN
ajcp-1634	335	5	,	,	PUNCT
ajcp-1634	335	6	1	1	NUM
ajcp-1634	335	7	-	-	SYM
ajcp-1634	335	8	9	9	NUM
ajcp-1634	335	9	.	.	X
ajcp-1634	335	10	robson	robson	PROPN
ajcp-1634	335	11	,	,	PUNCT
ajcp-1634	335	12	b.	b.	PROPN
ajcp-1634	335	13	(	(	PUNCT
ajcp-1634	335	14	2020	2020	NUM
ajcp-1634	335	15	)	)	PUNCT
ajcp-1634	335	16	.	.	PUNCT
ajcp-1634	336	1	bioinformatics	bioinformatic	NOUN
ajcp-1634	336	2	studies	study	NOUN
ajcp-1634	336	3	on	on	ADP
ajcp-1634	336	4	a	a	DET
ajcp-1634	336	5	function	function	NOUN
ajcp-1634	336	6	of	of	ADP
ajcp-1634	336	7	the	the	DET
ajcp-1634	336	8	sars	sar	NOUN
ajcp-1634	336	9	-	-	PUNCT
ajcp-1634	336	10	cov-2	cov-2	NOUN
ajcp-1634	336	11	spike	spike	ADJ
ajcp-1634	336	12	glycoprotein	glycoprotein	NOUN
ajcp-1634	336	13	as	as	ADP
ajcp-1634	336	14	the	the	DET
ajcp-1634	336	15	binding	binding	NOUN
ajcp-1634	336	16	of	of	ADP
ajcp-1634	336	17	host	host	NOUN
ajcp-1634	336	18	sialic	sialic	ADJ
ajcp-1634	336	19	acid	acid	NOUN
ajcp-1634	336	20	glycans	glycan	NOUN
ajcp-1634	336	21	.	.	PUNCT
ajcp-1634	337	1	computers	computer	NOUN
ajcp-1634	337	2	in	in	ADP
ajcp-1634	337	3	biology	biology	NOUN
ajcp-1634	337	4	and	and	CCONJ
ajcp-1634	337	5	medicine	medicine	NOUN
ajcp-1634	337	6	,	,	PUNCT
ajcp-1634	337	7	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	337	8	pa	pa	PROPN
ajcp-1634	337	9	ge	ge	PROPN
ajcp-1634	337	10	73	73	NUM
ajcp-1634	337	11	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1634	337	12	am	be	AUX
ajcp-1634	337	13	.	.	PUNCT
ajcp-1634	338	1	j.	j.	PROPN
ajcp-1634	338	2	chem	chem	PROPN
ajcp-1634	338	3	.	.	PUNCT
ajcp-1634	339	1	pharm	pharm	PROPN
ajcp-1634	339	2	.	.	PUNCT
ajcp-1634	340	1	2(2	2(2	NUM
ajcp-1634	340	2	)	)	PUNCT
ajcp-1634	341	1	66	66	NUM
ajcp-1634	341	2	-	-	SYM
ajcp-1634	341	3	73	73	NUM
ajcp-1634	341	4	,	,	PUNCT
ajcp-1634	341	5	2023	2023	NUM
ajcp-1634	341	6	122	122	NUM
ajcp-1634	341	7	,	,	PUNCT
ajcp-1634	341	8	103849	103849	NUM
ajcp-1634	341	9	.	.	PUNCT
ajcp-1634	342	1	sadarangani	sadarangani	PROPN
ajcp-1634	342	2	,	,	PUNCT
ajcp-1634	342	3	m.	m.	NOUN
ajcp-1634	342	4	,	,	PUNCT
ajcp-1634	342	5	marchant	marchant	NOUN
ajcp-1634	342	6	,	,	PUNCT
ajcp-1634	342	7	a.	a.	PROPN
ajcp-1634	342	8	,	,	PUNCT
ajcp-1634	342	9	&	&	CCONJ
ajcp-1634	342	10	kollmann	kollmann	PROPN
ajcp-1634	342	11	,	,	PUNCT
ajcp-1634	342	12	t.	t.	PROPN
ajcp-1634	342	13	r.	r.	PROPN
ajcp-1634	342	14	(	(	PUNCT
ajcp-1634	342	15	2021	2021	NUM
ajcp-1634	342	16	)	)	PUNCT
ajcp-1634	342	17	.	.	PUNCT
ajcp-1634	343	1	immunological	immunological	ADJ
ajcp-1634	343	2	mechanisms	mechanism	NOUN
ajcp-1634	343	3	of	of	ADP
ajcp-1634	343	4	vaccine	vaccine	NOUN
ajcp-1634	343	5	-	-	PUNCT
ajcp-1634	343	6	induced	induce	VERB
ajcp-1634	343	7	protection	protection	NOUN
ajcp-1634	343	8	against	against	ADP
ajcp-1634	343	9	covid-19	covid-19	PROPN
ajcp-1634	343	10	in	in	ADP
ajcp-1634	343	11	humans	human	NOUN
ajcp-1634	343	12	.	.	PUNCT
ajcp-1634	344	1	nature	nature	NOUN
ajcp-1634	344	2	reviews	review	VERB
ajcp-1634	344	3	immunology	immunology	NOUN
ajcp-1634	344	4	,	,	PUNCT
ajcp-1634	344	5	1	1	NUM
ajcp-1634	344	6	-	-	SYM
ajcp-1634	344	7	10	10	NUM
ajcp-1634	344	8	.	.	PUNCT
ajcp-1634	345	1	sadoff	sadoff	NOUN
ajcp-1634	345	2	,	,	PUNCT
ajcp-1634	345	3	j.	j.	PROPN
ajcp-1634	345	4	,	,	PUNCT
ajcp-1634	345	5	le	le	X
ajcp-1634	345	6	gars	gars	PROPN
ajcp-1634	345	7	,	,	PUNCT
ajcp-1634	345	8	m.	m.	NOUN
ajcp-1634	345	9	,	,	PUNCT
ajcp-1634	345	10	shukarev	shukarev	PROPN
ajcp-1634	345	11	,	,	PUNCT
ajcp-1634	345	12	g.	g.	PROPN
ajcp-1634	345	13	,	,	PUNCT
ajcp-1634	345	14	heerwegh	heerwegh	PROPN
ajcp-1634	345	15	,	,	PUNCT
ajcp-1634	345	16	d.	d.	PROPN
ajcp-1634	345	17	,	,	PUNCT
ajcp-1634	345	18	truyers	truyer	NOUN
ajcp-1634	345	19	,	,	PUNCT
ajcp-1634	345	20	c.	c.	NOUN
ajcp-1634	345	21	,	,	PUNCT
ajcp-1634	345	22	de	de	X
ajcp-1634	345	23	groot	groot	PROPN
ajcp-1634	345	24	,	,	PUNCT
ajcp-1634	345	25	a.	a.	NOUN
ajcp-1634	345	26	m.	m.	NOUN
ajcp-1634	345	27	,	,	PUNCT
ajcp-1634	345	28	...	...	PUNCT
ajcp-1634	345	29	&	&	CCONJ
ajcp-1634	345	30	schuitemaker	schuitemaker	PROPN
ajcp-1634	345	31	,	,	PUNCT
ajcp-1634	345	32	h.	h.	PROPN
ajcp-1634	345	33	(	(	PUNCT
ajcp-1634	345	34	2021	2021	NUM
ajcp-1634	345	35	)	)	PUNCT
ajcp-1634	345	36	.	.	PUNCT
ajcp-1634	346	1	interim	interim	ADJ
ajcp-1634	346	2	results	result	NOUN
ajcp-1634	346	3	of	of	ADP
ajcp-1634	346	4	a	a	DET
ajcp-1634	346	5	phase	phase	NOUN
ajcp-1634	346	6	1–2a	1–2a	NUM
ajcp-1634	346	7	trial	trial	NOUN
ajcp-1634	346	8	of	of	ADP
ajcp-1634	346	9	ad26	ad26	PROPN
ajcp-1634	346	10	.	.	PUNCT
ajcp-1634	347	1	cov2	cov2	PROPN
ajcp-1634	347	2	.	.	PUNCT
ajcp-1634	348	1	s	s	PART
ajcp-1634	348	2	covid-19	covid-19	PROPN
ajcp-1634	348	3	vaccine	vaccine	NOUN
ajcp-1634	348	4	.	.	PUNCT
ajcp-1634	349	1	new	new	PROPN
ajcp-1634	349	2	england	england	PROPN
ajcp-1634	349	3	journal	journal	PROPN
ajcp-1634	349	4	of	of	ADP
ajcp-1634	349	5	medicine	medicine	NOUN
ajcp-1634	349	6	,	,	PUNCT
ajcp-1634	349	7	384(19	384(19	NUM
ajcp-1634	349	8	)	)	PUNCT
ajcp-1634	349	9	,	,	PUNCT
ajcp-1634	349	10	1824	1824	NUM
ajcp-1634	349	11	-	-	SYM
ajcp-1634	349	12	1835	1835	NUM
ajcp-1634	349	13	.	.	PUNCT
ajcp-1634	350	1	schoeman	schoeman	PROPN
ajcp-1634	350	2	,	,	PUNCT
ajcp-1634	350	3	d.	d.	PROPN
ajcp-1634	350	4	,	,	PUNCT
ajcp-1634	350	5	&	&	CCONJ
ajcp-1634	350	6	fielding	fielding	PROPN
ajcp-1634	350	7	,	,	PUNCT
ajcp-1634	350	8	b.	b.	PROPN
ajcp-1634	350	9	c.	c.	PROPN
ajcp-1634	350	10	(	(	PUNCT
ajcp-1634	350	11	2019	2019	NUM
ajcp-1634	350	12	)	)	PUNCT
ajcp-1634	350	13	.	.	PUNCT
ajcp-1634	351	1	coronavirus	coronavirus	NOUN
ajcp-1634	351	2	envelope	envelope	NOUN
ajcp-1634	351	3	protein	protein	NOUN
ajcp-1634	351	4	:	:	PUNCT
ajcp-1634	351	5	current	current	ADJ
ajcp-1634	351	6	knowledge	knowledge	NOUN
ajcp-1634	351	7	.	.	PUNCT
ajcp-1634	352	1	virology	virology	NOUN
ajcp-1634	352	2	journal	journal	PROPN
ajcp-1634	352	3	,	,	PUNCT
ajcp-1634	352	4	16(1	16(1	NUM
ajcp-1634	352	5	)	)	PUNCT
ajcp-1634	352	6	,	,	PUNCT
ajcp-1634	352	7	1	1	NUM
ajcp-1634	352	8	-	-	SYM
ajcp-1634	352	9	22	22	NUM
ajcp-1634	352	10	.	.	PUNCT
ajcp-1634	353	1	shajahan	shajahan	PROPN
ajcp-1634	353	2	,	,	PUNCT
ajcp-1634	353	3	a.	a.	PROPN
ajcp-1634	353	4	,	,	PUNCT
ajcp-1634	353	5	pepi	pepi	PROPN
ajcp-1634	353	6	,	,	PUNCT
ajcp-1634	353	7	l.	l.	PROPN
ajcp-1634	353	8	e.	e.	PROPN
ajcp-1634	353	9	,	,	PUNCT
ajcp-1634	353	10	rouhani	rouhani	PROPN
ajcp-1634	353	11	,	,	PUNCT
ajcp-1634	353	12	d.	d.	PROPN
ajcp-1634	353	13	s.	s.	PROPN
ajcp-1634	353	14	,	,	PUNCT
ajcp-1634	353	15	heiss	heiss	PROPN
ajcp-1634	353	16	,	,	PUNCT
ajcp-1634	353	17	c.	c.	PROPN
ajcp-1634	353	18	,	,	PUNCT
ajcp-1634	353	19	&	&	CCONJ
ajcp-1634	353	20	azadi	azadi	PROPN
ajcp-1634	353	21	,	,	PUNCT
ajcp-1634	353	22	p.	p.	NOUN
ajcp-1634	353	23	(	(	PUNCT
ajcp-1634	353	24	2021	2021	NUM
ajcp-1634	353	25	)	)	PUNCT
ajcp-1634	353	26	.	.	PUNCT
ajcp-1634	354	1	glycosylation	glycosylation	NOUN
ajcp-1634	354	2	of	of	ADP
ajcp-1634	354	3	sars	sar	NOUN
ajcp-1634	354	4	-	-	PUNCT
ajcp-1634	354	5	cov-2	cov-2	NOUN
ajcp-1634	354	6	:	:	PUNCT
ajcp-1634	354	7	structural	structural	ADJ
ajcp-1634	354	8	and	and	CCONJ
ajcp-1634	354	9	functional	functional	ADJ
ajcp-1634	354	10	insights	insight	NOUN
ajcp-1634	354	11	.	.	PUNCT
ajcp-1634	355	1	analytical	analytical	ADJ
ajcp-1634	355	2	and	and	CCONJ
ajcp-1634	355	3	bioanalytical	bioanalytical	ADJ
ajcp-1634	355	4	chemistry	chemistry	NOUN
ajcp-1634	355	5	,	,	PUNCT
ajcp-1634	355	6	1	1	NUM
ajcp-1634	355	7	-	-	SYM
ajcp-1634	355	8	15	15	NUM
ajcp-1634	355	9	.	.	PUNCT
ajcp-1634	356	1	simmons	simmon	NOUN
ajcp-1634	356	2	,	,	PUNCT
ajcp-1634	356	3	g.	g.	PROPN
ajcp-1634	356	4	,	,	PUNCT
ajcp-1634	356	5	reeves	reeves	PROPN
ajcp-1634	356	6	,	,	PUNCT
ajcp-1634	356	7	j.	j.	PROPN
ajcp-1634	356	8	d.	d.	PROPN
ajcp-1634	356	9	,	,	PUNCT
ajcp-1634	356	10	rennekamp	rennekamp	PROPN
ajcp-1634	356	11	,	,	PUNCT
ajcp-1634	356	12	a.	a.	PROPN
ajcp-1634	356	13	j.	j.	PROPN
ajcp-1634	356	14	,	,	PUNCT
ajcp-1634	356	15	amberg	amberg	PROPN
ajcp-1634	356	16	,	,	PUNCT
ajcp-1634	356	17	s.	s.	PROPN
ajcp-1634	356	18	m.	m.	PROPN
ajcp-1634	356	19	,	,	PUNCT
ajcp-1634	356	20	piefer	piefer	VERB
ajcp-1634	356	21	,	,	PUNCT
ajcp-1634	356	22	a.	a.	PROPN
ajcp-1634	356	23	j.	j.	PROPN
ajcp-1634	356	24	,	,	PUNCT
ajcp-1634	356	25	&	&	CCONJ
ajcp-1634	356	26	bates	bates	PROPN
ajcp-1634	356	27	,	,	PUNCT
ajcp-1634	356	28	p.	p.	NOUN
ajcp-1634	356	29	(	(	PUNCT
ajcp-1634	356	30	2004	2004	NUM
ajcp-1634	356	31	)	)	PUNCT
ajcp-1634	356	32	.	.	PUNCT
ajcp-1634	357	1	characterization	characterization	NOUN
ajcp-1634	357	2	of	of	ADP
ajcp-1634	357	3	severe	severe	ADJ
ajcp-1634	357	4	acute	acute	ADJ
ajcp-1634	357	5	respiratory	respiratory	ADJ
ajcp-1634	357	6	syndrome	syndrome	NOUN
ajcp-1634	357	7	-	-	PUNCT
ajcp-1634	357	8	associated	associate	VERB
ajcp-1634	357	9	coronavirus	coronavirus	NOUN
ajcp-1634	357	10	(	(	PUNCT
ajcp-1634	357	11	sars	sars	NOUN
ajcp-1634	357	12	-	-	PUNCT
ajcp-1634	357	13	cov	cov	NOUN
ajcp-1634	357	14	)	)	PUNCT
ajcp-1634	357	15	spike	spike	ADJ
ajcp-1634	357	16	glycoprotein	glycoprotein	NOUN
ajcp-1634	357	17	-	-	PUNCT
ajcp-1634	357	18	mediated	mediate	VERB
ajcp-1634	357	19	viral	viral	ADJ
ajcp-1634	357	20	entry	entry	NOUN
ajcp-1634	357	21	.	.	PUNCT
ajcp-1634	358	1	proceedings	proceeding	NOUN
ajcp-1634	358	2	of	of	ADP
ajcp-1634	358	3	the	the	DET
ajcp-1634	358	4	national	national	PROPN
ajcp-1634	358	5	academy	academy	PROPN
ajcp-1634	358	6	of	of	ADP
ajcp-1634	358	7	sciences	sciences	PROPN
ajcp-1634	358	8	,	,	PUNCT
ajcp-1634	358	9	101(12	101(12	NUM
ajcp-1634	358	10	)	)	PUNCT
ajcp-1634	358	11	,	,	PUNCT
ajcp-1634	358	12	4240	4240	NUM
ajcp-1634	358	13	-	-	SYM
ajcp-1634	358	14	4245	4245	NUM
ajcp-1634	358	15	.	.	PUNCT
ajcp-1634	359	1	simmons	simmon	NOUN
ajcp-1634	359	2	,	,	PUNCT
ajcp-1634	359	3	g.	g.	PROPN
ajcp-1634	359	4	,	,	PUNCT
ajcp-1634	359	5	gosalia	gosalia	PROPN
ajcp-1634	359	6	,	,	PUNCT
ajcp-1634	359	7	d.	d.	PROPN
ajcp-1634	359	8	n.	n.	PROPN
ajcp-1634	359	9	,	,	PUNCT
ajcp-1634	359	10	rennekamp	rennekamp	PROPN
ajcp-1634	359	11	,	,	PUNCT
ajcp-1634	359	12	a.	a.	PROPN
ajcp-1634	359	13	j.	j.	PROPN
ajcp-1634	359	14	,	,	PUNCT
ajcp-1634	359	15	reeves	reeves	PROPN
ajcp-1634	359	16	,	,	PUNCT
ajcp-1634	359	17	j.	j.	PROPN
ajcp-1634	359	18	d.	d.	PROPN
ajcp-1634	359	19	,	,	PUNCT
ajcp-1634	359	20	diamond	diamond	PROPN
ajcp-1634	359	21	,	,	PUNCT
ajcp-1634	359	22	s.	s.	PROPN
ajcp-1634	359	23	l.	l.	PROPN
ajcp-1634	359	24	,	,	PUNCT
ajcp-1634	359	25	&	&	CCONJ
ajcp-1634	359	26	bates	bates	PROPN
ajcp-1634	359	27	,	,	PUNCT
ajcp-1634	359	28	p.	p.	NOUN
ajcp-1634	359	29	(	(	PUNCT
ajcp-1634	359	30	2005	2005	NUM
ajcp-1634	359	31	)	)	PUNCT
ajcp-1634	359	32	.	.	PUNCT
ajcp-1634	360	1	inhibitors	inhibitor	NOUN
ajcp-1634	360	2	of	of	ADP
ajcp-1634	360	3	cathepsin	cathepsin	NOUN
ajcp-1634	360	4	l	l	PROPN
ajcp-1634	360	5	prevent	prevent	VERB
ajcp-1634	360	6	severe	severe	ADJ
ajcp-1634	360	7	acute	acute	ADJ
ajcp-1634	360	8	respiratory	respiratory	ADJ
ajcp-1634	360	9	syndrome	syndrome	NOUN
ajcp-1634	360	10	coronavirus	coronavirus	NOUN
ajcp-1634	360	11	entry	entry	NOUN
ajcp-1634	360	12	.	.	PUNCT
ajcp-1634	361	1	proceedings	proceeding	NOUN
ajcp-1634	361	2	of	of	ADP
ajcp-1634	361	3	the	the	DET
ajcp-1634	361	4	national	national	PROPN
ajcp-1634	361	5	academy	academy	PROPN
ajcp-1634	361	6	of	of	ADP
ajcp-1634	361	7	sciences	sciences	PROPN
ajcp-1634	361	8	,	,	PUNCT
ajcp-1634	361	9	102(33	102(33	NUM
ajcp-1634	361	10	)	)	PUNCT
ajcp-1634	361	11	,	,	PUNCT
ajcp-1634	361	12	11876	11876	NUM
ajcp-1634	361	13	-	-	SYM
ajcp-1634	361	14	11881	11881	NUM
ajcp-1634	361	15	.	.	PUNCT
ajcp-1634	362	1	simmons	simmon	NOUN
ajcp-1634	362	2	,	,	PUNCT
ajcp-1634	362	3	g.	g.	PROPN
ajcp-1634	362	4	,	,	PUNCT
ajcp-1634	362	5	zmora	zmora	PROPN
ajcp-1634	362	6	,	,	PUNCT
ajcp-1634	362	7	p.	p.	NOUN
ajcp-1634	362	8	,	,	PUNCT
ajcp-1634	362	9	gierer	gierer	NOUN
ajcp-1634	362	10	,	,	PUNCT
ajcp-1634	362	11	s.	s.	PROPN
ajcp-1634	362	12	,	,	PUNCT
ajcp-1634	362	13	heurich	heurich	PROPN
ajcp-1634	362	14	,	,	PUNCT
ajcp-1634	362	15	a.	a.	PROPN
ajcp-1634	362	16	,	,	PUNCT
ajcp-1634	362	17	&	&	CCONJ
ajcp-1634	362	18	pöhlmann	pöhlmann	PROPN
ajcp-1634	362	19	,	,	PUNCT
ajcp-1634	362	20	s.	s.	PROPN
ajcp-1634	362	21	(	(	PUNCT
ajcp-1634	362	22	2013	2013	NUM
ajcp-1634	362	23	)	)	PUNCT
ajcp-1634	362	24	.	.	PUNCT
ajcp-1634	363	1	proteolytic	proteolytic	ADJ
ajcp-1634	363	2	activation	activation	NOUN
ajcp-1634	363	3	of	of	ADP
ajcp-1634	363	4	the	the	DET
ajcp-1634	363	5	sars	sar	NOUN
ajcp-1634	363	6	-	-	PUNCT
ajcp-1634	363	7	coronavirus	coronavirus	NOUN
ajcp-1634	363	8	spike	spike	ADJ
ajcp-1634	363	9	protein	protein	NOUN
ajcp-1634	363	10	:	:	PUNCT
ajcp-1634	363	11	cutting	cut	VERB
ajcp-1634	363	12	enzymes	enzyme	NOUN
ajcp-1634	363	13	at	at	ADP
ajcp-1634	363	14	the	the	DET
ajcp-1634	363	15	cutting	cut	VERB
ajcp-1634	363	16	edge	edge	NOUN
ajcp-1634	363	17	of	of	ADP
ajcp-1634	363	18	antiviral	antiviral	ADJ
ajcp-1634	363	19	research	research	NOUN
ajcp-1634	363	20	.	.	PUNCT
ajcp-1634	364	1	antiviral	antiviral	ADJ
ajcp-1634	364	2	research	research	NOUN
ajcp-1634	364	3	,	,	PUNCT
ajcp-1634	364	4	100(3	100(3	NUM
ajcp-1634	364	5	)	)	PUNCT
ajcp-1634	364	6	,	,	PUNCT
ajcp-1634	364	7	605	605	NUM
ajcp-1634	364	8	-	-	SYM
ajcp-1634	364	9	614	614	NUM
ajcp-1634	364	10	.	.	PUNCT
ajcp-1634	365	1	song	song	PROPN
ajcp-1634	365	2	,	,	PUNCT
ajcp-1634	365	3	w.	w.	PROPN
ajcp-1634	365	4	,	,	PUNCT
ajcp-1634	365	5	gui	gui	PROPN
ajcp-1634	365	6	,	,	PUNCT
ajcp-1634	365	7	m.	m.	NOUN
ajcp-1634	365	8	,	,	PUNCT
ajcp-1634	365	9	wang	wang	PROPN
ajcp-1634	365	10	,	,	PUNCT
ajcp-1634	365	11	x.	x.	PROPN
ajcp-1634	365	12	,	,	PUNCT
ajcp-1634	365	13	&	&	CCONJ
ajcp-1634	365	14	xiang	xiang	PROPN
ajcp-1634	365	15	,	,	PUNCT
ajcp-1634	365	16	y.	y.	PROPN
ajcp-1634	365	17	(	(	PUNCT
ajcp-1634	365	18	2018	2018	NUM
ajcp-1634	365	19	)	)	PUNCT
ajcp-1634	365	20	.	.	PUNCT
ajcp-1634	366	1	cryo	cryo	PROPN
ajcp-1634	366	2	-	-	PUNCT
ajcp-1634	366	3	em	em	PRON
ajcp-1634	366	4	structure	structure	NOUN
ajcp-1634	366	5	of	of	ADP
ajcp-1634	366	6	the	the	DET
ajcp-1634	366	7	sars	sars	PROPN
ajcp-1634	366	8	coronavirus	coronavirus	PROPN
ajcp-1634	366	9	spike	spike	ADJ
ajcp-1634	366	10	glycoprotein	glycoprotein	NOUN
ajcp-1634	366	11	in	in	ADP
ajcp-1634	366	12	complex	complex	NOUN
ajcp-1634	366	13	with	with	ADP
ajcp-1634	366	14	its	its	PRON
ajcp-1634	366	15	host	host	NOUN
ajcp-1634	366	16	cell	cell	NOUN
ajcp-1634	366	17	receptor	receptor	NOUN
ajcp-1634	366	18	ace2	ace2	PROPN
ajcp-1634	366	19	.	.	PUNCT
ajcp-1634	367	1	plos	plos	PROPN
ajcp-1634	367	2	pathogens	pathogen	NOUN
ajcp-1634	367	3	,	,	PUNCT
ajcp-1634	367	4	14(8	14(8	ADV
ajcp-1634	367	5	)	)	PUNCT
ajcp-1634	367	6	,	,	PUNCT
ajcp-1634	367	7	e1007236	e1007236	PROPN
ajcp-1634	367	8	.	.	PROPN
ajcp-1634	367	9	sternberg	sternberg	PROPN
ajcp-1634	367	10	,	,	PUNCT
ajcp-1634	367	11	a.	a.	PROPN
ajcp-1634	367	12	,	,	PUNCT
ajcp-1634	367	13	&	&	CCONJ
ajcp-1634	367	14	naujokat	naujokat	PROPN
ajcp-1634	367	15	,	,	PUNCT
ajcp-1634	367	16	c.	c.	PROPN
ajcp-1634	367	17	(	(	PUNCT
ajcp-1634	367	18	2020	2020	NUM
ajcp-1634	367	19	)	)	PUNCT
ajcp-1634	367	20	.	.	PUNCT
ajcp-1634	368	1	structural	structural	ADJ
ajcp-1634	368	2	features	feature	NOUN
ajcp-1634	368	3	of	of	ADP
ajcp-1634	368	4	coronavirus	coronavirus	NOUN
ajcp-1634	368	5	sars	sar	NOUN
ajcp-1634	368	6	-	-	PUNCT
ajcp-1634	368	7	cov-2	cov-2	NOUN
ajcp-1634	368	8	spike	spike	ADJ
ajcp-1634	368	9	protein	protein	NOUN
ajcp-1634	368	10	:	:	PUNCT
ajcp-1634	368	11	targets	target	NOUN
ajcp-1634	368	12	for	for	ADP
ajcp-1634	368	13	vaccination	vaccination	NOUN
ajcp-1634	368	14	.	.	PUNCT
ajcp-1634	369	1	life	life	NOUN
ajcp-1634	369	2	sciences	sciences	PROPN
ajcp-1634	369	3	,	,	PUNCT
ajcp-1634	369	4	118056	118056	NUM
ajcp-1634	369	5	.	.	PUNCT
ajcp-1634	370	1	tortorici	tortorici	PROPN
ajcp-1634	370	2	,	,	PUNCT
ajcp-1634	370	3	m.	m.	NOUN
ajcp-1634	370	4	a.	a.	PROPN
ajcp-1634	370	5	,	,	PUNCT
ajcp-1634	370	6	walls	wall	NOUN
ajcp-1634	370	7	,	,	PUNCT
ajcp-1634	370	8	a.	a.	PROPN
ajcp-1634	370	9	c.	c.	PROPN
ajcp-1634	370	10	,	,	PUNCT
ajcp-1634	370	11	lang	lang	PROPN
ajcp-1634	370	12	,	,	PUNCT
ajcp-1634	370	13	y.	y.	PROPN
ajcp-1634	370	14	,	,	PUNCT
ajcp-1634	370	15	wang	wang	PROPN
ajcp-1634	370	16	,	,	PUNCT
ajcp-1634	370	17	c.	c.	PROPN
ajcp-1634	370	18	,	,	PUNCT
ajcp-1634	370	19	li	li	PROPN
ajcp-1634	370	20	,	,	PUNCT
ajcp-1634	370	21	z.	z.	PROPN
ajcp-1634	370	22	,	,	PUNCT
ajcp-1634	370	23	koerhuis	koerhuis	PROPN
ajcp-1634	370	24	,	,	PUNCT
ajcp-1634	370	25	d.	d.	PROPN
ajcp-1634	370	26	,	,	PUNCT
ajcp-1634	370	27	&	&	CCONJ
ajcp-1634	370	28	veesler	veesler	PROPN
ajcp-1634	370	29	,	,	PUNCT
ajcp-1634	370	30	d.	d.	PROPN
ajcp-1634	370	31	(	(	PUNCT
ajcp-1634	370	32	2019	2019	NUM
ajcp-1634	370	33	)	)	PUNCT
ajcp-1634	370	34	.	.	PUNCT
ajcp-1634	371	1	structural	structural	ADJ
ajcp-1634	371	2	basis	basis	NOUN
ajcp-1634	371	3	for	for	ADP
ajcp-1634	371	4	human	human	ADJ
ajcp-1634	371	5	coronavirus	coronavirus	NOUN
ajcp-1634	371	6	attachment	attachment	NOUN
ajcp-1634	371	7	to	to	ADP
ajcp-1634	371	8	sialic	sialic	ADJ
ajcp-1634	371	9	acid	acid	NOUN
ajcp-1634	371	10	receptors	receptor	NOUN
ajcp-1634	371	11	.	.	PUNCT
ajcp-1634	372	1	nature	nature	NOUN
ajcp-1634	372	2	structural	structural	ADJ
ajcp-1634	372	3	&	&	CCONJ
ajcp-1634	372	4	molecular	molecular	ADJ
ajcp-1634	372	5	biology	biology	NOUN
ajcp-1634	372	6	,	,	PUNCT
ajcp-1634	372	7	26(6	26(6	NUM
ajcp-1634	372	8	)	)	PUNCT
ajcp-1634	372	9	,	,	PUNCT
ajcp-1634	372	10	481	481	NUM
ajcp-1634	372	11	-	-	SYM
ajcp-1634	372	12	489	489	NUM
ajcp-1634	372	13	.	.	PUNCT
ajcp-1634	373	1	verma	verma	PROPN
ajcp-1634	373	2	,	,	PUNCT
ajcp-1634	373	3	s.	s.	PROPN
ajcp-1634	373	4	(	(	PUNCT
ajcp-1634	373	5	2020	2020	NUM
ajcp-1634	373	6	)	)	PUNCT
ajcp-1634	373	7	.	.	PUNCT
ajcp-1634	374	1	the	the	DET
ajcp-1634	374	2	sialoside	sialoside	ADV
ajcp-1634	374	3	-	-	PUNCT
ajcp-1634	374	4	binding	bind	VERB
ajcp-1634	374	5	pocket	pocket	NOUN
ajcp-1634	374	6	of	of	ADP
ajcp-1634	374	7	sarscov-2	sarscov-2	NUM
ajcp-1634	374	8	spike	spike	ADJ
ajcp-1634	374	9	glycoprotein	glycoprotein	NOUN
ajcp-1634	374	10	structurally	structurally	ADV
ajcp-1634	374	11	resembles	resemble	VERB
ajcp-1634	374	12	mers	mer	NOUN
ajcp-1634	374	13	-	-	PUNCT
ajcp-1634	374	14	cov	cov	NOUN
ajcp-1634	374	15	.	.	PUNCT
ajcp-1634	375	1	vlasova	vlasova	PROPN
ajcp-1634	375	2	,	,	PUNCT
ajcp-1634	375	3	a.	a.	PROPN
ajcp-1634	375	4	n.	n.	PROPN
ajcp-1634	375	5	,	,	PUNCT
ajcp-1634	375	6	zhang	zhang	PROPN
ajcp-1634	375	7	,	,	PUNCT
ajcp-1634	375	8	x.	x.	PROPN
ajcp-1634	375	9	,	,	PUNCT
ajcp-1634	375	10	hasoksuz	hasoksuz	PROPN
ajcp-1634	375	11	,	,	PUNCT
ajcp-1634	375	12	m.	m.	NOUN
ajcp-1634	375	13	,	,	PUNCT
ajcp-1634	375	14	nagesha	nagesha	PROPN
ajcp-1634	375	15	,	,	PUNCT
ajcp-1634	375	16	h.	h.	PROPN
ajcp-1634	375	17	s.	s.	PROPN
ajcp-1634	375	18	,	,	PUNCT
ajcp-1634	375	19	haynes	haynes	PROPN
ajcp-1634	375	20	,	,	PUNCT
ajcp-1634	375	21	l.	l.	PROPN
ajcp-1634	375	22	m.	m.	PROPN
ajcp-1634	375	23	,	,	PUNCT
ajcp-1634	375	24	fang	fang	PROPN
ajcp-1634	375	25	,	,	PUNCT
ajcp-1634	375	26	y.	y.	PROPN
ajcp-1634	375	27	,	,	PUNCT
ajcp-1634	375	28	...	...	PUNCT
ajcp-1634	375	29	&	&	CCONJ
ajcp-1634	375	30	saif	saif	PROPN
ajcp-1634	375	31	,	,	PUNCT
ajcp-1634	375	32	l.	l.	PROPN
ajcp-1634	375	33	j.	j.	PROPN
ajcp-1634	375	34	(	(	PUNCT
ajcp-1634	375	35	2007	2007	NUM
ajcp-1634	375	36	)	)	PUNCT
ajcp-1634	375	37	.	.	PUNCT
ajcp-1634	376	1	two	two	NUM
ajcp-1634	376	2	-	-	PUNCT
ajcp-1634	376	3	way	way	NOUN
ajcp-1634	376	4	antigenic	antigenic	ADJ
ajcp-1634	376	5	cross	cross	NOUN
ajcp-1634	376	6	-	-	NOUN
ajcp-1634	376	7	reactivity	reactivity	NOUN
ajcp-1634	376	8	between	between	ADP
ajcp-1634	376	9	sars	sar	NOUN
ajcp-1634	376	10	-	-	PUNCT
ajcp-1634	376	11	coronavirus	coronavirus	NOUN
ajcp-1634	376	12	(	(	PUNCT
ajcp-1634	376	13	cov	cov	NOUN
ajcp-1634	376	14	)	)	PUNCT
ajcp-1634	376	15	and	and	CCONJ
ajcp-1634	376	16	group	group	NOUN
ajcp-1634	376	17	1	1	NUM
ajcp-1634	376	18	animal	animal	NOUN
ajcp-1634	376	19	covs	covs	NOUN
ajcp-1634	376	20	is	be	AUX
ajcp-1634	376	21	mediated	mediate	VERB
ajcp-1634	376	22	through	through	ADP
ajcp-1634	376	23	an	an	DET
ajcp-1634	376	24	antigenic	antigenic	ADJ
ajcp-1634	376	25	site	site	NOUN
ajcp-1634	376	26	in	in	ADP
ajcp-1634	376	27	the	the	DET
ajcp-1634	376	28	n	n	CCONJ
ajcp-1634	376	29	-	-	PUNCT
ajcp-1634	376	30	terminal	terminal	ADJ
ajcp-1634	376	31	region	region	NOUN
ajcp-1634	376	32	of	of	ADP
ajcp-1634	376	33	the	the	DET
ajcp-1634	376	34	sarscov	sarscov	PROPN
ajcp-1634	376	35	nucleoprotein	nucleoprotein	PROPN
ajcp-1634	376	36	.	.	PUNCT
ajcp-1634	377	1	journal	journal	PROPN
ajcp-1634	377	2	of	of	ADP
ajcp-1634	377	3	virology	virology	NOUN
ajcp-1634	377	4	.	.	PUNCT
ajcp-1634	378	1	wadman	wadman	PROPN
ajcp-1634	378	2	,	,	PUNCT
ajcp-1634	378	3	m.	m.	NOUN
ajcp-1634	378	4	(	(	PUNCT
ajcp-1634	378	5	2020	2020	NUM
ajcp-1634	378	6	)	)	PUNCT
ajcp-1634	378	7	.	.	PUNCT
ajcp-1634	379	1	the	the	DET
ajcp-1634	379	2	long	long	ADJ
ajcp-1634	379	3	shot	shot	NOUN
ajcp-1634	379	4	.	.	PUNCT
ajcp-1634	380	1	https://web.archive	https://web.archive	PROPN
ajcp-1634	380	2	.	.	PUNCT
ajcp-1634	381	1	org	org	PROPN
ajcp-1634	381	2	/	/	SYM
ajcp-1634	381	3	web/20201214123056id_/https://science	web/20201214123056id_/https://science	NOUN
ajcp-1634	381	4	.	.	PUNCT
ajcp-1634	382	1	sciencemag.org/content/sci/370/6517/649.full.pdf	sciencemag.org/content/sci/370/6517/649.full.pdf	PROPN
ajcp-1634	382	2	wang	wang	PROPN
ajcp-1634	382	3	,	,	PUNCT
ajcp-1634	382	4	s.	s.	PROPN
ajcp-1634	382	5	,	,	PUNCT
ajcp-1634	382	6	chou	chou	NOUN
ajcp-1634	382	7	,	,	PUNCT
ajcp-1634	382	8	t.	t.	PROPN
ajcp-1634	382	9	h.	h.	PROPN
ajcp-1634	382	10	w.	w.	PROPN
ajcp-1634	382	11	,	,	PUNCT
ajcp-1634	382	12	sakhatskyy	sakhatskyy	NOUN
ajcp-1634	382	13	,	,	PUNCT
ajcp-1634	382	14	p.	p.	NOUN
ajcp-1634	382	15	v.	v.	PROPN
ajcp-1634	382	16	,	,	PUNCT
ajcp-1634	382	17	huang	huang	PROPN
ajcp-1634	382	18	,	,	PUNCT
ajcp-1634	382	19	s.	s.	PROPN
ajcp-1634	382	20	,	,	PUNCT
ajcp-1634	382	21	lawrence	lawrence	PROPN
ajcp-1634	382	22	,	,	PUNCT
ajcp-1634	382	23	j.	j.	PROPN
ajcp-1634	382	24	m.	m.	PROPN
ajcp-1634	382	25	,	,	PUNCT
ajcp-1634	382	26	cao	cao	PROPN
ajcp-1634	382	27	,	,	PUNCT
ajcp-1634	382	28	h.	h.	PROPN
ajcp-1634	382	29	,	,	PUNCT
ajcp-1634	382	30	...	...	PUNCT
ajcp-1634	382	31	&	&	CCONJ
ajcp-1634	382	32	lu	lu	PROPN
ajcp-1634	382	33	,	,	PUNCT
ajcp-1634	382	34	s.	s.	PROPN
ajcp-1634	382	35	(	(	PUNCT
ajcp-1634	382	36	2005	2005	NUM
ajcp-1634	382	37	)	)	PUNCT
ajcp-1634	382	38	.	.	PUNCT
ajcp-1634	383	1	identification	identification	NOUN
ajcp-1634	383	2	of	of	ADP
ajcp-1634	383	3	two	two	NUM
ajcp-1634	383	4	neutralizing	neutralizing	ADJ
ajcp-1634	383	5	regions	region	NOUN
ajcp-1634	383	6	on	on	ADP
ajcp-1634	383	7	the	the	DET
ajcp-1634	383	8	severe	severe	ADJ
ajcp-1634	383	9	acute	acute	ADJ
ajcp-1634	383	10	respiratory	respiratory	ADJ
ajcp-1634	383	11	syndrome	syndrome	NOUN
ajcp-1634	383	12	coronavirus	coronavirus	NOUN
ajcp-1634	383	13	spike	spike	ADJ
ajcp-1634	383	14	glycoprotein	glycoprotein	NOUN
ajcp-1634	383	15	produced	produce	VERB
ajcp-1634	383	16	from	from	ADP
ajcp-1634	383	17	the	the	DET
ajcp-1634	383	18	mammalian	mammalian	ADJ
ajcp-1634	383	19	expression	expression	NOUN
ajcp-1634	383	20	system	system	NOUN
ajcp-1634	383	21	.	.	PUNCT
ajcp-1634	384	1	journal	journal	PROPN
ajcp-1634	384	2	of	of	ADP
ajcp-1634	384	3	virology	virology	NOUN
ajcp-1634	384	4	,	,	PUNCT
ajcp-1634	384	5	79(3	79(3	NUM
ajcp-1634	384	6	)	)	PUNCT
ajcp-1634	384	7	,	,	PUNCT
ajcp-1634	384	8	1906	1906	NUM
ajcp-1634	384	9	-	-	SYM
ajcp-1634	384	10	1910	1910	NUM
ajcp-1634	384	11	.	.	PUNCT
ajcp-1634	385	1	weiss	weiss	PROPN
ajcp-1634	385	2	,	,	PUNCT
ajcp-1634	385	3	s.	s.	PROPN
ajcp-1634	385	4	r.	r.	PROPN
ajcp-1634	385	5	,	,	PUNCT
ajcp-1634	385	6	&	&	CCONJ
ajcp-1634	385	7	leibowitz	leibowitz	PROPN
ajcp-1634	385	8	,	,	PUNCT
ajcp-1634	385	9	j.	j.	PROPN
ajcp-1634	385	10	l.	l.	PROPN
ajcp-1634	385	11	(	(	PUNCT
ajcp-1634	385	12	2011	2011	NUM
ajcp-1634	385	13	)	)	PUNCT
ajcp-1634	385	14	.	.	PUNCT
ajcp-1634	386	1	coronavirus	coronavirus	NOUN
ajcp-1634	386	2	pathogenesis	pathogenesis	PROPN
ajcp-1634	386	3	.	.	PUNCT
ajcp-1634	387	1	advances	advance	NOUN
ajcp-1634	387	2	in	in	ADP
ajcp-1634	387	3	virus	virus	NOUN
ajcp-1634	387	4	research	research	NOUN
ajcp-1634	387	5	,	,	PUNCT
ajcp-1634	387	6	81	81	NUM
ajcp-1634	387	7	,	,	PUNCT
ajcp-1634	387	8	85	85	NUM
ajcp-1634	387	9	-	-	SYM
ajcp-1634	387	10	164	164	NUM
ajcp-1634	387	11	.	.	PUNCT
ajcp-1634	388	1	walsh	walsh	PROPN
ajcp-1634	388	2	,	,	PUNCT
ajcp-1634	388	3	e.	e.	PROPN
ajcp-1634	388	4	e.	e.	PROPN
ajcp-1634	388	5	,	,	PUNCT
ajcp-1634	388	6	frenck	frenck	PROPN
ajcp-1634	388	7	jr	jr	PROPN
ajcp-1634	388	8	,	,	PUNCT
ajcp-1634	388	9	r.	r.	PROPN
ajcp-1634	388	10	w.	w.	PROPN
ajcp-1634	388	11	,	,	PUNCT
ajcp-1634	388	12	falsey	falsey	PROPN
ajcp-1634	388	13	,	,	PUNCT
ajcp-1634	388	14	a.	a.	PROPN
ajcp-1634	388	15	r.	r.	PROPN
ajcp-1634	388	16	,	,	PUNCT
ajcp-1634	388	17	kitchin	kitchin	PROPN
ajcp-1634	388	18	,	,	PUNCT
ajcp-1634	388	19	n.	n.	NOUN
ajcp-1634	388	20	,	,	PUNCT
ajcp-1634	388	21	absalon	absalon	PROPN
ajcp-1634	388	22	,	,	PUNCT
ajcp-1634	388	23	j.	j.	PROPN
ajcp-1634	388	24	,	,	PUNCT
ajcp-1634	388	25	gurtman	gurtman	NOUN
ajcp-1634	388	26	,	,	PUNCT
ajcp-1634	388	27	a.	a.	NOUN
ajcp-1634	388	28	,	,	PUNCT
ajcp-1634	388	29	...	...	PUNCT
ajcp-1634	388	30	&	&	CCONJ
ajcp-1634	388	31	gruber	gruber	PROPN
ajcp-1634	388	32	,	,	PUNCT
ajcp-1634	388	33	w.	w.	PROPN
ajcp-1634	388	34	c.	c.	PROPN
ajcp-1634	388	35	(	(	PUNCT
ajcp-1634	388	36	2020	2020	NUM
ajcp-1634	388	37	)	)	PUNCT
ajcp-1634	388	38	.	.	PUNCT
ajcp-1634	389	1	safety	safety	NOUN
ajcp-1634	389	2	and	and	CCONJ
ajcp-1634	389	3	immunogenicity	immunogenicity	NOUN
ajcp-1634	389	4	of	of	ADP
ajcp-1634	389	5	two	two	NUM
ajcp-1634	389	6	rna	rna	NOUN
ajcp-1634	389	7	-	-	PUNCT
ajcp-1634	389	8	based	base	VERB
ajcp-1634	389	9	covid-19	covid-19	PROPN
ajcp-1634	389	10	vaccine	vaccine	NOUN
ajcp-1634	389	11	candidates	candidate	NOUN
ajcp-1634	389	12	.	.	PUNCT
ajcp-1634	390	1	new	new	PROPN
ajcp-1634	390	2	england	england	PROPN
ajcp-1634	390	3	journal	journal	PROPN
ajcp-1634	390	4	of	of	ADP
ajcp-1634	390	5	medicine	medicine	NOUN
ajcp-1634	390	6	,	,	PUNCT
ajcp-1634	390	7	383(25	383(25	NUM
ajcp-1634	390	8	)	)	PUNCT
ajcp-1634	390	9	,	,	PUNCT
ajcp-1634	390	10	2439	2439	NUM
ajcp-1634	390	11	-	-	SYM
ajcp-1634	390	12	2450	2450	NUM
ajcp-1634	390	13	.	.	PUNCT
ajcp-1634	391	1	watanabe	watanabe	PROPN
ajcp-1634	391	2	,	,	PUNCT
ajcp-1634	391	3	y.	y.	PROPN
ajcp-1634	391	4	,	,	PUNCT
ajcp-1634	391	5	allen	allen	PROPN
ajcp-1634	391	6	,	,	PUNCT
ajcp-1634	391	7	j.	j.	PROPN
ajcp-1634	391	8	d.	d.	PROPN
ajcp-1634	391	9	,	,	PUNCT
ajcp-1634	391	10	wrapp	wrapp	PROPN
ajcp-1634	391	11	,	,	PUNCT
ajcp-1634	391	12	d.	d.	PROPN
ajcp-1634	391	13	,	,	PUNCT
ajcp-1634	391	14	mclellan	mclellan	PROPN
ajcp-1634	391	15	,	,	PUNCT
ajcp-1634	391	16	j.	j.	PROPN
ajcp-1634	391	17	s.	s.	PROPN
ajcp-1634	391	18	,	,	PUNCT
ajcp-1634	391	19	&	&	CCONJ
ajcp-1634	391	20	crispin	crispin	PROPN
ajcp-1634	391	21	,	,	PUNCT
ajcp-1634	391	22	m.	m.	NOUN
ajcp-1634	391	23	(	(	PUNCT
ajcp-1634	391	24	2020	2020	NUM
ajcp-1634	391	25	)	)	PUNCT
ajcp-1634	391	26	.	.	PUNCT
ajcp-1634	392	1	site	site	NOUN
ajcp-1634	392	2	-	-	PUNCT
ajcp-1634	392	3	specific	specific	ADJ
ajcp-1634	392	4	glycan	glycan	NOUN
ajcp-1634	392	5	analysis	analysis	NOUN
ajcp-1634	392	6	of	of	ADP
ajcp-1634	392	7	the	the	DET
ajcp-1634	392	8	sars	sar	NOUN
ajcp-1634	392	9	-	-	PUNCT
ajcp-1634	392	10	cov-2	cov-2	NOUN
ajcp-1634	392	11	spike	spike	NOUN
ajcp-1634	392	12	.	.	PUNCT
ajcp-1634	393	1	science	science	NOUN
ajcp-1634	393	2	,	,	PUNCT
ajcp-1634	393	3	369(6501	369(6501	NUM
ajcp-1634	393	4	)	)	PUNCT
ajcp-1634	393	5	,	,	PUNCT
ajcp-1634	393	6	330	330	NUM
ajcp-1634	393	7	-	-	NUM
ajcp-1634	393	8	333.w	333.w	NUM
ajcp-1634	393	9	who	who	PRON
ajcp-1634	393	10	.	.	PUNCT
ajcp-1634	394	1	(	(	PUNCT
ajcp-1634	394	2	n.d	n.d	PROPN
ajcp-1634	394	3	.	.	PROPN
ajcp-1634	394	4	)	)	PUNCT
ajcp-1634	394	5	.	.	PUNCT
ajcp-1634	395	1	covid-19	covid-19	PROPN
ajcp-1634	395	2	vaccine	vaccine	NOUN
ajcp-1634	395	3	tracker	tracker	NOUN
ajcp-1634	395	4	and	and	CCONJ
ajcp-1634	395	5	landscape	landscape	NOUN
ajcp-1634	395	6	.	.	PUNCT
ajcp-1634	396	1	world	world	NOUN
ajcp-1634	396	2	health	health	PROPN
ajcp-1634	396	3	organization	organization	PROPN
ajcp-1634	396	4	.	.	PUNCT
ajcp-1634	397	1	retrieved	retrieve	VERB
ajcp-1634	397	2	september	september	PROPN
ajcp-1634	397	3	13	13	NUM
ajcp-1634	397	4	,	,	PUNCT
ajcp-1634	397	5	2021	2021	NUM
ajcp-1634	397	6	,	,	PUNCT
ajcp-1634	397	7	from	from	ADP
ajcp-1634	397	8	https://www.who.int/publications/m/	https://www.who.int/publications/m/	VERB
ajcp-1634	397	9	item	item	NOUN
ajcp-1634	397	10	/	/	SYM
ajcp-1634	397	11	draft	draft	NOUN
ajcp-1634	397	12	-	-	PUNCT
ajcp-1634	397	13	landscape	landscape	NOUN
ajcp-1634	397	14	-	-	PUNCT
ajcp-1634	397	15	of	of	ADP
ajcp-1634	397	16	-	-	PUNCT
ajcp-1634	397	17	covid-19	covid-19	NOUN
ajcp-1634	397	18	-	-	PUNCT
ajcp-1634	397	19	candidate	candidate	NOUN
ajcp-1634	397	20	-	-	PUNCT
ajcp-1634	397	21	vaccines	vaccine	NOUN
ajcp-1634	397	22	wolfert	wolfert	NOUN
ajcp-1634	397	23	,	,	PUNCT
ajcp-1634	397	24	m.	m.	NOUN
ajcp-1634	397	25	a.	a.	PROPN
ajcp-1634	397	26	,	,	PUNCT
ajcp-1634	397	27	&	&	CCONJ
ajcp-1634	397	28	boons	boon	NOUN
ajcp-1634	397	29	,	,	PUNCT
ajcp-1634	397	30	g.	g.	PROPN
ajcp-1634	397	31	j.	j.	PROPN
ajcp-1634	397	32	(	(	PUNCT
ajcp-1634	397	33	2013	2013	NUM
ajcp-1634	397	34	)	)	PUNCT
ajcp-1634	397	35	.	.	PUNCT
ajcp-1634	398	1	adaptive	adaptive	ADJ
ajcp-1634	398	2	immune	immune	ADJ
ajcp-1634	398	3	activation	activation	NOUN
ajcp-1634	398	4	:	:	PUNCT
ajcp-1634	398	5	glycosylation	glycosylation	NOUN
ajcp-1634	398	6	does	do	AUX
ajcp-1634	398	7	matter	matter	NOUN
ajcp-1634	398	8	.	.	PUNCT
ajcp-1634	399	1	nature	nature	NOUN
ajcp-1634	399	2	chemical	chemical	PROPN
ajcp-1634	399	3	biology	biology	NOUN
ajcp-1634	399	4	,	,	PUNCT
ajcp-1634	399	5	9(12	9(12	NUM
ajcp-1634	399	6	)	)	PUNCT
ajcp-1634	399	7	,	,	PUNCT
ajcp-1634	399	8	776	776	NUM
ajcp-1634	399	9	-	-	SYM
ajcp-1634	399	10	784	784	NUM
ajcp-1634	399	11	.	.	PUNCT
ajcp-1634	400	1	world	world	NOUN
ajcp-1634	400	2	health	health	PROPN
ajcp-1634	400	3	organization	organization	PROPN
ajcp-1634	400	4	.	.	PUNCT
ajcp-1634	401	1	(	(	PUNCT
ajcp-1634	401	2	2021	2021	NUM
ajcp-1634	401	3	,	,	PUNCT
ajcp-1634	401	4	september	september	PROPN
ajcp-1634	401	5	)	)	PUNCT
ajcp-1634	401	6	.	.	PUNCT
ajcp-1634	402	1	weekly	weekly	ADJ
ajcp-1634	402	2	operational	operational	ADJ
ajcp-1634	402	3	update	update	NOUN
ajcp-1634	402	4	on	on	ADP
ajcp-1634	402	5	covid-196	covid-196	ADJ
ajcp-1634	402	6	september	september	PROPN
ajcp-1634	402	7	2021(71	2021(71	NUM
ajcp-1634	402	8	)	)	PUNCT
ajcp-1634	402	9	.	.	PUNCT
ajcp-1634	403	1	https://www.who.int/publications/m/item/weeklyoperational-update-on-covid-19---6-september-2021	https://www.who.int/publications/m/item/weeklyoperational-update-on-covid-19---6-september-2021	NOUN
ajcp-1634	403	2	wrapp	wrapp	PROPN
ajcp-1634	403	3	,	,	PUNCT
ajcp-1634	403	4	d.	d.	PROPN
ajcp-1634	403	5	,	,	PUNCT
ajcp-1634	403	6	wang	wang	PROPN
ajcp-1634	403	7	,	,	PUNCT
ajcp-1634	403	8	n.	n.	NOUN
ajcp-1634	403	9	,	,	PUNCT
ajcp-1634	403	10	corbett	corbett	PROPN
ajcp-1634	403	11	,	,	PUNCT
ajcp-1634	403	12	k.	k.	PROPN
ajcp-1634	403	13	s.	s.	PROPN
ajcp-1634	403	14	,	,	PUNCT
ajcp-1634	403	15	goldsmith	goldsmith	PROPN
ajcp-1634	403	16	,	,	PUNCT
ajcp-1634	403	17	j.	j.	PROPN
ajcp-1634	403	18	a.	a.	PROPN
ajcp-1634	403	19	,	,	PUNCT
ajcp-1634	403	20	hsieh	hsieh	PROPN
ajcp-1634	403	21	,	,	PUNCT
ajcp-1634	403	22	c.	c.	PROPN
ajcp-1634	403	23	l.	l.	PROPN
ajcp-1634	403	24	,	,	PUNCT
ajcp-1634	403	25	abiona	abiona	PROPN
ajcp-1634	403	26	,	,	PUNCT
ajcp-1634	403	27	o.	o.	PROPN
ajcp-1634	403	28	,	,	PUNCT
ajcp-1634	403	29	...	...	PUNCT
ajcp-1634	403	30	&	&	CCONJ
ajcp-1634	403	31	mclellan	mclellan	PROPN
ajcp-1634	403	32	,	,	PUNCT
ajcp-1634	403	33	j.	j.	PROPN
ajcp-1634	403	34	s.	s.	PROPN
ajcp-1634	403	35	(	(	PUNCT
ajcp-1634	403	36	2020	2020	NUM
ajcp-1634	403	37	)	)	PUNCT
ajcp-1634	403	38	.	.	PUNCT
ajcp-1634	404	1	cryo	cryo	PROPN
ajcp-1634	404	2	-	-	PUNCT
ajcp-1634	404	3	em	em	PRON
ajcp-1634	404	4	structure	structure	NOUN
ajcp-1634	404	5	of	of	ADP
ajcp-1634	404	6	the	the	DET
ajcp-1634	404	7	2019	2019	NUM
ajcp-1634	404	8	-	-	PUNCT
ajcp-1634	404	9	ncov	ncov	NOUN
ajcp-1634	404	10	spike	spike	NOUN
ajcp-1634	404	11	in	in	ADP
ajcp-1634	404	12	the	the	DET
ajcp-1634	404	13	prefusion	prefusion	NOUN
ajcp-1634	404	14	conformation	conformation	NOUN
ajcp-1634	404	15	.	.	PUNCT
ajcp-1634	405	1	science	science	NOUN
ajcp-1634	405	2	,	,	PUNCT
ajcp-1634	405	3	367(6483	367(6483	NUM
ajcp-1634	405	4	)	)	PUNCT
ajcp-1634	405	5	,	,	PUNCT
ajcp-1634	405	6	1260	1260	NUM
ajcp-1634	405	7	-	-	SYM
ajcp-1634	405	8	1263	1263	NUM
ajcp-1634	405	9	.	.	PUNCT
ajcp-1634	406	1	yan	yan	PROPN
ajcp-1634	406	2	,	,	PUNCT
ajcp-1634	406	3	r.	r.	PROPN
ajcp-1634	406	4	,	,	PUNCT
ajcp-1634	406	5	zhang	zhang	PROPN
ajcp-1634	406	6	,	,	PUNCT
ajcp-1634	406	7	y.	y.	PROPN
ajcp-1634	406	8	,	,	PUNCT
ajcp-1634	406	9	li	li	PROPN
ajcp-1634	406	10	,	,	PUNCT
ajcp-1634	406	11	y.	y.	PROPN
ajcp-1634	406	12	,	,	PUNCT
ajcp-1634	406	13	xia	xia	PROPN
ajcp-1634	406	14	,	,	PUNCT
ajcp-1634	406	15	l.	l.	PROPN
ajcp-1634	406	16	,	,	PUNCT
ajcp-1634	406	17	guo	guo	PROPN
ajcp-1634	406	18	,	,	PUNCT
ajcp-1634	406	19	y.	y.	PROPN
ajcp-1634	406	20	,	,	PUNCT
ajcp-1634	406	21	&	&	CCONJ
ajcp-1634	406	22	zhou	zhou	PROPN
ajcp-1634	406	23	,	,	PUNCT
ajcp-1634	406	24	q.	q.	PROPN
ajcp-1634	406	25	(	(	PUNCT
ajcp-1634	406	26	2020	2020	NUM
ajcp-1634	406	27	)	)	PUNCT
ajcp-1634	406	28	.	.	PUNCT
ajcp-1634	407	1	structural	structural	ADJ
ajcp-1634	407	2	basis	basis	NOUN
ajcp-1634	407	3	for	for	ADP
ajcp-1634	407	4	the	the	DET
ajcp-1634	407	5	recognition	recognition	NOUN
ajcp-1634	407	6	of	of	ADP
ajcp-1634	407	7	sarscov-2	sarscov-2	NUM
ajcp-1634	407	8	by	by	ADP
ajcp-1634	407	9	full	full	ADJ
ajcp-1634	407	10	-	-	PUNCT
ajcp-1634	407	11	length	length	NOUN
ajcp-1634	407	12	human	human	ADJ
ajcp-1634	407	13	ace2	ace2	PROPN
ajcp-1634	407	14	.	.	PUNCT
ajcp-1634	408	1	science	science	NOUN
ajcp-1634	408	2	,	,	PUNCT
ajcp-1634	408	3	367(6485	367(6485	NUM
ajcp-1634	408	4	)	)	PUNCT
ajcp-1634	408	5	,	,	PUNCT
ajcp-1634	408	6	1444	1444	NUM
ajcp-1634	408	7	-	-	SYM
ajcp-1634	408	8	1448	1448	NUM
ajcp-1634	408	9	.	.	PUNCT
ajcp-1634	409	1	zhou	zhou	PROPN
ajcp-1634	409	2	,	,	PUNCT
ajcp-1634	409	3	p.	p.	PROPN
ajcp-1634	409	4	,	,	PUNCT
ajcp-1634	409	5	yang	yang	PROPN
ajcp-1634	409	6	,	,	PUNCT
ajcp-1634	409	7	x.	x.	PROPN
ajcp-1634	409	8	l.	l.	PROPN
ajcp-1634	409	9	,	,	PUNCT
ajcp-1634	409	10	wang	wang	PROPN
ajcp-1634	409	11	,	,	PUNCT
ajcp-1634	409	12	x.	x.	PROPN
ajcp-1634	409	13	g.	g.	PROPN
ajcp-1634	409	14	,	,	PUNCT
ajcp-1634	409	15	hu	hu	PROPN
ajcp-1634	409	16	,	,	PUNCT
ajcp-1634	409	17	b.	b.	PROPN
ajcp-1634	409	18	,	,	PUNCT
ajcp-1634	409	19	zhang	zhang	PROPN
ajcp-1634	409	20	,	,	PUNCT
ajcp-1634	409	21	l.	l.	PROPN
ajcp-1634	409	22	,	,	PUNCT
ajcp-1634	409	23	zhang	zhang	PROPN
ajcp-1634	409	24	,	,	PUNCT
ajcp-1634	409	25	w.	w.	PROPN
ajcp-1634	409	26	,	,	PUNCT
ajcp-1634	409	27	...	...	PUNCT
ajcp-1634	409	28	&	&	CCONJ
ajcp-1634	409	29	shi	shi	PROPN
ajcp-1634	409	30	,	,	PUNCT
ajcp-1634	409	31	z.	z.	PROPN
ajcp-1634	409	32	l.	l.	PROPN
ajcp-1634	409	33	(	(	PUNCT
ajcp-1634	409	34	2020	2020	NUM
ajcp-1634	409	35	)	)	PUNCT
ajcp-1634	409	36	.	.	PUNCT
ajcp-1634	410	1	a	a	DET
ajcp-1634	410	2	pneumonia	pneumonia	NOUN
ajcp-1634	410	3	outbreak	outbreak	NOUN
ajcp-1634	410	4	associated	associate	VERB
ajcp-1634	410	5	with	with	ADP
ajcp-1634	410	6	a	a	DET
ajcp-1634	410	7	new	new	ADJ
ajcp-1634	410	8	coronavirus	coronavirus	NOUN
ajcp-1634	410	9	of	of	ADP
ajcp-1634	410	10	probable	probable	ADJ
ajcp-1634	410	11	bat	bat	NOUN
ajcp-1634	410	12	origin	origin	NOUN
ajcp-1634	410	13	.	.	PUNCT
ajcp-1634	411	1	nature	nature	NOUN
ajcp-1634	411	2	,	,	PUNCT
ajcp-1634	411	3	579(7798	579(7798	NUM
ajcp-1634	411	4	)	)	PUNCT
ajcp-1634	411	5	,	,	PUNCT
ajcp-1634	411	6	270	270	NUM
ajcp-1634	411	7	-	-	SYM
ajcp-1634	411	8	273	273	NUM
ajcp-1634	411	9	.	.	PUNCT
ajcp-1634	412	1	zhou	zhou	PROPN
ajcp-1634	412	2	,	,	PUNCT
ajcp-1634	412	3	q.	q.	PROPN
ajcp-1634	412	4	,	,	PUNCT
ajcp-1634	412	5	&	&	CCONJ
ajcp-1634	412	6	qiu	qiu	PROPN
ajcp-1634	412	7	,	,	PUNCT
ajcp-1634	412	8	h.	h.	PROPN
ajcp-1634	412	9	(	(	PUNCT
ajcp-1634	412	10	2019	2019	NUM
ajcp-1634	412	11	)	)	PUNCT
ajcp-1634	412	12	.	.	PUNCT
ajcp-1634	413	1	the	the	DET
ajcp-1634	413	2	mechanistic	mechanistic	ADJ
ajcp-1634	413	3	impact	impact	NOUN
ajcp-1634	413	4	of	of	ADP
ajcp-1634	413	5	n	n	NOUN
ajcp-1634	413	6	-	-	PUNCT
ajcp-1634	413	7	glycosylation	glycosylation	NOUN
ajcp-1634	413	8	on	on	ADP
ajcp-1634	413	9	stability	stability	NOUN
ajcp-1634	413	10	,	,	PUNCT
ajcp-1634	413	11	pharmacokinetics	pharmacokinetic	NOUN
ajcp-1634	413	12	,	,	PUNCT
ajcp-1634	413	13	and	and	CCONJ
ajcp-1634	413	14	immunogenicity	immunogenicity	NOUN
ajcp-1634	413	15	of	of	ADP
ajcp-1634	413	16	therapeutic	therapeutic	ADJ
ajcp-1634	413	17	proteins	protein	NOUN
ajcp-1634	413	18	.	.	PUNCT
ajcp-1634	414	1	journal	journal	NOUN
ajcp-1634	414	2	of	of	ADP
ajcp-1634	414	3	pharmaceutical	pharmaceutical	NOUN
ajcp-1634	414	4	sciences	science	NOUN
ajcp-1634	414	5	,	,	PUNCT
ajcp-1634	414	6	108(4	108(4	NUM
ajcp-1634	414	7	)	)	PUNCT
ajcp-1634	414	8	,	,	PUNCT
ajcp-1634	414	9	1366	1366	NUM
ajcp-1634	414	10	-	-	SYM
ajcp-1634	414	11	1377	1377	NUM
ajcp-1634	414	12	.	.	PUNCT
ajcp-1634	415	1	zhao	zhao	PROPN
ajcp-1634	415	2	,	,	PUNCT
ajcp-1634	415	3	x.	x.	PROPN
ajcp-1634	415	4	,	,	PUNCT
ajcp-1634	415	5	chen	chen	PROPN
ajcp-1634	415	6	,	,	PUNCT
ajcp-1634	415	7	h.	h.	PROPN
ajcp-1634	415	8	,	,	PUNCT
ajcp-1634	415	9	&	&	CCONJ
ajcp-1634	415	10	wang	wang	PROPN
ajcp-1634	415	11	,	,	PUNCT
ajcp-1634	415	12	h.	h.	PROPN
ajcp-1634	415	13	(	(	PUNCT
ajcp-1634	415	14	2021	2021	NUM
ajcp-1634	415	15	)	)	PUNCT
ajcp-1634	415	16	.	.	PUNCT
ajcp-1634	416	1	glycans	glycan	NOUN
ajcp-1634	416	2	of	of	ADP
ajcp-1634	416	3	sarscov-2	sarscov-2	NUM
ajcp-1634	416	4	spike	spike	ADJ
ajcp-1634	416	5	protein	protein	NOUN
ajcp-1634	416	6	in	in	ADP
ajcp-1634	416	7	virus	virus	NOUN
ajcp-1634	416	8	infection	infection	NOUN
ajcp-1634	416	9	and	and	CCONJ
ajcp-1634	416	10	antibody	antibody	NOUN
ajcp-1634	416	11	production	production	NOUN
ajcp-1634	416	12	.	.	PUNCT
ajcp-1634	417	1	frontiers	frontier	NOUN
ajcp-1634	417	2	in	in	ADP
ajcp-1634	417	3	molecular	molecular	ADJ
ajcp-1634	417	4	biosciences	bioscience	NOUN
ajcp-1634	417	5	,	,	PUNCT
ajcp-1634	417	6	8	8	NUM
ajcp-1634	417	7	,	,	PUNCT
ajcp-1634	417	8	53	53	NUM
ajcp-1634	417	9	.	.	PUNCT
ajcp-1634	418	1	zhu	zhu	PROPN
ajcp-1634	418	2	,	,	PUNCT
ajcp-1634	418	3	n.	n.	PROPN
ajcp-1634	418	4	,	,	PUNCT
ajcp-1634	418	5	zhang	zhang	PROPN
ajcp-1634	418	6	,	,	PUNCT
ajcp-1634	418	7	d.	d.	PROPN
ajcp-1634	418	8	,	,	PUNCT
ajcp-1634	418	9	wang	wang	PROPN
ajcp-1634	418	10	,	,	PUNCT
ajcp-1634	418	11	w.	w.	PROPN
ajcp-1634	418	12	,	,	PUNCT
ajcp-1634	418	13	li	li	PROPN
ajcp-1634	418	14	,	,	PUNCT
ajcp-1634	418	15	x.	x.	PROPN
ajcp-1634	418	16	,	,	PUNCT
ajcp-1634	418	17	yang	yang	PROPN
ajcp-1634	418	18	,	,	PUNCT
ajcp-1634	418	19	b.	b.	PROPN
ajcp-1634	418	20	,	,	PUNCT
ajcp-1634	418	21	song	song	PROPN
ajcp-1634	418	22	,	,	PUNCT
ajcp-1634	418	23	j.	j.	PROPN
ajcp-1634	418	24	,	,	PUNCT
ajcp-1634	418	25	...	...	PUNCT
ajcp-1634	418	26	&	&	CCONJ
ajcp-1634	418	27	tan	tan	PROPN
ajcp-1634	418	28	,	,	PUNCT
ajcp-1634	418	29	w.	w.	PROPN
ajcp-1634	418	30	(	(	PUNCT
ajcp-1634	418	31	2020	2020	NUM
ajcp-1634	418	32	)	)	PUNCT
ajcp-1634	418	33	.	.	PUNCT
ajcp-1634	419	1	a	a	DET
ajcp-1634	419	2	novel	novel	ADJ
ajcp-1634	419	3	coronavirus	coronavirus	NOUN
ajcp-1634	419	4	from	from	ADP
ajcp-1634	419	5	patients	patient	NOUN
ajcp-1634	419	6	with	with	ADP
ajcp-1634	419	7	pneumonia	pneumonia	NOUN
ajcp-1634	419	8	in	in	ADP
ajcp-1634	419	9	china	china	PROPN
ajcp-1634	419	10	,	,	PUNCT
ajcp-1634	419	11	2019	2019	NUM
ajcp-1634	419	12	.	.	PUNCT
ajcp-1634	420	1	new	new	PROPN
ajcp-1634	420	2	england	england	PROPN
ajcp-1634	420	3	journal	journal	PROPN
ajcp-1634	420	4	of	of	ADP
ajcp-1634	420	5	medicine	medicine	NOUN
ajcp-1634	420	6	.	.	PUNCT
ajcp-1634	421	1	zisman	zisman	ADJ
ajcp-1634	421	2	,	,	PUNCT
ajcp-1634	421	3	l.	l.	PROPN
ajcp-1634	421	4	s.	s.	PROPN
ajcp-1634	421	5	,	,	PUNCT
ajcp-1634	421	6	keller	keller	PROPN
ajcp-1634	421	7	,	,	PUNCT
ajcp-1634	421	8	r.	r.	PROPN
ajcp-1634	421	9	s.	s.	PROPN
ajcp-1634	421	10	,	,	PUNCT
ajcp-1634	421	11	weaver	weaver	PROPN
ajcp-1634	421	12	,	,	PUNCT
ajcp-1634	421	13	b.	b.	PROPN
ajcp-1634	421	14	,	,	PUNCT
ajcp-1634	421	15	lin	lin	PROPN
ajcp-1634	421	16	,	,	PUNCT
ajcp-1634	421	17	q.	q.	PROPN
ajcp-1634	421	18	,	,	PUNCT
ajcp-1634	421	19	speth	speth	PROPN
ajcp-1634	421	20	,	,	PUNCT
ajcp-1634	421	21	r.	r.	PROPN
ajcp-1634	421	22	,	,	PUNCT
ajcp-1634	421	23	bristow	bristow	PROPN
ajcp-1634	421	24	,	,	PUNCT
ajcp-1634	421	25	m.	m.	PROPN
ajcp-1634	421	26	r.	r.	PROPN
ajcp-1634	421	27	,	,	PUNCT
ajcp-1634	421	28	&	&	CCONJ
ajcp-1634	421	29	canver	canver	PROPN
ajcp-1634	421	30	,	,	PUNCT
ajcp-1634	421	31	c.	c.	PROPN
ajcp-1634	421	32	c.	c.	PROPN
ajcp-1634	421	33	(	(	PUNCT
ajcp-1634	421	34	2003	2003	NUM
ajcp-1634	421	35	)	)	PUNCT
ajcp-1634	421	36	.	.	PUNCT
ajcp-1634	421	37	increased	increase	VERB
ajcp-1634	421	38	angiotensin-(1	angiotensin-(1	NOUN
ajcp-1634	421	39	-	-	PUNCT
ajcp-1634	421	40	7)–forming	7)–forme	VERB
ajcp-1634	421	41	activity	activity	NOUN
ajcp-1634	421	42	in	in	ADP
ajcp-1634	421	43	failing	fail	VERB
ajcp-1634	421	44	human	human	ADJ
ajcp-1634	421	45	heart	heart	NOUN
ajcp-1634	421	46	ventricles	ventricle	NOUN
ajcp-1634	421	47	:	:	PUNCT
ajcp-1634	421	48	evidence	evidence	NOUN
ajcp-1634	421	49	for	for	ADP
ajcp-1634	421	50	upregulation	upregulation	NOUN
ajcp-1634	421	51	of	of	ADP
ajcp-1634	421	52	the	the	DET
ajcp-1634	421	53	angiotensin	angiotensin	NOUN
ajcp-1634	421	54	-	-	PUNCT
ajcp-1634	421	55	converting	convert	VERB
ajcp-1634	421	56	enzyme	enzyme	NOUN
ajcp-1634	421	57	homologue	homologue	NOUN
ajcp-1634	421	58	ace2	ace2	NOUN
ajcp-1634	421	59	.	.	PUNCT
ajcp-1634	422	1	circulation	circulation	NOUN
ajcp-1634	422	2	,	,	PUNCT
ajcp-1634	422	3	108(14	108(14	NUM
ajcp-1634	422	4	)	)	PUNCT
ajcp-1634	422	5	,	,	PUNCT
ajcp-1634	422	6	1707	1707	NUM
ajcp-1634	422	7	-	-	SYM
ajcp-1634	422	8	1712	1712	NUM
ajcp-1634	422	9	.	.	PUNCT
ajcp-1634	423	1	zost	zost	PROPN
ajcp-1634	423	2	,	,	PUNCT
ajcp-1634	423	3	s.	s.	PROPN
ajcp-1634	423	4	j.	j.	PROPN
ajcp-1634	423	5	,	,	PUNCT
ajcp-1634	423	6	parkhouse	parkhouse	PROPN
ajcp-1634	423	7	,	,	PUNCT
ajcp-1634	423	8	k.	k.	PROPN
ajcp-1634	423	9	,	,	PUNCT
ajcp-1634	423	10	gumina	gumina	PROPN
ajcp-1634	423	11	,	,	PUNCT
ajcp-1634	423	12	m.	m.	PROPN
ajcp-1634	423	13	e.	e.	PROPN
ajcp-1634	423	14	,	,	PUNCT
ajcp-1634	423	15	kim	kim	PROPN
ajcp-1634	423	16	,	,	PUNCT
ajcp-1634	423	17	k.	k.	PROPN
ajcp-1634	423	18	,	,	PUNCT
ajcp-1634	423	19	perez	perez	PROPN
ajcp-1634	423	20	,	,	PUNCT
ajcp-1634	423	21	s.	s.	PROPN
ajcp-1634	423	22	d.	d.	PROPN
ajcp-1634	423	23	,	,	PUNCT
ajcp-1634	423	24	wilson	wilson	PROPN
ajcp-1634	423	25	,	,	PUNCT
ajcp-1634	423	26	p.	p.	PROPN
ajcp-1634	423	27	c.	c.	PROPN
ajcp-1634	423	28	,	,	PUNCT
ajcp-1634	423	29	&	&	CCONJ
ajcp-1634	423	30	hensley	hensley	PROPN
ajcp-1634	423	31	,	,	PUNCT
ajcp-1634	423	32	s.	s.	PROPN
ajcp-1634	423	33	e.	e.	PROPN
ajcp-1634	423	34	(	(	PUNCT
ajcp-1634	423	35	2017	2017	NUM
ajcp-1634	423	36	)	)	PUNCT
ajcp-1634	423	37	.	.	PUNCT
ajcp-1634	424	1	contemporary	contemporary	ADJ
ajcp-1634	424	2	h3n2	h3n2	INTJ
ajcp-1634	424	3	influenza	influenza	NOUN
ajcp-1634	424	4	viruses	virus	NOUN
ajcp-1634	424	5	have	have	VERB
ajcp-1634	424	6	a	a	DET
ajcp-1634	424	7	glycosylation	glycosylation	NOUN
ajcp-1634	424	8	site	site	NOUN
ajcp-1634	424	9	that	that	PRON
ajcp-1634	424	10	alters	alter	VERB
ajcp-1634	424	11	binding	bind	VERB
ajcp-1634	424	12	of	of	ADP
ajcp-1634	424	13	antibodies	antibody	NOUN
ajcp-1634	424	14	elicited	elicit	VERB
ajcp-1634	424	15	by	by	ADP
ajcp-1634	424	16	egg	egg	NOUN
ajcp-1634	424	17	-	-	PUNCT
ajcp-1634	424	18	adapted	adapt	VERB
ajcp-1634	424	19	vaccine	vaccine	NOUN
ajcp-1634	424	20	strains	strain	VERB
ajcp-1634	424	21	.	.	PUNCT
ajcp-1634	425	1	proceedings	proceeding	NOUN
ajcp-1634	425	2	of	of	ADP
ajcp-1634	425	3	the	the	DET
ajcp-1634	425	4	national	national	PROPN
ajcp-1634	425	5	academy	academy	PROPN
ajcp-1634	425	6	of	of	ADP
ajcp-1634	425	7	sciences	sciences	PROPN
ajcp-1634	425	8	,	,	PUNCT
ajcp-1634	425	9	114(47	114(47	NUM
ajcp-1634	425	10	)	)	PUNCT
ajcp-1634	425	11	,	,	PUNCT
ajcp-1634	425	12	12578	12578	NUM
ajcp-1634	425	13	-	-	SYM
ajcp-1634	425	14	12583	12583	NUM
ajcp-1634	425	15	.	.	PUNCT
ajcp-1634	426	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	NOUN